0001280776-23-000004.txt : 20230223 0001280776-23-000004.hdr.sgml : 20230223 20230223070045 ACCESSION NUMBER: 0001280776-23-000004 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNIC, INC. CENTRAL INDEX KEY: 0001280776 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562358443 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36201 FILM NUMBER: 23655865 BUSINESS ADDRESS: STREET 1: 1200 AVENUE OF THE AMERICAS STREET 2: SUITE 200 CITY: NEW YORK STATE: X1 ZIP: 10036 BUSINESS PHONE: (332) 255-9818 MAIL ADDRESS: STREET 1: 1200 AVENUE OF THE AMERICAS STREET 2: SUITE 200 CITY: NEW YORK STATE: X1 ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: VITAL THERAPIES INC DATE OF NAME CHANGE: 20040219 10-K 1 imux-20221231.htm 10-K imux-20221231
00012807762022FYfalsehttp://fasb.org/us-gaap/2022#NonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#NonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrentP3Y00012807762022-01-012022-12-3100012807762022-06-30iso4217:USD00012807762023-02-17xbrli:shares00012807762022-12-3100012807762021-12-31iso4217:USDxbrli:shares00012807762021-01-012021-12-310001280776us-gaap:CommonStockMember2020-12-310001280776us-gaap:AdditionalPaidInCapitalMember2020-12-310001280776us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001280776us-gaap:RetainedEarningsMember2020-12-3100012807762020-12-310001280776us-gaap:RetainedEarningsMember2021-01-012021-12-310001280776us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001280776us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001280776imux:July2021PublicEquityOfferingMember2021-01-012021-12-310001280776us-gaap:CommonStockMemberimux:July2021PublicEquityOfferingMember2021-01-012021-12-310001280776us-gaap:AdditionalPaidInCapitalMemberimux:July2021PublicEquityOfferingMember2021-01-012021-12-310001280776imux:AtTheMarketSalesAgreementMember2021-01-012021-12-310001280776us-gaap:CommonStockMemberimux:AtTheMarketSalesAgreementMember2021-01-012021-12-310001280776us-gaap:AdditionalPaidInCapitalMemberimux:AtTheMarketSalesAgreementMember2021-01-012021-12-310001280776us-gaap:CommonStockMember2021-01-012021-12-310001280776us-gaap:CommonStockMemberimux:A4SCRoyaltySettlementMember2021-01-012021-12-310001280776us-gaap:AdditionalPaidInCapitalMemberimux:A4SCRoyaltySettlementMember2021-01-012021-12-310001280776imux:A4SCRoyaltySettlementMember2021-01-012021-12-310001280776us-gaap:CommonStockMember2021-12-310001280776us-gaap:AdditionalPaidInCapitalMember2021-12-310001280776us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001280776us-gaap:RetainedEarningsMember2021-12-310001280776us-gaap:RetainedEarningsMember2022-01-012022-12-310001280776us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001280776us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001280776imux:October2022PIPETransactionMember2022-01-012022-12-310001280776imux:October2022PIPETransactionMemberus-gaap:CommonStockMember2022-01-012022-12-310001280776imux:October2022PIPETransactionMemberus-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001280776imux:AtTheMarketSalesAgreementMember2022-01-012022-12-310001280776us-gaap:CommonStockMemberimux:AtTheMarketSalesAgreementMember2022-01-012022-12-310001280776us-gaap:AdditionalPaidInCapitalMemberimux:AtTheMarketSalesAgreementMember2022-01-012022-12-310001280776us-gaap:CommonStockMember2022-01-012022-12-310001280776us-gaap:CommonStockMember2022-12-310001280776us-gaap:AdditionalPaidInCapitalMember2022-12-310001280776us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001280776us-gaap:RetainedEarningsMember2022-12-310001280776imux:PublicOfferingMember2022-01-012022-12-310001280776imux:PublicOfferingMember2021-01-012021-12-310001280776imux:October2022PIPETransactionMember2021-01-012021-12-310001280776imux:July2021PublicEquityOfferingMember2022-01-012022-12-31imux:employeeimux:lease0001280776country:US2022-12-310001280776country:DE2022-12-310001280776country:AU2022-12-31imux:financialInstitution0001280776us-gaap:MoneyMarketFundsMembercountry:US2022-12-31xbrli:pure0001280776imux:AustraliaAndGermanyMembersrt:MinimumMember2022-12-310001280776imux:AustraliaAndGermanyMembersrt:MaximumMember2022-12-310001280776us-gaap:BankTimeDepositsMember2022-12-310001280776us-gaap:BankTimeDepositsMember2021-12-310001280776country:DEsrt:MinimumMemberus-gaap:BankTimeDepositsMember2022-12-310001280776country:DEsrt:MaximumMemberus-gaap:BankTimeDepositsMember2022-12-310001280776country:DEsrt:MinimumMemberus-gaap:BankTimeDepositsMember2022-01-012022-12-310001280776country:DEsrt:MaximumMemberus-gaap:BankTimeDepositsMember2022-01-012022-12-310001280776srt:MinimumMember2022-01-012022-12-310001280776srt:MaximumMember2022-01-012022-12-3100012807762022-10-012022-12-310001280776srt:MinimumMember2022-12-310001280776srt:MaximumMember2022-12-310001280776us-gaap:StockOptionMember2022-01-012022-12-310001280776us-gaap:StockOptionMember2021-01-012021-12-310001280776us-gaap:WarrantMember2022-01-012022-12-310001280776us-gaap:WarrantMember2021-01-012021-12-310001280776imux:GrafelfingGermanyMember2020-04-070001280776imux:NewYorkCityMember2022-01-012022-12-310001280776imux:GrafelfingGermanyMember2021-03-012021-03-310001280776imux:GrafelfingGermanyMember2022-08-012022-08-310001280776imux:NewYorkCityMember2022-12-012022-12-310001280776imux:NewYorkCityMember2022-12-3100012807762016-05-012016-05-3100012807762019-04-120001280776imux:ImmunicAGMember2021-03-312021-03-310001280776imux:ImmunicAGMember2021-03-310001280776us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280776us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280776us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001280776us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280776us-gaap:FairValueMeasurementsRecurringMember2022-12-310001280776us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280776us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001280776us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001280776us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280776us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280776us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001280776us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001280776us-gaap:FairValueMeasurementsRecurringMember2021-12-310001280776us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001280776us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001280776us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-3100012807762020-11-300001280776us-gaap:SubsequentEventMember2023-02-170001280776imux:December2020ATMMember2020-12-310001280776imux:December2020ATMMember2022-12-31utr:D0001280776imux:December2020ATMMemberus-gaap:SubsequentEventMember2023-02-170001280776imux:May2022ATMMember2022-05-100001280776imux:May2022ATMMember2022-12-310001280776us-gaap:SubsequentEventMemberimux:May2022ATMMember2023-02-170001280776imux:December2020ATMMember2022-01-012022-12-310001280776imux:December2020ATMMember2021-01-012021-12-310001280776us-gaap:CommonStockMember2022-10-102022-10-100001280776us-gaap:CommonStockMember2022-10-100001280776imux:PreFundedWarrantsMember2022-10-102022-10-100001280776imux:PreFundedWarrantsMember2022-10-1000012807762022-10-122022-10-120001280776imux:July2021PublicEquityOfferingMember2021-07-152021-07-150001280776imux:July2021PublicEquityOfferingMember2021-07-150001280776imux:July2021PublicEquityOfferingMember2021-07-192021-07-190001280776us-gaap:EmployeeStockOptionMemberimux:A2021EmployeeStockPurchasePlanMember2022-12-310001280776imux:PreFundedWarrantsMember2022-12-310001280776us-gaap:EmployeeStockOptionMember2022-12-310001280776imux:EmployeeStockOptionsforFutureGrantMemberimux:TwoThousandFourteenEquityIncentivePlanMember2022-12-310001280776imux:EmployeeStockOptionsforFutureGrantMemberimux:A2017InducementEquityIncentivePlanMember2022-12-310001280776imux:TwoThousandNineteenOmnibusEquityIncentivePlanMemberimux:EmployeeStockOptionsforFutureGrantMember2022-12-310001280776imux:A2021EmployeeStockPurchasePlanMember2021-04-252021-04-250001280776imux:A2021EmployeeStockPurchasePlanMember2021-04-250001280776imux:A2021EmployeeStockPurchasePlanMember2022-01-012022-12-310001280776imux:A2021EmployeeStockPurchasePlanMember2021-01-012021-12-310001280776imux:A2019OmnibusEquityIncentivePlanMember2019-07-310001280776imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember2019-07-012019-07-310001280776imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember2020-01-012021-09-300001280776srt:MaximumMemberimux:A2019OmnibusEquityIncentivePlanMember2022-01-012022-12-310001280776imux:IncentiveEmployeeStockOptionMemberimux:A2019OmnibusEquityIncentivePlanMember2022-01-012022-12-310001280776imux:NonStatutoryEmployeeStockOptionMemberimux:A2019OmnibusEquityIncentivePlanMembersrt:MinimumMember2022-01-012022-12-310001280776imux:NonStatutoryEmployeeStockOptionMembersrt:MaximumMemberimux:A2019OmnibusEquityIncentivePlanMember2022-01-012022-12-310001280776imux:TwoThousandNineteenOmnibusEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2021-12-310001280776imux:TwoThousandNineteenOmnibusEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001280776imux:TwoThousandNineteenOmnibusEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-12-310001280776imux:TwoThousandNineteenOmnibusEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2020-12-310001280776imux:TwoThousandNineteenOmnibusEquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2021-01-012021-12-310001280776imux:A2019OmnibusEquityIncentivePlanMember2022-01-012022-12-310001280776imux:A2019OmnibusEquityIncentivePlanMember2021-01-012021-12-310001280776us-gaap:ResearchAndDevelopmentExpenseMemberimux:EmployeeMember2022-01-012022-12-310001280776us-gaap:ResearchAndDevelopmentExpenseMemberimux:EmployeeMember2021-01-012021-12-310001280776imux:EmployeeMemberus-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001280776imux:EmployeeMemberus-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001280776imux:EmployeeMember2022-01-012022-12-310001280776imux:EmployeeMember2021-01-012021-12-310001280776imux:TwoThousandFourteenEquityIncentivePlanMember2022-12-310001280776imux:A2017InducementEquityIncentivePlanMember2017-09-300001280776imux:A2017InducementEquityIncentivePlanMember2021-01-012021-12-310001280776imux:A2017InducementEquityIncentivePlanMember2022-01-012022-12-310001280776us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2022-01-012022-12-310001280776us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-12-310001280776us-gaap:ForeignCountryMemberus-gaap:FederalMinistryOfFinanceGermanyMember2022-01-012022-12-310001280776us-gaap:ForeignCountryMemberus-gaap:FederalMinistryOfFinanceGermanyMember2021-01-012021-12-310001280776imux:ForeignExcludingGermanyMemberus-gaap:ForeignCountryMember2022-01-012022-12-310001280776imux:ForeignExcludingGermanyMemberus-gaap:ForeignCountryMember2021-01-012021-12-310001280776us-gaap:ForeignCountryMember2022-12-310001280776imux:TaxYearsPriorTo2018Memberus-gaap:DomesticCountryMember2022-12-310001280776us-gaap:DomesticCountryMemberimux:TaxYearsPost2017Member2022-12-310001280776srt:AffiliatedEntityMemberimux:DuaneNashMDJDMBAMembersrt:BoardOfDirectorsChairmanMemberimux:ExecutiveChairmanAgreementMember2021-01-012021-05-140001280776srt:AffiliatedEntityMemberimux:DuaneNashMDJDMBAMembersrt:BoardOfDirectorsChairmanMemberimux:ExecutiveChairmanAgreementMember2020-11-152020-11-150001280776srt:AffiliatedEntityMemberimux:DuaneNashMDJDMBAMembersrt:BoardOfDirectorsChairmanMemberimux:ExecutiveChairmanAgreementMember2021-04-152021-04-150001280776srt:AffiliatedEntityMemberimux:DuaneNashMDJDMBAMembersrt:BoardOfDirectorsChairmanMemberimux:ExecutiveChairmanAgreementMember2021-05-152021-12-310001280776srt:AffiliatedEntityMemberimux:DuaneNashMDJDMBAMembersrt:BoardOfDirectorsChairmanMemberimux:ExecutiveChairmanAgreementMember2022-03-152022-12-310001280776srt:AffiliatedEntityMemberimux:DuaneNashMDJDMBAMembersrt:BoardOfDirectorsChairmanMemberimux:ExecutiveChairmanAgreementMember2022-03-152022-03-150001280776srt:ScenarioForecastMembersrt:AffiliatedEntityMemberimux:DuaneNashMDJDMBAMembersrt:BoardOfDirectorsChairmanMemberimux:ExecutiveChairmanAgreementMember2022-12-282023-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 10-K
(Mark One)
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number: 001-36201
Immunic, Inc.
(Exact name of registrant as specified in its charter)
Delaware56-2358443
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
1200 Avenue of the Americas,Suite 200
New York, NY10036
(Address of principal executive offices)(Zip Code)
(332) 255-9818
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par valueIMUXThe Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No ☒
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes ☒    No ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the Registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b)☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐ No ☒
The aggregate market value of the common equity held by non-affiliates of the Registrant, based on the closing price of the common stock on The Nasdaq Stock Market on June 30, 2022 was $106.1 million.
On February 17, 2023, 44,403,838 shares of common stock, $0.0001 par value, were outstanding.
Documents Incorporated by Reference: Certain portions of the registrant’s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.


Immunic, Inc.
ANNUAL REPORT ON FORM 10-K
For the Fiscal Year Ended December 31, 2022
Table of Contents
 
 Page
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Item 15.



Special Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K (“Annual Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are based on our management’s current beliefs and assumptions and on information currently available to our management, and are contained principally in the sections entitled “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “best in class,” “could,” “seeks,” “estimates,” “expects,” “first-in-class,” “focused,” “goal,” “intends,” “may,” “objective,” “opportunity,” “pipeline,” “plans,” “potential,” “predicts,” “projects,” “pursuing,” “should,” “target,” “treatment option,” “will,” “would,” “might,” “can,” “continue” or similar expressions and the negatives of those terms.
These forward-looking statements include, among other things, statements about:

•the strategies, prospects, plans, expectations and objectives of management;

•our ability to maintain compliance with Nasdaq listing standards;

•strategies with respect to our development programs, including our ability to develop and commercialize our product candidates and the timing and expected data of clinical trials and preclinical studies;

•our estimates regarding revenues, expenses, capital requirements, projected cash requirements and needs for additional financing

•possible sources of funding for future operations;

•our ability to protect intellectual property rights and our intellectual property position;

•future economic conditions or performance;

•proposed products or product candidates;

•our ability to retain key personnel;

•our ability to maintain effective internal control over financial reporting; and

•beliefs and assumptions underlying any of the foregoing.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements including those described in “Risk Factors” and elsewhere in this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Annual Report, unless an earlier date is specified. You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the Securities and Exchange Commission ("SEC") as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect.
Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
1

PART I
Item 1. Business.

Overview

Immunic, Inc. ("Immunic," “we,” “us,” “our” or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gräfelfing near Munich, Germany. We currently have approximately 66 employees.

We are currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (“MS”); the izumerogant (proposed International Nonproprietary Name (“INN”) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (“RORγt”) that inhibits the interleukin-17 (“IL-17”) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.

The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates:


imux-20221231_g1.jpg

Our most advanced drug candidate, vidofludimus calcium (IMU-838), is being tested in several ongoing MS trials as part of its overall clinical program in order to support a potential approval for patients with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (“RMS”), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the supportive Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (“PMS”) are ongoing and actively enrolling patients. Our current expectation is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024. Moreover, we currently expect to report data from the interim analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials end of 2025. Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.

If approved, we believe that vidofludimus calcium, with combined anti-inflammatory, anti-viral, and neuroprotective effects, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS. Multiple publications from 2022 have highlighted the enhanced understanding of the triggers and ongoing neuronal destruction of MS, namely, that MS is triggered by infection from Epstein-Barr virus (“EBV”) followed by cross-reactive antibody production and associated auto-inflammation and neuronal damage. Vidofludimus calcium is a known inhibitor of the enzyme dihydroorotate dehydrogenase (“DHODH”), which is a key enzyme in the metabolism of overactive immune cells and virus-infected cells. This mechanism is associated with the anti-inflammatory and anti-viral effects of vidofludimus calcium. Additionally, recent evidence indicates that vidofludimus calcium activates a yet-to-be-disclosed target with direct neuroprotective properties, which may enhance its potential benefit for patients. We believe that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance shown in our Phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis (“RRMS”) patients, in particular, via data illustrating the potential to reduce magnetic resonance imaging (“MRI”) lesions, prevent relapses, reduce the rate of disability progression, and reduce levels of serum neurofilament light chain (“NfL”), an important biomarker of neuronal death. Vidofludimus calcium has a consistent pharmacokinetic (“PK”), safety and
2

tolerability profile and has already been exposed to more than 1,400 human subjects and patients in either of the drug’s formulations.

Our second drug candidate, izumerogant (proposed INN for IMU-935), is a highly potent and selective inverse agonist of a transcription factor called RORγ/RORγt. The nuclear receptor RORγt is believed to be the main driver for the differentiation of T helper 17 (“Th17”) cells and the release of cytokines involved in various inflammatory and autoimmune diseases. We believe this target is an attractive potential alternative to approaches acting on IL-23, the IL-17 receptor and directly on IL-17. We have observed strong cytokine inhibition targeting both Th1 and Th17 responses in preclinical testing, as well as indications of activity in animal models for psoriasis, graft versus host disease, MS and inflammatory bowel disease ("IBD"). Preclinical experiments indicated that izumerogant leads to a potent inhibition of Th17 differentiation, inhibition of cytokine secretion, and induction of regulatory T cells. Importantly, izumerogant did not affect thymocyte maturation, one of the important physiological functions of RORγt that should be maintained. Based on these preclinical data and the selectivity of the effect maintaining important physiological functions while providing the desired anti-Th17 effect, we believe that izumerogant has potential to be a first-and-best-in-class therapy for various autoimmune diseases.

A Phase 1 clinical trial exploring safety, tolerability, pharmacodynamics (“PD”), PK and exploratory efficacy of izumerogant in moderate-to-severe psoriasis patients is currently ongoing. A pre-planned group-level interim analysis revealed on October 20, 2022 noted that the initial two active dose cohorts did not separate from placebo at four weeks. The overall trial is ongoing. Administration of izumerogant and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We plan to provide further updates and guidance on potential next steps for this development program towards the end of the first quarter of 2023.

Additionally, izumerogant has been shown in preclinical models to target a mutated androgen receptor (“AR”), an established mechanism of treatment resistance to AR therapy, making it a potential treatment option for patients with metastatic castration-resistant prostate cancer (“mCRPC”). A Phase 1 clinical trial exploring safety and tolerability of increasing doses of izumerogant to establish the maximum tolerated dose and the recommended Phase 2 dose is currently ongoing in patients with mCRPC.

Our third program, IMU-856, is an orally available small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. We have not yet disclosed the molecular target for IMU-856 to the public. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, IBD, irritable bowel syndrome with diarrhea (“IBS-D”) and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications. The final portion of a Phase 1 clinical trial exploring the safety and tolerability of IMU-856 in celiac disease patients during periods of gluten-free diet and gluten challenge is currently ongoing, and we expect initial results to be available in mid-2023.

Additional antiviral-directed development activities remain ongoing through preclinical research examining the potential to treat a broad set of viral indications with new antiviral molecules. We have begun exploring several options to possibly support further development of our antiviral portfolio, including a potential spin-off into a new or existing company and potential licensing transactions.

We expect to continue to lead most of our research and development activities from our Gräfelfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this will result in timely, cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia to expedite the early clinical trials for izumerogant and IMU-856. We also conduct preclinical work in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.

Our business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of our clinical trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete the development and commercialization of our three development programs.

Strategy

We are focused on the development of new molecules that maximize the therapeutic benefits for patients by uniquely addressing biologically relevant immunological targets. We take advantage of our established research and development infrastructure and operations in Germany and Australia to more efficiently develop our product candidates in indications of high unmet need and where the product candidates have the potential to elevate the standard of care for the benefit of patients. Given the mechanisms of action and the data generated for our product candidates, to date, we continue to execute on the
3

clinical development of our programs for established indications as well as explore additional indications where patients could potentially benefit from the unique profiles of each product candidate.

We are currently focused on maximizing the potential of our development programs through the following strategic initiatives:

•Executing the ongoing Phase 3 ENSURE and Phase 2 CALLIPER clinical trial programs of vidofludimus calcium in MS.
•Executing the ongoing clinical trials of izumerogant in patients with psoriasis and in patients with mCRPC, with the path for future development to be assessed following analysis of the results.
•Executing the ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease.
•Continued preclinical research to complement the existing clinical activities, explore additional indications for future development, and where appropriate, generate additional molecules for future development.
•Facilitating readiness for potential commercial launch of our product candidates through targeted and stage-appropriate pre-commercial activities.
•Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities of strategic collaborators in order to enhance the potential and value of each product candidate.

Liquidity and Financial Condition
We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. We have an accumulated deficit of approximately $317.3 million and $196.9 million as of December 31, 2022 and December 31, 2021, respectively. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.
We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to advance our pipeline of product candidates. We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.
From inception through December 31, 2022, we have raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, the Company had cash and cash equivalents of approximately $106.7 million and investments - other of $9.6 million. With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.

Key Status Updates

Vidofludimus Calcium (IMU-838)

Phase 3 Program of Vidofludimus Calcium in RMS (ENSURE-1 and ENSURE-2 Trials)

The ongoing ENSURE program comprises two identical multicenter, randomized, double-blind Phase 3 clinical trials designed to evaluate the efficacy, safety, and tolerability of vidofludimus calcium versus placebo in RMS patients. Based on vidofludimus calcium’s highly significant activity in preventing lesion formation in our Phase 2 EMPhASIS trial in RMS, the strong and consistent correlation observed between lesion formation and clinical relapse in third-party clinical trials, and the drug’s robust safety profile, to date, we believe that this Phase 3 program should provide a straightforward path towards potential regulatory approval of vidofludimus calcium in RMS.

Each of the identical twin Phase 3 clinical trials, titled ENSURE-1 and ENSURE-2, is expected to enroll approximately 1,050 adult patients with active RMS at more than 100 sites in more than 15 countries, including the United States, India and countries in Latin America, Central and Eastern Europe. Patients will be randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo and the primary endpoint for both clinical trials is time to first relapse up to 72 weeks. Key secondary endpoints include volume of new T2-lesions, time to confirmed disability progression, time to sustained clinically relevant changes in cognition, and percentage of whole brain volume change. With regard to the disability
4

progression endpoint, the ENSURE program will apply a pooled analysis of confirmed disability worsening across both clinical trials.

The ENSURE trials are being run concurrently. The first patient in ENSURE-1 was enrolled in November 2021. The first patient in ENSURE-2 was enrolled in January 2022. An interim analysis to assess event rates is planned to occur after approximately half of the relapse events have occurred in the double-blind treatment periods. This analysis is intended to inform potential sample size adjustment and help ensure that final study readout is not planned to occur before sufficient events have been achieved. This interim analysis will also allow for a non-binding futility analysis. We currently expect to report data from the interim analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials end of 2025.

Phase 2 Clinical Trial of Vidofludimus Calcium in PMS (CALLIPER Trial)

The ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 CALLIPER trial of vidofludimus calcium is expected to enroll approximately 450 patients with PMS at more than 70 sites in North America, Western, Central and Eastern Europe with patients randomized to either 45 mg daily doses of vidofludimus calcium or placebo in a double-blinded fashion. The trial’s primary endpoint is the annualized rate of percent brain volume change up to 120 weeks. Key secondary endpoints include the annualized rate of change in whole brain atrophy and time to 24-week confirmed disability progression based on the Expanded Disability Status Scale (“EDSS”) which may further support disability data from the ENSURE trials. The first patient was enrolled in September 2021. Our current expectation is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024.

An interim analysis comprising an unblinded analysis of serum NfL and glial fibrillary acidic protein (“GFAP”) is planned to occur once approximately half of the enrolled patients have completed 24 weeks of treatment. NfL and GFAP have been shown in third-party research to consistently correlate with disease activity in neurodegenerative disorders and have become two of the most important serum biomarkers for axonal damage over the past few years. As previously reported, results of the Phase 2 EMPhASIS trial of vidofludimus calcium in RRMS showed a robust decrease in serum NfL at 24 weeks (-17.0% for 30 mg and -20.5% for 45 mg), as compared to baseline values, while the patients on placebo experienced a 6.5% increase in serum NfL over the same period.

The Phase 2 CALLIPER trial is intended to run concurrently with and to complement the Phase 3 program in RMS. In particular, CALLIPER is focused on progressive forms of MS and is designed to corroborate vidofludimus calcium’s neuroprotective potential, as exemplified by slowing of brain atrophy and delay in disability worsening. Neurodegeneration is a key concern in both PMS and RMS, since axonal and neural damage is responsible for the increasing and often severe disability experienced by patients. We believe that, if the CALLIPER trial is successful in showing a beneficial effect of vidofludimus calcium, this data, along with the ENSURE program and vidofludimus calcium’s strong safety and tolerability profile, may allow for a meaningful clinical differentiation of vidofludimus calcium from other oral MS medications and a potentially attractive commercial positioning. Although a supportive trial, we do not believe that data from the CALLIPER trial are a pre-condition for filing a New Drug Application (“NDA”) in RMS. Additional clinical studies and the potential regulatory path forward specific to the treatment of PMS will be informed by the results of the CALLIPER trial and will be further assessed accordingly.

Phase 2 Clinical Trial of Vidofludimus Calcium in RRMS (EMPhASIS Trial) – Open-Label Portion

On November 17, 2022, we reported newly available data from the Phase 2 EMPhASIS trial of vidofludimus calcium in RRMS. The trial includes an optional long-term open-label extension (“OLE”) phase running up to 9.5 years. An interim analysis was performed with data extraction in October 2022, when 209 patients remained on treatment in the OLE phase, some of whom have already received more than 180 continuous weeks (approximately four years) of active treatment with vidofludimus calcium. Long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, comparing favorably to historical trial data for currently available MS medications. During the 24-week double-blind main treatment period, 12-week and 24-week Confirmed Disability Worsening (“12w/24wCDW”) events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. In the OLE phase, the proportion of patients free from 12wCDW was 97.6% after 48 weeks and 94.5% after 96 weeks of vidofludimus calcium treatment as compared to the start of the OLE phase. Similar results were observed for 24wCDW and sustained CDW. The OLE phase also showed low relapse activity.
Phase 2 Clinical Trial of Vidofludimus Calcium in Ulcerative Colitis (CALDOSE-1 Trial)

On June 2, 2022, we reported top-line data from our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (“UC”). The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10. In addition, no meaningful
5

differences were observed between the three active dose groups for the overall intent-to-treat patient population (10 mg/day: 14.9%, 30 mg/day: 10.6%, 45 mg/day: 13.6%, placebo: 12.5%) or for the trial’s other secondary endpoints, including symptomatic remission, or endoscopic healing.

Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this clinical trial was observed to be safe and well-tolerated. No new safety signals were observed. As compared to placebo, there were no increased rates of infections and infestations, no elevated rates of liver events or liver enzyme elevations, and no elevated rates for changes in hematology-related laboratory variables. The most common adverse events in this clinical trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and coronavirus disease 2019 (“COVID-19”) (7/263 patients, 2.7%). Most adverse events were generally mild in severity.

As is common for the design of clinical trials in UC, the use of oral systemic corticosteroids (≤20 mg/day prednisolone equivalent) was allowed in CALDOSE-1 in patients who had been treated with corticosteroids for at least four weeks before randomization. Doses of corticosteroids were required to be kept constant throughout the induction phase (weaning was not allowed in this phase of the clinical trial), and the distribution of patients using corticosteroids was equal throughout all treatment groups. Surprisingly, CALDOSE-1 data suggest a previously unknown treatment interference between the efficacy of vidofludimus calcium and the concurrent use of corticosteroids in the UC patient population. More specifically, the non-steroid patient population showed an 11.4% advantage in clinical remission for vidofludimus calcium over placebo (pooled vidofludimus calcium treatment groups at week 10: 14.7%, placebo: 3.3%). Such a difference in clinical remission between active treatment and placebo would traditionally be considered as confirming therapeutic activity. In contrast, patients concomitantly taking vidofludimus calcium and corticosteroids during induction treatment had a lower rate of clinical remission at week 10 (11.5%) than placebo patients (20.6%) and also lower than the group of vidofludimus calcium monotherapy without concurrent use of steroids (14.7%). This treatment interference between vidofludimus calcium and corticosteroids was not expected based on our analysis of currently available preclinical or clinical data.

Based on these results, we announced that our development programs in the IBD indications will not be continued without a partner.

Izumerogant (IMU-935)

Phase 1 Clinical Trial of Izumerogant in Moderate-to-Severe Psoriasis Patients

On October 20, 2022, we announced the outcome of a pre-planned interim group-level data analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis. The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index ("PASI”) reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Administration of izumerogant and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We plan to provide further updates and guidance on potential next steps for this development program towards the end of the first quarter of 2023.

Following the announcement of our interim group-level data on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement and the recent prices raised in our October 10, 2022 Private Placement. We considered these to be triggering events indicating that it is more likely than not that goodwill is impaired. As a result, we recorded a full impairment of our goodwill of approximately $33.0 million in the quarter ended December 31, 2022.

Phase 1 Clinical Trial of Izumerogant in mCRPC

Based on strong preclinical results, we have initiated an open-label Phase 1 dose-escalation trial in mCRPC designed to evaluate the safety and tolerability of increasing doses of izumerogant to establish the maximum tolerated dose and the recommended phase 2 dose. The trial’s Principal Investigator is Johann Sebastian de Bono, MD, PhD, Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, London, United Kingdom. The trial was approved by the Medicines and Healthcare products Regulatory Agency (“MHRA”), the Research Ethics Committee (“REC”) and the Health Research Authority (“HRA”) in the United Kingdom. The first patient was enrolled in December 2021.

The pre-planned dose escalation in the trial with dosing of up to 900 mg daily of izumerogant has been completed. Initial safety data available, to date, show a promising safety profile, with only benign adverse events and no dose limiting toxicities.



6

IMU-856

Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

On September 20, 2022, we announced positive unblinded safety, tolerability and PK results from Part A (single ascending doses) and Part B (multiple ascending doses) of our Phase 1 clinical trial of IMU-856 in healthy human subjects.

In the single ascending doses part, healthy human subjects were randomized in a double-blinded manner to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg. Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. No serious adverse events occurred. Moreover, a dose-linear PK profile was observed across the investigated dose range.

In the multiple ascending doses part, healthy human subjects were dosed for 14 consecutive days with 40 mg, 80 mg or 160 mg once-daily of IMU-856 or placebo in a double-blinded manner. Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. Treatment emergent adverse events were mostly mild in severity. No Investigational Medicinal Product-related serious adverse events were reported. No dose-dependent changes in laboratory parameters (including no effects on liver enzymes or in hematological parameters), vital signs, physical examination or electrocardiographic evaluations were found. PK analysis showed a quick achievement of stable steady-state plasma concentrations within the first week and stable steady-state trough levels over the 14-day treatment period with a low accumulation factor for IMU-856, allowing predictable trough levels during daily dosing. PK parameters in steady-state revealed a Tmax (time to reach maximum plasma concentration) of 2 to 3 hours post-dose, a plasma half-life of 17.4 to 21.5 hours and dose proportional increases in Cmax (maximum plasma drug concentration) and AUC (area under the concentration-time curve).

Phase 1 Clinical Trial of IMU-856 in Celiac Disease

On May 5, 2022, we announced the start of the patient cohorts in our ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease. Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety, tolerability, PK, PD and biomarker responses of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge. Approximately 42 patients were planned to be enrolled in two consecutive cohorts with IMU-856 given once-daily over 28 days. Secondary objectives include PK and disease markers, including those evaluating gastrointestinal architecture and inflammation. Sites in Australia and New Zealand are participating in Part C. Initial results are expected to be available in mid-2023.

Product Acquisition History

Our wholly-owned subsidiary Immunic AG acquired vidofludimus calcium and izumerogant in September 2016 through asset acquisitions from 4SC AG (hereinafter, “4SC”), a publicly traded company based in Planegg-Martinsried, Germany. On March 31, 2021, Immunic AG and 4SC entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of a 4.4% royalty on net sales for $17.25 million. The payment was made 50% in cash and 50% in shares of Immunic’s common stock.

Our rights to IMU-856 are secured pursuant to an option and license agreement (the “Daiichi Sankyo Option”) with Daiichi Sankyo Co., Ltd. (hereinafter, "Daiichi Sankyo") in Tokyo, Japan. On January 5, 2020, Immunic AG exercised its option under the Daiichi Sankyo Option to acquire the exclusive global rights to commercialize IMU-856. The license also grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856. Concurrent with the option exercise, Immunic AG paid to Daiichi Sankyo a one-time upfront licensing fee. Going forward, Daiichi Sankyo is eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.

Leadership

We are led by a team of dedicated and committed experienced professionals with an entrepreneurial spirit and track record of successful licensing transactions in the healthcare industry, worldwide. The team brings together several decades of leadership experience in the pharmaceutical industry with a strong scientific background and sound knowledge in drug discovery, product development, chemistry, manufacturing and controls processes, intellectual property, clinical trial design, health economics and market access, merger and acquisitions, capital markets, corporate finance, business development, regulatory affairs and project valuation. Our team members are inventors on project-related patents and have successfully published project-related scientific publications.


7


Product Candidates

Vidofludimus Calcium (IMU-838)

Vidofludimus calcium is a small molecule investigational drug in development as an oral next-generation treatment option for patients with MS and other chronic inflammatory and autoimmune diseases. By inhibiting DHODH, a key enzyme of pyrimidine de novo biosynthesis, highly metabolically activated T and B immune cells experience metabolic stress, which leads to a modulation of their activity and function. Thereby, pro-inflammatory cytokines, such as interferon gamma (“IFNγ”), tumor necrosis factor alpha (“TNFα”), IL-17A and IL-17F, produced by activated Th1 and Th17 cells, which represent subtypes of so-called T helper cells, are repressed and thereby reduce the inflammation associated with MS and other chronic inflammatory diseases.

In preclinical studies of vidofludimus, the active moiety and free acid form of vidofludimus calcium, apoptosis (or programmed cell death) was induced in activated T cells, which we believe may also play a crucial role in the activity of the drug by further dampening the inflammatory response. We believe that a key advantage of DHODH inhibition, in general, is that the sensitivity of specific immune cells to DHODH inhibition correlates with their intracellular metabolic activation state, and therefore may not negatively impact “normal” immune and bone marrow cells. In animal studies of vidofludimus calcium, animals treated with large doses of the active moiety of vidofludimus calcium were shown to lack detrimental effects on bone marrow, supporting the lack of an unspecific anti-proliferative effect regularly seen with many traditional immunomodulators.

Based on the selectivity toward metabolically activated cells (with a high need for ribonucleic acid and deoxyribonucleic acid production), DHODH inhibition also leads to a direct antiviral effect, which has been observed in various virus infected cells, such as EBV infections, hepatitis C virus infections, severe acute respiratory syndrome coronavirus 2 (“SARS-CoV-2”) infections, cytomegalovirus infections and even hemorrhagic fever-causing viruses, such as Arena virus infections. Treatment with vidofludimus calcium may avoid virus infections and reactivations, one of the major drawbacks of the long-term use of traditional immunomodulators. We previously presented preclinical data demonstrating the activity of vidofludimus calcium to prevent the reactivation of latent EBV infection into lytic infection (Marschall et al., 2021). This mechanism may lead to reduce the regular cycle of reactivations and reinfections in the medium term, and thus the latent persistent EBV infection in patients in the long term.

Efficacy of vidofludimus has been observed in several animal disease models for IBD, MS, as well as systemic lupus erythematosus and transplant rejection. Previous filings by us with the SEC have summarized the development history of vidofludimus and the previous amorphous formulation of the free acid form of vidofludimus. After the consummation of the asset acquisition from 4SC, we developed and filed a patent application for a new specific polymorph of the calcium salt formulation of vidofludimus, vidofludimus calcium, which we believe exhibits improved physicochemical and PK properties. In 2017, we completed two Phase 1 studies of single or repeated once-daily doses of vidofludimus calcium in healthy volunteers, where we observed results supporting tolerability of repeated daily dosing of up to 50 mg of vidofludimus calcium.

We also completed a Phase 1 trial in a total of 24 patients with either no liver function impairment or liver disease of Child-Pugh A Child-Pugh B grade which was designed to explore dose optimization of vidofludimus calcium. The study showed little influence on the PK of vidofludimus calcium in patients with Child-Pugh A Child-Pugh B liver impairment.

Indication: Multiple Sclerosis

Diagnosis and Prevalence

MS is an autoimmune disease that affects the brain, spinal cord and optic nerve. In MS, myelin, the coating that protects the nerves, is attacked and damaged by the immune system. Thus, MS is considered an immune-mediated demyelinating disease of the central nervous system ("CNS"). MS is a progressive disease which, without effective treatment, leads to severe disability. We are developing vidofludimus calcium for the treatment of RMS, the most common form of MS. Approximately 85% of patients with MS are expected to develop RMS, with some patients developing more progressive forms of the disease. RMS is characterized by clearly defined attacks of new or increasing neurologic symptoms. These relapses are followed by periods of remissions, or partial or complete recovery. During remissions, all symptoms may disappear, or some symptoms may continue and become permanent.

MS is a disease with unpredictable symptoms that can vary widely. Common early signs of MS include vision problems, tingling and numbness or other unspecific neurological symptoms. Diagnosis of MS is confirmed via blood tests and a spinal tap, in which a small sample of fluid is removed from the spinal cord. However, most important for diagnosis are characteristic CNS lesions found using MRI.
8


According to the National Multiple Sclerosis Society (2019), there are nearly one million patients in the United States living with MS. The MS International Federation (2021) indicates there are more than one million patients with MS in Europe as well. The disease has a large economic impact as it affects mainly young adults in the prime working age, peaking around 30 years old, although MS can occur in children and in adults. MS is up to three times more common in women than in men. MS affects twice as many women and men in certain age cohorts and is more common in areas inhabited by people of northern European ancestry, such as Europe, the United States, Canada, New Zealand and parts of Australia.

Evolution in Understanding of Disease Drivers of MS

A recent publication shed new light on the role of infection with the EBV previously postulated to trigger MS. Bjornevik et al. (2022) analyzed EBV antibodies in serum from 801 individuals who developed MS among a cohort of more than 10 million people active in the US military over a 20-year period (1993 to 2013). Risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses, including the similarly transmitted cytomegalovirus. Serum levels of NfL, a biomarker of axonal damage, increased only after EBV seroconversion. These findings cannot be explained by any known risk factor for MS and suggest EBV as the leading cause of MS. In addition, antibody producing cells directed against the latent EBV protein EBNA1 were found in the CSF of MS patients. Cross reactivity of anti-EBNA1 antibodies against GlialCAM, a protein that is predominantly expressed in glial cells in the CNS and potentially important in the myelination process of axons, further corroborates the connection between EBV infections and pathologic processes in MS (Lanz et al., 2022). Schneider-Hohendorf et al. (2022) investigated the T cell repertoire in MS patients and control populations, basically highlighting the top antigens that are seen by T cells on an ongoing basis. The study found that EBV-related antigens were on top of the list of antigens seen by T cells in MS patients but not in other EBV-infected populations. These results suggest that ongoing EBV reactivation seems to be an ongoing trigger for the immune system in MS patients and may be the trigger for disease progression and ongoing neurogenerative processes. The presence of a “smoldering disease” in the background that leads to progression independent of relapse activity (“PIRA”) was suggested by another large meta-analysis of clinical data in more than 35,000 MS patients (Lublin et al., 2022). PIRA was traditionally believed to be dominant driver of disease worsening in PMS and this was confirmed by this study as well. However, the study also found that approximately half of the disability accumulating in RMS patients were not related to relapse activity. This suggests that PIRA contributes half of the disability to disease progression in RMS in a mechanism other than relapse. In addition, this investigation found that many currently available drugs were able to delay or avoid disability associated with relapse activity but was unable to diminish the impact of PIRA. This confirms that PIRA presumably is caused by a process that is not addressed by currently used anti-inflammatory medications remains a high medical need.

Current Treatment Options

There are currently two main approaches to treating RMS. Some therapies, such as short-term corticosteroid medications, are used for treating relapses of MS symptoms. Other approaches are used as long-term treatments to reduce the number of relapses and prevent or slow down disability progression. The latter are referred to as disease-modifying therapies. We intend to develop vidofludimus calcium as a disease-modifying therapy for RMS.

The initial treatment options for RMS patients are often beta interferons (either as interferon beta-1a or interferon beta-1b) or glatiramer acetate, all of which are given by injection. For patients requiring more advanced treatment options, there are several oral medications, such as dimethyl fumarate, fingolimod, siponimod, teriflunomide, ozanimod or cladribine, and biologics, such as natalizumab, ocrelizumab, ublituximab, ofatumumab or alemtuzumab, approved for commercial use in MS in various countries. In addition, some of these drugs already have generic versions available in some countries and other drugs will become generic in the next years.

There is no specific guidance on which therapies or medications are used in which sequence of the MS disease course. Typically, treatments are escalated over time, considering:

•Level and progression of MS disease activity (relapse(s), disability worsening, MRI lesions),
•Risks of long-term immunosuppression,
•Patient preferences or risks perceptions, and
•Safety/tolerability aspects.

Many drugs approved for patients with RMS work through anti-inflammatory mechanisms by suppressing the immune system, either broadly or by targeting classes of immune cells, altering how the immune system functions and fights certain infections. As a result, people who take these therapies are at higher risk for John Cunningham virus infection or re-activation, which is believed to be the cause of a rare and often lethal viral disease of the brain called progressive multifocal
9

leukoencephalopathy ("PML"). To date, occurrences of PML have been reported in individuals with RMS treated with natalizumab, ocrelizumab, dimethyl fumarate and fingolimod. No case of PML has yet been reported for the DHODH inhibitor teriflunomide, which has been one of the key differentiators of teriflunomide from other disease-modifying therapies in RMS. The active moiety of vidofludimus calcium has also shown direct antiviral effects in several models of virus-infected cells, which we believe is caused by DHODH inhibition. Subject to further clinical trials, we believe that could be an important potential differentiator against other drug classes in RMS.

Current Development Plan and Clinical Studies

Depending on the results of our ongoing clinical trials, we believe that vidofludimus calcium has the potential to demonstrate medically important advantages versus other treatments, due to its safety profile and its anti-inflammatory, anti-viral and neuroprotective properties observed-to-date. Vidofludimus calcium could provide MS patients with a distinctive therapy that is uniquely matched to the biological drivers of MS. In clinical trials, to date, it has shown data indicating:

•A targeted effect on hyperactive immune cells without suppression of normal immune function.
•Robust MRI lesion suppression by vidofludimus calcium, comparing favorably to other medications commercially available for RMS.
•Improved rates of confirmed disability worsening.
•A robust decrease in serum NfL, a biomarker for axonal damage, providing evidence of vidofludimus calcium’s potential neuroprotective activity.
•A potent interaction with a yet-to-be-disclosed protein target, which is involved in protection of relevant neurons from cell death.
•A very low discontinuation rate for vidofludimus calcium-treated RMS patients, substantially below placebo, which indicates an encouraging combination of tolerability and efficacy as well as maintenance of normal quality-of-life.
•Absence of hepatotoxicity signals and other relevant adverse events leading to discontinuations, which distinguishes vidofludimus calcium from other oral RMS treatments.
•The broad spectrum antiviral effect of vidofludimus calcium may support lowering the rate of viral infections and reactivations, including EBV reactivation, potentially resulting in slowing potential EBV-related neurodegenerative processes.

Phase 2 Clinical Trial of Vidofludimus Calcium in RRMS (EMPhASIS Trial)

Our Phase 2 EMPhASIS trial of vidofludimus calcium in RRMS consisted of two cohorts: The full data set of Cohort 1, which evaluated efficacy and safety of 30 mg or 45 mg once daily vidofludimus calcium compared to placebo, was published by us in August and September 2020, respectively. The Cohort 1 results were subsequently published in the peer reviewed journal, Annals of Clinical and Translational Neurology (Fox et al., 2022). Cohort 2, which evaluated efficacy and safety of 10 mg once daily vidofludimus calcium compared to placebo, was also published by us.

On August 2, 2020, we announced positive top-line data from our Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS. The trial achieved statistical significance on all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the trial met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active (“CUA”) MRI lesions up to week 24 in patients receiving 45 mg of vidofludimus calcium once daily, by 62% (p=0.0002), as compared to placebo. The trial also met its key secondary endpoint, showing a statistically significant reduction in the cumulative number of CUA MRI lesions for the 30 mg once daily dose by 70% (p<0.0001), as compared to placebo. On September 11, 2020, we published the full unblinded clinical data set from our Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS. The data confirmed and expanded on the previously announced top-line results.

On April 15, 2021, we announced interim data from Cohort 2 after 59 randomized patients completed week 12 MRI assessments. We concluded from this data, along with previously published data from Cohort 1, that 30 mg once daily vidofludimus calcium is the most appropriate anti-inflammatory dose for Phase 3 clinical trials in patients with RMS.

Final data from Cohort 2 showed that the anti-inflammatory effects of vidofludimus calcium at the 10 mg dose were observed to be lower (13% reduction of gadolinium-enhancing MRI lesions up to 24 weeks, as compared to placebo) than those found with the 30 mg vidofludimus calcium dose in the pooled Cohort 1 and 2 data (78% reduction), providing further support
10

for the selection of 30 mg dosing in the ongoing ENSURE trials in RMS. Final Cohort 2 data also provided evidence of dose-proportional neuroprotective activity. For instance, the highest decrease of the biomarker serum NfL was observed with the 45 mg dose of vidofludimus calcium versus placebo (-26.0% median of differences between percentage change of serum neurofilament, Hodges-Lehmann estimation), a substantial decrease was seen with the 30 mg dose (-18.0%), while the smallest decrease was observed with the 10 mg dose of Cohort 2 (-9.0%). The 10 mg group in Cohort 2 also showed a signal with respect to improvement in EDSS, consistent with those signals seen with the higher doses in Cohort 1, although all of these early signals need to be confirmed in a larger patient population with longer follow-up periods. Taken together, these last two observations suggest that higher doses, such as 45 mg vidofludimus calcium, may be preferred doses for clinical trials in which neuroprotective effects are the main mechanism for improvement, such as in PMS.

While Cohort 1 blinded treatment was completed right before the COVID-19 pandemic started, final Cohort 2 data provide additional evidence that ongoing vidofludimus calcium treatment may reduce the risk of COVID-19 infections, presumably related to its known antiviral activity. In the entire Cohort 2 population of 59 patients, who were enrolled during pandemic conditions, incidental COVID-19 infections in the active treatment group were less frequent (8.5%, n=4/47) than in the placebo group (25.0%, n=3/12). Additionally, we obtained preclinical data underlining that vidofludimus calcium shows potent anti-EBV activity. We also confirmed that vidofludimus calcium can be detected to a noteworthy degree in the cerebrospinal fluid of animals, after oral dosing. We believe that this finding suggests that vidofludimus calcium may be able to act directly within the CNS.

On November 17, 2022, we reported newly available data from the EMPhASIS trial. The trial includes an optional long-term OLE phase running up to 9.5 years. An interim analysis was performed with data extraction in October 2022, when 209 patients remained on treatment in the OLE phase, some of whom have already received more than 180 continuous weeks (approximately four years) of active treatment with vidofludimus calcium. Long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, comparing favorably to historical trial data for currently available MS medications. During the 24-week double-blind main treatment period, 12-week and 24-week Confirmed Disability Worsening (“12w/24wCDW”) events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. In the OLE phase, the proportion of patients free from 12wCDW was 97.6% after 48 weeks and 94.5% after 96 weeks of vidofludimus calcium treatment as compared to the start of the OLE phase. Similar results were observed for 24wCDW and sustained CDW. The OLE phase also showed low relapse activity.

Further information regarding our EMPhASIS trial in RRMS can be found on ClinicalTrials.gov under the identifier NCT03846219.

Phase 3 Program of Vidofludimus Calcium in RMS (ENSURE-1 and ENSURE-2 Trials)

On July 1, 2021, we announced U.S. Food and Drug Administration (“FDA”) clearance of our Investigational New Drug (“IND”) application for the Phase 3 ENSURE program of vidofludimus calcium in patients with RMS. The ENSURE program comprises two identical multicenter, randomized, double-blind Phase 3 clinical trials designed to evaluate the efficacy, safety, and tolerability of vidofludimus calcium versus placebo in RMS patients. Based on vidofludimus calcium’s highly significant activity in preventing lesion formation in our Phase 2 EMPhASIS trial in RMS, the strong and consistent correlation observed between lesion formation and clinical relapse in third-party clinical trials, and the drug’s robust safety profile, to date, we believe that this Phase 3 program should provide a straightforward path towards potential regulatory approval of vidofludimus calcium in RMS.

Each of the identical twin Phase 3 clinical trials, titled ENSURE-1 and ENSURE-2, is expected to enroll approximately 1,050 adult patients with active RMS at more than 100 sites in more than 15 countries, including the United States, India and countries in Latin America, Central and Eastern Europe. Patients will be randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo and the primary endpoint for both clinical trials is time to first relapse up to 72 weeks. Key secondary endpoints include volume of new T2-lesions, time to confirmed disability progression, time to sustained clinically relevant changes in cognition, and percentage of whole brain volume change. With regard to the disability progression endpoint, the ENSURE program will apply a pooled analysis of confirmed disability worsening across both clinical trials.

The ENSURE trials are being run concurrently. The first patient in ENSURE-1 was enrolled in November 2021. The first patient in ENSURE-2 was enrolled in January 2022. An interim analysis to assess event rates is planned to occur after approximately half of the relapse events have occurred in the double-blind treatment periods. This analysis is intended to inform potential sample size adjustment and help ensure that final study readout is not planned to occur before sufficient events
11

have been achieved. This interim analysis will also allow for a non-binding futility analysis. We currently expect to report data from the interim analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials end of 2025.

Further information regarding our ENSURE program in RMS can be found on ClinicalTrials.gov under the identifiers NCT05134441 (ENSURE-1) and NCT05201638 (ENSURE-2), respectively.

The execution of clinical Phase 3 clinical trials usually requires the use of a commercial formulation of the investigational drug manufactured at commercially usable quantities. Manufactures under contract with us have developed and produced a formulation of vidofludimus calcium which would allow commercially usable production batches. A Phase 1 bioequivalence study between the previous and the new formulation of vidofludimus calcium was completed and showed bioequivalence regarding drug exposure curve in blood plasma (area under the curve). A confirmatory relative bioavailability and food effect study demonstrated a high bioavailability of tablets as compared to a drinking solution and confirmed the in vitro finding of a complete and fast dissolution profile in human subjects. No food effect on the uptake or elimination of vidofludimus calcium after administration of the tablets was observed.

Additional investigations regarding metabolite characterization, metabolic modeling and potential drug-drug interactions, as well as other activities relating to clinical pharmacology are either ongoing or planned in anticipation for presentation to regulatory authorities.

Discussions on a pediatric development plan in pediatric-onset MS have been initiated with the FDA , based on a proposal developed with clinical and regulatory advisors.

Phase 2 Clinical Trial of Vidofludimus Calcium in PMS (CALLIPER Trial)

On July 1, 2021, we announced that the FDA also cleared our separate IND application for the supportive Phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS. The first patient was enrolled in September 2021. Our current expectation is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024.

The multicenter, randomized, double-blind, placebo-controlled Phase 2 CALLIPER trial of vidofludimus calcium is expected to enroll approximately 450 patients with PMS at more than 70 sites in North America, Western, Central and Eastern Europe with patients randomized to either 45 mg daily doses of vidofludimus calcium or placebo in a double-blinded fashion. The trial’s primary endpoint is the annualized rate of percent brain volume change up to 120 weeks. Key secondary endpoints include the annualized rate of change in whole brain atrophy and time to 24-week confirmed disability progression based on EDSS which may further support disability data from the ENSURE trials.

An interim analysis comprising an unblinded analysis of serum NfL and GFAP is planned to occur once approximately half of the enrolled patients have completed 24 weeks of treatment. NfL and GFAP have been shown in third-party research to consistently correlate with disease activity in neurodegenerative disorders and have become two of the most important serum biomarkers for axonal damage over the past few years. As previously reported, results of the Phase 2 EMPhASIS trial of vidofludimus calcium in RRMS showed a robust decrease in serum NfL at 24 weeks (-17.0% for 30 mg and -20.5% for 45 mg), as compared to baseline values, while the patients on placebo experienced a 6.5% increase in serum NfL over the same period.

The Phase 2 CALLIPER trial is intended to run concurrently with and to complement the Phase 3 program in RMS. In particular, CALLIPER is focused on progressive forms of MS and is designed to corroborate vidofludimus calcium’s neuroprotective potential, as exemplified by slowing of brain atrophy and delay in disability worsening. Neurodegeneration is a key concern in both PMS and RMS, since axonal and neural damage is responsible for the increasing and often severe disability experienced by patients. We believe that, if the CALLIPER trial is successful in showing a beneficial effect of vidofludimus calcium, this data, along with the ENSURE program and vidofludimus calcium’s strong safety and tolerability profile, may allow for a meaningful clinical differentiation of vidofludimus calcium from other MS medications and potentially attractive commercial positioning. Although a supportive trial, we do not believe that data from the CALLIPER trial are a pre-condition for filing an NDA in RMS. Additional clinical studies and the potential regulatory path forward specific to the treatment of PMS will be informed by the results of the CALLIPER trial and will be further assessed accordingly.

Further information regarding our CALLIPER trial in PMS can be found on ClinicalTrials.gov under the identifier NCT05054140.


12

Indication: Ulcerative Colitis

Phase 2 Clinical Trial of Vidofludimus Calcium in UC (CALDOSE-1 Trial)

The CALDOSE-1 trial of vidofludimus calcium in moderate-to-severe UC was a Phase 2b, dose-finding, multicenter, double-blind, placebo-controlled study including a blinded induction and maintenance phase, with double randomization (initial randomization for induction and second randomization for maintenance). CALDOSE-1 was conducted at more than 100 sites in 19 countries, including the United States and Western, Central and Eastern Europe. The primary endpoint comprised a composite of patient-reported outcome and endoscopy-assessed outcome, both evaluated following ten weeks of induction treatment with vidofludimus calcium or placebo. We have an active IND application for vidofludimus calcium in UC with the FDA.

On June 2, 2022, we reported top-line data from our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe UC. The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10. In addition, no meaningful differences were observed between the three active dose groups for the overall intent-to-treat patient population (10 mg/day: 14.9%, 30 mg/day: 10.6%, 45 mg/day: 13.6%, placebo: 12.5%) or for the trial’s other secondary endpoints, including symptomatic remission, or endoscopic healing.

Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this clinical trial was observed to be safe and well-tolerated. No new safety signals were observed. As compared to placebo, there were no increased rates of infections and infestations, no elevated rates of liver events or liver enzyme elevations, and no elevated rates for changes in hematology-related laboratory variables. The most common adverse events in this clinical trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and COVID-19 (7/263 patients, 2.7%). Most adverse events were generally mild in severity.

As is common for the design of clinical trials in UC, the use of oral systemic corticosteroids (≤20 mg/day prednisolone equivalent) was allowed in CALDOSE-1 in patients who had been treated with corticosteroids for at least four weeks before randomization. Doses of corticosteroids were required to be kept constant throughout the induction phase (weaning was not allowed in this phase of the clinical trial), and the distribution of patients using corticosteroids was equal throughout all treatment groups. Surprisingly, CALDOSE-1 data suggest a previously unknown treatment interference between the efficacy of vidofludimus calcium and the concurrent use of corticosteroids in the UC patient population. More specifically, the non-steroid patient population showed an 11.4% advantage in clinical remission for vidofludimus calcium over placebo (pooled vidofludimus calcium treatment groups at week 10: 14.7%, placebo: 3.3%). Such a difference in clinical remission between active treatment and placebo would traditionally be considered as confirming therapeutic activity. In contrast, patients concomitantly taking vidofludimus calcium and corticosteroids during induction treatment had a lower rate of clinical remission at week 10 (11.5%) than placebo patients (20.6%) and also lower than the group of vidofludimus calcium monotherapy without concurrent use of steroids (14.7%). This treatment interference between vidofludimus calcium and corticosteroids was not expected based on our analysis of currently available preclinical or clinical data.

Based on these results, we announced that our development programs in the IBD indications will not be continued without a partner.

Further information regarding our CALDOSE-1 trial in UC can be found on ClinicalTrials.gov under the identifier NCT03341962.

Indication: Crohn’s Disease

Based on the results of the Phase 2 CALDOSE-1 trial in UC, we announced that our development programs in the IBD indications will not be continued without a partner.

Indication: Primary Sclerosing Cholangitis

Phase 2 Clinical Trial of Vidofludimus Calcium in Primary Sclerosing Cholangitis

We had previously entered into a collaboration with investigators at the Mayo Clinic to explore the use of vidofludimus calcium in Primary Sclerosing Cholangitis (“PSC”). An investigator-sponsored proof-of-concept clinical trial of vidofludimus calcium in PSC, for which we provided the study medication, was conducted at the Mayo Clinic in Arizona and Minnesota,
13

both of which are tertiary referral centers for PSC patients. The study was led by Elizabeth Carey, M.D., Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, who had received Investigator IND approval from the FDA and had been granted Institutional Review Board ("IRB") approval to conduct the study. The study was supported by a grant from the National Institutes of Health (“NIH”).

The study planned to enroll 30 patients with PSC, aged 18 to 75 years, who received 30 mg of vidofludimus calcium once daily for a period of 24 weeks. Enrollment for the study took place between July 2019 and September 2020, but almost all enrollment occurred in 2019 and early 2020. During the COVID-19 pandemic, which began in early 2020, recruitment for this study was hampered, as patients with PSC are at a high risk of COVID-19 infections and were advised to avoid travel and unnecessary social contacts such as those required to participate in a clinical trial. Together with the investigators, we determined to readout data of the 18 patients who were enrolled prior to the COVID-19 pandemic. The ongoing pandemic situation also triggered the principal investigator’s decision to terminate the study in late 2020, before the intended recruitment goal of 30 patients was reached.

On February 18, 2021, we announced positive top-line data from the study which was designed to investigate vidofludimus calcium's potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation randomized PSC trials. 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, “ITT”), of whom only 11 patients completed the full vidofludimus calcium treatment course and were evaluable over the 24-week treatment period (per-protocol population, “PP”).

The primary objective of this study was to determine whether vidofludimus calcium reduces serum alkaline phosphatase (“ALP”) in adult patients diagnosed with PSC. The main analysis for the primary objective was whether patients could achieve a reduction of ALP at week 24 which is greater or equal to 25%, as compared to baseline, with an aspartate aminotransferase (“AST”) increase at week 24 of no more than 33%, as compared to baseline. This positive primary outcome was achieved by 3 of 11 patients in the PP population (27.3%, 95% CI: 6-61%). By virtue of inclusion criteria, patients at baseline had to have an elevated ALP value of at least 1.5 times the upper limit of normal. In addition, time from baseline was calculated as a continuous variable and treated as the primary predictor using a random intercept model which was adjusted for age at baseline and gender. For this longitudinal analysis of ALP from baseline to week 24 in the PP population, the ALP value statistically significantly (p=0.041) decreased by an average of 5.76 IU/L every 30 days (95% CI: -11.29, -0.23; statistical model). The time trend was not statistically significant in the ITT analysis (p=0.578) due to missing data following the high rate of treatment discontinuations during the COVID-19 pandemic. A consistent individual pattern of a stable decrease in ALP values was observed in the PP population between baseline and week 24, without any single patient showing an increase of more than 20% of ALP.

Secondary objectives were to investigate the liver biochemistry parameters, levels of AST and ALT, and total/direct/indirect bilirubin, as well as the concentrations of proinflammatory cytokines, as compared to baseline. The longitudinal analysis of both AST and ALT as well as total, direct and indirect bilirubin values showed a stable pattern in the PP population with no statistically significant change over time and the confidence interval to include the no-change scenario (AST: average 30 day change 1.22 IU/L, 95% CI: -0.53, 2.97, p=0.170; ALT: average 30 day change 0.85 IU/L, 95% CI -1.46, 3.15, p=0.467, total bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.02, p=0.561, direct bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.861, indirect bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.556). Similar results were found in the ITT population. In addition, a decrease in the Ulcerative Colitis Clinical Score was observed in evaluated patients, although the number of assessed patients was limited. The study also found that vidofludimus calcium is a safe and well-tolerated oral drug for PSC patients and treatment-emergent adverse events were rare and generally mild.

We decided not to continue the development of vidofludimus calcium in PSC.

Further information regarding the investigator-sponsored PSC study can be found on ClinicalTrials.gov under the identifier NCT03722576.

Indication: COVID-19

A publication from scientists in Wuhan, China (Xiong et al., 2020) had shown promising activity of DHODH inhibitors against SARS-CoV-2 in in vitro cellular studies. On April 21, 2020, we announced that vidofludimus calcium had successfully demonstrated preclinical activity against SARS-CoV-2. Specifically, vidofludimus calcium was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with COVID-19. In cellular assays, vidofludimus calcium demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with vidofludimus calcium dosing regimens studied in ongoing and previous clinical trials.

14

Phase 2 Clinical Trial of Vidofludimus Calcium in Moderate COVID-19 (CALVID-1 Trial)

The CALVID-1 trial was a prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial in hospitalized patients with moderate COVID-19, designed to evaluate efficacy, safety and tolerability of vidofludimus calcium. The aim of the CALVID-1 trial was to investigate vidofludimus calcium as an oral treatment option for COVID-19 and to support potential use of vidofludimus calcium as a treatment for current and potential future viral pandemic threats. Patients were enrolled at 20 sites in eleven countries, including the United States, Germany, and a range of other European countries. Patients were randomized to receive either 22.5 mg of vidofludimus calcium twice daily (45 mg/day), or placebo twice daily, for 14 consecutive days. Patients in both arms were also eligible to receive investigator’s choice of standard-of-care therapy throughout the duration of the study. Inclusion criteria called for hospitalized adult patients with a confirmed SARS-CoV-2 infection fulfilling clinical status category 3 or 4, as assessed with the nine-category ordinal scale proposed by the World Health Organization (“WHO”) COVID-19 Therapeutic Trial Synopsis, as well as certain additional clinical and laboratory criteria.

On February 17, 2021, we announced that vidofludimus calcium has shown evidence of clinical activity in hospitalized patients with moderate COVID-19. This planned main analysis of the CALVID-1 trial was based on data from 204 randomized patients and included top-line clinical efficacy, safety, disease marker, and virology data. Although the trial found very low rates of serious complications (e.g., mortality, rate of intensive care unit submissions and rate of invasive ventilations) in the population of hospitalized patients with moderate COVID-19, the data did show clinical activity of vidofludimus calcium based on multiple secondary endpoints, including clinically meaningful improvements in time to clinical recovery, time to clinical improvement, and disease markers. In addition, high-risk patients and patients over 65 years of age experienced a more substantial treatment effect of vidofludimus calcium. Vidofludimus calcium also prevented many COVID-19-related adverse events of higher severity. Finally, vidofludimus calcium was found to be safe and well-tolerated in this patient population.

The full analysis of all 223 randomized patients supports the conclusions made for the main analysis. However, the full analysis also provided data on a few additional endpoints that were not assessed in the main analysis. The rate and timing of anti-SARS-CoV-2 antibodies patients are developing in response to the infection was found to be identical between the vidofludimus calcium and placebo treatment arms. We believe that this is an important confirmation of the mechanism of action of vidofludimus calcium that selectively targets highly metabolically activated cells involved in the disease process, but leaves antibody production relatively unaffected. Although no specific data are available at this point, we also believe that these data may support that vaccinations, including those for SARS-CoV-2, may be effectively given during vidofludimus calcium therapy. Many immunomodulatory therapies are known to interfere with vaccinations, however several studies with another DHODH inhibitor (teriflunomide) had shown that this is not the case for these class of drugs. The CALVID-1 SARS-CoV-2 antibody data are supportive of this finding as well. The full analysis was also able to detect a relationship between drug trough levels in blood plasma and the clinical recovery endpoint. Higher drug levels correlate with shorter clinical recovery periods. We believe that this is another important finding to provide evidence of clinical activity in moderate COVID-19 patients.

The results of the CALVID-1 trial have been published in the peer reviewed journal, Infectious Diseases and Therapy (Vehreschild et al., 2022). The paper, authored by the principal investigator of one of the clinical sites participating in the study, Prof. Maria Vehreschild, M.D., Head of Infectious Diseases at University Hospital Frankfurt, is entitled, “Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.”

Further information regarding our CALVID-1 trial in COVID-19 can be found on ClinicalTrials.gov under the identifier NCT04379271.

The CALVID-1 trial was able to highlight important differentiators of vidofludimus calcium as compared to existing medications in MS. Many other immunomodulatory drugs commercially used provide a beneficial effect on the disease but are also known to have a higher rate of virus reactivations as adverse drug reactions. For example, drugs approved for MS have shown the rare but clinically very important side effect of PML which is highly lethal and caused by a virus reactivation and infection of the brain tissue. Vidofludimus calcium has not shown an increased rate of infections and infestations, as compared to placebo, in the CALVID-1 trial. The same finding was already observed in other controlled clinical trials of vidofludimus calcium. We believe that both the underlying selectivity of DHODH inhibition on the immune system and the broad antiviral properties of vidofludimus calcium contribute to these findings.

The results of the CALVID-1 trial also corroborate the broad antiviral activity of vidofludimus calcium, already known from previous in vitro testing in a range of different virus families. We believe that these results support the ability of a host-cell directed antiviral mechanism of vidofludimus calcium to provide antiviral activities largely independent of mutational variants. We will continue to explore the broad antiviral properties of vidofludimus calcium, including testing its combination potential
15

with other drugs in further in vitro and in vivo preclinical studies. In other clinically important virus diseases, such as hepatitis or acquired immunodeficiency syndrome (“AIDS”), combination treatments are already the mainstay of therapy, whereas monotherapy was found to be inferior to such combinations. This additional research will enable us to explore the potential of vidofludimus calcium to target preparedness for potential future pandemics and for clinically important and underserved viral diseases.

Investigator-Sponsored Phase 2 Trial of Vidofludimus Calcium in Combination with Oseltamivir in Moderate-to- Severe COVID-19 (IONIC Trial)

On July 27, 2020, we announced enrollment of the first patients in an investigator-sponsored Phase 2 trial of vidofludimus calcium for the treatment of patients with moderate-to-severe COVID-19. On June 23, 2022, sponsor and lead site, University Hospitals Coventry and Warwickshire NHS Trust, London, United Kingdom, informed us that the IONIC trial is being closed down. Recruitment for the trial ended on May 20, 2022 and the last patient follow-up occurred in September 2022. On September 29, 2022, we were informed that the sponsor submitted the end of trial declaration. The trial was a prospective, randomized, parallel-group, open-label Phase 2b trial, designed to evaluate efficacy and safety of vidofludimus calcium in combination with the neuraminidase inhibitor, Oseltamivir (TamifluⓇ), in approximately 120 adult patients with moderate to severe COVID-19.

Further information regarding the IONIC trial in COVID-19 can be found on ClinicalTrials.gov under the identifier NCT04516915.

Vidofludimus Calcium Registration Plan

All of our drug development candidates require approval from the FDA (for the United States), European Medicines Agency (“EMA”, for the European Union) and other national competent authorities (for any other territory) before they can be marketed for sale in the applicable jurisdiction. The activities required before drugs or biologics may be marketed in the United States include:

•preclinical laboratory tests, in vitro and in vivo preclinical studies and formulation and stability studies;
•the submission to the FDA of an investigational new drug application for human clinical testing, which is known as an IND;
•adequate and well-controlled human clinical trials to demonstrate the safety and effectiveness of the drug;
•satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice (“cGMP”), requirements to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity;
•the submission to the FDA of a new drug application, which is known as an NDA, for a drug; and
•the approval by the FDA of an NDA.

The FDA reviews all available data relating to safety, efficacy and quality and assesses the risk/benefit profile of a product candidate before granting approval. The data assessed by the FDA in reviewing an NDA includes preclinical testing data, including animal data, chemistry manufacturing and controls (“CMC”) data, PK, PD and drug-drug interaction data, and human clinical safety and efficacy data. Moreover, an agreement for a pediatric development plan (“PSP”) is required to be achieved with the FDA prior to NDA submission.

Future human clinical testing and marketing outside the United States will be subject to foreign regulatory requirements. These requirements vary by jurisdiction, may differ from those in the United States and may require us to perform additional preclinical or clinical testing regardless of whether FDA approval has been obtained. The amount of time required to obtain necessary approvals from foreign regulatory agencies may be longer or shorter than that required for FDA approval. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.

We have an ongoing Phase 3 program for vidofludimus calcium in RMS and an ongoing Phase 2 clinical trial for vidofludimus calcium in PMS. For our lead indication RMS, marketing approval would require completion of two successful, well-controlled Phase 3 clinical trials. Completing such clinical trials would require substantial financial and resource investments and may take several years to complete. In parallel, additional preclinical and clinical investigations need to be conducted in preparation for filing applications for regulatory approval, including additional pharmacological studies in special populations or drug-drug interaction studies. There are also additional steps required to develop and validate large-scale manufacturing capabilities as well as manufacturing controls.
16


Vidofludimus Calcium Manufacturing and Formulation

Vidofludimus calcium is provided as a white, uncoated immediate release tablet. Dose strengths for clinical trials are 5 mg, 15 mg, 22.5 mg, 30 mg and 45 mg, compared with placebo. The tablets are packaged in polyethylene bottles. Vidofludimus calcium has been synthesized in several batches of approximately 80 kg each of active pharmaceutical ingredient (“API”) and a drug product batch size of 500,000 tablets has been produced by manufacturers under contract with us. Our existing manufacturers have the capacity for manufacturing of up to several million units annually.

Vidofludimus Calcium Intellectual Property, Licenses and Royalties

Vidofludimus calcium is covered by several layers of patents and applications, all either granted or filed in the United States, the European Union and other territories. One layer of applications was filed to cover vidofludimus calcium’s active ingredient, the calcium salt of vidofludimus. These applications are granted in some jurisdictions and cover vidofludimus calcium until 2031, and U.S. Patent Term Extension (“PTE”) and/or European Supplementary Protection Certificates (“SPC”) could provide prolonged protection from generic entry up to 2036, depending on NDA submission time and IND filing in the United States and analogous filings in the European Union. Another layer consists of patent applications filed in early 2018 and directed to composition of matter of a newly-identified, specific polymorph of vidofludimus calcium and a related method of production of the clinical material for vidofludimus calcium, which is now the active ingredient of the currently used vidofludimus calcium formulation. This patent would offer exclusivity until 2039. In addition, a patent application covering the dosing scheme currently used with vidofludimus calcium was filed in 2017. This patent would cover all salt and free acid forms and offers the link between the expected label and respective patent claims. If issued, this patent could extend patent protection for vidofludimus calcium to 2038. Finally, an MS-specific patent application was filed in 2021 which would protect the dose strengths used for RMS and PMS until 2042. On top of the patent exclusivity, vidofludimus calcium as a new chemical entity will receive regulatory protection, which likely leads to five years plus a potential 30 months extension protection in the United States and eight plus two years protection in Europe. Further undisclosed patents dedicated to strengthen the exclusivity period for vidofludimus calcium and other forms of vidofludimus have been submitted or are planned to be submitted.

Vidofludimus calcium and izumerogant were acquired in a transaction with 4SC in September 2016. We have subsequently submitted additional patent applications for independently developed intellectual property relating to each of vidofludimus calcium and izumerogant. On March 31, 2021, our German subsidiary, Immunic AG, and 4SC entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of a 4.4% royalty on net sales for $17.25 million. The payment was made 50% in cash and 50% in shares of our common stock.

Izumerogant (IMU-935): Targeting RORγt and Th17

Izumerogant is a highly potent and selective inverse agonist of a transcription factor called RORγ/RORγt. The nuclear receptor RORγt is believed to be the main driver for the differentiation of Th17 cells and the release of cytokines involved in various inflammatory and autoimmune diseases. The target RORγt (RORC) has three known main functions in T cells: (i) it is a key regulator of Th17 cell differentiation, (ii) it is the crucial transcription factor for the genes encoding IL-17A and IL-17F, and (iii) it drives normal thymocyte maturation. We believe this target is an attractive potential alternative to approaches acting on IL-23, the IL-17 receptor and directly on IL-17.

Preclinical results confirm that izumerogant is a highly potent and selective inverse agonist of RORγt with an IC50 (the concentration of drug that inhibits 50% of the activity of the target) of around 24 nM in reporter assays and 20 nM in a microscale thermophoresis (“MST”) binding assay to the protein. The resulting effect of RORγt inhibition by izumerogant in vitro on IL-17A, IL-17F and IFNγ cytokine release from stimulated human lymphocytes is in the low single-digit nanomolar range, showing IC90 levels of 5-6 nM. Furthermore, izumerogant potently inhibits Th17 differentiation and has demonstrated dose dependent activity in several cellular test systems and in vivo in psoriasis/IL-17, graft versus host disease, experimental autoimmune encephalomyelitis (“EAE”) and IBD animal models.

One of the potential risks of drugs targeting RORγt was identified in prior research suggesting that RORγt knockout or inhibition impacts Th17 differentiation, IL-17 transcription and thymocyte maturation to the same extent. More recent research published in Nature Immunology (He et al., 2017) suggests that these functions are differentially mediated by small structural changes of the RORγt protein impacting the interaction with co-factors and other proteins.

Preclinical experiments indicated that izumerogant leads to a potent inhibition of Th17 differentiation, inhibition of cytokine secretion, and induction of regulatory T cells. Importantly, izumerogant did not affect thymocyte maturation, one of
17

the important physiological functions that should be maintained. Based on these preclinical data and the selectivity of the effect maintaining important physiological functions while providing the desired anti-Th17 effect, we believe that izumerogant has potential to be a first-and-best-in-class therapy for various autoimmune diseases. Newly obtained data from acute and chronic treatment of mice corroborated in vivo that izumerogant is the first molecule observed to impact neither thymus size, thymocyte numbers, nor the maturation status of thymocytes, in contrast to two other known inhibitors of RORγt.

The preclinical effect of targeting RORγt has been demonstrated in several preclinical experiments of competing RORγt modulators. Some molecules progressed to clinical stage. However, to our knowledge, izumerogant is currently the only product candidate in active clinical development.

IMU-935 recently received the proposed International Nonproprietary Name (“INN”), izumerogant, from the WHO.

Indication: Psoriasis

Diagnosis and Prevalence

Psoriasis is a chronic inflammatory disease of the skin with unknown etiology that leads to hyperproliferation of keratinocytes and endothelial cells. Most mechanistic data support the hypothesis that psoriasis is an autoimmune disease driven by activated T-lymphocytes which then release cytokines, chemokines and pro-inflammatory molecules into the dermis and epidermis.

Psoriasis is characterized clinically by development of red, scaly, itchy, symmetrical, dry plaques typically located on skin overlying the elbows, knees, lumbar area and scalp. Plaques vary from a few millimeters in diameter to several centimeters and can be localized to a specific area or extend over most of the body surface.

Psoriasis is one of the most common chronic inflammatory skin diseases affecting 2% to 4% of the population in Western countries (Di Meglio et al., 2014; Armstrong et al., 2022). The prevalence rates are influenced by age, geographic location, and genetic background (Chandran and Raychaudhuri, 2010). Psoriasis is considered equally prevalent between genders and can occur at any age. However, there seems to be a bimodal distribution of the age of disease onset, with a first peak occurring during the teen years. Approximately 40% of patients first experience the disease before the age of 20, and approximately 10% of cases occur before the age of ten. A second peak has been reported in patients who are in their mid-50s (DRG, Psoriasis: Disease Landscape & Forecast 2022).

Current Treatment Options

Current treatments for patients with psoriasis include topical therapies, oral therapies and biologics. Topical therapies, such as corticosteroids and vitamin D3 analogues, reduce inflammation, which slows the proliferation of keratinocytes and reduces itching. Oral therapies, such as methotrexate, cyclosporine, apremilast and deucravacitinib, target anti-inflammatory processes. Biologics block proteins produced by keratinocytes, dendritic cells, Th17 lymphocytes or other immune cells. Examples of biologics include anti-TNFα therapies, such as infliximab, etanercept and adalimumab. Monoclonal antibodies, such as secukinumab, ixekizumab and brodalumab, have been developed to target the pro-inflammatory cytokine IL-17. Anti-IL-23 agents, such as risankizumab, guselkumab and tildrakizumab, are further treatment options. Of note, therapies targeting the IL-17/IL-23 axis have largely revolutionized the treatment of patients with moderate to severe psoriasis as they have achieved highly successful skin clearance rates.

We intend to develop izumerogant as an oral and more convenient treatment option for patients with moderate to severe psoriasis with a mechanism of action and efficacy that more broadly addresses the pathophysiology of psoriasis as compared to IL-17 antibodies.

Indication: Castration-Resistant Prostate Cancer

Diagnosis and Prevalence

Castration-resistant prostate cancer (“CRPC”) is a form of advanced prostate cancer and defined by disease progression despite androgen depletion therapy and may present as either a continuous rise in serum prostate-specific antigen (“PSA”) levels, the progression of pre-existing disease, and/or the appearance of new metastases (Saad et al., 2010). With an estimated almost 1.4 million new cases and 375,000 deaths worldwide, prostate cancer was the second most frequent cancer and the fifth leading cause of cancer death among men in 2020 (Sung H et al., 2021).
18


Among patients whose prostate cancer is metastatic at the time of diagnosis, bone pain may be the leading symptom. Bone is the predominant site of disseminated prostate cancer, and pain is the most common manifestation of bone metastases. Other symptoms with metastatic disease may include hematuria, inability to void, incontinence, erectile dysfunction, weight loss, weakness or pain due to spinal cord compression, pain due to pathologic fractures, fatigue caused by anemia, or symptoms associated with chronic renal failure. Clinical signs associated with prostate cancer include an elevated PSA on laboratory testing and an abnormal prostate finding on digital rectal examination.

Current Treatment Options and Unmet Need

While docetaxel is still considered a reference chemotherapy for patients with CRPC, cabazitaxel, abiraterone acetate and enzalutamide are commonly prescribed for the majority of patients with CRPC based on the ability to improve overall survival in men who progress after docetaxel. However, de novo and acquired resistance to these therapies seem to be inevitable, meaning that almost all show disease progression despite treatment with these agents (Chopra S and Rashid P, 2015).

On July 12, 2021, we presented new preclinical data highlighting izumerogant's therapeutic potential in CRPC. Third-party studies have shown that RORγ plays an important pro-tumor role by driving expression of the AR, leading to tumor growth. AR has been shown to be mutated in a constitutively active form called AR-V7 in 18% of untreated patients and up to 95% of patients treated with abiraterone acetate and enzalutamide. This mutation leads to resistance of AR-axis-targeted therapies and is associated with poor outcomes of progression free survival and overall survival for patients on AR-axis-targeted therapies (Sciarra et al., 2019). In preclinical studies, izumerogant was observed to inhibit the expression of mutated AR-V7, and the tumor growth of prostate cancer cell lines in vitro. We believe izumerogant's potency in inhibiting tumorigenesis-promoting IL-17 and Th17 cells in vitro may result in further antitumoral activity in humans.

Current Development Plan and Clinical Studies

We are currently performing a Phase 1 clinical trial with izumerogant through our Australian subsidiary. We believe that this development approach could accelerate the program due to certain unique regulatory requirements and processes in Australia. In the third quarter of 2019, our Australian subsidiary received clearance from the Bellberry Human Research Ethics Committee in Australia to begin Phase 1 clinical trials of izumerogant under the Clinical Trial Notification scheme of the Australian Therapeutic Goods Administration.

The Phase 1 clinical trial of izumerogant is comprised of three parts:

Part A: Single Ascending Dose Part

The first part of the Phase 1 clinical trial was a single ascending dose, double-blind, placebo-controlled study of izumerogant in healthy human subjects. This part was designed to evaluate the drug’s safety and PK profile and also included the evaluation of food effects.

On December 14, 2021, we announced that unblinded data from the single ascending dose part of the ongoing Phase 1 clinical trial of a new powder-in-capsule formulation of izumerogant, in which healthy human subjects were treated with 100 mg, 200 mg, 300 mg and 400 mg of this new formulation or placebo, found these single ascending daily doses of izumerogant to be safe and well-tolerated, and no maximum tolerated dose was reached. No serious adverse events occurred. A dose-proportional PK profile was observed across the investigated dose range.

Part B: Multiple Ascending Dose Part

Following the single ascending dose part, we initiated a second portion of the Phase 1 clinical trial which was a multiple ascending dose, double-blind, placebo-controlled study in healthy human subjects with izumerogant given daily for 14 consecutive days. This part assessed the safety and PK properties of izumerogant.

On December 14, 2021, we also announced unblinded data from the multiple ascending dose part of the ongoing Phase 1 clinical trial, in which healthy human subjects were dosed for 14 days with 150 mg either once or twice daily doses of izumerogant or placebo, found these multiple ascending doses of izumerogant to be safe and well-tolerated, and no maximum tolerated dose was reached. Treatment emergent adverse events were generally mild in severity, with moderate treatment emergent adverse events reported in one of eleven izumerogant treated subjects, compared with one of four subjects on placebo. No serious adverse events were reported. No dose-dependent changes in laboratory values (including no effects on liver
19

enzymes or in hematological parameters), vital signs or in electrocardiographic evaluations were found. PK analysis showed that stable steady-state plasma concentrations were achieved within the first week of dosing with an accumulation factor for izumerogant allowing predictable trough levels during daily dosing.

Part C: Psoriasis Patients

In light of the favorable safety and tolerability data observed in healthy human subjects, we announced on October 27, 2021 that we have initiated part C of the ongoing Phase 1 clinical trial, where moderate-to-severe psoriasis patients are randomized to 28-day treatment with izumerogant or placebo. Assessments include safety, tolerability, PK and PD markers, as well as skin evaluations.

On October 20, 2022, we announced the outcome of a pre-planned interim group-level data analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis. The pre-planned interim analysis revealed that the group averages for PASI reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Administration of izumerogant and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We plan to provide further updates and guidance on potential next steps for this development program towards the end of the first quarter of 2023.

Further information regarding our Phase 1 clinical trial can be found on anzctr.org.au under the registration number ACTRN12619001544167.

Phase 1 Clinical Trial of Izumerogant in mCRPC

Based on strong preclinical results, we have initiated an open-label Phase 1 dose-escalation trial in mCRPC designed to evaluate the safety and tolerability of increasing doses of izumerogant to establish the maximum tolerated dose and the recommended phase 2 dose. The trial’s Principal Investigator is Johann Sebastian de Bono, MD, PhD, Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, London, United Kingdom. The trial was approved by the Medicines and Healthcare products Regulatory Agency ("MHRA"), the Research Ethics Committee ("REC") and the Health Research Authority ("HRA") in the United Kingdom. The first patient was enrolled in December 2021.

The pre-planned dose escalation in the trial with dosing of up to 900 mg daily of izumerogant has been completed. Initial safety data available, to date, show a promising safety profile, with only benign adverse events and no dose limiting toxicities.

Further information regarding Immunic’s Phase 1 clinical trial in mCRPC can be found on ClinicalTrials.gov under the identifier NCT05124795.

Izumerogant (IMU-935) Manufacturing and Formulation

IM105935, the API of the izumerogant drug product, is a small molecule compound and is currently synthesized at up to 30 kg scale. Clinical trials are supplied with a powder-in-capsule formulation produced by manufacturers under contract with us.

Izumerogant (IMU-935) Intellectual Property, Licenses and Royalties

On February 2, 2022 the Company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for patent application 16/644581, entitled, “IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation”. The company also received notice of allowance of patent application EP18762111.5 in Europe, and notice of grant of patent application 2018330633 in Australia. All three patents cover composition of matter of izumerogant and related formulations, and are expected to provide protection into at least 2038, without accounting for potential PTE in the United States or SPC in Europe, respectively.

Vidofludimus calcium and izumerogant were acquired in a transaction with 4SC in September 2016. We have subsequently submitted additional patent applications for independently developed intellectual property relating to each of vidofludimus calcium and izumerogant. On March 31, 2021, our German subsidiary, Immunic AG, and 4SC entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of a 4.4% royalty on net sales for $17.25 million. The payment was made 50% in cash and 50% in shares of our common stock.
20



IMU-856: Targeting Intestinal Barrier Function

IMU-856 is an orally available small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. We have not yet disclosed the molecular target for IMU-856 to the public. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, IBD, IBS-D and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications.

Bowel permeability is suspected to be involved in the initiation of many chronic inflammatory or autoimmune conditions, as the impaired intestinal barrier function may be one of the preconditions for antigens of the microbiome to be recognized by the body’s immune system. This is not only true for diseases of the bowel; the interaction of the immune system with components of the microbiome is suspected for many diseases throughout the body. To date, there are no good treatment strategies to ameliorate impaired bowel permeability.

Indication: Celiac Disease

Diagnosis and Prevalence

Celiac disease is a multifactorial, complex autoimmune disease caused by an inappropriate immune reaction against a degradation product of gluten in genetically susceptible individuals. It is characterized by small intestinal epithelial injury, elevated intestinal permeability, and nutrient malabsorption. Celiac disease is estimated to affect 1 in 100 people, worldwide (Celiac Disease Foundation, 2022). In the United States, alone, it is estimated that 2.5 million people are undiagnosed and are, therefore, at risk for long-term health complications.

Celiac disease causes debilitating symptoms and serious medical complications. Many patients suffer from gastrointestinal symptoms such as diarrhea and have abnormal bowel epithelial lining (mucosal atrophy and crypt enlargement). Small bowel damage often leads to nutrient malabsorption that can result in a range of further clinical manifestations such as fatigue, anemia, osteopenia, weight loss, failure to thrive in children. In addition, extra-intestinal symptoms and systemic manifestations are often present, such as dermatitis, infertility, or neurological and skeletal disorders. Patients with persistent villous atrophy show an increased risk of lymphoproliferative malignancy. The intestinal epithelia barrier, physiologically impermeable to macromolecules such as gliadin, is recognized to play an important role in the pathogenesis of celiac disease.

Current Treatment Options

There is currently no known cure or treatment for celiac disease and patients must adhere to a strict, life-long gluten-free diet which can help manage symptoms and avoid disease flareups. However, a significant number of patients continue to experience disease activity and persistent symptoms despite a gluten-free diet as gluten is present in numerous food products, medications, household products and cosmetics as impurity. Thus, there is an increasing number of different treatment options in clinical development to reduce the burden of living with celiac disease and improve long-term health outcomes.

Current Development Plan and Clinical Studies

Current treatments of many conditions of the bowel are aimed at inhibiting inflammation, but they do not target the impaired bowel wall barrier function. IMU-856 is designed to target pathways impacting the bowel wall barrier function and is aimed to normalize such function. We believe that normalized bowel wall barrier function may avoid bacterial triggers, which may lead to the achievement and maintenance of remission without significantly influencing the immune competency of the patient.

We are currently performing a Phase 1 clinical trial of IMU-856 through our Australian subsidiary. We believe that this development approach could accelerate the studies due to certain unique regulatory requirements and processes in Australia. The development activities for IMU-856 are intended to largely follow established processes and service provider relationships established for the izumerogant development program. This may lead to operational and financial synergies in study preparation
21

and execution. In the third quarter of 2020, our Australian subsidiary received clearance from the Bellberry Human Research Ethics Committee in Australia to begin Phase 1 clinical trials of IMU-856 under the Clinical Trial Notification scheme of the Australian Therapeutic Goods Administration.

The Phase 1 clinical trial of IMU-856 is comprised of three parts:

Part A: Single Ascending Dose Part

The first part of the Phase 1 clinical trial was a single ascending dose, double-blind, placebo-controlled study in healthy human subjects designed to assess safety, PD and PK properties of IMU-856. Healthy human subjects were randomized in a double-blinded manner to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg.

On September 20, 2022, we announced unblinded safety, tolerability and PK results from the single ascending dose part of the Phase 1 clinical trial of IMU-856 in healthy human subjects. Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. No serious adverse events occurred. Moreover, a dose-linear PK profile was observed across the investigated dose range.

Part B: Multiple Ascending Dose Part

The second portion of the Phase 1 clinical trial was a multiple ascending dose, double-blind, placebo-controlled study of IMU-856 in healthy human subjects. Healthy human subjects were dosed for 14 consecutive days with 40 mg, 80 mg or 160 mg once-daily of IMU-856 or placebo in a double-blinded manner. This part was designed to assess safety, PD and PK properties of IMU-856.

On September 20, 2022, we also announced unblinded results from the multiple ascending dose part of the ongoing Phase 1 clinical trial. Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. Treatment emergent adverse events were mostly mild in severity. No Investigational Medicinal Product-related serious adverse events were reported. No dose-dependent changes in laboratory parameters (including no effects on liver enzymes or in hematological parameters), vital signs, physical examination or electrocardiographic evaluations were found. PK analysis showed a quick achievement of stable steady-state plasma concentrations within the first week and stable steady-state trough levels over the 14-day treatment period with a low accumulation factor for IMU-856, allowing predictable trough levels during daily dosing. PK parameters in steady-state revealed a Tmax (time to reach maximum plasma concentration) of 2 to 3 hours post-dose, a plasma half-life of 17.4 to 21.5 hours and dose proportional increases in Cmax (maximum plasma drug concentration) and AUC (area under the concentration-time curve).

Part C: Celiac Disease Patients

On May 5, 2022, we announced the start of the patient cohorts in our ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease. Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety, tolerability, PK, PD and biomarker responses of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge. Approximately 42 patients were planned to be enrolled in two consecutive cohorts with IMU-856 given once-daily over 28 days. Secondary objectives include PK and disease markers, including those evaluating gastrointestinal architecture and inflammation. Sites in Australia and New Zealand are participating in Part C. Initial results are expected to be available in mid-2023.

IMU-856 Manufacturing and Formulation

The API of the IMU-856 drug product is a small molecule compound and is currently synthesized at up to 8 kg scale. It is formulated as a tablet. Although the IMU-856 tablets are produced in different countries by manufacturers under contract with us, the final release for clinical trials is done by a vendor in Australia.






22

IMU-856 Intellectual Property, Licenses and Royalties

Our rights to IMU-856 are secured pursuant to an option and license agreement (the “Daiichi Sankyo Option”) with Daiichi Sankyo Co., Ltd. (hereinafter, "Daiichi Sankyo") in Tokyo, Japan. On January 5, 2020, Immunic AG exercised its option under the Daiichi Sankyo Option to acquire the exclusive global rights to commercialize IMU-856. The license also grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856. Concurrent with the option exercise, Immunic AG paid to Daiichi Sankyo a one-time upfront licensing fee. Going forward, Daiichi Sankyo is eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.

On August 16, 2022, we announced that we have received a Notice of Allowance from the USPTO for patent application 16/646130, entitled, “Compound Having Cyclic Structure.” The patent covers composition-of-matter of IMU-856 and related pharmaceutical compositions and is expected to provide protection into at least 2038, without accounting for potential PTE.


Government Regulation - All Products

In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (“FDCA”), and its implementing regulations. All of Immunic’s drug development candidates require approval from the FDA (for the United States), EMA (for the European Union) and other national competent authorities (for any other territory) before they can be marketed for sale in the applicable jurisdiction. The activities required before drugs or biologics may be marketed in the United States include:
•preclinical laboratory tests, in vitro and in vivo preclinical studies and formulation and stability studies;
•the submission to the FDA of an application for human clinical testing, which is known as an IND application;
•adequate and well-controlled human clinical trials to demonstrate the safety and effectiveness of the drug;
•satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice (“cGMP”), requirements to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity;
•the submission to the FDA of an NDA for a drug; and
•the approval by the FDA of an NDA.

The FDA reviews all available data relating to safety, efficacy and quality and assesses the risk/benefit profile of a product candidate before granting approval. The data assessed by the FDA in reviewing an NDA includes animal or preclinical testing data, chemistry, drug-drug interaction data, manufacturing controls data and clinical safety and efficacy data.

Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. Preclinical trials must also be conducted in accordance with FDA, EMA, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (“ICH”) and other foreign authorities’ legal requirements, regulations or guidelines, including Good Laboratory Practice (“GLP”), an international standard meant to harmonize the conduct and quality of non-clinical studies and the archiving and reporting of findings. Before human clinical testing can begin in the US, a sponsor must submit the results of the preclinical tests and, where applicable, human clinical data obtained in trials outside of the US, together with manufacturing information and analytical data, to the FDA as part of the IND, which is a request for authorization from the FDA to administer an IND product candidate to humans in clinical trials. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding safety concerns before the clinical trial can begin. The FDA may impose a clinical hold at any time before or during clinical trials due to safety concerns about proposed or ongoing clinical trials or non-compliance with FDA requirements, and the trials may not commence or continue until the FDA notifies the sponsor that the hold has been lifted.

All clinical trials must be conducted under the supervision of one or more qualified investigators pursuant to protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection, inclusion/exclusion criteria and the safety and effectiveness criteria to be evaluated. The trial sponsor submits the protocol, as well as any subsequent protocol amendments, to the FDA as part of the IND. Sponsors must also provide all participating investigators and FDA safety reports of any serious and unexpected adverse events and any findings from laboratory tests in animals that suggest a significant risk for human subjects. For each institution where a clinical trial will be conducted, an IRB must review and approve the clinical trial protocol and informed consent form required to be provided to each trial subject or his or her legal representative prior to a clinical trial commencing, and conduct ongoing monitoring of the study until completed or termination to assure that appropriate steps are taken to protect the human subjects participating in the research.
23


Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

Phase 1: In Phase 1 studies, the product candidate is initially introduced into healthy human subjects and tested for safety, dosage and tolerability, absorption, distribution, metabolism, excretion, and effect on the body.

Phase 2: Phase 2 studies are conducted in a limited patient population. These studies continue to evaluate safety while gathering preliminary data on effectiveness in patients with the targeted disease or condition, especially studying the potentially therapeutically effective dose.

Phase 3: Phase 3 trials further evaluate efficacy and safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling.

Post-approval studies, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval from the FDA. These studies are used to gather additional information about a product’s safety and/or efficacy in patients affected by the therapeutic indication. The FDA may require Phase 4 studies as a condition of approval of an NDA.

Clinical trials must also be conducted in accordance with legal requirements, regulations or guidelines of the FDA and comparable foreign authorities, including human subject protection requirements and current good clinical practice (“cGCP” or “GCP”). In addition, clinical trials must be conducted using product candidates produced under cGMP requirements. The FDA or the sponsor may suspend a clinical trial at any time for various reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB may suspend or terminate approval of a clinical trial at an institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts, known as a data safety monitoring board or committee, which monitors data from the trial to ensure patient safety and data integrity and may also make recommendations to alter or terminate a trial based on concerns for patient safety.

Before obtaining marketing approval for the commercial sale of any drug product, a sponsor must demonstrate in preclinical studies and well-controlled clinical trials that the product is safe and effective for its intended use and that the manufacturing facilities, processes and controls are adequate to preserve the drug’s identity, strength, quality and purity. The results of these preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information such as an agreed pediatric development plan (agreed “PSP”) are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees ($3,242,026 for 2023); under certain limited circumstances, a waiver of such fees may be obtained. After the submission of an NDA, but before approval of the NDA, the manufacturing facilities used to manufacture a product candidate must be inspected by the FDA to ensure compliance with the applicable cGMP requirements. The FDA may also inspect clinical trial sites and audit clinical study data to ensure that the sponsor’s studies were properly conducted in accordance with the IND regulations, human subject protection regulations, and cGCP.

Under the current Prescription Drug User Fee Act (“PDUFA”) guidelines, the FDA goal for acting on the submission of an NDA for a new molecular entity is ten months from the date of “filing.” The FDA conducts a preliminary review of an NDA within 60 days after submission to determine whether it is sufficiently complete to permit substantive review, before accepting the NDA for filing. This two month preliminary review effectively extends the typical NDA review period to twelve months. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.

Following the FDA’s evaluation of an NDA, it will issue an approval letter or a complete response letter (“CRL”). An approval letter authorizes the sponsor to begin commercial marketing of the drug for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL describes the specific deficiencies in the NDA identified by the FDA. When possible, a CRL will recommend actions that the applicant might take, including providing additional clinical data, such as an additional Phase 3 clinical trial or other significant and time consuming requirements related to clinical trials, nonclinical studies or manufacturing, to place the application in condition for approval. If a CRL is issued, the sponsor must resubmit the NDA addressing all of the deficiencies identified in the letter, or withdraw the application. Even if the sponsor submits the recommended data and information, the FDA may decide that the resubmitted NDA does not satisfy the criteria for approval.
24


As condition to a product’s regulatory approval, the FDA may require a sponsor to conduct Phase 4 studies designed to further assess the drug’s safety and effectiveness after NDA approval, or may require other testing and surveillance programs to monitor the safety of the approved product. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy (“REMS”) to assure the safe use of the drug. A REMS could include medication guides, communication plans to healthcare professionals or other activities to assure safe use, such as provider certification or training, restricted distribution methods, and patient registries.

Research and Development

We recognized $71.3 million and $61.1 million in research and development expenses in the years ended December 31, 2022 and 2021, respectively.

Geographic Information

Substantially all of our long-lived assets were located within both the United States and Germany in 2022 and 2021.

Human Capital

As of February 23, 2023, we had 66 employees, nine of whom held M.D. degrees. Of the employees, 50 were engaged in research and development and 16 in administration. We consider our employee relations to be good.

We emphasize several measures and objectives in managing our human capital assets, including, among others, (i) employee safety and wellness, (ii) talent acquisition and retention, (iii) employee engagement, development and training, (iv) diversity and inclusion and (v) compensation. These targeted ideals may include annual bonuses, stock-based compensation awards, a 401(k) plan, healthcare, and insurance benefits, paid time-off, family leave, employee assistance programs. We also provide our employees with access to various innovative, flexible, and convenient health and wellness programs. We designed these programs to support employees’ physical and mental health by providing tools and resources to improve or maintain their health status and encourage engagement in healthy behaviors.

Corporate Information and Website

Prior to April 12, 2019, we were a clinical-stage biotherapeutic company known as Vital Therapies, Inc. that had historically been focused on the development of a cell-based therapy targeting the treatment of acute forms of liver failure. Vital Therapies, Inc. was originally incorporated in the State of California in May of 2003 as Vitagen Acquisition Corp., subsequently changed its name to Vital Therapies, Inc. in June 2003, and reincorporated in Delaware in January 2004. In April 2019, we completed an exchange transaction with Immunic AG pursuant to which holders of ordinary shares of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the exchange, we changed our name to Immunic, Inc. and we became a clinical-stage biopharmaceutical company focused on the development of selective oral therapies in immunology with the goal of becoming a leader in treatments for chronic inflammatory and autoimmune diseases.

Our corporate headquarters are located at 1200 Avenue of the Americas, Suite 200, New York, New York 10036. We also have an office at Lochhamer Schlag 21, 82166 Grafelfing, Germany. Our telephone number is (332) 255-9818.

We maintain a website at www.imux.com. The information contained on, or that can be accessed through, the website is not a part of this Annual Report on Form 10-K.

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page of our internet website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

Item 1A. Risk Factors.

Investing in our common stock involves a high degree of risk. Before deciding to invest in our company or deciding to maintain or increase your investment, you should consider carefully the risks and uncertainties described below. The risks and uncertainties described below and in our other filings with the SEC are not the only risks we face. If one or more of the
25

following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the market price for our common stock could decline, and you may lose your entire investment.

Risk Factor Summary

The following is a summary of certain important factors that may make an investment in our Company speculative or risky. You should carefully consider the fuller risk factor disclosure set forth in this Annual Report, in addition to the other information herein, including the section of this report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes.

•The coronavirus pandemic has caused interruptions or delays of our business plan and may continue to have a significant adverse effect on our business.

•Continued inflation and uncertainty in global economic conditions could negatively affect our business, results of operations and financial condition.

•Our clinical trials have been delayed as a result of the ongoing military action by Russia in Ukraine and the continuation of this conflict could have further adverse effects on our business.

•We have a limited operating history with our current business plan, have incurred significant losses since 2016, anticipate that we will continue to incur significant and increasing losses for the foreseeable future and may never achieve or maintain profitability. The absence of any commercial sales and our limited operating history make it difficult to assess our future viability.

•We currently have no source of product sales revenue and may never earn product revenue or be profitable.

•We will require substantial additional funding, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or future commercialization efforts.

•Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

•The marketing approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed.

•Clinical drug development involves a lengthy and expensive process with an uncertain outcome.

•Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive marketing approval. The effect of failure or results different than expectations can result in significant market value decline and possible negative financial results or asset related impairment.

•Our product candidates may cause undesirable adverse effects or have other properties that could delay or prevent their marketing approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if obtained.

•We are heavily dependent on the success of our product candidates, which are in the early stages of clinical development. We may not be able to generate data for any of our product candidates sufficient to receive regulatory approval in our planned indications, which will be required before they can be commercialized.
26


•Due to our limited resources and access to capital, we must decide to prioritize development of our current product candidates for certain indications and at certain doses. These decisions may prove to have been wrong and may materially adversely affect our business, financial condition, results of operations and prospects.

•If we fail to attract and retain key management and scientific personnel, we may be unable to successfully develop or commercialize our product candidates.

•Even if we obtain the required regulatory approvals in the United States and other territories, the commercial success of our product candidates will depend on market awareness and acceptance of our product candidates.

•We currently have limited marketing and sales experience. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, if and when regulatory approval is received, we may be unable to generate any revenue.

•If we fail to enter into strategic relationships or collaborations, our business, financial condition, commercialization prospects and results of operations may be materially adversely affected.

•Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.

•We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do.

•The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates.

•We may be unable to realize the potential benefits of any collaboration.

•Our proprietary rights may not adequately protect our technologies and product candidates.

•We may not be able to protect our intellectual property rights throughout the world.

•Intellectual property rights do not protect against all potential threats to our competitive advantage.

•We incur significant costs and demands upon management as a result of complying with the laws and regulations affecting public companies.

•The market price of our common stock has been and is expected to continue to be volatile.

•We do not anticipate that we will pay any cash dividends in the foreseeable future.

Macroeconomic Risks

The coronavirus pandemic has caused interruptions or delays of our business plan and may continue to have a significant adverse effect on our business.

COVID-19 has had and continues to have a significant impact around the world. In an effort to contain and mitigate the spread of COVID-19, many countries imposed unprecedented restrictions on travel, quarantines, vaccine mandates and other public health safety measures. Although some of these restrictions have been loosened or lifted in the United States and other countries, new variants continue to emerge, new outbreaks are periodically reported and significant uncertainty and concern remain.
27


The extent to which the pandemic may continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted, but the development of clinical supply materials could be delayed and enrollment of patients in our ongoing studies may be delayed or suspended, if hospitals and clinics in areas where we are conducting trials have to shift resources to cope with the COVID-19 pandemic and may limit access or close clinical facilities due to the COVID-19 pandemic. Additionally, if our trial participants are unable to travel to our clinical study sites as a result of quarantines, vaccine mandates, travel bans or other restrictions resulting from the COVID-19 pandemic, we may experience higher discontinuation rates or delays in our clinical studies, as occurred in our investigator-sponsored trial of vidofludimus calcium in PSC that was conducted at the Mayo Clinic. Government-imposed quarantines and restrictions may also require us to temporarily terminate our clinical sites. Furthermore, if we determine that our trial participants may suffer from exposure to COVID-19 as a result of their participation in our clinical trials, we may voluntarily terminate certain clinical sites as a safety measure until we reasonably believe that the likelihood of exposure has subsided. As a result, our expected development timelines for our product candidates may be negatively impacted. We cannot predict the continuing impact of the COVID-19 pandemic, as consequences of such an event are highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts that have affected and may continue to affect our business, or our clinical studies in general. The COVID-19 pandemic has already adversely affected our operations and may further materially disrupt or delay our business operations, further divert the attention and efforts of the medical community to coping with COVID-19, disrupt the marketplace in which we operate, and/or have continuing material adverse effects on our operations.

The COVID-19 pandemic could further disrupt our business and operations, interrupt our sources of supply, hamper our ability to raise additional funds or sell our securities, continue to slow down the overall economy or curtail consumer spending.

Continued inflation and uncertainty in global economic conditions could negatively affect our business, results of operations and financial condition.

Adverse macroeconomic conditions, including inflation, slower growth or recession, higher interest rates, currency fluctuations, supply chain delays or shortages, high unemployment or personnel shortages could hurt our business. We have already seen a general increase in many of our costs as a result of inflation, although inflation has not yet had a material impact on our results of operations. However, the economies of Germany, the United States, Australia and other countries in which we do business have experienced high rates of inflation during 2022 and, if inflation were to continue for a prolonged period of time or the rate of inflation in our markets were to increase, or if a global recession were to occur, our expenses could increase substantially, resulting in increased losses from operations and net loss. A downturn in the economic environment can also lead to limitations on our ability to obtain financing, reduced liquidity and declines in our stock price.

Our clinical trials have been delayed as a result of the ongoing military action by Russia in Ukraine and the continuation of this conflict could have further adverse effects on our business.

Our clinical trials of vidofludimus calcium were originally planned to be conducted at more than 60 sites in Ukraine and Russia, but most had to be relocated to other countries because of the invasion of Ukraine by Russia in February 2022 and resulting sanctions imposed on Russia by the United States and other countries. These disruptions delayed our clinical development program, increased our costs and may disrupt future planned clinical development activities in these two countries. This military action has continued for more than a year and its future course and effects on our Company are highly unpredictable. We currently have 19 active sites in western Ukraine and the ongoing conflict could put the data associated with these patients in jeopardy as well as extend patient recruitment timelines. We anticipate that Ukraine will make up approximately 15%-20% of our ENSURE- 1 and ENSURE-2 phase 3 patient population. In addition, no clinical sites in Russia have been activated or are intended to be used in the future. Alternative sites to fully and timely compensate for our clinical trial activities in Ukraine may not continue to be available. If our clinical trials are further interrupted, our clinical development program could experience further delays and increased costs and we may have insufficient data to support regulatory approvals of vidofludimus calcium, and any commercialization may be delayed or not approved, which could limit our potential revenue and hurt the competitive position of our potential products.

Risks Related to Our Business and Financial Condition

We have a limited operating history with our current business plan, have incurred significant losses since 2016, anticipate that we will continue to incur significant and increasing losses for the foreseeable future and may never achieve or maintain profitability. The absence of any commercial sales and our limited operating history make it difficult to assess our future viability.

28

We are a development-stage pharmaceutical company with a limited operating history with our current business plan. Our net losses were $120.4 million and $92.9 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $317.3 million and to date and have not generated any revenue from our current product candidates. Moreover, Immunic AG, the company’s operating subsidiary, has only a limited operating history upon which stockholders can evaluate our business and prospects, is not profitable and has incurred losses in each year since its inception in 2016. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry.

We have devoted substantially all of our financial resources to identify, acquire and develop our product candidates, including providing general and administrative support for our operations. We expect our losses to increase as we continue to conduct clinical trials and continue to develop our lead product candidates. We expect to invest significant funds into the research and development of our current product candidates to determine the potential to advance these product candidates to seek regulatory approval. To date, we have financed our operations primarily through the sale of equity securities. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations or grants.

We do not expect to generate significant revenue unless and until we are able to obtain marketing approval for, and successfully commercialize, any current or future product candidate. However pharmaceutical product development is an extremely costly and highly speculative undertaking and involves a substantial degree of risk. In addition, if we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive regulatory approval, and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates. Even if we eventually obtain adequate market share for our product candidates, to the extent they receive regulatory and market approval, the potential markets for our product candidates may not be large enough for us to become profitable.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and our expenses will increase substantially if and as we:
•continue the clinical development of our product candidates;
•continue efforts to discover, develop and/or acquire new product candidates;
•undertake the manufacturing of our product candidates for clinical development and, potentially, commercialization, or increase volumes manufactured by third parties;
•advance our programs into larger, more expensive clinical trials;
•initiate additional preclinical, clinical, or other trials or studies for our product candidates;
•seek regulatory and marketing approvals and reimbursement for our product candidates;
•experience any delays or encounter issues with the development and process for regulatory approval of our product candidates such as safety issues, clinical trial accrual delays, longer follow-up for planned studies, additional major studies or supportive studies necessary to support marketing approval;
•establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market for our self;
•make milestone, royalty or other payments under any third-party license agreements;
•seek to maintain, protect and expand our intellectual property portfolio;
•seek to retain current skilled personnel and attract additional personnel; and
•add operational, financial and management, and information systems personnel, including personnel to support our product development and commercialization efforts.

Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. Failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, expand our pipeline of product candidates or continue our operations.




29

We currently have no source of product sales revenue and may never earn product revenue or be profitable.

We have not generated any revenues from commercial sales of any of our current product candidates. Our ability to generate product revenue depends upon our ability to successfully commercialize these product candidates or other product candidates that we may develop, in-license or acquire in the future. We do not anticipate generating revenue from the sale of products for the foreseeable future. Our ability to generate revenue from our current or future product candidates also depends on a number of additional factors, including our ability to:
•successfully complete research and clinical development of current and future product candidates;
•establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of product candidates;
•obtain regulatory approval from relevant regulatory authorities in jurisdictions where we intend to market our product candidates;
•launch and commercialize any product candidates for which we obtain marketing approval, and if launched independently, successfully establish a sales force and marketing and distribution infrastructure;
•obtain coverage and adequate product reimbursement from insurance companies and other third-party payors, including government payors;
•achieve market acceptance for any approved products;
•establish, maintain and protect our intellectual property rights; and
•attract, hire and retain qualified personnel.

In addition, because of the numerous risks and uncertainties associated with clinical product development, including that our product candidates may not advance through development or achieve regulatory approval, we are unable to predict the timing or amount of any potential future product sale revenues. Our expenses also could increase beyond expectations if we decide to, or are required by the FDA or comparable foreign regulatory authorities to, perform studies or trials in addition to those that we currently anticipate. Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with launching and commercializing any product candidates that may be approved.

We will require substantial additional funding, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or future commercialization efforts.

Since the inception of Immunic AG, substantially all of our resources have been dedicated to the clinical development of our product candidates. Developing pharmaceutical products, including conducting preclinical and non-clinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We have consumed substantial amounts of cash since our inception. For example, in the years ended December 31, 2022 and December 31, 2021, we used net cash of $65.1 million and $83.8 million, respectively, in our operating activities, substantially all of which related to development of our current product candidates. We believe that we will continue to expend substantial resources for the foreseeable future toward the completion of clinical development and regulatory preparedness of our product candidates, preparations for a commercial launch of any approved product candidates, and development of any other current or future product candidates we may choose to further develop. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, seeking marketing approvals, and manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any drug development process is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any current or future product candidates that may be approved for marketing.

Our operating plan may change as a result of factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to our stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2024. Our estimate as to how long we expect our existing cash and cash
30

equivalents to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume cash and cash equivalents significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future capital requirements depend on many factors, including:
•the scope, progress, results and costs of researching and developing our current product candidates, future product candidates and related preclinical and clinical trials;
•the cost of commercialization activities if our current product candidates and future product candidates are approved for sale, including marketing, sales and distribution costs and preparedness of our corporate infrastructure;
•the cost of manufacturing current product candidates and future product candidates that we may obtain approval for and successfully commercialize;
•our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;
•the number and characteristics of any additional product candidates we may develop or acquire;
•any product liability or other lawsuits related to our products or otherwise commenced against us;
•the expenses needed to attract and retain skilled personnel;
•the costs associated with being a public company;
•the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property rights, including litigation costs and the outcome of any such litigation; and
•the timing, receipt and amount of sales of, or royalties on, any future approved products.

Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate:
•preclinical studies, clinical trials or other development activities for our current product candidates or any future product candidates;
•our research and development activities; or
•our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our future product candidates.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic collaborations and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that adversely affect the rights of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, acquire or license intellectual property rights, redeem stock or declare dividends, and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.

Risks Related to the Clinical Development and Marketing Approval of Our Product Candidates

The marketing approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed.

None of our current product candidates have gained marketing approval for sale in the United States or any other country, and we cannot guarantee that we will ever have marketable products. Our business is substantially dependent on our ability to complete the development of, obtain marketing approval for, and successfully commercialize, our product candidates in a timely manner. We cannot commercialize our product candidates in the United States without first obtaining approval from the FDA to market each product candidate. Similarly, we cannot commercialize our product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Our product candidates could fail to receive marketing approval for many reasons, including the following:
31

•the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
•the FDA or comparable foreign regulatory authorities may find the human subject protections for our clinical trials inadequate and place a clinical hold on (i) an investigational new drug (“IND”) application at the time of its submission, precluding commencement of any trials, or (ii) one or more clinical trials at any time during the conduct of such trials;
•we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;
•the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
•we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
•the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
•the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application “NDA”) to obtain marketing approval in the United States or elsewhere;
•the FDA or comparable foreign regulatory authorities may find inadequate the manufacturing processes or facilities of manufacturers with which we contract for clinical and commercial supplies of our product candidates; and
•the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner that would delay marketing approval.

Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. We cannot be certain that any NDA submissions we may make will be accepted for filing and reviewed by the FDA, or ultimately be approved. If an application is not accepted for review, the FDA may require that we conduct additional clinical studies or preclinical testing, or take other actions before it will reconsider our application. If the FDA requires additional studies or data, we would incur increased costs and delays in the marketing approval process, which may require us to expend more resources than we have available. In addition, the FDA may not consider any additional information to be complete or sufficient to support the filing or approval of the NDA.

Regulatory authorities outside of the United States, such as in Europe and Japan and in emerging markets, also have requirements for approval of drugs for commercial sale with which we must comply prior to marketing in those jurisdictions. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates into the relevant markets. Clinical trials conducted in one country may not be accepted or the results may not be found adequate by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. However, the failure to obtain regulatory approval in one jurisdiction could have a negative impact on our ability to obtain approval in a different jurisdiction. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods. Seeking foreign regulatory approval could require additional non-clinical studies or clinical trials, which could be costly and time-consuming. Foreign regulatory approval may be subject to all of the risks associated with obtaining FDA approval. For all of these reasons, we may not obtain foreign regulatory approvals on a timely basis, if at all.

The process to develop, obtain marketing approval for, and commercialize product candidates both inside and outside of the United States is long, complex and costly, and approval is never guaranteed. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary between jurisdictions. Even if our product candidates were to successfully obtain approval from regulatory authorities, any such approval might significantly limit the approved indications for use, including conditioning approval on the requirement of (i) more limited patient populations, (ii) precautions, warnings or contraindications on the product labeling, including “black box” warnings of serious risks, (iii) expensive and time-consuming post-approval clinical studies, risk evaluation and mitigation strategies ("REMS"), or surveillance, or (iv) limiting the claims that the product label may make, any of which may impede the successful commercialization of our product candidates. Following any approval for commercial sale of our product candidates, certain changes to the product, such as changes in manufacturing processes and additional labeling claims, as well as new safety information, may require costly new studies and will be subject to additional FDA notification, or review and approval. Also,
32

marketing approval for any of our product candidates may be withdrawn. If we are unable to obtain and maintain marketing approval for our product candidates in one or more jurisdictions, or any approval contains significant limitations, our ability to market our product candidates to our full target market will be reduced and our ability to realize the full market potential of our product candidates will be impaired. Furthermore, we may not be able to obtain sufficient funding or generate sufficient revenue and cash flows to continue or complete the development of any of our current or future product candidates.

Clinical drug development involves a lengthy and expensive process with an uncertain outcome.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. The FDA and comparable foreign regulatory authorities have substantial discretion when and if to grant approval to our product candidates. Even if we believe the data collected from clinical trials of our current product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. Our future clinical trial results also may not be successful.

It is impossible to predict the extent to which the clinical trial process may be affected by existing or prospective legislative and regulatory developments. Due to these and other factors, our current or future product candidates could take significantly longer than expected to gain marketing approval, if at all. This could delay or eliminate any potential product revenue by delaying or terminating the potential commercialization of our current product candidates.

Our clinical trials are conducted at multiple sites, including some sites in countries outside the United States and the European Union, which may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of foreign and non-European Union contract research organizations ("CROs"), as well as expose us to risks associated with clinical investigators who are unknown to the FDA or European regulatory authorities, and with different standards of diagnosis, screening and medical care. Most of our clinical trials of vidofludimus calcium planned at sites in Ukraine and Russia had to be delayed, suspended or relocated because of the invasion of Ukraine by Russia in February 2022, which caused disruptions to our clinical development program and increased our costs.

To date, we have not completed all clinical trials required for the approval of any of our current product candidates. The commencement and completion of clinical trials for our current product candidates may be delayed, suspended or terminated as a result of many factors, including but not limited to:
•the delay or refusal of regulators or institutional review boards (“IRBs”) at the medical institutions where the clinical trials are conducted. to authorize us to commence a clinical trial at a prospective trial site;
•changes in regulatory requirements, policies and guidelines;
•the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;
•failure to reach agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
•delays in patient enrollment and variability in the number and types of patients available for clinical trials;
•the inability to enroll a sufficient number of patients in trials to ensure adequate statistical power to detect statistically significant treatment effects;
•lower than anticipated retention rates of patients and volunteers in clinical trials;
•clinical sites deviating from trial protocols or dropping out of a trial;
•adding new clinical trial sites or relocating planned or existing clinical trial sites;
•negative or inconclusive results, which may require us to conduct additional preclinical or clinical trials or to abandon projects that we expect to be promising;
•safety or tolerability concerns, which could cause us to suspend or terminate a trial if we find that participants are exposed to unacceptable health risks;
•regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;
•our third-party research and manufacturing contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
33

•third-party researchers becoming debarred or otherwise penalized by the FDA or other regulatory authorities for violations of regulatory requirements, which could call into question data collected by such researcher and potentially affecting our ability rely on some or all of the data in support of our marketing applications;
•difficulty in maintaining contact with patients after treatment, resulting in incomplete data;
•delays in establishing the appropriate dosage levels;
•the quality or stability of our current product candidates falling below acceptable standards;
•the inability to produce or obtain sufficient quantities of our current product candidates to complete clinical trials; and
•exceeding budgeted costs due to difficulty in accurately predicting the costs associated with clinical trials.

Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, and competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating.

There are significant requirements imposed on us and on clinical investigators who conduct clinical trials that we sponsor. Although we are responsible for selecting qualified clinical investigators, providing them with the information they need to conduct the clinical trial properly, ensuring proper monitoring of the clinical trial, and ensuring that the clinical trial is conducted in accordance with the general investigational plan and protocols contained in the IND, we cannot ensure that clinical investigators will maintain compliance with all regulatory requirements at all times. The pharmaceutical industry has experienced cases where clinical investigators have been found to incorrectly record, omit, or even falsify data. We cannot ensure that the clinical investigators in our trials will not make mistakes or otherwise compromise the integrity or validity of data, any of which would have a significant negative effect on our ability to obtain marketing approval, our business, and our financial condition.

We could encounter delays if a clinical trial is suspended or terminated by us, the IRBs or ethics committees of the institutions in which such trial is being conducted, the independent steering committee, the data safety monitoring board for such trial, or the FDA or comparable foreign regulatory authorities. We or such authorities may impose a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using the drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Delay or termination of clinical trials of our current product candidates will harm their commercial prospects and impair our ability to potentially generate revenues from such product candidates. In addition, any delays in completion of our clinical trials will increase our costs, slow our development and approval process and jeopardize our ability to commence product sales and generate revenues.

Moreover, clinical investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. We are required to report certain financial relationships with clinical investigators to the FDA and, where applicable, take steps to minimize the potential for bias resulting from such financial relationships. The FDA may evaluate the reported information and conclude that a financial relationship between us and a clinical investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. The FDA may refuse to accept our marketing applications, and other delays or even denial of marketing approval could result.

Preclinical testing or clinical trials of any development candidate may also show new and unexpected findings regarding safety and tolerability. Such findings may harm the ability to conduct further development of product candidates, delay such development, require additional expensive tests, harm our ability to partner these development candidates, or delay or prevent marketing approval by regulatory agencies. Such findings may also harm the ability to compete in the market with other products or to achieve certain pricing thresholds.

Any of these occurrences could materially adversely affect our business, financial condition, results of operations, and prospects. In addition, many of the factors that could cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our product candidates. Significant clinical trial delays could also allow our competitors to bring products to market before we can, shorten any periods during which we may have the
34

exclusive right to commercialize any approved product candidates, and impair our ability to commercialize any approved product candidates, which may harm our business, financial condition, results of operations and prospects.

Use of patient-reported outcomes in our clinical trials may delay the development of our product candidates or increase development costs.

In recent years, due to regulatory changes, patient-reported outcomes ("PROs"), may have an important role in the development and regulatory approval of any of our product candidates. PROs involve patients’ subjective assessments of efficacy, and this subjectivity increases the uncertainty in determining achievement of clinical endpoints. Such assessments can be influenced by factors outside of our control, and can vary widely from day-to-day for a particular patient, and from patient-to-patient and site-to-site within a clinical trial. Use of PROs may make the outcome of trials more uncertain and may increase our costs and time to finish regulatory approval trials.

Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive marketing approval.

Clinical failure can occur at any stage of clinical development. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials.

A number of pharmaceutical companies have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical or preclinical testing. For example, we announced in October 2022 the analysis of interim group-level data of our Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis did not separate from placebo. Following this announcement, our stock price declined significantly, which caused us to record a full impairment of our goodwill in the quarter ended December 31, 2022. Data obtained from trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent marketing approval of our product candidates. In addition, the design of a clinical trial can determine whether its results will support approval of a product, or approval of a product for desired indications, and flaws or shortcomings in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to properly design and execute a clinical trial to support marketing approval for our desired indications. Further, clinical trials of product candidates often reveal that it is not practical or feasible to continue development efforts. If one of our product candidates is found to be unsafe or lack efficacy, we will not be able to obtain marketing approval for such product candidate and our business would be harmed. If the results of our clinical trials of our product candidates do not achieve pre-specified endpoints, we are unable to provide primary or secondary endpoint measurements deemed acceptable by the FDA or comparable foreign regulators, or we are unable to demonstrate an acceptable level of safety relative to the efficacy associated with our proposed indications, the prospects for approval of our product candidates would be materially and adversely affected. For example, we announced in June 2022 that a phase 2 clinical trial of our most advanced drug candidate, vidofludimus calcium, did not achieve its primary endpoint in patients with moderate-to-severe ulcerative colitis. As a result, we do not plan any further drug development activities in ulcerative colitis without a partner. A number of companies in the pharmaceutical industry, including those with greater resources and experience than we, have suffered significant setbacks in Phase 2 and Phase 3 clinical trials, even after seeing promising results in earlier clinical trials.

In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including differences in trial protocols and design, the size and type of the patient population, adherence to the dosing regimen and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we may conduct will demonstrate consistent and/or adequate efficacy and safety to obtain marketing approval for our product candidates.

Our product candidates may cause undesirable adverse effects or have other properties that could delay or prevent their marketing approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if obtained.

Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive “approved use” label or the delay or denial of marketing approval by the
35

FDA or other comparable foreign regulatory authorities. If any of our current or future product candidates is associated with serious adverse, undesirable or unacceptable side effects, we may need to abandon such candidate’s development or limit development to certain uses or sub-populations in which such side effects are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many drug candidates that initially showed promise in early-stage or clinical testing have later been found to cause side effects that prevented their further development. Results of our trials could reveal a high and unacceptable prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Drug-related side effects could also adversely affect patient recruitment or the ability of enrolled patients to complete the trial, or could result in potential product liability claims.

If our product candidates receive marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:
•regulatory authorities may withdraw approvals of such products;
•we may be required to recall a product or change the way such product is administered to patients;
•additional restrictions may be imposed on the marketing of the particular product or the manufacturing process for the product or any component thereof;
•regulatory authorities may require the addition of labeling statements, such as a precaution, “black box” warning of serious risks or other warnings or a contraindication;
•we or our collaborators may be required to implement a REMS or create a medication guide outlining the risks of such side effect for distribution to patients;
•we or our collaborators could be sued and held liable for harm caused to patients;
•the product may become less competitive and revenues could decline substantially; and
•our reputation would suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of any approved product candidates, and could materially adversely affect our business, financial condition, results of operations and prospects.

We are heavily dependent on the success of our product candidates, most of which are in the early stages of clinical development. We may not be able to generate data for any product candidates sufficient to receive regulatory approval in its planned indications, which will be required before it can be commercialized.

We have invested substantially all of our efforts and financial resources to identify, acquire and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully further develop, obtain regulatory approval for, and commercialize one or more product candidates. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a product candidate.

Our most advanced product candidate, vidofludimus calcium, had the first patient enrolled in a Phase 3 program for relapsing multiple sclerosis (“RMS”) in November 2021 and we do not expect the readout of topline data from this trial until the end of 2025. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.

We may use our limited financial and operational resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and operational resources, we may forego or delay pursuit of opportunities in some programs, product candidates or indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or more profitable market opportunities. Our spending on current and future research and development programs and future product candidates for specific indications may not yield any commercially viable products. We may also enter into strategic collaboration agreements to develop and commercialize some of our programs and potential product candidates in indications with potentially large commercial markets.
36

If we do not accurately evaluate and predict the commercial potential or target market for a particular product candidate, we may (i) relinquish valuable rights to that product candidate through strategic collaborations, licensing or other royalty arrangements when it would have been more advantageous to retain sole development and commercialization rights to such product candidate, or (ii) allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaborative arrangement.

We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied. Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates.

Identifying and qualifying sufficient numbers of eligible patients to participate in clinical trials of our product candidates is essential to our success. The timing of our clinical trials depends in part on the rate at which we can recruit eligible patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment.

The specific eligibility criteria of our planned clinical trials may further limit the population of available eligible trial participants. We may not be able to identify, recruit, and enroll a sufficient number of eligible patients to initiate or complete our clinical trials in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, and the willingness of physicians to participate in our planned clinical trials. If patients are unwilling to participate in our clinical trials for any reason, the timeline for conducting trials and obtaining regulatory approval of our product candidates may be delayed.

If we experience delays in the completion of, or experiences termination of, any clinical trials of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from product candidates could be delayed or impaired. We have recently experienced delays in our planned clinical trials of vidofludimus calcium at sites in Ukraine and Russia because of the invasion of Ukraine by Russia. These and other delays we may encounter in initiating or completing clinical trials would likely increase our overall costs, impair product candidate development and impair our ability to obtain regulatory approval. Any of these occurrences may harm our business, financial condition, and prospects significantly.

Even if we receive marketing approval for any of our product candidates, such approved products will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, any approved product candidates could be subject to labeling and other restrictions, and we may be subject to penalties and legal sanctions if we fail to comply with regulatory requirements or experience unanticipated problems with any of our approved products.

If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, packaging, distribution, adverse event reporting, storage, labeling, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP regulations and GCP for any clinical trials that we conduct post-approval. Any marketing approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or subject to conditions of approval, or contain requirements for potentially costly post-approval studies, including Phase 4 clinical trials, and surveillance to monitor safety and efficacy. The FDA may also require us to implement a Risk Evaluation and Mitigation Strategy drug safety program as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools

Later discovery of previously unknown problems with an approved product, including adverse events of unanticipated severity or frequency, or problems with manufacturing operations or processes, or failure to comply with regulatory requirements, or evidence of acts that raise questions about the integrity of data supporting the product approval, may result in, among other things:
•restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;
•restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;
•fines, warning letters, untitled letters, or holds on clinical trials;
37

•refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product approvals;
•product seizure or detention, or refusal to permit the import or export of products; and
•injunctions or the imposition of civil or criminal penalties.

The FDA’s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval, manufacturing or commercialization of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other jurisdictions. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or not able to maintain regulatory compliance, we may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.

The occurrence of any event described above may limit our ability to commercialize any approved product candidates and harm our business, financial condition, and prospects significantly.

If we fail to obtain regulatory approval in jurisdictions outside the United States, we will not be able to market our products in those jurisdictions.

We intend to market any approved product candidates in international markets, either ourselves or in conjunction with collaborators. Such marketing will require separate regulatory approvals in each market and compliance with numerous and varying regulatory requirements. The approval procedures vary from country to country and may require testing in addition to what is required for a marketing application in the United States. Moreover, the time required to obtain approval in other countries may be different than in the United States. In addition, in many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval in another jurisdiction. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and additional or different risks. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in some or all of the international markets in which we intend to market any approved product candidates, which would significantly harm our business, results of operations and prospects.

Agencies like the FDA and national competition regulators in European countries strictly regulate the marketing and promotion of drugs. If we are found to have improperly promoted any of our product candidates for uses beyond those that are approved, we may become subject to significant liability.

Regulatory authorities like the FDA and national competition laws in Europe strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or comparable foreign regulatory authorities as reflected in the product’s approved labeling, known as “off-label” use, nor may a product be promoted prior to marketing approval. If we receive marketing approval for a product candidate for its proposed indication(s), physicians may nevertheless prescribe the product for their patients in a manner that is inconsistent with the approved label if the physicians personally believe in their professional medical judgment it could be used in such manner. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses.

In addition, the FDA requires that promotional claims not be “false or misleading” as such terms are interpreted by the FDA. For example, the FDA requires substantial evidence, which generally consists of two adequate and well-controlled head-to-head clinical trials, for a company to make a claim that its product is superior to another product in terms of safety or effectiveness. Generally, unless we perform clinical trials meeting that standard comparing our product candidates to competing products and these claims are approved for our product labeling, we will not be able promote our product candidates as superior to competing products.

In the United States, regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted our product, including for an off-label use, we may become subject to significant liability. Numerous drug manufacturers have been the subject of investigations related to off-label promotion resulting in multi-billion dollar settlements, consent decrees, and on-going monitoring under corporate integrity agreements or
38

deferred prosecution agreements. In addition, the FDA could also seek permanent injunctions under which specified promotional conduct is monitored, changed or curtailed.

Our current and future relationships with healthcare professionals, investigators, consultants, collaborators, actual customers, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to sanctions.

Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we may obtain marketing approval. Our current and future arrangements with healthcare professionals, investigators, consultants, collaborators, actual customers, potential customers and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act ("FCA"), which may constrain the business or financial arrangements and relationships through which we sell, market and distribute any drug candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy and security regulation by the federal government and by the U.S. states and foreign jurisdictions in which we conduct business. The applicable federal, state and foreign healthcare laws that may affect our ability to operate include the following:

•The federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. Remuneration has been interpreted broadly to include anything of value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor. A conviction for violation of the Anti-Kickback Statute results in mandatory exclusion from participation in federal healthcare programs. This statute has been applied to arrangements between pharmaceutical manufacturers and those in a position to purchase products or refer others including prescribers, patients, purchasers and formulary managers. In addition, the Affordable Care Act amended the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute also constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, the penalties for which are described below.

•Federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or for making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties (tied to inflation) of $12,537 to $25,076 (after May 9, 2022) per false claim or statement.
•The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
•The federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") imposes criminal and civil penalties for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters.
39

•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations impose obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.
•The federal Open Payments program, created under the Physician Payment Sunshine Act, also known as Section 6002 of the Patient Protection and Affordable Care Act (the “Affordable Care Act”), and its implementing regulations, impose annual reporting requirements for certain manufacturers of drugs, devices, biologicals and medical supplies for payments and “transfers of value” provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The SUPPORT for Patients and Communities Act expanded the scope of reporting such that companies must also report payments and transfers of value provided to other types of healthcare professionals. Failure to submit timely, accurately and completely the required information for all covered payments, transfers of value and ownership or investment interests may result in civil monetary penalties.
•There are many analogous state and foreign laws, such as: state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
•The Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it.

Efforts to ensure that our future business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could significantly harm our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including current and any future collaborators, are found not to be in compliance with applicable laws, those persons or entities may be subject to criminal, civil or administrative sanctions, including exclusion from participation in government healthcare programs, which could also negatively affect our business.

We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties and other remedial measures, and incur legal expenses, which could adversely affect our business, financial condition, results of operations, stock price and prospects.

Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act ("FCPA"), and other anti-corruption laws that apply in countries where we do, or may in the future do, business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We also may participate in collaborations and relationships with third parties whose actions, if non-compliant, could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing or future laws might be administered or interpreted.

40

We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and authorities in the European Union, including applicable import and export control regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as trade control laws.

We may not be effective in ensuring our compliance with all applicable anti-corruption laws or other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and incur substantial legal expenses, which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. Likewise, any investigation of any potential violations of these anti-corruption laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, business, financial condition, results of operations, stock price and prospects.

The impact on us of recent and future healthcare reform legislation and other changes in the healthcare industry and healthcare spending is currently unknown, and may adversely affect our business model.

In the United States and some foreign jurisdictions, legislative and regulatory changes and proposed changes regarding the healthcare system could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any drug candidates for which we obtain marketing approval.

Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and other jurisdictions. We operate in a highly regulated industry and new laws, regulations, judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery of, or payment for, healthcare products and services could negatively impact our business, financial condition, results of operations and prospects. There continues to be significant interest in promoting healthcare reform, as evidenced by the enactment in the United States of the Affordable Care Act and efforts to repeal, invalidate or modify portions of the act. Among other things, the Affordable Care Act contains provisions that may reduce the profitability of drug products, including, for example, revising the methodology by which rebates owed by manufacturers for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, extending Medicaid rebates to individuals enrolled in Medicaid managed care plans, imposing mandatory discounts for certain Medicare Part D beneficiaries who fall into a coverage gap, and subjecting drug manufacturers to payment of an annual fee based on its market share of prior year total sales of branded programs to certain federal healthcare programs.

There have been judicial and congressional challenges to the Affordable Care Act, some of which have been successful, as well as efforts to repeal or replace certain aspects of the Affordable Care Act. If a new law is enacted, or if the Affordable Care Act is overturned, repealed or modified, in whole or in part, by judicial or legislative action, many if not all of the provisions of the Affordable Care Act may no longer apply to prescription drugs. While we are unable to predict what changes may ultimately be enacted, to the extent that future changes affect how any future prescription drug products are paid for and reimbursed by government and private payors, our business could be adversely impacted.

In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of 2% per fiscal year, which started in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, also reduced Medicare payments to several categories of healthcare providers. The Biden administration and Congress may announce initiatives intended to result in lower drug prices. We are not in a position to know at this time whether such initiatives will become law or what impact they may potentially have on our business.

We expect that additional healthcare reform measures and drug pricing regulations that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the revenue that we may potentially receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue or commercialize our drug candidates.

It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing healthcare legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies,
41

managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:
•the demand for any drug products for which we may obtain marketing approval;
•our ability to set a price for our products that we believe is fair;
•our ability to obtain coverage and reimbursement approval for a product approved for marketing;
•our ability to generate revenues and achieve or maintain profitability; and
•the level of taxes that we are required to pay.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition or results of operations.

Our research and development activities and the activities of our contract manufacturers and suppliers involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at facilities of ours and our manufacturers, pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, or the risk of environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our contract manufacturers and suppliers for handling and disposing of these materials generally comply with the current standards prescribed by applicable laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In the event of contamination of injury, we may be held liable for any resulting damages, which could exceed our resources or result in government-imposed restrictions on our use of specified materials or interruptions of our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have generally tended to become more stringent over time. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.

Other Risks Related to Our Business

Due to our limited resources and access to capital, we must decide to prioritize development of our current product candidates for certain indications and at certain doses. These decisions may prove to have been wrong and may materially adversely affect our business, financial condition, results of operations and prospects.

Because we have limited resources and access to capital to fund our operations, we must decide which dosages and indications to pursue for the clinical development of our current product candidates and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward dosages or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding the market potential of our current product candidates or if we misread trends in the pharmaceutical industry, our business, financial condition, results of operations and prospects could be materially adversely affected.

We may not be able to win contracts or grants from governments, academic institutions or non-profits.

From time to time, we may apply for contracts or grants from government agencies, non-profit entities and academic institutions. Such contracts or grants can be highly attractive because they provide capital to fund the ongoing development of our product candidates without diluting our stockholders. However, there is often significant competition for these contracts or grants. Entities offering contracts or grants may have requirements to apply for, or to otherwise be eligible for, certain contracts or grants that our competitors may be able to satisfy that we cannot satisfy. In addition, such entities may make arbitrary decisions as to whether to offer contracts or make grants, to whom the contracts or grants may or will be awarded and the conditions and size of the contracts or grants to each awardee. Even if we are able to satisfy the award requirements, we may not be able to win any contracts or grants in a timely manner, if at all.

42

In addition, even if we enter into contracts with or receives grants from government agencies, non-profit entities or academic institutions, we may lose such contracts or grants due to failure to comply with applicable terms, limitations, or government regulations. As a result, our business, results of operations, financial condition and prospects could be harmed.

If we fail to attract and retain key management and scientific personnel, we may be unable to successfully develop or commercialize our product candidates.

Our success as a biotechnology company depends on our continued ability to attract, retain and motivate highly qualified management and scientific and clinical personnel. The loss of the services of any such personnel could delay or prevent obtaining marketing approval or commercialization of our product candidates.

We may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a limited number of qualified personnel among biotechnology, pharmaceutical and other companies. Our failure to attract, hire, integrate and retain qualified personnel could impair our ability to achieve our business objectives.

If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of applicable insurance coverage, we could be forced to pay substantial damage awards.

The use of any of our product candidates in clinical trials and the sale of any approved products may expose us to product liability claims. We currently maintain a limited amount of product liability insurance. We intend to monitor the amount of coverage we maintain as the size and design of our clinical trials evolve and seek to adjust the amount of coverage we maintain accordingly. However, we may not maintain insurance coverage that adequately protects us against some or all of the claims to which we might become subject. We might not be able to maintain adequate insurance coverage at a reasonable cost or in sufficient amounts or scope to protect us against potential losses. In the event a claim is brought against us, we might be required to pay legal and other expenses to defend the claim, as well as uncovered damages awards resulting from a claim brought against us. Furthermore, whether or not we are ultimately successful in defending any such claims, we might be required to divert substantial financial and managerial resources to such defense, and adverse publicity could result, all of which could harm our business.

We could have liability if our employees, independent contractors, investigators, CROs, consultants, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk that our employees and other parties with which we do business may engage in fraudulent conduct or other illegal activity. Misconduct by employees and other parties could include intentional, reckless and/or negligent conduct or violation of FDA regulations and laws that require reporting true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare fraud and abuse laws and regulations, or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commissions, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and other third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate. Even if we are ultimately successful in defending any such actions, we could be required to divert financial and managerial resources to such action and adverse publicity could result, all of which could harm our business.

We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.

43

We currently have approximately 66 employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing our growth. As we advance our product candidates through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities. As our operations expand, we expect that we will need to manage additional relationships with such third parties, as well as additional collaborators and suppliers.

We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure and internal controls, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

Our internal computer systems, or those of our development collaborators, third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.

Our internal computer systems and those of our current and any future strategic collaborators, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, cybersecurity threats, war and telecommunication and electrical failures. We may experience cyber-attacks on our information technology systems by threat actors of all types (including but not limited to nation states, organized crime, other criminal enterprises, individual actors and/or advanced persistent threat groups). In addition, we may experience intrusions on our physical premises by any of these threat actors. If any such cyber-attack or physical intrusion were to cause interruptions in our operations, such as a material disruption of our development programs or our manufacturing operations, whether due to a loss of our trade secrets or other proprietary information, it would have a material and adverse effect on us. For example, the loss of clinical trial data from one or more ongoing or completed or future clinical trials could result in delays in our regulatory approval efforts, significantly increase our costs to recover or reproduce the data and expose us to liability. In addition, any breach of our computer systems or physical premises could result in a loss of data or compromised data integrity across more than one of our programs in different stages of development. Any such breach, loss, or compromise of clinical trial participant personal data may also subject us to civil fines and penalties or claims for damages, either under the General Data Protection Regulation and relevant member state law in the European Union, other foreign laws, and HIPAA, and other relevant state and federal privacy laws in the United States including the California Consumer Privacy Act. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, including but not limited to information related to our vidofludimus calcium product candidate, we could incur liability, our competitive and reputational position could be harmed, and the further development and commercialization of our investigational medicines could be delayed. On July 31, 2020 we discovered that an email account at the Company was subject to attempted unauthorized access for a period of up to 24 hours and we hired an investigator to ascertain what, if any, Company or patient information was impacted. We do not believe any confidential or proprietary information was compromised and have taken steps to prevent unauthorized action in the future such as implementing two factor authentication for our email accounts. While we believe that our insurance policies include liability coverage for security breaches, we could be subject to indemnity claims or other damages that exceed, or are outside the scope of, our insurance coverage. As a result, the ramifications of a potential security breach could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as cause a decline in the trading price of our common stock.

Risks Related to Commercialization of Our Product Candidates

Even if we obtain the required regulatory approvals in the United States and other territories, the commercial success of our product candidates will depend on market awareness and acceptance of our product candidates.

Even if we obtain marketing approval for our current product candidates or any other product candidates that we may develop or acquire in the future, our products may not gain market acceptance among physicians, key opinion leaders, healthcare payors, patients and the medical community. Market acceptance of any approved products depends on a number of factors, including:
•the timing of market introduction;
•the efficacy and safety of the product, as demonstrated in clinical trials;
44

•the clinical indications for which the product is approved and the label approved by regulatory authorities for use with the product, including any precautions, warnings or contraindications that may be required on the label;
•acceptance by physicians, key opinion leaders and patients of the product as a safe and effective treatment;
•the cost, safety and efficacy of treatment in relation to alternative treatments;
•the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;
•the number, cost and clinical profile of competing products;
•the growth of drug markets in our various indications;
•relative convenience and ease of administration;
•marketing and distribution support;
•the prevalence and severity of adverse side effects; and
•the effectiveness of our sales and marketing efforts.

Market acceptance is critical to our ability to generate revenue. Any approved and commercialized product candidate may be accepted in only limited capacities or not at all. If any approved products are not accepted by the market to the extent that we expect, we may not be able to generate sufficient revenue and our business would suffer.

We currently have no marketing and sales experience. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, if and when regulatory approval is received, we may be unable to generate any revenue.

We have never commercialized a product candidate, and we currently have no marketing and sales organization. To the extent our product candidates are approved for marketing, if we are unable to establish marketing and sales capabilities or enter into agreements with third parties to effectively market and sell our product candidates, we may not be able to successfully market and sell our product candidates or generate product revenue.

In addition, we currently do not have marketing, sales or distribution capabilities for our product candidates. In order to commercialize any of our products that receive marketing approval, we would have to build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In the event of successful development of our product candidates, if we elect to build a targeted specialty sales force, such an effort would be expensive and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have their own sales forces and established distribution systems, in lieu of or to augment any sales force and distribution systems we may create. If we are unable to enter into collaborations with third parties for the commercialization of any approved products on acceptable terms or at all, or if any such collaborator does not devote sufficient resources to the commercialization of our product or otherwise fails in commercialization efforts, we may not be able to successfully commercialize our product candidates even if we receive marketing approval. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future revenue will be materially and adversely impacted.

If we fail to enter into strategic relationships or collaborations, our business, financial condition, commercialization prospects and results of operations may be materially adversely affected.

Our product development programs and the potential commercialization of our current product candidates will require substantial additional cash to fund expenses. Therefore, in addition to financing the development of our product candidates through additional equity financings or through debt financings, we may decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of our product candidates in the United States or foreign markets. We announced in June 2022 that we do not plan further drug development activities in ulcerative colitis without a partner, following the failure of our phase 2 clinical trial to achieve its primary endpoint.

We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. Any of these contingencies may require us to curtail the development of a particular product, reduce or delay one or more of our development programs, delay our potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we
45

elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring any approved product candidates to market and generate product revenue. If we do enter into a new collaboration agreement, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects and financial condition:
•we may not be able to control the amount or timing of resources that the collaborator devotes to the product development program;
•the collaborator may experience financial difficulties and thus not commit sufficient financial resources or personnel to the product development program;
•we may be required to relinquish important rights such as marketing, distribution and intellectual property rights;
•a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors; or
•business combinations or significant changes in a collaborator’s business strategy may adversely affect our or the collaborator’s willingness to complete our respective obligations under any arrangement.

Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.

The pricing, coverage, and reimbursement of any of our approved products must be sufficient to support our commercial efforts and other development programs, and the availability and adequacy of coverage and reimbursement by third-party payors, including governmental and private insurers, are essential for most patients to be able to afford expensive treatments. Sales of any of our approved product candidates will depend substantially, both domestically and in other jurisdictions, on the extent to which the costs of any of our approved products will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government payors and private payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free, which would harm our potential revenues and profits, or we may not be able to successfully commercialize our products.

In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare & Medicaid Services ("CMS"), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for our novel product candidates and what reimbursement codes our product candidates may receive if approved. There also may be delays in obtaining coverage for newly-approved drugs. Obtaining coverage and reimbursement approval is time-consuming and costly, requiring us to provide payors with scientific, clinical, and cost-effectiveness data. Further, eligibility for coverage does not necessarily signify that a drug will be reimbursed in all cases or at a rate that covers our costs. Thus, even if we succeed in bringing a product to market, it may not be considered medically necessary or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis.

Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we may be able to charge for any of our products. Accordingly, the potential revenue and profits from markets outside the United States may be commercially inadequate.

Moreover, increasing efforts by governmental and private payors in the United States and other jurisdictions to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations, pharmacy benefit management organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs in particular, has and is expected to continue to increase in the future. For instance, government and private payors who reimburse patients or healthcare providers are increasingly seeking greater upfront discounts, additional rebates and other concessions to reduce prices for pharmaceutical products. As a result, it may be difficult for any of our products to achieve profitability, even if they receive regulatory approval.
46


We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do.

The development and commercialization of new drug products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities and other research institutions worldwide with respect to our product candidates that we may seek to develop or commercialize in the future. Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors.

In particular, the field of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, are highly competitive. Our competitors in the United States and elsewhere include major pharmaceutical, biotechnology and biosimilar manufacturers. Some of these competitors may have more extensive research and development, regulatory compliance, manufacturing, marketing and sales capabilities than we have. Many competitors also have significantly greater financial resources. These companies may succeed in developing products that are more effective or more economical than any of our product candidates and may also be more successful than we in manufacturing, developing and obtaining regulatory approvals and reimbursement for products. In addition, technological advances or different approaches developed by one or more of our competitors may render our products obsolete, less effective or uneconomical.

If our competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than we do, they could establish a strong market position before we are able to enter the market. Third-party payors, including governmental and private insurers, also may encourage the use of less expensive generic products. Failure of any approved product candidates of ours to effectively compete against established treatment options or to compete in the future with new products currently in development would harm our business, financial condition, results of operations and prospects.

The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates.

The potential market opportunities for our product candidates are difficult to estimate and will depend on a number of factors beyond our control. Our estimates of potential market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys. Although we believe that our internal assumptions are reasonable based on currently available information, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be substantially smaller than our estimates.

Negative developments in the field of oral therapies for chronic inflammatory and autoimmune diseases could damage public perception of our product candidates and negatively affect our business.

The commercial success of our product candidates will depend in part on public acceptance of the use of oral therapies for the treatment of chronic inflammatory and autoimmune diseases. Adverse events in clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments that may occur in the future, including in connection with competitors’ therapies, could result in a decrease in demand for our product candidates. These events could also result in the suspension, discontinuation, or clinical hold of, or modifications to, our clinical trials. Our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials. As a result, we may not be able to continue, or may be delayed in conducting, our development programs.

Price controls may be imposed in foreign markets, which may adversely affect our future profitability.

47

In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.

Risks Related to Third Parties

We rely on third-party suppliers and other third parties for production of our product candidates, and our dependence on these third parties may impair the advancement of our research and development programs and the development of our product candidates.

We do not currently own or operate manufacturing facilities for clinical or commercial production of our product candidates. We lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. Instead, we rely on, and expect to continue to rely on, third parties for the supply of raw materials and manufacture of drug supplies necessary to conduct our preclinical studies and clinical trials. Our reliance on third parties for manufacturing exposes us to additional risks. Delays in production by third parties could delay our clinical trials or have an adverse impact on any commercial activities. In addition, our dependence on third parties for the manufacture of and formulation of our product candidates subjects us to the risk that such product candidates may have manufacturing defects that we has limited ability to prevent or control. Although we oversee these activities to ensure compliance with our quality standards, budgets and timelines, we have, and will continue to have, less control over the manufacturing of our product candidates than if we were to manufacture our product candidates. Further, the third parties we contract with could have staffing difficulties, might undergo changes in priorities or may become financially distressed, any of which would adversely affect the manufacturing and production of our product candidates. In addition, a third party could be acquired by, or enter into an exclusive arrangement with, one of our competitors, which would adversely affect our ability to access the formulations we require for the manufacturing of our product candidates.

The facilities used by our current contract manufacturers and any future manufacturers to manufacture our product candidates must be inspected by the FDA after we submit our NDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturers for compliance with the regulatory requirements, known as cGMPs, for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the FDA may refuse to approve our NDA. If the FDA does not approve our NDA because of concerns about the manufacture of our product candidates, or if significant manufacturing issues arise in the future, we may need to find alternative manufacturing facilities, which would significantly delay and adversely impact our ability to develop our product candidates, obtain marketing approval of our NDA or to continue to market any approved product candidates. Although we are ultimately responsible for ensuring compliance with these regulatory requirements, we do not have day-to-day control over a contract manufacturing organization’s ("CMO"), or other third-party manufacturer’s compliance with applicable laws and regulations, including cGMPs and other laws and regulations, such as those related to environmental, health and safety matters. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation. In addition, third-party contractors, such as our CMOs, may elect not to continue to work with us due to factors beyond our control. They may also refuse to work with us because of their own financial difficulties, business priorities or other reasons, at a time that is costly or otherwise inconvenient for us. If we was unable to find adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed.

Problems with the quality of the work performed by third parties may lead us to seek to terminate our working relationships and seek alternative service providers. However, making this change may be costly and may substantially delay clinical trials. In addition, it may be very challenging, and in some cases impossible, to find replacement service providers that can develop and manufacture our drug candidates in an acceptable manner and at an acceptable cost and on a timely basis. The
48

sale of products containing any defects or any delays in the supply of necessary products or services could adversely affect our business, financial condition, results of operations, and prospects.

Growth in the costs and expenses of components or raw materials may also adversely affect our business, financial condition, results of operations, and prospects. Supply sources could be interrupted from time to time and, if interrupted, supplies may not be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all.

We currently rely on and plan to continue to rely on third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, it may cause delays in commencing and completing clinical trials of our product candidates or we may be unable to obtain marketing approval for or commercialize our product candidates.

Clinical trials must meet applicable FDA and foreign regulatory requirements. We do not have the ability to independently conduct clinical trials for any of our product candidates. We rely and expect to continue relying on third parties, such as CROs, medical institutions, clinical investigators and contract laboratories, to conduct all of our clinical trials of our product candidates; however, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with IND and human subject protection regulations and cGCPs for conducting, monitoring, recording, and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. Our reliance on third parties does not relieve us of these responsibilities and requirements. Regulatory authorities enforce eGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors fail to comply with applicable eGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Upon inspection by a given regulatory authority, such regulatory authority may determine that one or more of our clinical trials do not comply with eGCPs. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process and increase our expenses.

The pharmaceutical industry has experienced cases where clinical investigators have been found to incorrectly record data, omit data, or even falsify data. We cannot ensure that the CROs or clinical investigators in our trials will not make mistakes or otherwise compromise the integrity or validity of data, any of which would have a significant negative effect on our ability to obtain marketing approval, our business, and our financial condition.

We or the third parties we rely on may encounter problems in clinical trials that may cause us or the FDA or foreign regulatory agencies to delay, suspend or terminate our clinical trials at any phase. These problems could include the possibility that we may not be able to manufacture sufficient quantities of materials for use in our clinical trials, conduct clinical trials at our preferred sites, enroll a sufficient number of patients for our clinical trials at one or more sites, or begin or successfully complete clinical trials in a timely fashion, if at all. Furthermore, we, the FDA or foreign regulatory agencies may suspend clinical trials of our product candidates at any time if we or they believe the subjects participating in the trials are being exposed to unacceptable health risks, whether as a result of adverse events occurring in our trials or otherwise, or if we or they find deficiencies in the clinical trial process or conduct of the investigation. The FDA or foreign regulatory agencies could also require additional clinical trials before or after granting marketing approval for any products, which would result in increased costs and significant delays in the development and commercialization of such products and could result in the withdrawal of such products from the market even if marketing approval has already been obtained. Our failure to adequately demonstrate the safety and efficacy of a product candidate in clinical development could delay or prevent marketing approval of the product candidate. Even if market approval has already been obtained, adverse data from post-approval studies could result in the product being withdrawn from the market. Any of these occurrences would likely have a material adverse effect on our business.

We may be unable to realize the potential benefits of any collaboration.

Even if we are successful in entering into a collaboration with respect to the development and/or commercialization of one or more product candidates, the collaboration may not be successful. Collaborations pose a number of risks, including:
•collaborators often have significant discretion in determining the extent of efforts and resources that they will apply to the collaboration, and may not commit sufficient attention and financial or other resources to the development, marketing or commercialization of the product or products that are subject to the collaboration;
•collaborators may not perform their obligations as expected;
49

•any such collaboration may significantly limit our share of potential future profits from the associated program, and may require us to relinquish potentially valuable rights to our current product candidates, potential product candidates or proprietary technologies, or to grant licenses on terms that are not favorable to us;
•collaborators may cease to devote sufficient resources to the development or commercialization of our product candidates, especially if the collaborators view our product candidates as competitive with their own products or product candidates;
•disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the course of development, might cause delays or termination of the development or commercialization of product candidates, and might result in legal proceedings, which would be time-consuming, distracting and expensive;
•collaborators may be impacted by changes in their strategic focus or available funding, or business combinations involving them, which could cause them to divert resources away from our collaboration;
•collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;
•the collaborations may not result in our achieving revenues to justify such transactions; and
•collaborations may be terminated, which may require us to raise additional capital to pursue further development or commercialization of the applicable product candidate.

As a result of any of these factors, a collaboration may not result in the successful development or commercialization of our product candidates.

We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.

In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees’ exercise of rights under the agreements.

Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.

If our contract manufacturers fail to comply with continuing regulations, resulting enforcement action could adversely affect us.

If any of our contract manufacturers fail to comply with regulatory requirements or if previously unknown problems with products, manufacturers or manufacturing processes are discovered, we or the manufacturer could be subject to administrative or judicially imposed sanctions, including restrictions on the products or the manufacturers or manufacturing processes we use, warning letters, untitled letters (which the FDA uses as an initial notification of violations), civil or criminal penalties, fines, injunctions, product seizures or detentions, import bans, voluntary or mandatory product recalls and publicity requirements, suspension or withdrawal of regulatory approvals, total or partial suspension of production, and refusal to approve pending applications for marketing approval of new products.

Risks Related to Our Intellectual Property

Our proprietary rights may not adequately protect our technologies and product candidates.

Our commercial success will depend in part on our ability to obtain additional patents and protect our existing patent position as well as our ability to maintain adequate protection of other intellectual property for our technologies, product candidates, and any future products in the United States and other countries. If we do not adequately protect our intellectual
50

property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. The laws of some foreign countries, in particular China and India, do not protect our proprietary rights to the same extent or in the same manner as U.S. laws, and we may encounter significant problems in protecting and defending our proprietary rights in these and other countries. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets.

We apply for patents covering both our technologies and product candidates as we deem appropriate. However, we may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies or developing competing products and technologies. We cannot be certain that our patent applications will be approved or that any patents issued will adequately protect our intellectual property.

Moreover, the patent positions of pharmaceutical companies are highly uncertain and involve complex legal and factual questions for which important legal principles are evolving and remain unresolved. As a result, the validity and enforceability of patents cannot be predicted with certainty. In addition, we do not know whether:
•we or our licensors were the first to make the inventions covered by each of our issued patents and pending patent applications;
•we or our licensors were the first to file patent applications for these inventions;
•any of the patents that cover our product candidates will be eligible to be listed in the FDA’s compendium of “Approved Drug Products with Therapeutic Equivalence Evaluations,” sometimes referred to as the FDA’s Orange Book;
•others will independently develop similar or alternative technologies or duplicate any of our technologies;
•any of our or our licensors’ pending patent applications will result in issued patents;
•any of our or our licensors’ patents will be valid or enforceable;
•any patents issued to us or our licensors and collaborators will provide us with any competitive advantages, or will be challenged by third parties;
•we will develop additional proprietary technologies that are patentable;
•governmental authorities will exercise any of their statutory rights to our intellectual property that was developed with government funding; or
•our business may infringe the patents or other proprietary rights of others.

The actual protection afforded by a patent varies based on products or processes, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country, the validity and enforceability of the patents and our financial ability to enforce our patents and other intellectual property rights. Our ability to maintain and solidify our proprietary rights to our product candidates and future products will depend on our success in obtaining effective claims and enforcing those claims once granted. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, invalidated or circumvented, and the rights granted under any issued patents may not provide us with proprietary protection or competitive advantages against competitors with similar products. Due to the extensive amount of time required for the development, testing and regulatory review of a product candidate, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent.

We may also rely on trade secrets to protect some of our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to maintain. While we use reasonable efforts to protect our trade secrets, our or any of our collaborators’ employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our proprietary information to competitors or others and we may not have adequate remedies in respect of such disclosure. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain. In addition, foreign courts are sometimes less willing than U.S. courts to protect trade secrets. If our competitors independently develop equivalent knowledge, methods or know-how, we would not be able to assert our rights to trade secrets and our business could be harmed.


51

We are a party to license agreements under which we license intellectual property and receive commercialization rights relating to certain of our product candidates. If we fail to comply with obligations in such agreements or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business; any termination of such agreements would adversely affect our business.

We are a party to license agreements that give us various commercialization rights, the loss of which (whether due to our actions or inactions or those of the respective counterparties) may adversely affect our business. For instance, in November 2018, Immunic AG and Daiichi Sankyo entered into a license and option agreement that grants us an exclusive global option to license IMU-856 and related molecules. In January 2020, we exercised this option and acquired the rights to commercialization of IMU-856 in all countries including the U.S., Europe and Japan.

The loss of (i) the licenses granted to us under our agreements with Daiichi Sankyo and other licensors, or (ii) the rights provided under such agreements, would prevent us from developing, manufacturing or marketing products covered by the license or subject to supply commitments, and could materially harm our business, financial condition, results of operations and prospects.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our technologies in all countries outside the United States, or from selling or importing products made using our technologies in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection, to develop their own products and further, may export otherwise infringing products to territories where we have patent protection but enforcement rights are weaker than in the United States. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual rights may not be effective or sufficient to prevent such competition.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries do not favor the enforcement of patents and other intellectual property rights, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights throughout the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, we may be unable to extend the term of marketing exclusivity for our product candidates and our business may be materially harmed.

Depending on the timing, duration and specifics of any FDA marketing approval of any of our product candidates, one of the U.S. patents covering each such approved product or the use thereof may be eligible for up to five years of patent term restoration under the Hatch-Waxman Act. The Hatch-Waxman Act allows extension of a maximum of one patent per FDA-approved product. Patent term extension or special protection certificates also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, among other things, failing to apply prior to applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension afforded as well as the scope of patent protection during any such extension could be less than we request.

If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we or our collaborators request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following expiration of our patent, and our potential revenue could be materially reduced.
52


We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent issued to others, which could adversely affect our ability to develop and market our product candidates.

Our patent searches or analyses (including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents) might not be accurate, complete or thorough, and could fail to identify each and every patent and pending application in the United States and other jurisdictions that is or may potentially be relevant to or necessary for the commercialization of our product candidates in any jurisdiction.

The scope of a patent claim is determined by legal interpretation, the written disclosure in a patent and the patent’s prosecution history. If our interpretation of the relevance or the scope of a patent or a pending application is not accurate and we incorrectly determine that our product candidates are not covered by a third-party patent, we could be potentially liable for infringement, prevented from marketing our product candidate, or required to seek costly licenses from patent holders.

Many patents may cover a marketed product, including but not limited to patents covering the composition, methods of use, formulations, production processes and purification processes of or for the product. The identification of all patents and their expiration dates relevant to the production and sale of a therapeutic product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. Our determination of the expiration date of any patent in the United States or other jurisdictions that we consider relevant may be incorrect, which could negatively impact our ability to develop and market our product candidates.

Obtaining and maintaining patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

The United States Patent and Trademark Office ("USPTO"), and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We employ an outside firm and rely on outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market sooner, which would have a material adverse effect on our business.

The patent protection for our product candidates may expire before we are able to maximize their commercial value, which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue.

The patents for our product candidates have, and any patents issued in the future will have, varying expiration dates and, when these patents expire, we may be subject to increased competition and we may not be able to recover our development costs or market any of our approved products profitably. In some of the larger potential markets, such as the United States and Europe, patent term extension or restoration may be available to compensate for time taken during aspects of the product’s development and regulatory review. However, extensions might not be granted or, if granted, the applicable time period or the scope of patent protection afforded during any extension period could be inadequate. In addition, even though some regulatory authorities may provide some other exclusivity for a product under their own laws and regulations, we may not be able to qualify the product or obtain exclusivity. If we are unable to obtain patent term extension, restoration or some other exclusivity, we could be subject to increased competition and our opportunity to establish or maintain product revenue could be substantially reduced or eliminated. Furthermore, we may not have sufficient time to recover our development costs prior to the expiration of our U.S. and foreign patents.

We may become involved in lawsuits or interference proceedings to protect patents held by us or our licensors or other intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful.

Competitors may infringe our patents or other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, directly or through our licensors, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of our licensor is not valid or is unenforceable, or
53

may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of the patents we own or license at risk of being invalidated or interpreted narrowly and could put our licensors’ patent applications at risk of not issuing.

Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to patents and patent applications of our licensors or those of our current or future collaborators. An unfavorable outcome could require us to cease using the technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if a prevailing party does not offer us a license on terms that are acceptable to us. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent, alone or with our collaborators, misappropriation of our proprietary rights, particularly in countries whose laws do not grant the same protections to intellectual property as fully as the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential and proprietary information could be compromised by disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price of our common stock.

Third-party claims of intellectual property infringement or misappropriation may adversely affect our business and could prevent us from developing or commercializing our product candidates.

Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation and other challenges, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex-parte review, inter party review and post-grant review proceedings before the USPTO and foreign patent offices. Numerous U.S. and foreign patents and patent applications exist in the fields in which we are developing and may develop our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to third-party claims of patent infringement. Third-party claims that we infringe on their products or technology could present a number of issues, including:
•infringement and other intellectual property claims, whether with or without merit, can be extremely expensive and time-consuming to litigate and can divert management’s attention from our core business;
•the risk of substantial court-imposed damages for past infringement;
•a court prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it would not be required to do;
•even if a license is available from the patent holder, we may have to pay substantial royalties or grant cross licenses to our patents; and
•we may need to redesign our processes to avoid further infringement, which may not be possible or could require expenditure of substantial funds and time.

Third parties may assert that we are employing their proprietary technology without authorization. We may be unaware of third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, applications filed before November 29, 2000, and certain applications filed after that date that will not be filed outside the United States, remain confidential until issued as patents. Except for the preceding exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of approximately 18 months after the earliest filing. Therefore, patent applications covering our product candidates may have been filed by others without the knowledge of us or our licensors. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use or manufacture of our product candidates. We may also face misappropriation claims if a third party believes that we inappropriately obtained and used its trade secrets. If the third-party prevails on such claims, we may be prevented from further using such trade secrets, limiting our ability to develop our product candidates, and may be required to pay damages.

If a court of competent jurisdiction held that any third-party patents covers aspects of our materials, formulations, methods of manufacture or methods for treatment, the holders of any such patents would be able to block our ability to develop and commercialize the applicable product candidate until such patent expired or unless we obtain a license. A license may not be
54

available on acceptable terms, if at all. Even if we were able to obtain a license, the rights could be nonexclusive, which could result in our competitors having access to our licensed intellectual property.

Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms or at all. In addition, during the course of any patent or other intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our product candidates, programs, or intellectual property could be diminished. Accordingly, the market price of our common stock may decline.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defending against claims of patent infringement or misappropriation of trade secrets could be costly and time-consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible to obtain or require substantial expenditure of time and money. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into collaborative arrangements that would help us bring our product candidates to market.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents and patent rights. Obtaining and enforcing patents and patent rights in the biotechnology industry involves both technological and legal complexity and, therefore, is costly, time-consuming and inherently uncertain. In addition, some patent reform legislation and court rulings in the United States have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents and patent rights, once obtained.

For our U.S. patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act ("the AIA"), was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and reviewed after issuance, and may also affect patent litigation. USPTO regulations and procedures govern administration of the AIA and many of the substantive changes to patent law associated with the AIA. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of patent rights, all of which could have a material adverse effect on our business and financial condition.

An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a “first-inventor-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date, but before we or our licensor files a patent application, could therefore be awarded a patent covering an invention of ours even if we or our licensor had made the invention before the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patent rights depends on whether the differences between the licensor’s or our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain if we (or our licensor) was the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications.

Among other changes, the AIA limits where a patentee may file a patent infringement suit and provides opportunities for third parties to challenge any issued patent in the USPTO. This applies to all U.S. patents, even those issued before March 16, 2013. Because the evidentiary standard to invalidate a patent claim in USPTO proceedings is lower than for a procedure in U.S.
55

federal court, a challenger may attempt to use the USPTO procedures to invalidate our patent rights that would not have been invalidated in federal court.

Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.

Because of the expense and uncertainty of litigation, we may conclude that, even if a third party is infringing our patents or our licensors’ patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of us or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.

Intellectual property rights do not protect against all potential threats to our potential competitive advantage.

The degree of future protection afforded by our intellectual property rights is highly uncertain because intellectual property rights have limitations and may not adequately protect our business, or permit us to maintain any competitive advantage we may gain. The following examples are illustrative:
•Others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we license from others or may license or own in the future.
•Others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights.
•Any of our collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we license or may, in the future, own or license.
•Any of our collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that we license or may, in the future, license.
•Issued patents that have been licensed to us may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.
•Our competitors might conduct research and development activities in countries where we do not have license rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.
•Ownership of patents or patent applications licensed to us may be challenged by third parties.
•The patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.

Confidentiality agreements with employees, consultants and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.

Trade secrets and/or confidential know-how can be difficult to maintain as confidential. In an effort to protect this type of information against disclosure or appropriation by competitors, we require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is challenging, expensive, time-consuming and unpredictable. The extent to which confidentiality agreements may be enforced does vary from jurisdiction to jurisdiction.

Failure to obtain or maintain trade secrets and/or trade protection of our confidential know-how could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection of that information. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how.

56

We may need to license certain intellectual property from third parties, and such licenses may not be available on commercially reasonable terms, or at all.

A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from such third parties. Such a license may not be available on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed to us or others confidential information of their former employers or other owners of confidential information.

Further, we may be subject to ownership disputes in the future arising from, among other things, consultants or third-parties who are involved in developing our product candidates. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to, and use of, confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights to certain intellectual property. Such an outcome could have a material adverse effect on our business.

Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents and other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who have been involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could be extremely costly and distract our management and other employees.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we rely on third parties to assist with research and development and to manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements are intended to limit the rights of the third parties to use, disclose or publish our confidential information, including our trade secrets. Despite these contractual restrictions, the need to share trade secrets and other confidential information increases the risk that such trade secrets could become known to our competitors, could be inadvertently incorporated into the technology of others, or could be disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent
57

development, or publication of information by any of our third-party collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. If we cannot adequately protect our trademarks and trade names, then we may not be able to build name recognition in our markets of interest and our business would be harmed. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our trademarks or trade names. Over the long term, if we are unable to successfully register and protect our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.

Risks Related to Being a Public Company

We incur significant costs and demands upon management as a result of complying with the laws and regulations affecting public companies.

We incur significant legal, accounting and other expenses that we would not incur as a private company, including costs associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), as well as existing and new rules implemented by the SEC and The Nasdaq Stock Market ("Nasdaq"). These rules and regulations increase the company’s legal and financial compliance costs and make some activities more time-consuming and costly. Not all members of our management have previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. These rules and regulations may also make it difficult and expensive for us to obtain directors’ and officers’ liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers of our company, which may adversely affect investor confidence in us and could cause our business and stock price to suffer.

Effective December 31, 2019, we are no longer an “emerging growth company,” and the reduced disclosure requirements applicable to “emerging growth companies” no longer apply, and we are required to report on internal control over financial reporting, which will increase our costs as a public company and increase the demands on management.

Effective December 31, 2019, the fiscal year-end following the fifth anniversary of the completion of our initial public offering, we are no longer an “emerging growth company” as defined in the Jumpstart Our Business Startups Act. As a result, we are incurring significant additional expenses in complying with certain provisions of the Sarbanes-Oxley Act and rules implemented by the SEC. Moreover, if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. Furthermore, investor perceptions of us may suffer if, in the future, material weaknesses are found, and this could cause a decline in the market price of our stock. Any failure of our internal control over financial reporting could have a material adverse effect on the company’s stated operating results and harm our reputation. If we are unable to implement these changes effectively or efficiently, it could harm our operations, financial reporting and financial results and could result in an adverse opinion on internal control from our independent registered public accounting firm.

In addition, we are no longer eligible for reduced disclosure requirements applicable to emerging growth companies regarding executive compensation and exemptions from the requirements of holding advisory say-on-pay votes on executive compensation. These increased disclosure requirements require additional attention from management and increased costs to the company, including higher legal fees, accounting fees and fees associated with investor relations activities, among others.
58


Risks Related to Our Common Stock

The market price of our common stock has been and is expected to continue to be volatile.

The market price of our common stock has been, and is expected to continue to be, subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:
•reports on or the perception of clinical trial progress, or the lack thereof, which we experienced in October 2022 when our stock price and market capitalization decreased significantly after announcing Phase 1b interim analysis of IMU-935 for the first two dose patient cohorts with moderate-to-severe psoriasis;
•our ability to obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals;
•failure of any of our approved product candidates to achieve commercial success;
•failure to maintain our existing third-party license, supply and manufacturing agreements;
•failure by us or our licensors to prosecute, maintain, or enforce our intellectual property rights;
•changes in laws or regulations (or their interpretation) applicable to our product candidates;
•any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices;
•adverse regulatory authority decisions or delays;
•introduction of new products, services, or technologies by our competitors;
•failure to meet or exceed financial and development projections that we may provide to the public;
•failure to meet or exceed the financial and development projections of the investment community;
•the perception of the pharmaceutical industry in general, and companies addressing our disease indications in particular, by the public, legislatures, regulators and the investment community;
•announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by us or our competitors;
•disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;
•additions or departures of key personnel;
•significant lawsuits, including patent, product liability or stockholder litigation;
•if securities or industry analysts do not publish research or reports about our business, or if they issue negative or misleading opinions regarding our business and stock;
•changes in the market valuations of similar companies;
•general market or macroeconomic conditions;
•sales of common stock by the company or our stockholders in the future;
•trading volume of our common stock;
•announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;
•adverse publicity relating to the markets in which we operate, including with respect to other products and product candidates in such markets;
•the introduction of technological innovations or new therapies that compete or might compete with our product candidates;
•changes in the structure of healthcare payment systems; and
•period-to-period fluctuations in our financial results.

Moreover, stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations have had, and can be expected to continue to have, adverse effects on the trading price of our common stock.

In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.
59


Additionally, a decrease in our stock price may cause our common stock to no longer satisfy the continued listing standards of The Nasdaq Global Select Market. If we are not able to maintain the requirements for listing on The Nasdaq Global Select Market, we could be delisted, which would likely result in an immediate and significant decline in the trading price and liquidity of our stock, and would have a materially adverse effect on our ability to raise additional funds.

Anti-takeover provisions in our organizational documents and Delaware law might discourage or delay acquisition attempts for the company that stockholders might consider favorable.

Our Amended and Restated Certificate of Incorporation, and Amended and Restated Bylaws, contain provisions that may delay or prevent an acquisition or change in control of the company. Our certificate of incorporation and bylaws include provisions that:
•authorize our board of directors to issue without further action by the stockholders, up to 20,000,000 shares of undesignated preferred stock;
•require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;
•establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
•provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; and
•establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms.

Further, as a Delaware corporation, we are subject to provisions of Delaware corporations law, which may impair a takeover attempt that our stockholders may find beneficial. These anti-takeover provisions and other provisions under Delaware law could discourage, delay or prevent a transaction involving a change in control of our company, including actions that our stockholders may deem advantageous, or could negatively affect the trading price of our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and to cause us to take other corporate actions they desire.

We may experience adverse consequences because of required indemnification of officers and directors.

Provisions of our certificate of incorporation and bylaws provide that we will indemnify any director and officer as to liabilities incurred in their capacity as a director or officer and on those terms and conditions set forth therein to the fullest extent of Delaware law. Further, we have purchased directors and officers insurance on behalf of any such persons whether or not we would have the power to indemnify such person against the liability insured against. The foregoing could result in substantial expenditures by us and prevent any recovery from our officers, directors, agents and employees for losses incurred by the company as a result of their actions.

We do not anticipate that we will pay any cash dividends in the foreseeable future.

The current expectation is that we will retain any future earnings to fund the development and growth of our business. As a result, any capital appreciation of the common stock of the company will be stockholders’ sole source of any gain for the foreseeable future.

General Risk Factors

If we fail to maintain proper and effective internal controls, our ability to produce accurate financial
statements on a timely basis could be impaired.

We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and Nasdaq rules and regulations. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. We must perform system and process evaluation and testing of our internal controls over financial reporting to allow
60

management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K for each year, as required by Section 404 of the Sarbanes-Oxley Act ("Section 404"). This requires significant management efforts and requires us to incur substantial professional fees and internal costs to expand our accounting and finance functions. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal controls over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our financial statements, or may identify other areas for further attention or improvement. Furthermore, we cannot be certain that our efforts will be sufficient to remediate or prevent future material weaknesses or significant deficiencies from occurring.

If we are not able to comply with the requirements of Section 404, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock would likely decline and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities.

Our business and stock price could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.

Stockholders may, from time to time, engage in proxy solicitations or put forth stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition and divert management’s attention. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or management team arising from a proxy contest or initiatives of activist stockholders could lead to the perception of a change in the direction of our business or instability, which may result in the loss of potential business opportunities, make it more difficult to pursue strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results and the trading price of our stock. If individuals are ultimately elected to our board of directors with a specific agenda, our ability to effectively implement our business strategy and create additional value for our stockholders may be adversely effected. We may choose to initiate, or may become subject to, litigation as a result of a proxy contest or matters arising from a proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant negative or other fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.

An active trading market for our common stock may not be sustained and our stockholders may not be able to resell their shares of common stock for a profit, if at all.

An active trading market for our shares of common stock may not be sustained. If an active market for our common stock is not sustained, it may be difficult for stockholders to sell their shares at an attractive price or at all.

Future sales of shares by existing stockholders could cause our stock price to decline.

If existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, whether after legal restrictions on resale lapse or at other times, the trading price of our common stock could decline.

If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.

The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. If we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could substantially decline immediately if one or more equity research analysts downgrade our stock or issue other
61

unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price and trading volume to decline.

If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations.

We have incurred net losses since our inception, and expect to continue to incur operating losses for the foreseeable future. If we become profitable in the future, our ability to use net operating loss carryforwards, or NOLs, and other tax attributes to offset future taxable income or reduce taxes may be subject to limitations. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” (generally defined as a greater than 50% cumulative change by value in its equity ownership of certain stockholders over a rolling three-year period) is subject to an annual limitation on its ability to utilize its pre-change NOLs and other tax attributes (including any research and development credit carryforwards). Similar provisions of state tax law may also apply to limit the use of our state NOLs and other tax attributes.

We have not performed an analysis to determine whether our past issuances of stock and other changes in our stock ownership may have resulted in one or more ownership changes within the meaning of Sections 382 and 383 of the Code. In addition, we may experience an ownership change in the future as a result of subsequent changes in our stock ownership, some of which are outside our control; and we are not intending to take any steps to prohibit any subsequent changes in our stock ownership in order to avoid such an ownership change. If an ownership change has occurred in the past or occurs in the future, we may not be able to use a material portion of our NOLs and other tax attributes to offset future taxable income or taxes if we attain profitability.

In addition to any limitation imposed by Section 382 of Code, the use of NOLs arising after December 31, 2017 generally is limited to a deduction of 80% of taxable income for the corresponding taxable year. NOLs arising after December 31, 2017, with certain exceptions, may not be carried back to previous taxable years, but may be carried forward indefinitely.

Item 1B. Unresolved Staff Comments.
Not applicable.
Item 2. Properties.
As of December 31, 2022, we lease approximately 24,300 square feet in Germany in Gräfelfing and approximately 3,300 square feet of office space in the U.S. in New York City.
The New York City lease, which we entered into in November 2019, expires in July 2025 and provides the principal location for our U.S. operations. The Gräfelfing, Germany lease, which was effective July 1, 2020 and then adjusted on March 1, 2021 and August 1, 2022 to add more square footage, expires in June 2025.
Item 3. Legal Proceedings.

We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.
Item 4. Mine Safety Disclosures.
Not applicable.
62

PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information
Our common stock is listed on the Nasdaq Global Select Market under the symbol "IMUX".
Holders
As of February 17, 2023, there were 42 holders of record of our common stock, which excludes stockholders whose shares were held in nominee or street name by brokers. The actual number of common stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
Dividend Policy
We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.
Securities Authorized for Issuance under Equity Compensation Plans
Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.
Unregistered Sales of Equity Securities
None.
Issuer Purchases of Equity Securities
None.
63

Item 6. Selected Financial Data.
Not applicable.
64

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in “Risk Factors” included elsewhere in this Annual Report. As used in this report, unless the context suggests otherwise, “we,” “us,” our” or “the Company” refer to Immunic, Inc. and its subsidiaries.
Overview
We are a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gräfelfing near Munich, Germany. We currently have approximately 66 employees.

We are currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (“MS”); the izumerogant (proposed International Nonproprietary Name (“INN”) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (“RORγt”) that inhibits the interleukin-17 (“IL-17”) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.
We have incurred net losses since inception of $317.3 million through December 31, 2022. We anticipate that we will continue to incur losses for at least the next several years. Due to the uncertainties involved with therapeutic product development and the clinical trial process, we cannot predict the timing or level of future expenses with certainty, when product approval might occur, if ever, or when profitability may be achieved or sustained.
Recent Events
$60 Million Private Placement Equity Financing
On October 10, 2022, we entered into a Securities Purchase Agreement for a private placement with select accredited investors and certain existing investors. Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants to purchase Common Stock, at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return. All of the pre-funded warrants were exercised in January 2023.

The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0 million, before deducting offering expenses payable by us of approximately $4.0 million. We intend to use the net proceeds from the Private Placement to fund the ongoing clinical development of our three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.

New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential

On November 17, 2022, we reported newly available data from the Phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis (“RRMS”). The trial includes an optional long-term open-label extension (“OLE”) phase running up to 9.5 years. An interim analysis was performed with data extraction in October 2022, when 209 patients remained on treatment in the OLE phase, some of whom have already received more than 180 continuous weeks (approximately four years) of active treatment with vidofludimus calcium.
65


Long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, comparing favorably to historical trial data for currently available MS medications. During the 24-week double-blind main treatment period, 12-week and 24-week Confirmed Disability Worsening (“12w/24wCDW”) events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. In the OLE phase, the proportion of patients free from 12wCDW was 97.6% after 48 weeks and 94.5% after 96 weeks of vidofludimus calcium treatment as compared to the start of the OLE phase. Similar results were observed for 24wCDW and sustained CDW. The OLE phase also showed low relapse activity.

Presentation of Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS at ACTRIMS Forum 2023

On February 22, 2023, we announced that Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present data from the blinded and OLE parts of our phase 2 EMPhASIS trial of vidofludimus calcium in RRMS at the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023, taking place February 23-25 in San Diego, California. The poster presentation includes our previously announced data from the trial showing that long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, comparing favorably to historical trial data for currently available MS medications.

Publication of Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in Peer Reviewed Journal

On June 15, 2022, we announced that data from our Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS has been published in the peer reviewed journal, Annals of Clinical and Translational Neurology. The paper, authored by coordinating investigator, Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, is entitled, “Safety and efficacy of vidofludimus calcium, a selective dihydroorotate dehydrogenase inhibitor, in relapsing-remitting multiple sclerosis (EMPhASIS): a double-blind, randomized, placebo-controlled Phase 2 trial.”

Results of Phase 1 Trial of Vidofludimus Calcium in Hepatic Impaired Patients

We completed a Phase 1 trial in a total of 24 patients with either no liver function impairment or liver disease of Child-Pugh A Child-Pugh B grade which was designed to explore dose optimization of vidofludimus calcium. The study showed little influence on the PK of vidofludimus calcium in patients with Child-Pugh A Child-Pugh B liver impairment.

Update on the Use of Steroids in the Phase 2 EMPhASIS Trial in RRMS

Based on the observed interaction between vidofludimus calcium and chronic steroid use in the CALDOSE-1 trial in ulcerative colitis patients, we performed a post-hoc analysis of our Phase 2 EMPhASIS data in RRMS patients to explore the potential influence of steroids on these study results. As anticipated, steroid use was rare and among those RRMS patients who received any steroids, the majority received only short steroid courses following relapse events or acute neurological events. Only four patients received any steroids for reasons other than relapse (COVID-19 infection, eczema, acute bronchitis, and contact urticaria, one patient each). Most patients only had one single short course of steroids, and only nine patients had two or more steroid courses. The average duration of steroid treatment in this RRMS trial was 4.4 days with a maximum duration of 10 days. This indicates to us that steroids are rarely used in MS patients and mostly for a very short duration. In conclusion, comparing patients who received at least one dose of corticosteroids with those who did not, we do not see any difference in clinical parameters or any evidence that the rare, short-term use of steroids in RRMS patients has any influence on the effectiveness of vidofludimus calcium in this patient population.

Celiac Disease Research and Development Webcast

On February 9, 2023, we hosted a celiac disease research and development webcast. Our management, including Daniel Vitt, Ph.D., Chief Executive Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, were joined by renowned key opinion leaders to discuss the dynamics of this multifactorial, complex autoimmune disease, immune stimulation and its connection to clinical symptoms, the role of the epithelial barrier in the pathogenesis of the disease, current and potential treatment options, and the continued unmet medical need for effective therapeutics, which is driving an increased focus within the industry.


66

Phase 1 Clinical Trial of IMU-856, Results of Parts A and B in Healthy Human Subjects

On September 20, 2022, we announced positive unblinded safety, tolerability and pharmacokinetic (“PK”) results from Part A (single ascending doses) and Part B (multiple ascending doses) of our Phase 1 clinical trial of IMU-856 in healthy human subjects.

In the single ascending doses part, healthy human subjects were randomized in a double-blinded manner to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg. Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. No serious adverse events occurred. Moreover, a dose-linear PK profile was observed across the investigated dose range.

In the multiple ascending doses part, healthy human subjects were dosed for 14 consecutive days with 40 mg, 80 mg or 160 mg once-daily of IMU-856 or placebo in a double-blinded manner. Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. Treatment emergent adverse events were mostly mild in severity. No Investigational Medicinal Product-related serious adverse events were reported. No dose-dependent changes in laboratory parameters (including no effects on liver enzymes or in hematological parameters), vital signs, physical examination or electrocardiographic evaluations were found. PK analysis showed a quick achievement of stable steady-state plasma concentrations within the first week and stable steady-state trough levels over the 14-day treatment period with a low accumulation factor for IMU-856, allowing predictable trough levels during daily dosing. PK parameters in steady-state revealed a Tmax (time to reach maximum plasma concentration) of 2 to 3 hours post-dose, a plasma half-life of 17.4 to 21.5 hours and dose proportional increases in Cmax (maximum plasma drug concentration) and AUC (area under the concentration-time curve).

IMU-856 Composition-of-Matter Patent Granted

On August 16, 2022, we announced that we have received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for patent application 16/646130, entitled, “Compound Having Cyclic Structure.” The patent covers composition-of-matter of IMU-856 and related pharmaceutical compositions and is expected to provide protection into at least 2038, without accounting for potential PTE.

Start of Patient Cohorts in Phase 1 Clinical Trial of IMU-856 in Celiac Disease

On May 5, 2022, we announced the start of the patient cohorts in our ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease. Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety, tolerability, PK, pharmacodynamic (“PD”) and biomarker responses of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge. Approximately 42 patients were planned to be enrolled in two consecutive cohorts with IMU-856 given once-daily over 28 days. Secondary objectives include PK and disease markers, including those evaluating gastrointestinal architecture and inflammation. Sites in Australia and New Zealand are participating in Part C. Initial results are expected to be available in mid-2023.
Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis

On June 2, 2022, we reported top-line data from our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (“UC”). The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10. In addition, no meaningful differences were observed between the three active dose groups for the overall intent-to-treat patient population (10 mg/day: 14.9%, 30 mg/day: 10.6%, 45 mg/day: 13.6%, placebo: 12.5%) or for the trial’s other secondary endpoints, including symptomatic remission, or endoscopic healing.

Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this clinical trial was observed to be safe and well-tolerated. No new safety signals were observed. As compared to placebo, there were no increased rates of infections and infestations, no elevated rates of liver events or liver enzyme elevations, and no elevated rates for changes in hematology-related laboratory variables. The most common adverse events in this clinical trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and COVID-19 (7/263 patients, 2.7%). Most adverse events were generally mild in severity.

As is common for the design of clinical trials in UC, the use of oral systemic corticosteroids (≤20 mg/day prednisolone equivalent) was allowed in CALDOSE-1 in patients who had been treated with corticosteroids for at least four weeks before
67

randomization. Doses of corticosteroids were required to be kept constant throughout the induction phase (weaning was not allowed in this phase of the clinical trial), and the distribution of patients using corticosteroids was equal throughout all treatment groups. Surprisingly, CALDOSE-1 data suggest a previously unknown treatment interference between the efficacy of vidofludimus calcium and the concurrent use of corticosteroids in the UC patient population. More specifically, the non-steroid patient population showed an 11.4% advantage in clinical remission for vidofludimus calcium over placebo (pooled vidofludimus calcium treatment groups at week 10: 14.7%, placebo: 3.3%). Such a difference in clinical remission between active treatment and placebo would traditionally be considered as confirming therapeutic activity. In contrast, patients concomitantly taking vidofludimus calcium and corticosteroids during induction treatment had a lower rate of clinical remission at week 10 (11.5%) than placebo patients (20.6%) and also lower than the group of vidofludimus calcium monotherapy without concurrent use of steroids (14.7%). This treatment interference between vidofludimus calcium and corticosteroids was not expected based on our analysis of currently available preclinical or clinical data.

Based on these results, we announced that our development programs in the IBD indications will not be continued without a partner.

Investigator-Sponsored Phase 2 IONIC Trial in Moderate-to-Severe COVID-19 Closed Down

On June 23, 2022, sponsor and lead site, University Hospitals Coventry and Warwickshire NHS Trust, London, United Kingdom, informed us that the investigator-sponsored Phase 2 IONIC trial for the treatment of patients with moderate-to-severe COVID-19 is being closed down. Recruitment for the trial ended on May 20, 2022 and the last patient follow-up occurred in September 2022. On September 29, 2022, we were informed that the sponsor submitted the end of trial declaration. The trial was a prospective, randomized, parallel-group, open-label Phase 2b trial, designed to evaluate efficacy and safety of vidofludimus calcium in combination with the neuraminidase inhibitor, Oseltamivir (TamifluⓇ), in approximately 120 adult patients with moderate-to-severe COVID-19.

Pre-Planned Phase 1b Interim Analysis of Izumerogant in Moderate-to-Severe Psoriasis and Goodwill Impairment

On October 20, 2022, we announced the outcome of a pre-planned interim group-level data analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis. The overall trial is ongoing. The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index ("PASI”) reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Administration of izumerogant and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We plan to provide further updates and guidance on potential next steps for this development program towards the end of the first quarter of 2023.

Following the announcement of our interim group level data on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement and the recent prices raised in our October 10, 2022 Private Placement. We considered these to be triggering events indicating that it is more likely than not that goodwill is impaired. Upon further evaluation we incurred a non-cash full impairment of our goodwill of approximately $33.0 million in the quarter ended December 31, 2022.

Phase 1 Clinical Trial of Izumerogant in mCRPC

The pre-planned dose escalation in the Phase 1 clinical trial of izumerogant in mCRPC with dosing of up to 900 mg daily has been completed. Initial safety data available, to date, show a promising safety profile, with only benign adverse events and no dose limiting toxicities.

Izumerogant Composition-of-Matter Patents Granted

On February 2, 2022, we received a Notice of Allowance from the USPTO for patent application 16/644581, entitled, “IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation”. We also received notice of allowance of patent application EP18762111.5 in Europe, and notice of grant of patent application 2018330633 in Australia. All three patents cover composition-of-matter of izumerogant and related formulations, and are expected to provide protection into at least 2038, without accounting for potential Patent Term Extension ("PTE") in the United States or Supplementary Protection Certificates in Europe, respectively.



68

Results of Exploratory Phase 1 Drug-Drug Interaction Study of Izumerogant

An exploratory Phase 1 study was completed in 15 evaluable healthy human subjects to assess the drug-drug interaction potential of izumerogant. No relevant signals for drug-drug interaction potential were observed and treatment was safe and well-tolerated.

Phase 1 Clinical Trial of Izumerogant, Results of Parts A and B in Healthy Human Subjects

On July 12, 2021, we provided an update on our izumerogant program, including new preclinical and clinical data. The main result from preclinical investigations was that izumerogant inhibits cytokine production (thought to be a pre-condition for its use in immunological and autoimmune diseases) while maintaining the known and required physiological functions of maturing T lymphocytes. In ex vivo mouse cell differentiation and maturation assays, izumerogant was observed to selectively inhibit RORγt-dependent gene expression during Th17 differentiation without affecting either RORγt-dependent gene regulation relevant to thymocyte development, or the viability of these cells. In third-party research, impairment of thymocyte development has been shown to be associated with serious safety issues, including, among others, T cell malfunction and potential lymphoma formation. We believe that izumerogant's observed selectivity may enable it to inhibit both the generation of Th17 cells and the production of IL-17 cytokines that are responsible for the development of autoimmune diseases, without impairing thymocyte development, which is associated with the potential risk of lymphoma seen with other, third-party RORγt programs.

On December 14, 2021, we provided an update on the preclinical and clinical development of izumerogant, announcing that:

•Unblinded data from the single ascending dose part of the ongoing Phase 1 clinical trial of a new powder-in-capsule formulation of izumerogant, in which healthy human subjects were treated with 100 mg, 200 mg, 300 mg and 400 mg of this new formulation or placebo, found these single ascending daily doses of izumerogant to be safe and well-tolerated, and no maximum tolerated dose was reached. No serious adverse events occurred. A dose-proportional PK profile was observed across the investigated dose range.

•Unblinded data from the multiple ascending dose part of the ongoing Phase 1 clinical trial, in which healthy human subjects were dosed for 14 days with 150 mg either once or twice daily doses of izumerogant or placebo, found these multiple ascending doses of izumerogant to be safe and well-tolerated, and no maximum tolerated dose was reached. Treatment emergent adverse events were generally mild in severity, with moderate treatment emergent adverse events reported in one of eleven izumerogant treated subjects, compared with one of four subjects on placebo. No serious adverse events were reported. No dose-dependent changes in laboratory values (including no effects on liver enzymes or in hematological parameters), vital signs or in electrocardiographic evaluations were found. PK analysis showed that stable steady-state plasma concentrations were achieved within the first week of dosing with an accumulation factor for izumerogant allowing predictable trough levels during daily dosing.

•Based on the favorable safety and tolerability data observed in healthy human subjects, our Phase 1 clinical trial of izumerogant was expanded in October 2021 to include a third portion, part C, in which moderate-to-severe psoriasis patients are randomized to 28-day treatment of izumerogant or placebo. Assessments include safety, tolerability, PK and PD markers, as well as skin evaluations.

•In previous preclinical in vitro data, it was shown that izumerogant selectively inhibits Th17 differentiation and IL-17 production, whereas RORγt was unaffected by izumerogant during thymocyte maturation and, therefore, does not harm normal thymocyte maturation. Data from acute and chronic treatment of mice corroborated in vivo that izumerogant is the first molecule observed to impact neither thymus size, thymocyte numbers, nor the maturation status of thymocytes, in contrast to two other known inhibitors of RORγt.


Changes in Board of Directors

On July 6, 2022, we announced the appointment of Monika Maria Törnsén as a member of our Board of Directors, effective as of July 5, 2022. As a Class III director, Ms. Törnsén’s term lasts until the Company’s 2023 annual meeting of stockholders. Concurrently, we also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche’s resignation effective July 5, 2022. Mr. Van den Bossche’s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.

69

Executive Chairman Agreement with Duane Nash

On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the “Executive Chairman Agreement”) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an “at will” employment relationship with a base salary of $25,417 per month pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, the Company and Dr. Nash entered into an addendum (the “First Addendum”) to extend the term of the Executive Chairman Agreement to April 15, 2021. In connection with the First Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 120,000 shares of Company common stock, which vests monthly over six months commencing on November 15, 2020. On April 15, 2021, the Company and Dr. Nash entered into Addendum No. Two (the “Second Addendum”) to extend the term of the Executive Chairman Agreement to April 15, 2022. In connection with the Second Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly over 12 months commencing on May 15, 2021, and to increase Dr. Nash’s monthly base salary to $27,960 from $25,417. On March 15, 2022, the Company and Dr. Nash entered into Addendum No. Three (the “Third Addendum”), which extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month. In connection with the Third Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company’s common stock, which vests monthly over 12 months commencing on April 10, 2022. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company’s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.

Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States ("US"), or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, management makes its best estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are typically recognized in the period when new information regarding estimates becomes available to management. Actual results could differ from those estimates.
Our significant accounting policies are described in more detail in Note 2, "Summary of Significant Accounting Policies," in the notes to the consolidated financial statements. See below for what we believe are our Critical Accounting Policies.
Foreign Currency Translation and Presentation
Our reporting currency is US dollars. During the twelve months ended December 31, 2022 and 2021, Immunic AG’s operations were located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.’s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the US dollar are translated into US dollar equivalents at exchange rates as follows:
• assets and liabilities at reporting period-end rates;
• income statement accounts at average exchange rates for the reporting period; and
• components of equity at historical rates.
Gains and losses from translation of the financial statements into US dollars are recorded in stockholders’ equity net of the anticipated income tax effects as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (loss). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.

70

Goodwill
Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry or market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.
On October 20, 2022, we announced the outcome of a significant interim analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis which was not deemed positive progress. On October 21, 2022, we experienced a significant decrease in our market capitalization. We considered this to be a triggering event as the fair market value of the company was less than its book value indicating that it is more likely than not that goodwill is impaired. Upon further evaluation, we recorded an approximately $33.0 million goodwill impairment charge in the fourth quarter of 2022 which represents a full write down of our previous goodwill balance. We did not have any goodwill impairment during the year ended December 31, 2021.
Research and Development Expenses
These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC, PMS and COVID-19.
Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.
The Company enters into agreements with contract research organizations (“CROs”) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (“MSA”). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.
Collaboration Arrangements
Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers” and ASU No. 2018-18, “Collaborative Arrangements” ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.
In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.
71

On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent & Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.
Stock-Based Compensation 
The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award’s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.
The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company’s common stock, the expected volatility of the price of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, the Company’s stock-based compensation expense could be materially different in the future.
Income Taxes
We are subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.
We utilize the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December 31, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.
It is our policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. we recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We are subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2017 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.
Components of Results of Operations
Revenue
To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates or achieving market acceptance and commercial success for any product that does receive regulatory approval.

72

Research and Development Expenses
Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include:

•external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and

•internal personnel expenses.
We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.
Since our inception in March 2016, we have spent a total of approximately $214.8 million in research and development expenses through December 31, 2022.
These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. We have spent the majority of our research and development resources on vidofludimus calcium, our lead development program, for clinical trials in MS, UC, COVID-19 and PSC.
In August 2019, Immunic AG received a grant of up to approximately $730,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project. The grant funds have been used to fund a three-year research project relating to autoimmune diseases by us and our three project partners. Since the inception of the grant, we have recorded $611,000 of income in total of which $254,000 and $178,000 were recorded in 2022 and 2021, respectively, and were classified in Other Income in the accompanying consolidated statement of operations.
Our research and development expenses are expected to increase in the foreseeable future as we continue to conduct ongoing research and development activities, initiate new preclinical and clinical trials and build our pipeline of product candidates. Our research and development expenses may also increase in the foreseeable future due to the current inflationary environment as well as supply chain shortages, which result in increased costs. The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.
Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate’s commercial potential.
General and Administrative Expenses
General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation.
Other Income (Expense), Net
Interest Income
Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has been increasing throughout 2022 as interest rates in the U.S. have been increasing.
Other Income (Expense), Net
Other income (expense) consists primarily of a research and development tax incentive related to clinical trials performed in Australia and foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the
73

foreseeable future. The intercompany loan between Immunic Inc. and Immunic AG was settled on September 28, 2022 through an equity infusion from Immunic Inc. to Immunic AG.

Results of Operations
Comparison of Fiscal Years Ended December 31, 2022 and 2021
The following table summarizes our operating expenses for the years ended December 31, 2022 and 2021 (dollars in thousands):
 Years Ended December 31,Change
 20222021$%
Operating expenses:
Research and development$71,255 $61,115 $10,140 17 %
General and administrative15,263 13,300 1,963 15 %
Goodwill impairment (see Note 2)32,970 — 32,970 NM
4SC royalty settlement (see note 4)— 17,250 (17,250)NM
Total operating expenses119,488 91,665 27,823 30 %
Loss from operations(119,488)(91,665)(27,823)30 %
Total other expense, net(919)(1,280)361 (28)%
Net loss(120,407)(92,945)(27,462)30 %

Research and development expenses increased by $10.1 million during the twelve months ended December 31, 2022, as compared to the twelve months ended December 31, 2021. The increase reflects (i) a $9.2 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $3.9 million increase in external development costs related to the clinical trials of izumerogant, (iii) a $3.9 million increase in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in progressive multiple sclerosis, (iv) a $2.5 million increase in personnel expense in research and development, $1.5 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, and (v) a $1.4 million increase in external development costs related to the Phase 1 clinical trial of IMU-856. The increases were partially offset by (i) a decrease of $5.8 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis, (ii) a $3.0 million decrease in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in COVID-19, (iii) a decrease of $1.3 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in relapsing-remitting multiple sclerosis, and (iv) a decrease of $0.7 million in external development costs across numerous categories.

General and administrative expenses increased by $2.0 million during the twelve months ended December 31, 2022, as compared to the twelve months ended December 31, 2021. The increase was primarily due to (i) a $1.6 million increase in personnel expense in general and administrative, $0.5 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, (ii) a $0.3 million increase in travel expenses, and (iii) a $0.1 million net increase across numerous categories.
On October 20, 2022, we announced the outcome of a significant interim analysis of our Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis, which was not deemed positive progress. On October 21, 2022, we experienced a significant decrease in the Company's market capitalization. The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired. Upon further evaluation, we recorded an approximately $33.0 million non-cash goodwill impairment charge in the fourth quarter of 2022 which represents a full write down of our previous goodwill balance.

On March 31, 2021, Immunic AG and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25 million (Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic’s common stock. No further payment obligations remain between Immunic and 4SC AG.

Other expense decreased by $0.4 million during the twelve months ended December 31, 2022, as compared to the twelve months ended December 31, 2021. The decrease was primarily attributable to (i) a $1.0 million increase in interest income as a
74

result of higher interest rates, and (ii) a $0.5 million increase in research and development tax incentives for clinical trials in Australia as a result of increased spending on clinical trials in Australia. This was offset by a $1.1 million decrease in grants.
Liquidity and Capital Resources
Overview
We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. Our net losses were approximately $120.4 million and $92.9 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of approximately $317.3 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.
We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to operate as a company with an advanced pipeline of product candidates. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.
From inception through December 31, 2022, we have raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, we had cash and cash equivalents of approximately $106.7 million and investments - other of $9.6 million. With these funds we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.
In November 2020, we filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement"). The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of February 17, 2023, there is $75.0 million remaining on this shelf registration statement.
In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink as agent ("December 2020 ATM"). We have used and intend to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days’ prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on us. As of February 17, 2023, $8.4 million in capacity remains under the December 2020 ATM.
In May 2022, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Securities LLC as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Securities LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days’ prior notice, or by SVB Securities LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company. As of February 17, 2023, $80.0 million in capacity remains under the May 2022 ATM.
For the year ended December 31, 2022, we raised gross proceeds of $40.9 million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6 million after deducting underwriter commissions of $1.2 million.
75

Equity Offerings
$60 Million Private Placement Equity Financing
On October 10, 2022, we entered into a Securities Purchase Agreement for a private placement with select accredited investors and certain existing investors. Pursuant to the Securities Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants to purchase Common Stock, at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, are immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. All of the Pre-Funded Warrants were exercised in January 2023.

The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0 million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.
July 2021 Public Equity Offering

On July 15, 2021, we entered into an underwriting agreement with Piper Sandler & Co., as representative of the several underwriters listed on Schedule A thereto, in connection with our public offering of 4,500,000 shares of our common stock, $0.0001 par value per share, at a public offering price of $10.00 per share. Under the terms of the underwriting agreement, we granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 675,000 shares of common stock at the public offering price, less underwriting discounts and commissions. This option was not exercised.

On July 19, 2021, we closed the offering. The net proceeds to us from the offering were approximately $42.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
Future Capital Requirements
As noted above, we have not generated any revenue from product sales and we do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we expect our expenses to increase as we continue the ongoing research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. We also incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations.
Our future expenses and capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:
76

•the timing and structure of any strategic options and transactions, if any;
•the cost, timing and outcome of any future litigation;
•personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;
•the scope, progress, duration, results and costs of research and development and ongoing clinical trials;
•the cost and timing of future regulatory submissions;
•the cost and timing of developing and validating the manufacturing processes for any potential product candidates;
•the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;
•our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;
•the number and characteristics of any future product candidates we pursue;
•the costs involved with being a public company;
•the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and
•the timing, receipt and amount from the sales of, or royalties on, any future products.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. Recent developments, however, will make it more difficult and costly for us to obtain funding for our cash needs. We do not expect to achieve revenue from product sales prior to the use of the net proceeds from our public and private offerings to date. We do not have any committed external source of funds. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders. Sales of equity securities will also be more difficult for at least the foreseeable future because of general volatility in the equity markets for companies like us, as well as the significant decline in the trading price of our stock following our announcement on October 21, 2022 of the Phase 1b interim analysis of izumerogant in moderate-to-severe psoriasis. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. Also, the cost of debt financing has increased due to the rise in interest rates beginning in March 2022. If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, we may relinquish all control over the organization and could experience detrimental tax effects. If we are unable to raise adequate funds, we may have to liquidate some or all of our assets. Any of these factors could harm our operating results and could result in substantial declines in the trading price of our common stock.
As of December 31, 2022, we had cash and cash equivalents of approximately $106.7 million.
Cash Flows
The following table shows a summary of our cash flows for the years ended December 31 (in thousands):
20222021
Cash (used in) provided by:
Operating activities$(65,144)$(83,233)
Investing activities(9,741)(67)
Financing activities95,760 42,841 
77

Net cash used in operating activities
During the year ended December 31, 2022, operating activities used $65.1 million of cash. The use of cash related to our net loss of $120.4 million adjusted for non-cash charges of $45.7 million related to $33.0 million of goodwill impairment, $7.9 million of stock-based compensation and a $4.8 million foreign currency loss as well as a $9.5 million net change in our operating assets and liabilities. Changes in our operating assets and liabilities consisted primarily of an decrease of $7.5 million in prepaid expenses and other current assets combined with a $2.0 million increase in other current liabilities, accrued expenses and accounts payable. The decrease in prepaid expenses and other current assets is primarily due to lower prepaid clinical costs. The increase in liabilities is primarily due to an increase in clinical costs as a result of the start of our Phase 3 clinical studies for RMS and Phase 2 clinical studies for PMS.
During the year ended December 31, 2021, operating activities used $83.2 million of cash. The use of cash related to our net loss of $92.9 million adjusted for non-cash charges of $8.6 million related to common stock issued for the 4SC AG transaction, $5.9 million related to stock-based compensation and a $4.3 million unrealized foreign currency loss as well as a $9.3 million net change in our operating assets and liabilities. Changes in our operating assets and liabilities consisted primarily of an increase of $12.8 million in prepaid expenses and other current assets partially offset by $3.5 million increase in other current liabilities, accrued expenses and accounts payable. The increase in prepaid expenses and other current assets is primarily due to higher prepaid clinical costs and an increased receivable for the Australian research and development credit. The increase in liabilities is primarily due to an increase in clinical costs as a result of the start of our Phase 3 clinical studies for RMS and Phase 2 clinical studies for PMS.
Net cash used in investing activities
During the year ended December 31, 2022, net investing activities used $9.7 million of cash, primarily due to purchase of 9.6 million of time deposits that had an original maturity of greater than three months and the purchase of equipment.
During the year ended December 31, 2021, net investing activities used $0.1 million of cash, primarily due to purchase of equipment.
Net cash provided by financing activities
During the year ended December 31, 2022, financing activities provided $95.8 million of cash of consisting of net cash proceeds from the sale of common stock under the $60 Million Private Placement Equity Financing and the December 2020 ATM.
During the year ended December 31, 2021, financing activities provided $42.8 million of cash of consisting of net cash proceeds from the sale of common stock under the July 2021 equity offering and the December 2020 ATM.
Off-Balance Sheet Arrangements
Through December 31, 2022, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.
Other Commitments and Obligations
In May 2016, the Company entered into a purchase agreement with 4SC whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction was accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company’s common stock to 4SC at the time, while keeping the obligation to pay Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.3 million (Tranche III of the purchase agreement). The payment was made 50% in cash and 50% in shares of Immunic’s common stock. Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the
78

resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.
See Note 2 - Collaboration Arrangements of the Notes to the Financial Statements regarding the Company’s obligations under the option agreement with Daiichi Sankyo, which includes the potential payment of future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.
 Maturities of the operating lease obligation are as follows as of December 31, 2022 (in thousands):
2023$647 
2024$680 
2025$355 
2026$— 
2027$— 
Thereafter$— 
Total lease payments$1,682 
Less: interest portion$147 
Present value of lease obligation$1,535 
Contractual Obligations
As of December 31, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium, izumerogant and IMU-856 totaling approximately $4.5 million, all of which is expected to be paid in 2023.
Recently Adopted Accounting Standards
There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.
Interest Rate Sensitivity
We had cash and cash equivalents of $106.7 million as of December 31, 2022, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $28.9 million of these funds are held in German bank accounts that were earning between 1%-2.5% interest as of December 31, 2022. Decreases or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.
Foreign Currency Exchange Risk
Our primary research and development operations are conducted in our facilities in Germany. We have entered into and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.
79

The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders’ equity. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). Our German subsidiary is currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on their financial position or results of operations.
Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German and Australian subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our consolidated balance sheets. As of December 31, 2022, our German and Australian subsidiaries had net current assets (defined as current assets less current liabilities), subject to foreign currency translation risk, of $27.7 million. A decrease of approximately $2.8 million in net current assets would result as of December 31 2022, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, primarily due to the euro. In addition, a 10% change in the foreign currency exchange rates for the year ended December 31, 2022, would have impacted our net loss by approximately $7.3 million, primarily due to the euro.
Effects of Inflation
We have experienced a general increase in costs as a result of global inflation, however, we do not believe that inflation and changing prices had a material impact on our results of operations for any periods presented herein.
Item 8. Financial Statements and Supplementary Data.
The consolidated financial statements required pursuant to this item are included in Part IV, Item 15 of this Annual Report, and are presented beginning on page F-1.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.
80

Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Management, with the participation of our Chief Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term “disclosure controls and procedures,” as defined in Rule 13a-15(e) of the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and Principal Financial Officer have concluded that, as of December 31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.
Management's Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance (a) that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, (b) that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (c) regarding the prevention or timely detection of the unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
As of December 31, 2022, our management conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013). Based on this evaluation, our management concluded that, as of December 31, 2022, our internal control over financial reporting was effective.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information.
None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not Applicable

81

PART III
Item 10. Directors, Executive Officers and Corporate Governance.
Information required by this item will be contained in our definitive proxy statement (the “Definitive Proxy Statement”), to be filed with the SEC in connection with our 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2022, under the headings “Election of Directors,” “Board of Directors and Corporate Governance,” “Executive Officers,” and “Section 16(a) Beneficial Ownership Reporting Compliance,” and is incorporated herein by reference.
We have a written Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer and our principal accounting officer and every other director, officer and employee of Immunic. The Code of Business Conduct and Ethics is available on our Internet website at www.imux.com. A copy of the Code of Business Conduct and Ethics will be provided free of charge by making a written request and mailing it to our corporate headquarters offices to the attention of the Investor Relations Department. If any amendment to, or a waiver from, a provision of the Code of Business Conduct and Ethics that applies to the principal executive officer, principal financial officer and principal accounting officer is made, such information will be posted on our Internet website within four business days at www.imux.com.
Item 11. Executive Compensation.
Information required by this item will be found in our Definitive Proxy Statement under the heading "Executive Compensation" and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Information required by this item will be found in our Definitive Proxy Statement under the heading "Security Ownership" and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.

Information required by this item will be found in our Definitive Proxy Statement under the headings "Board of Directors and Corporate Governance" and "Related Person Transactions" and is incorporated herein by reference.
Item 14. Principal Accounting Fees and Services.

Information required by this item will be found in our Definitive Proxy Statement under the heading "Ratification of Appointment of Independent Registered Public Accounting Firm" and is incorporated herein by reference.

82

PART IV
Item 15. Exhibits, Financial Statement Schedules.
Page
1. Financial Statements. We have filed the following documents as part of this Annual Report:
 
Report of Baker Tilly US, LLP, Independent Registered Public Accounting Firm
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
2. Financial Statement Schedules. None.
3. Exhibits. The following exhibits are filed herewith or are incorporated by reference to exhibits previously
filed with the U.S. Securities and Exchange Commission.
 
83

EXHIBITS
 
  Incorporated by Reference
Exhibit
Number
Exhibit TitleFormExhibitFiling Date
3.18-K3.1 July 17, 2019
3.28-K3.1 July 17, 2019
4.1S-84.1 September 20, 2019
  4.2*8-K4.2 February 26, 2020
4.38-K4.3 October 11, 2022
10.1

8-K10.1 July 17, 2019
10.28-K10.2 July 17, 2019
10.38-K10.3 July 17, 2019
10.4+8-K10.4 July 17, 2019
10.5+*
10.6+*
10.7+8-K10.5 July 17, 2019
10.8+8-K10.1 September 5, 2019
10.9+8-K99.3 September 5, 2019
10.10+8-K99.2 September 5, 2019
10.11+8-K99.4 September 5, 2019
10.128-K10.2 April 20, 2020
10.138-K10.1April 19, 2021
10.148-K10.1April 20, 2020
10.158-K10.2April 20, 2020
10.168-K10.1June 12, 2020
10.178-K10.2June 12, 2020
10.188-K1.1August 10, 2020
10.198-K10.1October 20, 2020
10.208-K10.2October 20, 2020
10.21+8-K10.1January 4, 2021
10.22+8-K10.1November 13, 2020
84

10.23+8-K10.1March 31, 2021
10.24+8-K10.1April 15, 2021
10.25+8-K10.1June 10, 2021
10.26+8-K10.2June 10, 2021
10.27+8-K10.3June 10, 2021
10.28+8-K10.4June 10, 2021
10.29+8-K99.2June 10, 2021
10.30+8-K1.1July 15, 2021
10.31+8-K10.1October 14, 2021
10.32+8-K10.1January 10, 2022
10.33+8-K10.2January 10, 2022
10.34+8-K10.3January 10, 2022
10.35+8-K10.1March 15, 2022
10.368-K10.1May 2, 2022
10.378-K10.1October 11, 2022
10.38+8-K10.1December 30, 2022
10.39+8-K10.1January 16, 2023
10.40+8-K10.2January 16, 2023
10.41+8-K10.3January 16, 2023
85

21.1*
23.1*
24.1*
31.1
31.2
32.1*
32.2*
101.INS*XBRL Instance Document.
101.SCH*XBRL Taxonomy Extension Schema Document.
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*XBRL Taxonomy Extension Definition Linkbase Database.
101.LAB*XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document.
104*Cover Page Interactive Data File


+Indicates a management contract or compensatory plan or arrangement.
*In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

86

IMMUNIC, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

F- 1


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the shareholders and the board of directors of Immunic, Inc.:

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Immunic, Inc. (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which it relates.

Assessment of accrual for research and development costs related to clinical trial activities

Critical Audit Matter Description

As described in Note 2 and 3 to the consolidated financial statements, the Company records expenses and accruals for estimated costs of research and development activities, including third party contract services costs for clinical research. Clinical trial activities performed by third parties are expensed based upon estimates of work completed in accordance with agreements with the respective Clinical Research Organization. Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements.

Auditing the accounting for accrued clinical trial expenses is complex because of the high volume of data used in management’s estimates, the assumptions used by management to develop their estimates and the procedures necessary to verify the cost and extent of unbilled work performed during the reporting period.


F- 2



How We Addressed the Matter in Our Audit

We obtained an understanding of the Company’s process and evaluated the design and implementation of internal controls related to the completeness and valuation of accrued clinical trial expenses.

To test the clinical trial accrual, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating and testing the significant assumptions used by management to estimate the accruals. To test the significant assumptions, we corroborated the progress of clinical trials and other research and development projects with the Company’s research and development personnel that oversee the clinical trials, and obtained information received directly from third parties, which included the third parties’ estimate of costs incurred to date. We also tested subsequent invoicing received from third parties.



Baker Tilly US, LLP

We have served as the Company's auditor since 2019.

Minneapolis, MN

February 23, 2023
F- 3

IMMUNIC, INC.
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
 December 31,
 20222021
Assets
Current assets:
Cash and cash equivalents$106,745 $86,863 
Investments - other9,629 — 
Other current assets and prepaid expenses9,490 18,125 
Total current assets125,864 104,988 
Property and equipment, net294 152 
Goodwill (note 2)— 32,970 
Right of use asset, net1,552 948 
Other long-term assets43 42 
Total assets$127,753 $139,100 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$4,281 $3,745 
Accrued expenses7,986 7,071 
Other current liabilities810 585 
Total current liabilities13,077 11,401 
Long-term liabilities:
Operating lease liabilities992 584 
Total long-term liabilities992 584 
Total liabilities14,069 11,985 
Commitments and contingencies (note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December 31, 2022 and 2021
— — 
Common stock, $0.0001 par value; 130,000,000 shares authorized and 39,307,286 and 26,335,418 shares issued and outstanding at December 31, 2022 and 2021, respectively
4 3 
Additional paid-in capital427,925 324,237 
Accumulated other comprehensive income (loss)3,035 (252)
Accumulated deficit(317,280)(196,873)
Total stockholders’ equity113,684 127,115 
Total liabilities and stockholders’ equity$127,753 $139,100 
The accompanying notes are an integral part of these consolidated financial statements.
F- 4

IMMUNIC, INC.
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
 Years Ended December 31,
 20222021
Operating expenses:
Research and development$71,255 $61,115 
General and administrative15,263 13,300 
Goodwill impairment (see Note 2)32,970 — 
4SC Royalty Settlement (See Note 4)— 17,250 
Total operating expenses119,488 91,665 
Loss from operations(119,488)(91,665)
Other income (expense):
Interest income1,041 66 
Other expense, net(1,960)(1,346)
Total other expense, net(919)(1,280)
Net loss$(120,407)$(92,945)
Net loss per share, basic and diluted$(3.78)$(3.93)
Weighted-average common shares outstanding, basic and diluted31,819,006 23,652,779 
The accompanying notes are an integral part of these consolidated financial statements.
F- 5

IMMUNIC, INC.
Consolidated Statements of Comprehensive Loss
(In thousands)
 Years Ended December 31,
 20222021
Net loss$(120,407)$(92,945)
Other comprehensive income:
Foreign currency translation income, net of tax3,287 3,860 
Total comprehensive loss$(117,120)$(89,085)
The accompanying notes are an integral part of these consolidated financial statements.
F- 6

IMMUNIC, INC.
Consolidated Statements of Stockholders’ Equity
(In thousands, except shares)

 Additional Paid-in CapitalAccumulated
Other
Comprehensive
Income (Loss)		Accumulated
Deficit		Total
Stockholders’
Equity
 SharesAmount
Balance at December 31, 202021,168,240 $2 $266,823 $(4,112)$(103,928)$158,785 
Net loss— — — — (92,945)(92,945)
Foreign exchange translation adjustment— — — 3,860 — 3,860 
Stock-based compensation— — 5,949 — — 5,949 
Issuance of common stock - July 2021 equity offering net of issuance costs of $2,980
4,500,000 1 42,019 — — 42,020 
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $23
73,221 — 729— — 729 
Shares issued in connection with the Company's employee stock purchase plan12,758 — 92— — 92 
Issuance of common stock in connection with the 4SC royalty settlement (see note 4)581,199 — 8,625 — — 8,625 
Balance at December 31, 202126,335,418 3 $324,237 $(252)$(196,873)$127,115 
Net loss— — — — (120,407)(120,407)
Foreign exchange translation adjustment— — — 3,287 — 3,287 
Stock-based compensation— — 7,929 — — 7,929 
Issuance of common stock and Pre-funded Warrants - October 2022 PIPE transaction, net of issuance costs of $4,012
8,696,552 1 55,988— — 55,989 
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $1,226
4,204,113 — 39,584— — 39,584 
Shares issued in connection with the Company's employee stock purchase plan70,351 — 182— — 182 
Shares issued in connection with the Company's stock option plan852 — 5— — 5 
Balance at December 31, 202239,307,286 4 $427,925 $3,035 $(317,280)$113,684 
The accompanying notes are an integral part of these consolidated financial statements.
F- 7

IMMUNIC, INC.
Consolidated Statements of Cash Flows
(In thousands)
 Years Ended December 31,
 20222021
Cash flows from operating activities:
Net loss$(120,407)$(92,945)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization77 85 
Goodwill impairment (see Note 2)32,970 — 
Stock-based compensation7,929 5,949 
Foreign currency loss4,757 4,332 
Common stock issued in connection with the 4SC royalty settlement (see Note 4)— 8,625 
Changes in operating assets and liabilities:
Prepaid expenses and other assets7,493 (12,800)
Accounts payable799 176 
Other liabilities(124)170 
Accrued expenses and other current liabilities1,362 3,175 
Net cash used in operating activities(65,144)(83,233)
Cash flows from investing activities:
Purchases of Investments-other(9,629)— 
Purchases of property and equipment(112)(67)
Net cash used in investing activities(9,741)(67)
Cash flows from financing activities:
Proceeds from public offering of common stock through At The Market offering, net of issuance costs of $1,226 and $23, respectively
39,584 729 
Proceeds from shares issued in connection with the Company's employee stock purchase plan182 92 
Issuance of common stock and Pre-funded Warrants - October 2022 PIPE transaction, net of issuance costs of $4,012 and $0, respectively
55,989 — 
Proceeds from the exercise of stock options5 — 
Proceeds from July 2021 public equity offering, net of issuance costs of $2,980
— 42,020 
Net cash provided by financing activities95,760 42,841 
Effect of exchange rate changes on cash and cash equivalents(993)(130)
Net change in cash and cash equivalents19,882 (40,589)
Cash and cash equivalents, beginning of year86,863 127,452 
Cash and cash equivalents, end of year$106,745 $86,863 
Supplemental disclosure of noncash investing and financing activities:
Common stock issued in connection with the 4SC royalty settlement (see Note 4)$— $8,625 
Operating lease right-of use asset obtained in exchange for lease obligation$974 $435 

The accompanying notes are an integral part of these consolidated financial statements.
F- 8

Notes to Consolidated Financial Statements
1. Description of Business and Basis of Financial Statements
Description of Business
Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gräfelfing near Munich, Germany. The Company currently has approximately 66 employees.
The Company is currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (“MS”); the izumerogant (proposed International Nonproprietary Name (“INN”) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (“RORγt”) that inhibits the interleukin-17 (“IL-17”) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.
The Company’s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.
Liquidity and Financial Condition
Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $317.3 million as of December 31, 2022 and approximately $196.9 million as of December 31, 2021. Substantially all of Immunic’s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.
Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.
From inception through December 31, 2022, Immunic has raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, the Company had cash and cash equivalents of approximately $106.7 million and investments - other of $9.6 million. With these funds the Company expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying financial statements.
Basis of Presentation and Consolidation
The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018). All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.
F- 9

Foreign Currency Translation and Presentation
The Company’s reporting currency is United States (“U.S.”) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.’s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:
• assets and liabilities at reporting period-end rates;
• income statement accounts at average exchange rates for the reporting period; and
• components of equity at historical rates.
Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders’ equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.
Cash and Cash Equivalents and Investments- other
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Time Deposits with an original maturity greater than three months are classified as Investments-other
Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7 million, Germany of approximately $19.1 million and Australia of approximately $1.9 million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of —% to 0.87%
Investments - other consists of the following as of (in thousands):
December 31, 2022December 31, 2021
Time Deposits$9,629$0
$9,629$0
The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.
Fair Value Measurement
Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.
Level 2— Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.
F- 10

Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.
The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.
Property and Equipment
Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years. Depreciation and amortization expense was $77,000 and $85,000 for the years ended December 31, 2022 and 2021, respectively.
Impairment of Long-Lived Assets
The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the years ended December 31, 2022 and 2021 other than goodwill which is described below.
Goodwill
Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.
On October 20, 2022, the Company announced the outcome of a significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization. The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired. The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0 million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance. The Company did not have any goodwill impairment during the year ended December 31, 2021. The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):
Carrying amount of goodwill at December 31, 2021$32,970 
Impairment of goodwill during the year ended December 31, 2022(32,970)
Carrying amount of goodwill at December 31, 2022$— 
Research and Development Expenses
These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.
Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.
F- 11

The Company enters into agreements with contract research organizations (“CROs”) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (“MSA”). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.
Collaboration Arrangements
Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers” and ASU No. 2018-18, “Collaborative Arrangements” ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.
In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.
On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent & Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.
Government assistance
Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We recognized $2.3 million and $1.7 million of other income related to research activities performed during the years ended December 31, 2022 and 2021, respectively.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.
Stock-Based Compensation 
The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award’s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.
The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company’s common stock, the expected volatility of the price of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the
F- 12

application of management’s judgment. If factors change and different assumptions are used, the Company’s stock-based compensation expense could be materially different in the future.
Leases
The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.
The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company’s balance sheet. A right-of-use lease asset represents the Company’s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.
Comprehensive Income (Loss)
Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders’ equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).
Income Taxes
The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.
The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December 31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.
It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.
Warrants
The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) or ASC 815-40, Accounting
F- 13

for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (“ASC 815-40”). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.
Net Loss Per Share
Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position
Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:
As of December 31,
20222021
Options to purchase common stock3,791,688 2,157,460 
Prefunded stock warrants5,096,552 — 
8,888,240 2,157,460 
Recently Adopted Accounting Standards
There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.


F- 14

3. Balance Sheet Details
Prepaid Expenses and Other Current Assets
Prepaid Expense and Other Current Assets consist of (in thousands):
December 31,
20222021
Prepaid clinical and related costs$5,608 $14,853 
VAT receivable296 279 
Australian research and development tax incentive2,361 1,871 
Other1,225 1,122 
Total$9,490 $18,125 
Accounts Payable
Accounts Payable consist of (in thousands):
December 31,
20222021
Clinical and related costs$3,749 $3,427 
Legal and audit costs288 72 
Other244 246 
Total$4,281 $3,745 
Accrued Expenses
Accrued Expenses consist of (in thousands):
 December 31,
 20222021
Accrued clinical and related costs$6,807 $6,214 
Accrued legal and audit costs169 96 
Accrued compensation890 674 
Accrued other120 87 
Total$7,986 $7,071 
Other Current Liabilities
Other Current Liabilities consist of (in thousands):
December 31,
20222021
Lease liabilities$571 $408 
Other239 177 
Total$810 $585 
4. Commitments and Contingencies
Operating Lease
The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office and June 30, 2025 for the Gräfelfing, Germany office. The Company formerly leased office space in
F- 15

Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gräfelfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gräfelfing, Germany office. Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions to right of use assets of $435,000 and $642,000 as a result of signing for additional lease space at the Gräfelfing, Germany office in March 2021 and August 2022, respectively. There were net additions to right of use assets of $332,000 as a result of extending the New York City lease in December 2022.
 The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.
 Immunic’s operating lease costs and variable lease costs were $727,000 and $503,000 for the years ended December 31, 2022 and 2021, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.
 Maturities of the operating lease obligation are as follows as of December 31, 2022 (in thousands):
2023$647 
2024$680 
2025$355 
2026$— 
2027$— 
Thereafter$— 
Total lease payments$1,682 
Less: interest portion$147 
Present value of lease obligation$1,535 
Contractual Obligations
As of December 31, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs in vidofludimus calcium, izumerogant and IMU-856 totaling approximately $4.5 million, all of which is expected to be paid in 2023.
Other Commitments and Obligations
In May 2016, the Company entered into a purchase agreement (the “Agreement”) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company’s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019.
On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25 million
F- 16

(Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic’s common stock (the “Shares”). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.
Legal Proceedings
The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.
5. Fair Value
The following fair value hierarchy table present information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):
Fair Value Measurement at December 31, 2022
Fair ValueLevel 1Level 2Level 3
Assets
Money market funds85,521 85,521 — — 
Total assets at fair value$85,521 $85,521 $— $— 
Fair Value Measurement at December 31, 2021
Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$31,630 $31,630 $— $— 
Total assets at fair value$31,630 $31,630 $— $— 

There were no transfers between Level 1, Level 2 or Level 3 assets during the periods presented.
For the Company’s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations.
Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 4.3% in a U.S. Government money market fund.
The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of December 31, 2022. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.
The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same. For the assessment of the fair value of goodwill and the related impairment of goodwill we used a level one assessment in our testing of goodwill. See Note 2, Summary of significant accounting policies "Goodwill".
6. Common Stock
Shelf Registration Statements
F- 17

In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of February 17, 2023, there is $75.0 million remaining on this shelf registration statement

In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days’ prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company. As of February 17, 2023, $8.4 million in capacity remains under the December 2020 ATM.

In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days’ prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company. As of February 17, 2023, $80.0 million in capacity remains under the May 2022 ATM.
  The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.
For the year ended December 31, 2022, the Company raised gross proceeds of $40.9 million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6 million after deducting underwriter commissions of $1.2 million.
For the year ended December 31, 2021, the Company raised gross proceeds of $0.8 million pursuant to the December 2020 ATM through the sale of 73,221 shares of common stock at a weighted average price of $10.27 per share. The net proceeds from the December 2020 ATM were $0.7 million after deducting underwriter commissions of $22,555.
F- 18

Equity Offerings
$60 Million Private Placement Equity Financing
On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with select accredited investors and certain existing investors (each, a “Purchaser” and collectively, the “Purchasers”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return. All of the pre-funded warrants were exercised in January of 2023.

The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0 million, before deducting offering expenses payable by the Company of approximately $4.0 million. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.

The registration statement for these securities was deemed effective by Securities and Exchange Commission on December 20, 2022.
July 2021 Public Equity Offering

On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler & Co., in connection with the Company’s public offering of 4,500,000 shares of the Company’s common stock, $0.0001 par value per share, at a public offering price of $10.00 per share.

On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was approximately $42.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
Common Stock
As of December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001. The voting, dividend and liquidation rights of the holders of the Company’s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December 31, 2022, no cash dividends had been declared or paid.
Preferred Stock
The Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue 20,000,000 shares of $0.0001 par value preferred stock, rights and preferences to be set by the board of directors. No preferred shares were outstanding as of December 31, 2022.


F- 19

Stock Reserved for Future Issuance
Shares reserved for future issuance as of December 31, 2022 are as follows:
 Number of
Shares
Common stock reserved for issuance for:
2021 Employee stock purchase plan116,891 
Prefunded stock warrants5,096,552 
Outstanding stock options3,791,688 
Common stock options available for future grant:
2014 Equity Incentive Plan43,311 
2017 Inducement Equity Incentive Plan46,250 
2019 Omnibus Equity Incentive Plan188,655 
Total common shares reserved for future issuance9,283,347 

7. Stock-based Compensation Plans
2021 Employee Stock Purchase Plan

On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company’s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.

The Company has issued 70,351 and 12,758 shares under the ESPP for the twelve months ended December 31, 2022 and 2021, respectively. The Company recognized $96,000 and $46,000 of expense related to the plan in the twelve months ended December 31, 2022 and 2021, respectively.
Stock Option Programs
In July 2019, the Company’s stockholders approved the 2019 Omnibus Equity Incentive Plan (the “2019 Plan”) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company’s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company’s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over three or four years.
Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards.


F- 20

Movements during the year
The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:
OptionsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding as of January 1, 20222,157,460 $13.54 
Granted1,886,263 $8.73 
Exercised(852)$5.67 
Forfeited or expired(251,183)$10.79 
Outstanding as of December 31, 20223,791,688 $11.33 8.35$375 
Options vested and expected to vest as of December 31, 20223,791,688 $11.33 8.35$375 
Options exercisable as of December 31, 20221,398,490 $13.33 7.50$— 
OptionsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding as of January 1, 20211,117,160 $12.96 
Granted1,193,809 $14.08 
Exercised— $— 
Forfeited or expired(153,509)$13.50 
Outstanding as of December 31, 20212,157,460 $13.54 8.74$302,155 
Options vested and expected to vest as of December 31, 20212,157,460 $13.54 8.74$302,155 
Options exercisable as of December 31, 2021752,954 $13.48 8.15$79,431 
Measurement
The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:
Risk-Free Interest Rate
The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.
Expected Dividend Yield
The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.
Expected Volatility
Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards.


F- 21

Expected Term
The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.
The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December 31, 2022 and 2021 was $6.81 and $10.52, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:
20222021
Risk-free interest rate2.09%0.93%
Expected dividend yield0%0%
Expected volatility97.8%93.0%
Expected term of options (years)6.06.0
Stock-Based Compensation Expense
Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands):
 Year
 Ended December 31,
 20222021
Research and development$3,219 $1,760 
General and administrative4,710 4,189 
Total$7,929 $5,949 
As of December 31, 2022 there was $15.6 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.74 years.
Summary of Equity Incentive Plans Assumed from Vital
Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital’s 2012 Stock Option Plan (the “2012 Plan”), Vital’s 2014 Equity Incentive Plan (the “2014 Plan”) and Vital’s 2017 Inducement Equity Incentive Plan (the “Inducement Plan”), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.
There remain 43,311 shares available for grant under the 2014 Plan as of December 31, 2022.
In September 2017, Vital’s Board of Directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital’s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.
No expense was recorded for the plans assumed from Vital during the twelve months ended December 31, 2022 and 2021, respectively.



F- 22

8. Income Taxes
Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):
 Years Ended December 31,
 20222021
United States$(47,049)$(11,222)
Germany(67,448)(78,869)
Foreign(5,911)(2,854)
$(120,408)$(92,945)
The rate reconciliation consists of the following:
 Years Ended December 31,
 20222021
Federal statutory rate21.0 %21.0 %
Foreign rate differential2.2 %3.2 %
Stock options(1.1)%(0.9)%
Tax effect of rate change0.0 %0.0 %
Goodwill impairment(5.7)%0.0 %
Other(0.7)%(0.4)%
Change in valuation allowance(15.7)%(22.9)%
Effective tax rate0.0 %0.0 %

Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is no current or deferred income tax expense in the years ended December 31, 2022 and 2021, respectively.

Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.
F- 23

 December 31,
 20222021
 (in thousands)
Deferred tax assets:
Net operating loss carryforwards$19,830 $18,437 
Stock-based compensation742 576 
Intangible Assets2,923 3,848 
Foreign net operating loss carryforwards47,179 34,819 
Unrealized gain or loss1,686 1,130 
Other, net693 9 
     Total deferred tax assets73,053 58,819 
Deferred tax liabilities:
Property, plant and equipment— (2)
     Total deferred tax liability — (2)
Net deferred tax assets73,053 58,817 
Less valuation allowance(73,053)(58,817)
$— $— 

The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $14.2 million and $22.3 million and for the years ended December 31, 2021 and 20, respectively.

As of December 31, 2022, Immunic had available NOLs of approximately $190.2 million in Germany and Australia. These NOLs do not expire.

The U.S. federal NOL carryforwards of $15.6 million were generated prior to 2018 and expire over 20 years beginning in 2023. The $78.9 million of post 2017 federal NOL carryforwards do not expire. Sections 382 of the Internal Revenue Code of 1986 subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined. The Company may have undergone ownership changes and therefore may be limited in the amount of net operating losses available for utilization in the future.

The Company did not have any uncertain tax positions for the years ended December 31, 2022 and 2021, respectively.

Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are no uncertain tax positions that would impact the effective tax rate if recognized.

The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2018 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.

Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented.


9. Related Party Transactions
F- 24


Executive Chairman Agreement with Duane Nash

On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the “Executive Chairman Agreement”) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an “at will” employment relationship with a base salary of $25,417 per month pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, the Company and Dr. Nash entered into an addendum (the “First Addendum”) to extend the term of the Executive Chairman Agreement to April 15, 2021. In connection with the First Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 120,000 shares of Company common stock, which vests monthly over six months commencing on November 15, 2020. On April 15, 2021, the Company and Dr. Nash entered into Addendum No. Two (the “Second Addendum”) to extend the term of the Executive Chairman Agreement to April 15, 2022. In connection with the Second Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly over 12 months commencing on May 15, 2021, and to increase Dr. Nash’s monthly base salary to $27,960 from $25,417. On March 15, 2022, the Company and Dr. Nash entered into Addendum No. Three (the “Third Addendum”), which extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month. In connection with the Third Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company’s common stock, which vests monthly over 12 months commencing on April 10, 2022. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company’s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.


F- 25

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
Immunic, Inc.
Date: February 23, 2023By:/s/ DANIEL VITT
Daniel Vitt
Chief Executive Officer and President


POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel Vitt and Glenn Whaley, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature  Title  Date
    
/s/ DANIEL VITT  Director, Chief Executive Officer and President  February 23, 2023
Daniel Vitt
/s/ GLENN WHALEYChief Financial OfficerFebruary 23, 2023
Glenn Whaley
/s/ DUANE D. NASH  Executive Chairman  February 23, 2023
Duane D. Nash
/s/ TAMAR HOWSONDirectorFebruary 23, 2023
Tamar Howson
/s/ JOERG NEERMANN  Director  February 23, 2023
Joerg Neermann
/s/ VINCENT OSSIPOW  Director  February 23, 2023
Vincent Ossipow
/s/ BARCLAY A. PHILLIPSDirectorFebruary 23, 2023
Barclay A. Phillips
/s/ MARIA TORNSENDirector  February 23, 2023
Maria Tornsen


 EX-4.2 2 exhibit422022.htm EX-4.2 Document

Exhibit 4.2
DESCRIPTION OF CAPITAL STOCK

General

Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share.

The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer to our certificate of incorporation and our bylaws that are incorporated by reference into the Annual Report on Form 10-K of which this exhibit is a part.

Common Stock

As of December 31, 2020, there were 21,168,240 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stockholders will not be able to elect directors on the basis of their votes alone.

Subject to preferences that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of us, holders of the common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any of our outstanding preferred stock.

Listing

Our common stock is listed on the Nasdaq Global Select Market under the symbol “IMUX.”

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC (“AST”). The transfer agent and registrar’s address is 6201 15th Avenue, Brooklyn, New York 11219.

Dividends

We have not declared any cash dividends on our common stock since inception and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.

Possible Anti-Takeover Effects of Delaware Law and our Charter Documents

Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer, an acquisition of us by means of a proxy contest or otherwise, or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the market price for our shares.

These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.




Delaware Anti-Takeover Statute

We are subject to Section 203 of the Delaware General Corporation Law (the “DGCL”), an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation’s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.

Undesignated Preferred Stock.

The ability of our board of directors, without action by the stockholders, to issue up to 20,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.

Requirements for Advance Notification of Stockholder Nominations and Proposals.

Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.

Elimination of Stockholder Action by Written Consent.

Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.

Staggered Board.

Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.

Removal of Directors.

Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.

Stockholders Not Entitled to Cumulative Voting.

Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.

Authorized but Unissued Shares

Our authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary


obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the future. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.

Director Liability

Our bylaws limit the extent to which our directors are personally liable to us and our stockholders, to the fullest extent permitted by the DGCL. The inclusion of this provision in our bylaws may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders or management from bringing a lawsuit against directors for breach of their duty of care.

The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest.


 EX-10.5 3 imux-ex105dienstvertragand.htm EX-10.5 Document

image_0.jpgDIENSTVERTRAG
SERVICE AGREEMENT
zwischenbetween
Immunic AG,
vertreten durch den Vorsitzenden des Aufsichtsrates		Immunic AG,
represented by the Chairman of the Supervisory Board
- nachfolgend „Gesellschaft" genannt -- hereinafter referred to as the "Company" -
undand
Herrn Dr. med. Rolf Andreas Mühler,Dr. med. Rolf Andreas Mühler,
- nachfolgend „Vorstand" genannt -- hereinafter referred to as the "Board Member" -
§ 1
Aufgabenbereich und Pflichten
§ 1
Responsibilities and Obligations
1.Herr Dr. Rolf Andreas Mühler ist mit Beschluss des Aufsichtsrates der Gesellschaft vom 23.03.2016 (Anlage 1) für ein Jahr zum ordentlichen Mitglied des Vorstandes der Gesellschaft bestellt worden. Diese Bestellung soll bis zum Ablauf des 31. August 2019 verlängert werden. Er wird als Vorstand für den Bereich Medical (Chief Medical Officer, CMO) der Gesellschaft bestellt und vertritt die Gesellschaft gemeinsam mit einem Vorstand oder einem Prokuristen. Der Aufsichtsrat kann dem Vorstand Einzelvertretungsbefugnis erteilen sowie von den Beschränkungen des § 181 Alt. 2 BGB befreien.
1.Dr. Rolf Andreas Mühler was appointed a member of the Management Board of the Company for one year by resolution of the Supervisory Board of the Company dated 23 March 2016 (Annex 1). This appointment is to be extended until the end of 31 August 2019. He is appointed as Chief Medical Officer (CMO) of the Company and represents the Company together with a member of the Management Board or an authorized signatory. The Supervisory Board may grant the Board Member sole power of representation as well as exemption from the restrictions of § 181 Alt. 2 of the German Civil Code (BGB).

Germany 10363757.1
Seite 2 von 23

1.Der Vorstand führt die Geschäfte der Gesellschaft nach Maßgabe der Gesetze, der Satzung, der Geschäftsordnung für den Vorstand und dieses Dienstvertrages. Der Vorstand hat insbesondere für die laut einer Geschäftsordnung des Vorstands unter Zustimmungsvorbehalt stehenden Geschäfte und Maßnahmen die Zustimmung des Aufsichtsrats einzuholen.
1.The Board Member shall conduct the business of the Company in accordance with the law, the Articles of Association, the rules of procedure for the Management Board and this Service Agreement. In particular, the Board Member shall obtain the approval of the Supervisory Board for transactions and measures subject to approval in accordance with the rules of procedure of the Management Board.
1.Dem Vorstand obliegen insbesondere die Aufgaben, die im Sinne des jeweiligen Geschäftsverteilungsplans zum Geschäftsbereich des Medicalvorstands (CMO) gehören.

1.In particular, the Board Member is responsible for the tasks that belong to the business area of the Chief Medical Officer (CMO) within the meaning of the respective schedule of responsibilities.
1.Dienstort ist München/Planegg-Martinsried. Sofern die Pflichten nach diesem Vertrag es zulassen, ist der Vorstand frei in der Wahl des Ortes der Ausübung seiner Tätigkeit.

1.The place of work is Munich/Planegg-Martinsried. If the obligations according to this agreement allow it, the Board Member is free in the choice of the place of the exercise of its activity.

§ 1
Nebentätigkeiten

Ancillary Activities
1.Der Vorstand wird seine ganze Arbeitskraft und seine sämtlichen fachlichen Kenntnisse und Erfahrungen der Gesellschaft widmen. Die Übernahme einer entgeltlichen Nebentätigkeit sowie von Aufsichtsrats-, Beirats- oder ähnlichen Mandanten bedarf der vorherigen Zustimmung durch den Aufsichtsratsvorsitzenden.

1.The Board Member will devote all its working capacity and all its professional knowledge and experience to the Company. The assumption of an ancillary commercial activity as well as mandates in a supervisory board or advisory board or similar mandates require the prior consent of the Chairman of the Supervisory Board.
Dem Aufsichtsratsgremium ist bekannt, dass der Vorstand zum Zeitpunkt der Unterzeichnung dieses Vertrages die in Anlage 2 aufgelisteten Mandate innehat und erteilt zu deren Fortführung seine Zustimmung.
The Supervisory Board is aware that the Board Member holds the mandates listed in Annex 2 at the time of signing of this agreement and grants its approval to their continuation.

Germany 10363757.1
Seite 3 von 23

1.Für den Vorstand gilt das Wettbewerbsverbot des § 88 AktG. Während der Dauer dieses Vertrages wird sich der Vorstand auch nicht an Unternehmen beteiligen, die mit der Gesellschaft in Wettbewerb stehen oder mit denen die Gesellschaft Geschäftsverbindungen unterhält, es sei denn, der Aufsichtsrat hat vorher seine schriftliche Zustimmung erteilt.

1.The Board Member is subject to the non-competition clause of Section 88 of the German Stock Corporations Act (AktG). During the term of this agreement, the Board Member will also not invest in companies that compete with the Company or with which the Company has business relationships, unless the Supervisory Board has given its prior written consent.
Das Wettbewerbsverbot gilt nicht für Beteiligungen an Unternehmen in Gestalt von Wertpapieren, die an Börsen gehandelt und zum Zwecke der Kapitalanlage erworben werden. Darüber hinaus sind etwaig bestehende, vorrangige Regelungen aus einem Investment Agreement und/oder Shareholders' Agreement zu Wettbewerbsverboten bzw. erlaubten Tätigkeiten des Vorstands zu beachten.
The non-competition clause does not apply to interests in companies in the form of bonds traded on the stock exchange and acquired for the purpose of capital investment. In addition, any existing overriding regulation from an Investment Agreement and/or Shareholders' Agreement on restraints of competition or permitted activities of the Board Member must be observed.
§ 1
Vergütung und Bonus
§ 1
Remuneration and bonus
1.Der Vorstand erhält für seine Tätigkeit
1.The Board Member receives for its activities
a)ein festes Jahresgehalt („Grundvergütung") in Höhe von EUR 156.000,00 brutto, das in 12 gleichen Monatsraten jeweils nachträglich am Monatsletzten ausbezahlt wird. Sofern dieser Vertrag nicht während der Dauer eines gesamten Kalenderjahres besteht, wird das Jahresfestgehalt zeitanteilig gezahlt.
a)a fixed annual salary ("Basic Remuneration") in the amount of EUR 156,000.00 gross, paid in 12 equal monthly instalments at the end of each month. If this agreement does not exist for the duration of an entire calendar year, the fixed annual salary shall be paid pro rata temporis.

Germany 10363757.1
Seite 4 von 23

a)eine jährliche variable Vergütung, die bei 100-prozentigem Erreichen der festgelegten Jahresziele maximal EUR 24.000,00 brutto beträgt. Die Einzelheiten, insbesondere zum Verfahren der Zielfestlegung, zur Feststellung der Zielerreichung und zur Fälligkeit ergeben sich aus dem Rahmenvertrag zur Zielvereinbarung in seiner jeweils geltenden Fassung. Die Art der Ziele, die Voraussetzungen für ihre Erreichung und ihre Gewichtung zueinander werden für das jeweilige Geschäftsjahr in einer gesonderten Zielfestlegung niedergelegt.
a)an annual variable remuneration of up to EUR 24,000.00 gross if the defined annual targets are achieved 100 percent. The details, in particular with regard to the procedure for setting targets, determining the achievement of targets and the due date, are set out in the Framework Agreement regarding the targets (Rahmenvertrag zur Zielvereinbarung) in its current version. The nature of the objectives, the conditions for their achievement and their weighting in relation to each other are laid down for each financial year in a separate target setting.
1.Die Grundvergütung und die variable Vergütung werden jährlich durch den Aufsichtsrat überprüft. Dabei sind die wirtschaftliche Entwicklung der Gesellschaft sowie die persönliche Leistung des Vorstandes zu berücksichtigen.
1.The Basic Remuneration and the variable remuneration are reviewed annually by the Supervisory Board. The economic development of the Company and the personal performance of the Board Member must be taken into account.
1.Im Übrigen kann der Aufsichtsrat die Bezüge des Vorstands insgesamt auf die angemessene Höhe herabsetzen, wenn sich die Lage der Gesellschaft so verschlechtert, dass die Weitergewährung der Bezüge unbillig für die Gesellschaft wäre; Ruhegehalt, Hinterbliebenenbezüge und Leistungen verwandter Art können dabei nur in den ersten drei Jahren nach Ausscheiden aus der Gesellschaft herabgesetzt werden (§ 87 (2) AktG). Der Vorstand kann in diesem Fall diesen Dienstvertrag außerordentlich mit einer Frist von sechs Wochen zum Schluss des nächsten Kalendervierteljahres nach Erklärung der Herabsetzung kündigen (§ 87 (2) Satz 3 AktG). Entfällt eine verschlechterte Lage der Gesellschaft, ist die Herabstufung wieder rückgängig zu machen.
1.Otherwise, the Supervisory Board may reduce the total remuneration of the Board Member to the appropriate amount, if the situation of the Company deteriorates to such an extent that the continued granting of the remuneration would be inequitable for the Company; retirement pension, survivors benefits and benefits of a related kind may only be reduced in the first three years after leaving the Company (Section 87 (2) AktG). In this case, the Board Member may terminate this Service Agreement extraordinarily with six weeks' notice to the end of the next calendar quarter after declaration of the reduction (Section 87 (2) sentence 3 AktG). If a deterioration in the situation of society does not apply, the downgrade shall be reversed.
§ 1
Versicherungen und Nebenleistungen
§ 1
Insurance and Fringe Benefits

Germany 10363757.1
Seite 5 von 23

1.Auch soweit keine gesetzliche Versicherungspflicht besteht, zahlt die Gesellschaft an das Vorstandsmitglied monatliche Zuschüsse zur Kranken-und Pflegeversicherung des Vorstandsmitglieds. Die einzelnen Zuschüsse entsprechen in ihrer Höhe der Hälfte der vom Vorstandsmitglied gezahlten Beiträge, höchstens jedoch dem jeweils unter Berücksichtigung der jeweils geltenden Beitragsbemessungsgrenzen gesetzlich geschuldeten Höchstbetrag des Arbeitgeberanteils der gesetzlichen Kranken- und Pflegeversicherung. Die von der Gesellschaft geschuldeten Zuschüsse werden dem Vorstandsmitglied jeweils am Kalendermonatsende gezahlt. Die auf diese Zahlungen etwaig anfallende Einkommensteuer trägt das Vorstandsmitglied.
1.Even if there is no statutory insurance obligation, the Company shall pay the Board Member monthly health and long-term care insurance contributions for the Board Member. The individual contributions are in their amount equivalent to the amount of the contributions paid by the Board Member, but limited to the amount of the employer's contribution to the statutory health and long-term care insurance legally owed in each case, taking into account the applicable contribution assessment thresholds. The contributions owed by the Company are paid to the Board Member at the end of each calendar month. Any income tax payable on these payments shall be borne by the Board Member.
1.Die Gesellschaft zahlt an das Vorstandsmitglied monatliche Zuschüsse zur Bayerischen Ärzteversorgung des Vorstandsmitglieds. Die einzelnen Zuschüsse entsprechen in ihrer Höhe der Hälfte der vom Vorstandsmitglied gezahlten Beiträge. Die von der Gesellschaft geschuldeten Zuschüsse werden dem Vorstandsmitglied jeweils am Kalendermonatsende gezahlt. Die auf diese Zahlungen etwaig anfallende Einkommensteuer trägt das Vorstandsmitglied.
1.The Company pays the Board Member monthly contributions for Bayerische Ärzteversorgung of the Board Member. The individual contributions correspond in their amount to half of the contributions paid by the Board Member. The contributions owed by the Company are paid to the Board Member at the end of each calendar month. Any income tax payable on these payments shall be borne by the Board Member.
1.Der Vorstand erhält in angemessenem Umfang für die im Gesellschaftsinteresse erforderlichen Aufwendungen Ersatz. Erforderliche Reisekosten werden gegen Einzelnachweis erstattet. Die darin enthaltenen Tage- und Übernachtungsgelder können im Rahmen der steuerlich zulässigen Beträge auch pauschal abgerechnet werden.
1.The Board Member shall be reimbursed to an appropriate extent for the expenses required in the interest of the Company. Required travel expenses will be reimbursed against itemization. The daily and overnight allowances contained therein may also be settled as a lump sum within the limits of the amount permissible for tax purposes.

Germany 10363757.1
Seite 6 von 23

1.Die Gesellschaft kann den Vorstand nach ihrem Ermessen für die Dauer dieses Dienstvertrages im Rahmen einer Risiko-Lebensversicherung in Höhe von EUR 500.000,00 für den Todesfall und im Rahmen einer Unfallversicherung in Höhe von EUR 700.000,00 für den Invaliditätsfall versichern bzw. eine bereits bestehende Versicherung fortführen. Der Vorstand hat das Recht, den/die Bezugsberechtigten zu bestimmen.

1.At its discretion, the Company may insure the Board Member for the duration of this Service Agreement under a risk life insurance policy in the amount of EUR 500,000.00 in the event of death and under an accident insurance policy in the amount of EUR 700,000.00 in the event of disability or continue an existing insurance policy. The Board Member is entitled to determine the beneficiary/beneficaries.
1.Im Falle der Übernahme einer bestehenden Direktversicherung kann diese gemäß § 40 b EStG in ihrer geltenden Fassung weiter geführt werden. Die pauschale Versteuerung übernimmt in diesem Fall die Gesellschaft.

1.In the event that an existing direct insurance policy is taken over, this insurance policy can be managed in its current version under Section 40 b German Income Tax Act (EStG). In this case, the lump sum taxation is paid by the Company.

Germany 10363757.1
Seite 7 von 23

1.Die Gesellschaft bietet dem Vorstand die Möglichkeit zur Teilnahme an einer Pensionskasse, Unterstützungskasse oder einer ähnlichen betrieblichen Altersversorgung (BAV) bzw. zur Übernahme einer bereits bestehenden BAV. In diesem Zusammenhang kann der Vorstand einen Teil seiner Gehaltsansprüche zugunsten einer betrieblichen Altersversorgungszusage umwandeln. Die dem Vorstand gemäß § 3 (1) lit. a) gewährte Grundvergütung wird dabei mit Wirkung zum Beginn einer betrieblichen Altersversorgungszusage entsprechend um einen monatlichen Bruttobetrag gekürzt, um in eine wertgleiche Zusage auf betriebliche Versorgungsleistung umgewandelt zu werden. In Höhe dieses Betrags verringert sich der Anspruch des Vorstands auf Zahlung der Grundvergütung. Sollte der Vorstand die Versorgungszusage im weiteren Verlauf ganz oder teilweise wieder kündigen oder ruhen lassen, so lebt der entsprechende Vergütungsanspruch wieder auf.
1.The Company offers the Board Member the opportunity to participate in a pension fund, support fund or similar company pension scheme (betriebliche Altersvorsorge, BAV) or to take over an existing BAV. In this context, the Board Member can convert part of its salary entitlements into a company pension commitment. The Basic Remuneration granted to the Board Member pursuant to § 3 (1) lit. a) shall be reduced by a gross monthly amount with effect from the beginning of a company pension commitment to be converted into an equal-value commitment to company pension benefits. The Board Member's entitlement to payment of the Basic Remuneration is reduced by this amount. If the Board Member rescinds or suspends the pension commitment in whole or in part in the further course of the plan, the corresponding entitlement to compensation shall revive.

Germany 10363757.1
Seite 8 von 23

1.Die Gesellschaft schließt für den Vorstand eine Vermögensschaden-Haftpflichtversicherung (D&O) für den Fall ab, dass der Vorstand wegen einer in Ausübung seiner Tätigkeit begangenen Pflichtverletzung von einem Dritten oder der Gesellschaft aufgrund gesetzlicher Haftpflichtbestimmungen privatrechtlichen Inhalts für einen Vermögensschaden in Anspruch genommen wird. Der Vorstand trägt dabei eine Selbstbeteiligung in Höhe des Mindestwerts gemäß § 93 (2) AktG (derzeit je Schadensfall 10% des Schadens, maximal aber das 11/2-fache der Grundvergütung pro Jahr (jährliche Höchstgrenze). Kommt es zu mehreren Schadensfällen in einem Jahr, gilt die jährliche Höchstgrenze für alle Schadensfälle zusammen. Der Selbstbehalt passt sich bei Änderung der Grundvergütung (bzw. bei Änderung von § 93 (2) AktG) automatisch an; der Vorstand ist verpflichtet, die entsprechenden Änderungen beim Selbstbehalt des D&O Versicherungsvertrages zu veranlassen, und / oder sämtliche in diesem Zusammenhang erforderlichen Erklärungen abzugeben. Das Bezugsjahr für den anzuwendenden Selbstbehalt ist das Jahr des Pflichtverstoßes.
1.The Company enters into a directors' and officers' liability insurance policy (D&O) for the Board Member for the event that a third party or the Company makes a claim against the Board Member for a loss of assets due to a breach of duty committed in the performance of its duties due to statutory liability provisions under private law. The Board Member bears a deductible in the amount of the minimum value pursuant to Section 93 (2) of the German Stock Corporation Act (AktG) (currently 10% of the damage per claim, but not more than one and a half times the basic annual remuneration (annual maximum limit). In case of several loss events in one year, the annual maximum limit applies to all loss events in combination. The deductible is automatically adjusted in the event of a change in the Basic Renumaration (or in the event of a change in Section 93 (2) AktG); the Board Member is obliged to arrange for the corresponding changes to the deductible in the D&O insurance agreement and / or to provide all declarations required in this regard. The reference year for the deductible to be applied is the year of the violation.
§ 1
Urlaub
§ 1
Holiday
1.Der Vorstand hat Anspruch auf einen Jahresurlaub von 30 Arbeitstagen. Arbeitstage sind alle Kalendertage mit Ausnahme von Samstagen, Sonntagen und gesetzlichen Feiertagen am Sitz der Gesellschaft. Bei unterjährigem Beschäftigungsbeginn oder -ende wird der Jahresurlaub in diesem Kalenderjahr zeitanteilig gewährt.
1.The Board Member is entitled to an annual vacation of 30 working days. Working days are all calendar days except Saturdays, Sundays and public holidays at the registered office of the Company. If employment begins or ends during the course of the year, annual vacation in this calendar year will be granted pro rata temporis.
1.Die Urlaubszeit ist unter Berücksichtigung der Geschäftslage mit den anderen Vorstandsmitgliedern abzustimmen.
1.The holiday period shall be coordinated with the other members of the Executive Board, taking into account the business situation.

Germany 10363757.1
Seite 9 von 23


Bezüge bei Krankheit, Arbeitsunfähigkeit oder Tod
Beneficiaries in the event of illness, incapacity for work or death
1.lm Fall einer Dienstverhinderung (z.B. infolge Erkrankung) ist das Vorstandsmitglied verpflichtet, den Aufsichtsratsvorsitzenden der Gesellschaft unverzüglich über Grund und Dauer der Dienstverhinderung zu informieren und auf vordringlich zu erledigende Aufgaben hinzuweisen. Dauert die Dienstverhinderung länger als eine Woche, hat das Vorstandsmitglied im Fall einer Erkrankung ein ärztliches Attest oder im Fall einer sonstigen Dienstverhinderung eine schriftliche Erklärung vorzulegen, woraus sich der Grund der Arbeitsunfähigkeit sowie deren voraussichtliche Dauer ergeben.
1.In the event of an unforeseen absence (e.g. due to illness), the Board Member is obliged to inform the Chairman of the Supervisory Board of the Company without undue delay of the reason for and probable duration of the impediment to service and draw the attention on the tasks to be performed urgently. If the absence lasts longer than one week, the Board Member must submit a medical certificate or in the event of any other incapacity or a written declaration in the event of any other disability, stating the reason for the incapacity and its probable duration.
Das Vorstandsmitglied tritt bereits jetzt etwaige (Schadensersatz-)Ansprüche in Höhe der nach dieser Regelung von der Gesellschaft geleisteten oder zu leistenden Zahlungen an die Gesellschaft ab, die ihm gegenüber Dritten wegen der Arbeitsverhinderung zustehen. Das Vorstandsmitglied ist verpflichtet, der Gesellschaft unverzüglich sämtliche zur Geltendmachung derartiger (Schadensersatz-)Ansprüche notwendigen Angaben zu machen sowie hierfür notwendige Unterlagen zu überlassen.
The Board Member hereby assigns to the Company any (compensation) claims in the amount of the payments made or to be made by the Company in accordance with this provision to which he is entitled in respect of third parties due to the impediment to work. The Board Member is obligated to provide the Company with all information necessary for asserting such (compensation) claims and to provide the Company with the necessary documents without undue delay.

Germany 10363757.1
Seite 10 von 23

1.Bei einer vorübergehenden krankheitsbedingten oder sonstigen unverschuldeten Arbeitsunfähigkeit des Vorstandes wird die Grundvergütung gemäß § 3 (1) lit. a) während der Zeit der Arbeitsunfähigkeit bis zu einer Dauer von sechs Monaten, längstens jedoch bis zur Beendigung dieses Dienstvertrages weitergezahlt. Dauert die Arbeitsunfähigkeit länger als ununterbrochen 3 Monate an, kann der Aufsichtsrat die variable Vergütung nach Anlage 4 unter Berücksichtigung der Dauer der Arbeitsunfähigkeit angemessen reduzieren.
1.In the event of a temporary illness or other non-culpable incapacity to work, the basic remuneration pursuant to § 3 (1) lit. a) shall continue to be paid during the period of the incapacity to work up to a period of six months, at the latest until the termination of this Service Agreement. If the incapacity to work lasts longer than three months without interruption, the Supervisory Board may reduce the variable remuneration in accordance with Annex 4 by a reasonable amount, taking into account the duration of the incapacity to work.
1.Bei einer dauernden Arbeitsunfähigkeit des Vorstandes endet der Dienstvertrag mit dem Ende des Quartals, in dem die dauernde Arbeitsunfähigkeit festgestellt worden ist.
1.In the event of permanent incapacity to work of the Board Member, the employment agreement ends at the end of the quarter in which the permanent incapacity to work was determined.
Ist der Vorstand länger als sechs Monate außerstande, seiner Tätigkeit nachzugehen, kann der Aufsichtsrat verlangen, dass das Vorliegen einer dauernden Arbeitsunfähigkeit durch einen von ihm ausgewählten Arzt auf Kosten der Gesellschaft nachgeprüft wird. Nimmt der Vorstand den Termin trotz zweimaliger Aufforderung durch den Aufsichtsrat nicht wahr, gilt der Vorstand als dauernd arbeitsunfähig. Die Aufforderungen haben mit einer Woche zeitlichen Abstands voneinander zu erfolgen.
If the Board Member is unable to carry out its duties for more than six months, the Supervisory Board may demand that the existence of a permanent incapacity to work be reviewed by a doctor of its choice at the Company's expense. If the Board Member fails to meet the demand despite two requests by the Supervisory Board, the Board Member shall be deemed permanently incapacitated for work. The requests shall be made at intervals of one week.
Eine Abfindung ist bei einer Beendigung des Dienstvertrags wegen dauernder Arbeitsunfähigkeit nicht zu leisten.
A severance payment shall not be made in the event of termination of the employment agreement due to permanent incapacity to work.
1.Stirbt der Vorstand während der Dauer des Dienstvertrages, ist die Grundvergütung nach § 3 (1) lit. a) noch für den Sterbemonat und für die zwei darauf folgenden Monate zu zahlen.
1.If the Board Member dies during the term of this Service Agreement, the Basic Remuneration according to § 3 (1) lit. a) shall still be payable for the month of death and for the following two months.

Germany 10363757.1
Seite 11 von 23

Die Boni nach § 3 (1) lit. b) werden entsprechend Anlage 4 Ziff. 3 durch den Aufsichtsrat festgelegt und an den Ehepartner, bei deren Fehlen an die unterhaltsberechtigten Kinder des Vorstands (letztere als Gesamtgläubiger) oder seine Erben bezahlt.
The bonuses pursuant to § 3 (1) lit. b) are determined by the Supervisory Board in accordance with Annex 4 No. 3 and paid to the spouse, in the event of their absence to the dependent children of the Board Member (the latter as joint creditor) or his heirs.

Sonderleistungen und Sonderkündigungsrecht bei Kontrollerwerb
§ 1
Special services and special right of termination in the event of acquisition of control

Germany 10363757.1
Seite 12 von 23

1.Kommt es nach der Unterzeichnung dieses Vertrags zu einem Kontrollerwerb im Sinne eines Anteilserwerbs von mehr als 50% durch einen Aktionär, Dritten oder gemeinsam handelnde Personen oder zu einer wirtschaftlich vergleichbaren Transaktion (z.B. Verkauf des Geschäftsbetriebs oder eines wesentlichen Teils davon durch die Gesellschaft, Verkauf von wesentlichen Beteiligungsgesellschaften der Gesellschaft, Verschmelzung auf ein anderes Unternehmen, Verkauf von mehr als 50% der Anteile der Gesellschaft nach einem „Delisting" der Gesellschaft, etc.) und will sich die Gesellschaft in diesem Zusammenhang oder in dessen Folge von dem Vorstand durch vorzeitige Vertragsauflösung trennen, ohne hierfür einen wichtigen Grund im Sinn des § 626 BGB zu haben, so erhält der Vorstand zusätzlich zu der Vergütung und allen Leistungen, die ihm bis zum Trennungszeitpunkt zustehen, eine Abfindung. Die Höhe der Abfindung entspricht der Summe der Gesamtvergütung (Grundvergütung, variable Vergütung sowie Nebenleistungen), die der Vorstand bis zum Ablauf der in § 10 (1) definierten Dauer gemäß diesem Vertrag erhalten hatte, wäre der Vertrag nicht vorzeitig beendet, sondern bis zum Ende der vollen Amtszeit erfüllt worden. Für Zwecke der Berechnung der Abfindung nach diesem Absatz (1) wird davon ausgegangen, dass dem Vorstand jeweils der maximale Bonus gemäß Anlage 4 (ggf. pro rata temporis bis zum Ende der Vertragslaufzeit) gezahlt worden wäre. Beträgt die ordentliche Laufzeit dieses Vertrages gemäß § 10 (1) zum Zeitpunkt des Wirksamwerdens der Trennung nach diesem Absatz (1) weniger als 15 Monate, berechnet sich die zu zahlende Abfindung auf Basis einer fiktiven Restlaufzeit von 15 Monaten, d. h. die Abfindung wird berechnet auf Basis einer angenommenen Restlaufzeit von mindestens 15 Monaten.
1.If, after the signing of this Agreement, control is acquired in the sense of a share acquisition of more than 50% by a shareholder, third party or persons acting jointly or in the sense of an economically comparable transaction (e.g. sale of the business operations or a substantial part thereof by the Company, sale of substantial associated companies of the Company, merger with another company, sale of more than 50% of the shares of the Company after a delisting of the Company, etc.) and if the Company wishes to terminate the agreement with the Board Member in this context or as a result thereof by early termination of the agreement without having an important reason within the meaning of Section 626 of the German Civil Code (BGB), the Board Member shall receive a severance payment in addition to the remuneration and all benefits to which it is entitled up to the time of termination. The amount of the severance payment corresponds to the sum of the total remuneration (basic remuneration, variable remuneration as well as fringe benefits) that the Board Member would have received until expiry of the term defined in § 10 (1) of this agreement, if the agreement would not have been terminated prematurely, but would have been fulfilled up until the end of the full term of office. For the purpose of calculating the severance payment pursuant to this paragraph (1), it is assumed that the maximum bonus would have been paid to the Board Member in each case in accordance with Annex 4 (if applicable pro rata temporis until the end of the agreement term). If the ordinary term of this agreement pursuant to § 10 (1) is less than 15 months at the time the separation pursuant to this paragraph (1) takes effect, the severance payment to be made shall be calculated on the basis of a fictitious remaining term of 15 months, i.e. the severance payment shall be calculated on the basis of an assumed remaining term of at least 15 months.
Während der Vertragslaufzeit stattfindende Anhebungen der Vergütung gemäß § 3 (1) werden bei den beschriebenen Berechnungen berücksichtigt.
Any increases in remuneration in accordance with § 3 (1) that take place during the term of the agreement shall be taken into account in the calculations described.
1.Die Abfindung ist in voller Höhe zusammen mit dem Gehalt für den Monat, zu dessen Ende die Trennung nach Absatz (1) wirksam wird, zur Zahlung fällig.
1.The severance payment shall be payable in full together with the salary for the month at the end of which the separation referred to in paragraph (1) takes effect.

Germany 10363757.1
Seite 13 von 23

1.Im Falle dieses Absatzes (1) wird dem Vorstand ein außerordentliches Sonderkündigungsrecht zu diesem Dienstvertrag eingeräumt. Das Sonderkündigungsrecht kann innerhalb von sechs Wochen ab Kenntnis des Vorstands über den rechtskräftigen Vollzug des Kontrollwechsels im Sinne des Absatzes (1) mit einer Frist von drei Monaten zum Monatsende ausgeübt werden. Darüber hinaus besteht ein Sonderkündigungsrecht des Vorstands auch dann, wenn der Vorstand innerhalb von einem Jahr nach Vollzug des Kontrollwechsels abberufen wird. In diesem Fall beträgt die Sonderkündigungsfrist zwei Wochen. Die Kündigung kann innerhalb von vier Wochen nach Abberufung durch den Vorstand erklärt werden.
1.In the event of this paragraph (1), the Board Member shall be granted an extraordinary right of termination of this Service Agreement. The special right of termination may be exercised within six weeks of the knowledge of the Board Member of the legally binding execution of the change of control within the meaning of paragraph (1) with a notice period of three months to the end of the month. In addition, the Board Member has a special right of termination even if the Board Member is dismissed within one year of the completion of the change of control. In this case, the special notice period is two weeks. The termination may be declared by the Board Member within four weeks after dismissal.
§ 1
Diensterfindungen und Schutzrechte
§ 1
Service inventions and industrial property rights

Germany 10363757.1
Seite 14 von 23

1.Erfindungen des Vorstands sowie seine technischen oder organisatorischen Verbesserungsvorschläge werden entsprechend den jeweils geltenden Bestimmungen des Gesetzes über Arbeitnehmererfindungen vom 25.7.1957 mit folgender Maßgabe behandelt: Der Vorstand wird der Gesellschaft Diensterfindungen, freie Erfindungen und technische wie organisatorische Verbesserungsvorschläge unverzüglich melden und der Gesellschaft zur ausschließlichen, beschränkten oder unbeschränkten Inanspruchnahme anbieten. Die Erklärung der Inanspruchnahme hat seitens der Gesellschaft innerhalb von vier Monaten nach der Meldung zu erfolgen. Die Gesellschaft hat das Recht, jedoch nicht die Verpflichtung, zur Anmeldung von Schutzrechten im In- und Ausland. Im Fall einer Diensterfindung oder eines technischen oder organisatorischen Verbesserungsvorschlags sind sich die Parteien darin einig, dass eine etwaige Vergütung für eine von der Gesellschaft in Anspruch genommene Diensterfindung mit der Zahlung der Grundvergütung nach § 3 (1) lit. a) dieses Vertrages vollständig abgegolten ist. Im Fall einer freien Erfindung ist dem Vorstandsmitglied eine marktübliche Vergütung zu zahlen.
1.Inventions by the Board Member and its technical or suggestions for organizational improvements shall be treated in accordance with the applicable provisions of the Act on Employee Inventions of 25 July 1957, subject to the following provisions: The Board Member will immediately notify the Company of job-related inventions, free inventions and technical and organizational suggestions for improvement and offer them to the Company for exclusive, limited or unlimited use. The Company must declare the claim within four months of notification. The Company is entitled, but not obliged, to register intellectual property rights in Germany and abroad. In the case of a job-related invention or a technical or organizational suggestion for improvement, the parties agree that any remuneration for a service invention claimed by the Company shall be paid in full upon payment of the basic remuneration pursuant to § 3 (1) lit. a) of this Agreement. In the case of a free invention, the Board Member shall be paid remuneration in line with market-based conditions.
1.Der Vorstand überträgt der Gesellschaft ausschließliche, zeitlich, räumlich und inhaltlich unbeschränkte Nutzungs- und Verwertungsrechte für alle etwaigen nach dem Urhebergesetz schutzfähigen Tätigkeitsergebnisse, die das Vorstandsmitglied während der Dauer seines Dienstvertrages während seiner Arbeitszeit oder, sofern sie Bezug zu seinen dienstvertraglichen Aufgaben haben, auch außerhalb seiner Arbeitszeit erstellt. Die Übertragung der urheberrechtlichen Nutzungs- und Verwertungsrechte umfasst auch etwaige bei Vertragsschluss noch unbekannte Nutzungsarten. Die Übertragung der Nutzungs- und Verwertungsrechte umfasst insbesondere auch die Erlaubnis zur Bearbeitung und Lizenzvergabe an Dritte. Das Vorstandsmitglied verzichtet ausdrücklich auf sonstige ihm etwa als Urheber zustehende Rechte an den Tätigkeitsergebnissen, insbesondere auf das Recht auf Namensnennung, auf Bearbeitung und auf Zugänglichmachung des Werkes.
1.The Board Member shall grant the Company exclusive rights of use and exploitation, unlimited in terms of time, space and content, for any works which may be protected under the Copyright Act and which the Board Member produces during the term of this Service Agreement during his working hours or, if they relate to his duties under the Service Agreement, also outside of his working hours. The transfer of the copyrighted rights of use and exploitation also includes any types of use still unknown at the time of conclusion of the agreement. The transfer of the rights of use and exploitation includes in particular the permission for processing and licensing to third parties. The Board Member expressly waives any other rights to the works, which he is entitled as the author, in particular the right to name, edit and make accessible the work.

Germany 10363757.1
Seite 15 von 23

1.Soweit Tätigkeitsergebnisse, die der Vorstand während der Dauer seines Dienstvertrages während seiner Arbeitszeit oder, sofern sie Bezug zu seinen dienstvertraglichen Aufgaben haben, auch außerhalb seiner Arbeitszeit erstellt, nicht bereits nach Absatz (1) und (2) übertragen sind, überträgt der Vorstand der Gesellschaft sämtliche Rechte an diesen Tätigkeitsergebnissen, insbesondere Marken- und sonstige Kennzeichenrechte sowie eingetragene Designs.
1.Insofar as works which the Board Member produces during the term of its Service Agreement, during its working hours or, insofar as they relate to its duties under the Service Agreement, also outside its working hours, have not already been transferred in accordance with paragraphs (1) and (2), the Board Member shall transfer to the Company all rights to these works, in particular trademark and other distinctive rights as well as registered designs.
1.Die Parteien sind sich einig, dass die Einräumung dieser Rechte und der Verzicht auf Rechte nach dieser Regelung vollumfänglich mit der Zahlung der Grundvergütung nach § 3 (1) lit. a) dieses Vertrages abgegolten sind, soweit dem nicht zwingende gesetzliche Regelungen entgegenstehen. Der Vorstand ist verpflichtet, jedwedes seiner schutzrechtsfähigen Tätigkeitsergebnisse unverzüglich der Gesellschaft, vertreten durch den Aufsichtsrat, zu meiden und die Gesellschaft im erforderlichen Umfang, auch nach Beendigung dieses Dienstvertrages, bei der Erlangung von Schutzrechten zu unterstützen. Soweit der Vorstand seine Mitwirkungspflichten nach der Beendigung dieses Dienstvertrages erfüllt, erhält der Vorstand hierfür einen angemessenen Tagessatz sowie eine Erstattung aller Aufwendungen, die ihm durch seine Mitwirkung entstanden sind.
1.The parties agree that the granting of these rights and the waiver of rights under this provision are fully covered by the payment of the Basic Remuneration under § 3 (1) lit. a) this agreement, unless otherwise provided for by mandatory legal provisions. The Board Member is obliged to notify any of the works that are capable of being protected by intellectual property rights without delay to the Company, represented by the Supervisory Board, and to support the Company to the necessary extent, even after termination of this Service Agreement, in obtaining intellectual property rights. To the extent that the Board Member fulfils its duties to cooperate after the termination of this Service Agreement, the Board Member shall receive an appropriate daily rate as well as a reimbursement of all expenses incurred by him resulting from his cooperation.

Geheimhaltung und Rückgabe von Unterlagen, Interessenkonflikte
§ 1
Confidentiality and return of documents, conflicts of interest

Germany 10363757.1
Seite 16 von 23

1.Der Vorstand verpflichtet sich, über alle ihm im Rahmen seiner Tätigkeit oder sonst zur Kenntnis gelangenden geschäftlichen und betrieblichen Angelegenheiten der Gesellschaft und aller Verbundenen Unternehmen strengstes Stillschweigen zu bewahren, einschließlich des Inhalts dieses Dienstvertrages sowie den Vertragsverhandlungen, die dem Abschluss dieses Dienstvertrages zugrunde liegen. Der Vorstand verpflichtet sich weiterhin, diese Informationen nicht für den eigenen oder den Nutzen anderer zu verwenden und alle solche geschäftlichen und betrieblichen Angelegenheiten betreffenden Geschäftsunterlagen der Gesellschaft und der Verbundenen Unternehmen unter Verschluss zu halten. Unter geschäftlichen und betrieblichen Angelegenheiten im Sinne dieser Regelung verstehen die Parteien insbesondere Geschäfts- und Betriebsgeheimnisse sowie alle Informationen und Daten mit Bezug zu vertraulichen Angelegenheiten und geschäftsbezogenem Know-how, sämtliche Informationen über alle mit dem existenten oder künftigen Geschäft der Gesellschaft und der Verbundenen Unternehmen in Zusammenhang stehenden Geschäftspläne und Geschäftsstrategien, Verfahren, Preis- oder Marktstrategien und Produkt-, Dienstleistungs- oder Entwicklungsplanungen, geplante Unternehmenserwerbe oder -veräußerungen, sämtliche Geschäftszahlen und Details der organisatorischen Strukturen sowie die wesentlichen Ideen und Prinzipien, welche diesen Strategien und Planungen zugrunde liegen, und alle Informationen, von denen vernünftigerweise erwartet werden kann, dass sie zu solchen Strategien oder Planungen führen würden und die von der Gesellschaft, von Verbundenen Unternehmen oder dem Vorstandsmitglied während der Dauer dieses Dienstvertrages erdacht, erfunden, überarbeitet, entdeckt, entwickelt, erworben, beurteilt, getestet oder angewendet worden sind.
1.The Board Member undertakes to maintain the strictest secrecy with regard to all business and operational matters of the Company and old affiliated companies that come to its attention in the course of its activities or otherwise, including the contents of this Service Agreement and the negotiations on which the conclusion of this Service Agreement is based. The Board Member further undertakes not to use this information for its own benefit or for the benefit of others and to keep all business documents of the Company and its affiliates relating to such business and operational matters under lock and key. For the purposes of this provision, business and operational matters shall mean, in particular, business and trade secrets and all information and data relating to confidential matters and business-related know-how, all information, all business plans and strategies, procedures, price or market strategies and product, service or development plans relating to the existing or future business of the Company and its affiliates, planned corporate acquisitions or disposals, all business figures and details of the organizational structures and the principal ideas and principles underlying such strategies and plans, and all information that can reasonably be expected to result in such strategies or plans and that has been invented, redacted, discovered, developed, assessed, tested or applied by the Company, its affiliates or the Board Member during the term of this Service Agreement.
1.Die Geheimhaltungsverpflichtung nach vorstehendem Absatz (1) dauert auch nach Beendigung des Dienstverhältnisses fort. Im Rahmen einer von dem Vorstand nach Beendigung dieses Dienstvertrages ausgeübten beruflichen oder unternehmerischen Tätigkeit kann er sein als Vorstandsmitglied erworbenes Wissen einsetzen, sofern dabei die gesetzlichen Beschränkungen – insbesondere nach §§ 3, 17 UWG, § 823 (1) und (2) BGB i.V.m. UWG, § 826 BGB und den datenschutzrechtlichen Regelungen – sowie die Beschränkungen aus dem nachvertraglichen Wettbewerbsverbot nach § 16 dieses Vertrages strikt beachtet werden.
1.The obligation to maintain secrecy pursuant to paragraph (1) above shall continue even after the termination of the employment relationship. The Board Member may use the knowledge acquired as a Board Member within the scope of a professional or entrepreneurial activity carried out by the Board Member after termination of this Service Agreement, provided that he complies with the statutory restrictions - in particular Sections 3, 17 UWG, Section 823 (1) and (2) BGB in conjunction with Sections 3, 17 UWG, Section 823 (1) and (2) BGB associated with UWG, Section 826 BGB and the data protection regulations.
1.Der Vorstand ist verpflichtet, in Zweifelsfällen über den Umfang der Geheimhaltungsverpflichtung nach vorstehenden Absätzen (1) und (2) mit dem Aufsichtsrat der Gesellschaft eine Klärung herbeizuführen.
1.In cases of doubt, the Board Member is obliged to reach a clarification with the Supervisory Board of the Company regarding the scope of the confidentiality obligation pursuant to paragraphs (1) and (2) above.

Germany 10363757.1
Seite 17 von 23

1.Der Vorstand verpflichtet sich, auf Verlangen der Gesellschaft jederzeit und spätestens bei Ende seiner Bestellung zum Organ auch ohne gesonderte Aufforderung alle in seinem Besitz befindlichen Unterlagen der Gesellschaft oder Verbundener Unternehmen, insbesondere alle Notizen, Memoranden, Aufzeichnungen, Protokolle und Berichte, Akten sowie alle anderen ähnlichen Dokumente (einschließlich Abschriften, Ablichtungen, Kopien oder sonstiger Reproduktionen), die im Zusammenhang mit seiner Tätigkeit stehen, unverzüglich und vollständig an die Gesellschaft zurückzugeben. Ein Zurückbehaltungsrecht ist ausgeschlossen. Diese Regelung gilt sinngemäß für elektronisch gespeicherte Daten sowie die jeweiligen Daten- oder Programmträger.
1.The Board Member undertakes, at the request of the Company at any time and at the latest at the end of its appointment to the board and without separate request, to return to the Company all documents of the Company or affiliated companies in its possession, in particular all notes, memoranda, records, minutes and reports, files as well as all other similar documents (including copies, photocopies or other reproductions) in connection with its activities without delay and in full. A right of retention is excluded. This provision applies to electronically stored data as well as to the respective data or program carriers.
1.Die Herausgabeverpflichtung bezieht sich auch auf sonstiges, im Besitz des Vorstands befindliches Eigentum der Gesellschaft oder Verbundener Unternehmen bzw. von der Gesellschaft oder von einem Verbundenen Unternehmen geleaste Gegenstände. Diese Herausgabeverpflichtung erstreckt sich insbesondere auch auf ein dem Vorstand etwa überlassenes Mobiltelefon, Laptop oder sonstige Geräte der Datenverarbeitung, bei Ende seiner Bestellung zum Organ auch, wenn insoweit eine private Nutzung gestattet war.
1.The release obligation also applies to other property of the Company or affiliates or items leased by the Company or an affiliate that is in possession of the Board Member. This release obligation also extends in particular to a mobile phone, laptop or other data processing device left in the possession of the Board Member, at the end of its appointment to the Board even if private use was permitted in this respect.
1.Der Vorstand hat mögliche und tatsächliche Interessenkonflikte unverzüglich dem Aufsichtsrat gegenüber offenzulegen und die anderen Vorstandsmitglieder hierüber zu informieren.
1.The Board Member must immediately disclose possible and actual conflicts of interest to the Supervisory Board and inform the other members of the Management Board hereof.
§ 1
Vertragsdauer

Term of the Agreement

Germany 10363757.1
Seite 18 von 23

1.Dieser Vertrag wird mit Wirkung zum 22. August 2016 abgeschlossen. Er endet mit Ablauf des 31. August 2019.
1.This agreement will be concluded with effect as of 22 August 2016. It ends at the end of 31 August 2019.
1.Das Recht zur außerordentlichen Kündigung bleibt unberührt.
1.The right to extraordinary termination remains unaffected.
1.Im Fall eines Widerrufs der Bestellung, der Amtsniederlegung durch das Vorstandsmitglied oder bei einer sonstigen Beendigung der Organstellung endet dieser Dienstvertrag mit Ablauf eines Jahres nach dem Ende des Amtes, spätestens jedoch zum Ende der Laufzeit nach Absatz (1). Eine etwaige frühere Beendigung aufgrund Absatz (2) dieses Vertrages bleibt unberührt.
1.In the event of revocation of the appointment, demission by the Board Member or other termination of the position, this Service Agreement shall end at the end of one year after the end of the term of office, at the latest, however, at the end of the term pursuant to paragraph (1). A possible termination due to paragraph (2) of this agreement remains unaffected.
1.Der Vorsitzende des Aufsichtsrats wird dem Vorstand spätestens neun Monate vor Ablauf dieses Vertrages, also bis zum 30. November 2018, schriftlich mitteilen, ob und unter welchen Bedingungen der Aufsichtsrat den Vorstand erneut zum Vorstandsmitglied bestellen wird und ob er bereit ist, den Dienstvertrag entsprechend der Dauer der neuen Bestellung zu verlängern oder einen neuen Dienstvertrag zu mindestens gleichen Bedingungen mit ihm abzuschließen, Der Vorstand wird innerhalb von zwei Monaten ab Zugang des Angebots des Aufsichtsratsvorsitzenden erklären, ob er die erneute Bestellung annimmt und bereit ist, den für die Fortsetzung oder Erneuerung des Dienstvertrages angebotenen Bedingungen zuzustimmen.
1.The Chairman of the Supervisory Board will inform the Board Member in writing no later than nine months before the expiry of this agreement, i.e. by 30 November 2018, whether and under what conditions the Supervisory Board will reappoint the Board Member and whether he is willing to extend the Service Agreement for the duration of the new appointment or to conclude a new Service Agreement on at least the same terms. Within two months of receipt of the Supervisory Board Chairman's offer, the Board Member will declare whether it accepts the reappointment and is prepared to agree to the terms and conditions offered for the continuation or renewal of the Service Agreement.
1.Die Gesellschaft ist berechtigt, den Vorstand nach dem Widerruf seiner Bestellung gemäß § 84 (3) AktG oder im Zusammenhang mit einer Beendigung des Dienstvertrages, insbesondere nach einer Kündigung oder im Anschluss an den Abschluss eines Aufhebungsvertrages, ganz oder teilweise von seiner Pflicht zur Dienstleistung unter Fortzahlung der Grundvergütung gemäß § 3 (1) lit. a) widerruflich oder unwiderruflich freizustellen. Im Fall der unwiderruflichen Freistellung werden offene Urlaubs- und sonstige Freizeitausgleichsansprüche angerechnet, die damit erledigt sind. Der Dienstvertrag im Übrigen wird von der Freistellung nicht berührt; insoweit bestehen insbesondere die Verschwiegenheitspflicht und das vertragliche Wettbewerbsverbot bis zum Ende des Dienstvertrages fort. Anderweitiger Verdienst während der Freistellungszeit wird gemäß § 615 Satz 2 BGB angerechnet. Eine Anrechnung erfolgt nicht, wenn und soweit der anderweitige Verdienst aus einer genehmigten Nebentätigkeit (§ 2 (1) dieses Dienstvertrages) stammt.
1.The Company is entitled, after the revocation of its appointment pursuant to Section 84 (3) AktG or in connection with a termination of the Service Agreement, in particular following a termination or following the conclusion of a termination agreement, to release the Board Member in whole or in part from its obligation to provide services with continued payment of the Basic Remuneration pursuant to § 3 (1) a) revocably or irrevocably. In the event of irrevocable release, receivable holiday and other time off compensation claims shall be credited and settled. The rest of the Service Agreement is not affected by the indemnification; in this respect, the obligation to maintain secrecy and the contractual non-competition clause continue to apply until the end of the Service Agreement. Other earnings during the exemption period shall be credited in accordance with Section 615 sentence 2 BGB. Crediting does not take place if and as far as the other earnings originate from an approved secondary activity (§ 2 (1) of this Service Agreement).

Germany 10363757.1
Seite 19 von 23

1.Der Dienstvertrag endet spätestens am Ende des Kalenderjahres, in dem das Vorstandsmitglied sein 65. Lebensjahr vollendet, sofern dieser Dienstvertrag nicht bereits nach Absatz (1) bis (2) dieses Vertrages vor diesem Zeitpunkt geendet hat.
1.The Service Agreement shall end at the latest at the end of the calendar year in which the Board Member reaches the age of 65, unless this Service Agreement has not already ended before this date in accordance with paragraphs (1) to (2) of this agreement.
1.Bei vorzeitiger Beendigung der Vorstandstätigkeit ohne wichtigen Grund entsprechen die Zahlungen an den Vorstand einschließlich Nebenleistungen maximal dem Wert von zwei Jahresvergütungen (Abfindungs-Cap) und überschreiten nicht die Gesamtvergütung (Grundvergütung, variable Vergütung sowie Nebenleistungen) für die Restlaufzeit des Dienstvertrages. Bei einem Kontrollerwerb nach § 7 gilt ein Abfindungs-Cap von maximal drei Jahresvergütungen.
1.In the event of premature termination of the board activity without good cause, payments to the Board Member including fringe benefits shall not exceed the value of two years' remuneration (severance payment cap) and shall not exceed the total remuneration (Basic Remuneration, variable remuneration and fringe benefits) for the remaining term of the Service Agreement. In the case of an acquisition of control pursuant to § 7, a severance payment cap of a maximum of three years' remuneration applies.
§ 1
Ausschlussfristen
§ 1
Cut-off Periods

Germany 10363757.1
Seite 20 von 23

1.Ansprüche der Gesellschaft und des Vorstands aus dem Dienstverhältnis oder im Zusammenhang mit diesem Dienstverhältnis verfallen, ungeachtet ihres Rechtsgrundes, wenn die bzw. der Anspruchsberechtigte den Anspruch nicht innerhalb einer Frist von sechs Monaten, berechnet ab dem Zeitpunkt der Fälligkeit und der Kenntnis oder grob fahrlässigen Unkenntnis des Anspruchsberechtigten von den anspruchsbegründenden Umständen, durch schriftliche Erklärung gegenüber der jeweils anderen Vertragspartei geltend macht. Für die Beurteilung der Rechtzeitigkeit der Geltendmachung ist der Zugang der schriftlichen Erklärung maßgeblich. Dies gilt nicht für die Geltendmachung von Ansprüchen wegen Verletzung des Lebens, des Körpers oder der Gesundheit sowie bei vorsätzlichen Pflichtverletzungen. Die Versäumung der Ausschlussfrist führt zum Verlust des Anspruchs.
1.Claims of the Company and the Board Member arising from or in connection with the employment relationship shall expire, irrespective of their legal basis, if the entitled person does not assert the claim within a period of six months, calculated from the due date and the knowledge or grossly negligent ignorance of the entitled person of the circumstances giving rise to the claim, by means of a written declaration to the respective other party. For the assessment of the timeliness of the assertion, the receipt of the written declaration is decisive. This does not apply to the assertion of claims due to injury to life, body or health as well as in the case of intentional breaches of duty. Failure to comply with the cut-off period will result in the loss of the claim.
1.Etwaige Ansprüche der Gesellschaft nach § 93 (2) und (3) AktG gegen das Vorstandsmitglied bleiben gemäß § 93 (4) Satz 3 AktG von vorstehendem Absatz (1) unberührt.
1.Any claims of the Company pursuant to Section 93 (2) and (3) AktG against the Board Member shall remain unaffected by the above paragraph (1) pursuant to Section 93 (4) sentence 3 AktG.
§ 1
Schlussbestimmungen
§ 1
Final Provisions
1.Dieser Vertrag enthält die gesamte Vereinbarung zwischen den Parteien. Bereits getroffene Vereinbarungen zwischen den Parteien werden hiermit ausdrücklich aufgehoben.
1.This agreement contains the entire agreement between the parties. Prior agreements between the parties are hereby expressly cancelled.
1.Änderungen oder Ergänzungen dieses Vertrages einschließlich dieser Schriftformklausel bedürfen zu ihrer Wirksamkeit der Schriftform.
1.Changes or additions to this agreement, including this written form clause, must be made in writing to be effective.
1.Dieser Vertrag unterliegt dem Recht der Bundesrepublik Deutschland.
1.This agreement is subject to the law of the Federal Republic of Germany.

Germany 10363757.1
Seite 21 von 23

1.Erfüllungsort ist der Sitz der Gesellschaft, Gerichtsstand für Streitigkeiten aus diesem Vertrag ist der Sitz der Gesellschaft.
1.Place of performance is the seat of the Company, place of jurisdiction for disputes from this agreement is the seat of the Company.
1.Sollte eine Bestimmung dieses Vertrages ganz oder teilweise rechtsunwirksam oder undurchführbar sein oder werden, so wird die Gültigkeit der übrigen Bestimmungen dieses Vertrages nicht berührt. Vielmehr ist die ganz oder teilweise rechtsunwirksame oder undurchführbare Bestimmung durch eine Bestimmung zu ersetzen, die den mit der unwirksamen Bestimmung angestrebten wirtschaftlichen Erfolg soweit wie möglich erreicht. Das gleiche gilt im Fall von Lücken dieses Vertrages.
1.Should any provision of this agreement be or become invalid or unenforceable in whole or in part, the validity of the remaining provisions of this agreement shall not be affected. Rather, the invalid or unenforceable provision, in whole or in part, shall be replaced by a provision that achieves as far as possible the economic purpose intended by the invalid provision. The same shall apply in the event of any gaps in this agreement.
Martinsried, denMartinsried, den
/s/ Dr. Jörg Neermann/s/ Dr. Andreas Mühler
Immunic AG,
vertreten durch den Aufsichtsratsvorsitzenden
Dr. Jörg Neermann		Dr. Andreas Mühler


Germany 10363757.1
Seite 22 von 23

AnlagenverzeichnisSchedule of Annexes
Anlage 1:    AR-Beschluss vom 23.03.2016Annex 1:    AR resolution of 23.03.2016
Anlage 2:    Genehmigte Nebentätigkeiten des VorstandsAnnex 2:    Approved ancillary activity of the Board Member





Germany 10363757.1
Seite 23 von 23

Anlage 1: AR-Beschluss vom 23.03.2016 / Annex 1: AR resolution of 23.03.2016


Germany 10363757.1
Seite 24 von 23

Anlage 2: Genehmigte Nebentätigkeiten des Vorstands / Annex 2: Approved ancillary activity of the Board Member
•Takeda Group, einschließlich der 100%-igen Tochtergesellschaft Takeda Pharmaceuticals International, vormals Millennium Pharmaceuticals (durchschnittlicher Aufwand beschränkt auf maximal 8 Stunden pro Woche) /

Takeda Group, including its wholly owned subsidiary Takeda Pharmaceuticals International, formerly Millennium Pharmaceuticals (average effort limited to a maximum of 8 hours per week)

Germany 10363757.1
 EX-10.6 4 imux-ex106dienstvertragdan.htm EX-10.6 Document


DIENSTVERTRAGSERVICE AGREEMENT
zwischenbetween
Immunic AG,
vertreten durch den Vorsitzenden des Aufsichtsrates
Immunic AG,
represented by the Chairman of the Supervisory Board
- nachfolgend „Gesellschaft" genannt -- hereinafter referred to as the
"Company" -
undand
Herrn Daniel Vitt,Mr. Daniel Vitt,
- nachfolgend „Vorstand" genannt -- hereinafter referred to as the "Board Member" -
§ 1
Aufgabenbereich und Pflichten
§ 1
Responsibilities and Obligations
1.Herr Daniel Vitt soll zum ordentlichen Mitglied des Vorstandes der Gesellschaft bestellt werden. Er wird als geschäftsführendes Vorstandsmitglied (CEO) der Gesellschaft bestellt und vertritt die Gesellschaft gemeinsam mit einem Vorstand oder einem Prokuristen. Der Aufsichtsrat kann dem Vorstand die Befreiung von § 181 BGB erteilen.
1.Mr. Daniel Vitt is to be appointed as a member of the Company's Management Board. He will be appointed as the managing director (CEO) of the Company and represents the Company together with a member of the Management Board or an authorized signatory. The Supervisory Board may grant the Board Member exemption from Section 181 of the German Civil Code (BGB).
1.Der Vorstand führt die Geschäfte der Gesellschaft nach Maßgabe der Gesetze, der Satzung, der Geschäftsordnung für den Vorstand und dieses Dienstvertrages. Der Vorstand hat insbesondere für die in § 7 der Geschäftsordnung des Vorstands genannten Geschäfte und Maßnahmen die Zustimmung des Aufsichtsrats einzuholen.
1.The Board Member shall conduct the business of the Company in accordance with the law, the Articles of Association, the rules of procedure for the Management Board and this Service Agreement. In particular, the Board Member shall obtain the approval of the Supervisory Board for transactions and measures subject to approval in accordance with the rules of procedure of the Management Board.

Germany 10363769.1
Seite 2 von 19

1.Dem Vorstand obliegen insbesondere die Aufgaben, die im Sinne des jeweiligen Geschäftsverteilungsplans (Anlage 1) zum Geschäftsbereich des geschäftsführenden Vorstandsmitglieds (CEO) gehören.
1.In particular, the Board Member is responsible for those tasks which, within the meaning of the respective schedule of responsibilities (Annex 1), belong to the business area of the managing director of the Executive Board (CEO).
1.Dienstort ist München/Planegg-Martinsried.
1.The place of work is Munich/Planegg-Martinsried.
§ 1
Nebentätigkeiten
§ 1
Ancillary Activities
1.Der Vorstand wird seine ganze Arbeitskraft und seine sämtlichen fachlichen Kenntnisse und Erfahrungen der Gesellschaft widmen. Die Übernahme einer entgeltlichen Nebentätigkeit sowie von Aufsichtsrats-, Beirats- oder ähnlichen Mandanten bedarf der vorherigen Zustimmung durch den Aufsichtsratsvorsitzenden.
1.The Board Member will devote all its working capacity and all its professional knowledge and experience to the Company. The assumption of an ancillary commercial activity as well as mandates in a supervisory board or advisory board or similar mandates require the prior consent of the Chairman of the Supervisory Board.
Dem Aufsichtsratsgremium ist bekannt, dass der Vorstand zum Zeitpunkt der Unterzeichnung dieses Vertrages die in Anlage 2 aufgelisteten Mandate innehat und erteilt zu deren Fortführung seine Zustimmung.
The Supervisory Board is aware that the Board Member holds the mandates listed in Annex 2 at the time of signing of this agreement and grants its approval to their continuation.
1.Für den Vorstand gilt das Wettbewerbsverbot des § 88 AktG. Während der Dauer dieses Vertrages wird sich der Vorstand auch nicht an Unternehmen beteiligen, die mit der Gesellschaft in Wettbewerb stehen oder mit denen die Gesellschaft Geschäftsverbindungen unterhält, es sei denn, der Aufsichtsrat hat vorher seine schriftliche Zustimmung erteilt.
1.The Board Member is subject to the non-competition clause of Section 88 of the German Stock Corporations Act (AktG). During the term of this agreement, the Board Member will also not invest in companies that compete with the Company or with which the Company has business relationships, unless the Supervisory Board has given its prior written consent.
Das Wettbewerbsverbot gilt nicht für Beteiligungen an Unternehmen in Gestalt von Wertpapieren, die an Börsen gehandelt und zum Zwecke der Kapitalanlage erworben werden.
The non-competition clause does not apply to interests in companies in the form of bonds traded on stock exchanges and acquired for the purpose of capital investment.
§ 1
Vergütung und Bonus
§ 1
Remuneration and Bonus

Germany 10363769.1
Seite 3 von 19

1.Der Vorstand erhält für seine Tätigkeit
1.The Board Member receives for its activities
a)ein festes Jahresgehalt („Grundvergütung") in Höhe von EUR 215.000,00 brutto, das in 12 gleichen Monatsraten jeweils nachträglich am Monatsletzten ausbezahlt wird. Sofern dieser Vertrag nicht während der Dauer eines gesamten Kalenderjahres besteht, wird das Jahresfestgehalt zeitanteilig gezahlt.
a)a fixed annual salary ("Basic Remuneration") in the amount of EUR 215,000.00 gross, paid in 12 equal monthly instalments at the end of each month. If this agreement does not exist for the duration of an entire calendar year, the fixed annual salary shall be paid pro rata temporis.
a)eine jährliche variable Vergütung, die bei 100-prozentigem Erreichen der festgelegten Jahresziele maximal EUR 30.000,00 brutto beträgt. Die Einzelheiten, insbesondere zum Verfahren der Zielfestlegung, zur Feststellung der Zielerreichung und zur Fälligkeit ergeben sich aus dem Rahmenvertrag zur Zielvereinbarung in seiner jeweils geltenden Fassung. Die Art der Ziele, die Voraussetzungen für ihre Erreichung und ihre Gewichtung zueinander werden für das jeweilige Geschäftsjahr in einer gesonderten Zielfestlegung niedergelegt.
a)an annual variable remuneration of up to EUR 30,000.00 gross if the defined annual targets are achieved 100 percent. The details, in particular with regard to the procedure for setting targets, determining the achievement of targets and the due date, are set out in the Framework Agreement regarding the targets (Rahmenvertrag zur Zielvereinbarung) in its current version. The nature of the objectives, the conditions for their achievement and their weighting in relation to each other are laid down for each financial year in a separate target setting.
1.Die Grundvergütung und die variable Vergütung werden jährlich durch den Aufsichtsrat überprüft. Dabei sind die wirtschaftliche Entwicklung der Gesellschaft sowie die persönliche Leistung des Vorstandes zu berücksichtigen.
1.the Basic Remuneration and the variable remuneration are reviewed annually by the Supervisory Board. The economic development of the Company and the personal performance of the Board Member must be taken into account.

Germany 10363769.1
Seite 4 von 19

1.lm Übrigen kann der Aufsichtsrat die Bezüge des Vorstands insgesamt auf die angemessene Höhe herabsetzen, wenn sich die Lage der Gesellschaft so verschlechtert, dass die Weitergewährung der Bezüge unbillig für die Gesellschaft wäre; Ruhegehalt, Hinterbliebenenbezüge und Leistungen verwandter Art können dabei nur in den ersten drei Jahren nach Ausscheiden aus der Gesellschaft herabgesetzt werden (§ 87 (2) AktG). Der Vorstand kann in diesem Fall diesen Dienstvertrag außerordentlich mit einer Frist von sechs Wochen zum Schluss des nächsten Kalendervierteljahres nach Erklärung der Herabsetzung kündigen (§ 87 (2) Satz 3 AktG). Entfällt eine verschlechterte Lage der Gesellschaft, ist die Herabstufung wieder rückgängig zu machen.
1.otherwise, the Supervisory Board may reduce the total remuneration of the Board Member to the appropriate amount if the situation of the Company deteriorates to such an extent that the continued granting of the remuneration would be inequitable for the Company; retirement pension, survivors' benefits and benefits of a related kind may only be reduced in the first three years after leaving the Company (Section 87 (2) AktG). In this case, the Board Member may terminate this Service Agreement extraordinarily with six weeks' notice to the end of the next calendar quarter after declaration of the reduction (Section 87 (2) sentence 3 AktG). If a deterioration in the situation of society does not apply, the downgrade shall be reversed.
§ 1
Versicherungen und Nebenleistungen
§ 1
Insurance and Fringe Benefits

Germany 10363769.1
Seite 5 von 19

1.Auch soweit keine gesetzliche Versicherungspflicht besteht, zahlt die Gesellschaft an das Vorstandsmitglied monatliche Zuschüsse zur Kranken-und Pflegeversicherung des Vorstandsmitglieds. Die einzelnen Zuschüsse entsprechen in ihrer Höhe der Hälfte der vom Vorstandsmitglied gezahlten Beiträge, höchstens jedoch dem jeweils unter Berücksichtigung der jeweils geltenden Beitragsbemessungsgrenzen gesetzlich geschuldeten Höchstbetrag des Arbeitgeberanteils der gesetzlichen Kranken- und Pflegeversicherung. Die von der Gesellschaft geschuldeten Zuschüsse werden dem Vorstandsmitglied jeweils am Kalendermonatsende gezahlt. Die auf diese Zahlungen etwaig anfallende Einkommensteuer trägt das Vorstandsmitglied.
1.Even if there is no statutory insurance obligation, the Company shall pay the Board Member monthly health and long-term care insurance contributions for the Board Member. The individual contributions are in their amount equivalent to the amount of the contributions paid by the Board Member, but at the most to the maximum amount of the employer's contribution to the statutory health and long-term care insurance legally owed in each case, taking into account the applicable contribution assessment thresholds. The contributions owed by the Company are paid to the Board Member at the end of each calendar month. Any income tax payable on these payments shall be borne by the Board Member.
1.Der Vorstand erhält in angemessenem Umfang für die im Gesellschaftsinteresse erforderlichen Aufwendungen Ersatz. Erforderliche Reisekosten werden gegen Einzelnachweis erstattet. Die darin enthaltenen Tage- und Übernachtungsgelder können im Rahmen der steuerlich zulässigen Beträge auch pauschal abgerechnet werden.
1.The Board Member shall be reimbursed to an appropriate extent for the expenses required in the interest of the Company. Required travel expenses will be reimbursed against itemization. The daily and overnight allowances contained therein may also be settled as a lump sum within the limits of the amount permissible for tax purposes.
1.Die Gesellschaft kann den Vorstand nach ihrem Ermessen für die Dauer dieses Dienstvertrages im Rahmen einer Risiko-Lebensversicherung in Höhe von EUR 500.000,00 für den Todesfall und im Rahmen einer Unfallversicherung in Höhe von EUR 700.000,00 für den Invaliditätsfall versichern bzw. eine bereits bestehende Versicherung fortführen. Der Vorstand hat das Recht, den/die Bezugsberechtigten zu bestimmen.
1.At its discretion, the Company may insure the Board Member for the duration of this Service Agreement under a risk life insurance policy in the amount of EUR 500,000.00 in the event of death and under an accident insurance policy in the amount of EUR 700,000.00 in the event of disability or continue an existing insurance policy. The Board Member is entitled to determine the beneficiary/beneficaries.
1.Im FaIle der Übernahme einer bestehenden Direktversicherung kann diese gemäß § 40 b EStG in ihrer geltenden Fassung weiter geführt werden. Die pauschale Versteuerung übernimmt in diesem Fall die Gesellschaft.
1.In the event that an existing direct insurance policy is taken over, this insurance policy can be managed in its current version under Section 40 b German Income Tax Act (EStG). In this case, the lump sum taxation is paid by the Company.

Germany 10363769.1
Seite 6 von 19

1.Die Gesellschaft bietet dem Vorstand die Möglichkeit zur Teilnahme an einer Pensionskasse, Unterstützungskasse oder einer ähnlichen betrieblichen Altersversorgung (BAV) bzw. zur Übernahme einer bereits bestehenden BAV. In diesem Zusammenhang kann der Vorstand einen Teil seiner Gehaltsansprüche zugunsten einer betrieblichen Altersversorgungszusage umwandeln. Die dem Vorstand gemäß § 3 (1) lit. a) gewährte Grundvergütung wird dabei mit Wirkung zum Beginn einer betrieblichen Altersversorgungszusage entsprechend um einen monatlichen Bruttobetrag gekürzt, um in eine wertgleiche Zusage auf betriebliche Versorgungsleistung umgewandelt zu werden. In Höhe dieses Betrags verringert sich der Anspruch des Vorstands auf Zahlung der Grundvergütung. Sollte der Vorstand die Versorgungszusage im weiteren Verlauf ganz oder teilweise wieder kündigen oder ruhen lassen, so lebt der entsprechende Vergütungsanspruch wieder auf.
1.The Company offers the Board Member the opportunity to participate in a pension fund, support fund or similar company pension scheme (betriebliche Altersvorsorge, BAV) or to take over an existing BAV. In this context, the Board Member can convert part of its salary entitlements into a company pension commitment. The Basic Remuneration granted to the Board Member pursuant to § 3 (1) lit. a) shall be reduced by a gross monthly amount with effect from the beginning of a company pension commitment to be converted into an equal-value commitment to company pension benefits. The Board Member's entitlement to payment of the Basic Remuneration is reduced by this amount. If the Board Member rescinds or suspends the pension commitment in whole or in part in the further course of the plan, the corresponding entitlement to compensation shall revive.

Germany 10363769.1
Seite 7 von 19

1.Die Gesellschaft schließt für den Vorstand eine Vermögensschaden-Haftpflichtversicherung (D&O) für den Fall ab, dass der Vorstand wegen einer in Ausübung seiner Tätigkeit begangenen Pflichtverletzung von einem Dritten oder der Gesellschaft aufgrund gesetzlicher Haftpflichtbestimmungen privatrechtlichen Inhalts für einen Vermögensschaden in Anspruch genommen wird. Der Vorstand trägt dabei eine Selbstbeteiligung in Höhe des Mindestwerts gemäß § 93 (2) AktG (derzeit je Schadensfall 10% des Schadens, maximal aber das 1 ½-fache der Grundvergütung pro Jahr (jährliche Höchstgrenze). Kommt es zu mehreren Schadensfällen in einem Jahr, gilt die jährliche Höchstgrenze für alle Schadensfälle zusammen. Der Selbstbehalt passt sich bei Änderung der Grundvergütung (bzw. bei Änderung von § 93 (2) AktG) automatisch an; der Vorstand ist verpflichtet, die entsprechenden Änderungen beim Selbstbehalt des D&O Versicherungsvertrages zu veranlassen, und/oder sämtliche in diesem Zusammenhang erforderlichen Erklärungen abzugeben. Das Bezugsjahr für den anzuwendenden Selbstbehalt ist das Jahr des Pflichtverstoßes.
1.The Company enters into a directors' and officers' liability insurance policy (D&O) for the Board Member for the event that a third party or the Company makes a claim against the Board Member for a loss of assets due to a breach of duty committed in the performance of its duties due to statutory liability provisions under private law. The Board Member bears a deductible in the amount of the minimum value pursuant to Section 93 (2) of the German Stock Corporation Act (AktG) (currently 10% of the damage per claim, but not more than one and a half times the Basic Remuneration per year (annual maximum limit). In case of several loss events in one year, the annual maximum limit applies to all loss events in combination. The deductible is automatically adjusted in the event of a change in the Basic Renumaration (or in the event of a change in Section 93 (2) AktG); the Board Member is obliged to arrange for the corresponding changes to the deductible in the D&O insurance agreement and / or to provide all declarations required in this regard. The reference year for the deductible to be applied is the year of the violation.
§ 1
Urlaub
§ 1
Holiday
1.Der Vorstand hat Anspruch auf einen Jahresurlaub von 30 Arbeitstagen. Arbeitstage sind alle Kalendertage mit Ausnahme von Samstagen, Sonntagen und gesetzlichen Feiertagen am Sitz der Gesellschaft. Bei unterjährigem Beschäftigungsbeginn oder -ende wird der Jahresurlaub in diesem Kalenderjahr zeitanteilig gewährt.
1.The Board Member is entitled to an annual vacation of 30 working days. Working days are all calendar days except Saturdays, Sundays and public holidays at the registered office of the Company. If employment begins or ends during the course of the year, annual vacation in this calendar year will be granted pro rata temporis.

Germany 10363769.1
Seite 8 von 19

1.Die Urlaubszeit ist unter Berücksichtigung der Geschäftslage mit den anderen Vorstandsmitgliedern abzustimmen.
1.The holiday period shall be coordinated with the other members of the Executive Board, taking into account the business situation.

Bezüge bei Krankheit, Arbeitsunfähigkeit oder Tod
§ 1
Beneficiaries in the event of illness, incapacity for work or death
1.Im Fall einer Dienstverhinderung (z.B. infolge Erkrankung) ist das Vorstandsmitglied verpflichtet, den Aufsichtsratsvorsitzenden der Gesellschaft unverzüglich über Grund und Dauer der Dienstverhinderung zu informieren und auf vordringlich zu erledigende Aufgaben hinzuweisen. Dauert die Dienstverhinderung länger als eine Woche, hat das Vorstandsmitglied im Fall einer Erkrankung ein ärztliches Attest oder im Fall einer sonstigen Dienstverhinderung eine schriftliche Erklärung vorzulegen, woraus sich der Grund der Arbeitsunfähigkeit sowie deren voraussichtliche Dauer ergeben. Das Vorstandsmitglied tritt bereits jetzt etwaige (Schadensersatz-)Ansprüche in Höhe der nach dieser Regelung von der Gesellschaft geleisteten oder zu leistenden Zahlungen an die Gesellschaft ab, die ihm gegenüber Dritten wegen der Arbeitsverhinderung zustehen. Das Vorstandsmitglied ist verpflichtet, der Gesellschaft unverzüglich sämtliche zur Geltendmachung derartiger (Schadensersatz-)Ansprüche notwendigen Angaben zu machen sowie hierfür notwendige Unterlagen zu überlassen.
1.In the event of an unforeseen absence (e.g. due to illness), the Board Member is obliged to inform the Chairman of the Supervisory Board of the Company without undue delay of the reason for and probable duration of the absence and draw the attention on the tasks to be performed urgently. If the absence lasts longer than one week, the Board Member must submit a medical certificate in the event of illness or a written declaration in the event of any other incapacity, stating the reason for the incapacity and its probable duration. The Board Member hereby assigns to the Company any (compensation) claims in the amount of the payments made or to be made by the Company in accordance with this provision to which he is entitled in respect of third parties due to the impediment to work. The Board Member is obligated to provide the Company with all information necessary for asserting such (compensation) claims and to provide the Company with the necessary documents without undue delay.
1.Bei einer vorübergehenden krankheitsbedingten oder sonstigen unverschuldeten Arbeitsunfähigkeit des Vorstandes wird die Grundvergütung gemäß § 3 (1) lit. a) während der Zeit der Arbeitsunfähigkeit bis zu einer Dauer von sechs Monaten, längstens jedoch bis zur Beendigung dieses Dienstvertrages weitergezahlt. Dauert die Arbeitsunfähigkeit länger als ununterbrochen 3 Monate an, kann der Aufsichtsrat die variable Vergütung nach Anlage 4 unter Berücksichtigung der Dauer der Arbeitsunfähigkeit angemessen reduzieren.
1.In the event of a temporary illness or other non-culpable incapacity to work, the basic remuneration pursuant to § 3 (1) lit. a) shall continue to be paid during the period of the incapacity to work up to a period of six months, at the latest until the termination of this Service Agreement. If the incapacity to work lasts longer than three months without interruption, the Supervisory Board may reduce the variable remuneration in accordance with Annex 4 by a reasonable amount, taking into account the duration of the incapacity to work.
1.Bei einer dauernden Arbeitsunfähigkeit des Vorstandes endet der Dienstvertrag mit dem Ende des Quartals, in dem die dauernde Arbeitsunfähigkeit festgestellt worden ist.
1.In the event of permanent incapacity to work of the Board Member, the employment agreement ends at the end of the quarter in which the permanent incapacity to work was determined.
Ist der Vorstand länger als sechs Monate außerstande, seiner Tätigkeit nachzugehen, kann der Aufsichtsrat verlangen, dass das Vorliegen einer dauernden Arbeitsunfähigkeit durch einen von ihm ausgewählten Arzt auf Kosten der Gesellschaft nachgeprüft wird. Nimmt der Vorstand den Termin trotz zweimaliger Aufforderung durch den Aufsichtsrat nicht wahr, gilt der Vorstand als dauernd arbeitsunfähig. Die Aufforderungen haben mit einer Woche zeitlichen Abstands voneinander zu erfolgen.
If the Board Member is unable to carry out its duties for more than six months, the Supervisory Board may demand that the existence of a permanent incapacity to work be reviewed by a doctor of its choice at the Company's expense. If the Board Member fails to meet the demand despite two requests by the Supervisory Board, the Board Member shall be deemed permanently incapacitated for work. The requests shall be made at intervals of one week.

Germany 10363769.1
Seite 9 von 19

Eine Abfindung ist bei einer Beendigung des Dienstvertrags wegen dauernder Arbeitsunfähigkeit nicht zu leisten.
A severance payment shall not be made in the event of termination of the employment agreement due to permanent incapacity to work.
1.Stirbt der Vorstand während der Dauer des Dienstvertrages, ist die Grundvergütung nach § 3 (1) lit. a) noch für den Sterbemonat und für die zwei darauf folgenden Monate zu zahlen.
1.If the Board Member dies during the term of this Service Agreement, the Basic Remuneration according to § 3 (1) lit. a) shall still be payable for the month of death and for the following two months.
Die Boni nach § 3 (1) lit. b) werden entsprechend Anlage 4 Ziff. 3 durch den Aufsichtsrat festgelegt und an den Ehepartner, bei deren Fehlen an die unterhaltsberechtigten Kinder des Vorstands (letztere als Gesamtgläubiger) oder seine Erben bezahlt.
The bonuses pursuant to § 3 (1) lit. b) are determined by the Supervisory Board in accordance with Annex 4 No. 3 and paid to the spouse, in the event of their absence to the dependent children of the Board Member (the latter as joint creditor) or his heirs.

Sonderleistungen und Sonderkündigungsrecht bei Kontrollerwerb
§ 1
Special services and special right of termination in the event of acquisition of control
1.Kommt es nach der Unterzeichnung dieses Vertrags zu einem Kontrollerwerb im Sinne eines Anteilserwerbs von mehr als 50% durch einen Aktionär, Dritten oder gemeinsam handelnde Personen oder zu einer wirtschaftlich vergleichbaren Transaktion (z.B. Verkauf des Geschäftsbetriebs oder eines wesentlichen Teils davon durch die Gesellschaft, Verkauf von wesentlichen Beteiligungsgesellschaften der Gesellschaft, Verschmelzung auf ein anderes Unternehmen, Verkauf von mehr als 50% der Anteile der Gesellschaft nach einem „Delisting" der Gesellschaft, etc.) und will sich die Gesellschaft in diesem Zusammenhang oder in dessen Folge von dem Vorstand durch vorzeitige Vertragsauflösung trennen, ohne hierfür einen wichtigen Grund im Sinn des § 626 BGB zu haben, so erhält der Vorstand zusätzlich zu der Vergütung und allen Leistungen, die ihm bis zum Trennungszeitpunkt zustehen, eine Abfindung. Die Höhe der Abfindung entspricht der Summe der Gesamtvergütung (Grundvergütung, variable Vergütung sowie Nebenleistungen), die der Vorstand bis zum Ablauf der in § 10 (1) definierten Dauer gemäß diesem Vertrag erhalten hätte, wäre der Vertrag nicht vorzeitig beendet, sondern bis zum Ende der vollen Amtszeit erfüllt worden. Für Zwecke der Berechnung der Abfindung nach diesem Absatz (1) wird davon ausgegangen, dass dem Vorstand jeweils der maximale Bonus gemäß Anlage 4 (ggf. pro rata temporis bis zum Ende der Vertragslaufzeit) gezahlt worden wäre. Beträgt die ordentliche Laufzeit dieses Vertrages gemäß § 10 (1) zum Zeitpunkt des Wirksamwerdens der Trennung nach diesem Absatz (1) weniger als 15 Monate, berechnet sich die zu zahlende Abfindung auf Basis einer fiktiven Restlaufzeit von 15 Monaten, d. h. die Abfindung wird berechnet auf Basis einer angenommenen Restlaufzeit von mindestens 15 Monaten. Während der Vertragslaufzeit stattfindende Anhebungen der Vergütung gemäß § 3 (1) werden bei den beschriebenen Berechnungen berücksichtigt.
1.If, after the signing of this agreement, control is acquired in the sense of a share acquisition of more than 50% by a shareholder, third party or persons acting jointly or in the sense of an economically comparable transaction (e.g. sale of the business operations or a substantial part thereof by the Company, sale of substantial associated companies of the Company, merger with another company, sale of more than 50% of the shares of the Company after a delisting of the Company, etc) and if the Company wishes to terminate the agreement with the Board Member in this context or as a result thereof by early termination of the agreement without having an important reason within the meaning of Section 626 of the German Civil Code (BGB), the Board Member shall receive a severance payment in addition to the remuneration and all benefits to which it is entitled up to the time of termination. The amount of the severance payment corresponds to the sum of the total remuneration (basic remuneration, variable remuneration as well as fringe benefits) that the Board Member would have received until expiry of the term defined in § 10 (1) of this agreement, if the agreement would not have been terminated prematurely, but would have been fulfilled by the end of the full term of office. For the purpose of calculating the severance payment pursuant to this paragraph (1), it is assumed that the maximum bonus would have been paid to the Board Member in each case in accordance with Annex 4 (if applicable pro rata temporis until the end of the agreement term). If the ordinary term of this agreement pursuant to § 10 (1) is less than 15 months at the time the separation pursuant to this paragraph (1) takes effect, the severance payment to be made shall be calculated on the basis of a fictitious remaining term of 15 months, i.e. the severance payment shall be calculated on the basis of an assumed remaining term of at least 15 months. Any increases in remuneration in accordance with § 3 (1) that take place during the term of the agreement shall be taken into account in the calculations described.
1.Die Abfindung ist in voller Höhe zusammen mit dem Gehalt für den Monat, zu dessen Ende die Trennung nach Absatz (1) wirksam wird, zur Zahlung fällig.
1.The severance payment shall be payable in full together with the salary for the month at the end of which the separation referred to in paragraph (1) takes effect.

Germany 10363769.1
Seite 10 von 19

1.Im Falle dieses Absatzes (1) wird dem Vorstand ein außerordentliches Sonderkündigungsrecht zu diesem Dienstvertrag eingeräumt. Das Sonderkündigungsrecht kann innerhalb von sechs Wochen ab Kenntnis des Vorstands über den rechtskräftigen Vollzug des Kontrollwechsels im Sinne des Absatzes (1) mit einer Frist von drei Monaten zum Monatsende ausgeübt werden. Darüber hinaus besteht ein Sonderkündigungsrecht des Vorstands auch dann, wenn der Vorstand innerhalb von einem Jahr nach Vollzug des Kontrollwechsels abberufen wird. In diesem Fall beträgt die Sonderkündigungsfrist zwei Wochen. Die Kündigung kann innerhalb von vier Wochen nach Abberufung durch den Vorstand erklärt werden.
1.In the event of this paragraph (1), the Board Member shall be granted an extraordinary right of termination to this Service Agreement. The extraordinary right of termination may be exercised within six weeks of the knowledge of the Board Member of the legally binding execution of the change of control within the meaning of paragraph (1) with a notice period of three months to the end of the month. In addition, the Board Member has a special right of termination even if the Board Member is dismissed within one year of the completion of the change of control. In this case, the special notice period is two weeks. The termination may be declared by the Board Member within four weeks after dismissal.
§ 1
Diensterfindungen und Schutzrechte
§ 1
Service inventions and industrial property rights

Germany 10363769.1
Seite 11 von 19

1.Erfindungen des Vorstands sowie seine technischen oder organisatorischen Verbesserungsvorschläge werden entsprechend den jeweils geltenden Bestimmungen des Gesetzes über Arbeitnehmererfindungen vom 25.7.1957 mit folgender Maßgabe behandelt: Der Vorstand wird der Gesellschaft Diensterfindungen, freie Erfindungen und technische wie organisatorische Verbesserungsvorschläge unverzüglich melden und der Gesellschaft zur ausschließlichen, beschränkten oder unbeschränkten Inanspruchnahme anbieten. Die Erklärung der Inanspruchnahme hat seitens der Gesellschaft innerhalb von vier Monaten nach der Meldung zu erfolgen. Die Gesellschaft hat das Recht, jedoch nicht die Verpflichtung, zur Anmeldung von Schutzrechten im In- und Ausland. Im Fall einer Diensterfindung oder eines technischen oder organisatorischen Verbesserungsvorschlags sind sich die Parteien darin einig, dass eine etwaige Vergütung für eine von der Gesellschaft in Anspruch genommene Diensterfindung mit der Zahlung der Grundvergütung nach § 3 (1) lit. a) dieses Vertrages vollständig abgegolten ist. Im Fall einer freien Erfindung ist dem Vorstandsmitglied eine marktübliche Vergütung zu zahlen.
1.Inventions by the Board Member and its technical or organizational suggestions for improvement shall be treated in accordance with the applicable provisions of the Act on Employee Inventions of 25 July 1957, subject to the following provisions: The Board Member will immediately notify the Company of job-related inventions, free inventions and technical and organizational suggestions for improvement and offer them to the Company for exclusive, limited or unlimited use. The Company must declare acceptance within four months of notification. The Company is entitled, but not obliged, to register intellectual property rights in Germany and abroad. In the case of a job-related invention or a technical or organizational suggestion for improvement, the parties agree that any remuneration for a service invention claimed by the Company shall be paid in full upon payment of the basic remuneration pursuant to § 3 (1) lit. a) of this agreement. In the case of a free invention, the Board Member shall be paid a remuneration in line with market-based conditions.

Germany 10363769.1
Seite 12 von 19

1.Der Vorstand überträgt der Gesellschaft ausschließliche, zeitlich, räumlich und inhaltlich unbeschränkte Nutzungs- und Verwertungsrechte für alle etwaigen nach dem Urhebergesetz schutzfähigen Tätigkeitsergebnisse, die das Vorstandsmitglied während der Dauer seines Dienstvertrages während seiner Arbeitszeit oder, sofern sie Bezug zu seinen dienstvertraglichen Aufgaben haben, auch außerhalb seiner Arbeitszeit erstellt. Die Übertragung der urheberrechtlichen Nutzungs- und Verwertungsrechte umfasst auch etwaige bei Vertragsschluss noch unbekannte Nutzungsarten. Die Übertragung der Nutzungs- und Verwertungsrechte umfasst insbesondere auch die Erlaubnis zur Bearbeitung und Lizenzvergabe an Dritte. Das Vorstandsmitglied verzichtet ausdrücklich auf sonstige ihm etwa als Urheber zustehende Rechte an den Tätigkeitsergebnissen, insbesondere auf das Recht auf Namensnennung, auf Bearbeitung und auf Zugänglichmachung des Werkes.
1.The Board Member shall grant the Company exclusive rights of use and exploitation, unlimited in terms of time, space and content, for any works which may be protected under the German Copyright Act and which the Board Member produces during the term of his Service Agreement during his working hours or, if they relate to his duties under the Service Agreement, also outside his working hours. The transfer of the rights of use and exploitation also includes any types of use still unknown at the time of conclusion of the agreement. The transfer of the rights of use and exploitation includes in particular the permission for processing and licensing to third parties. The Board Member expressly waives any other rights to the works to which he is entitled as the author, in particular the right to name, edit and make accessible the work.
1.Soweit Tätigkeitsergebnisse, die der Vorstand während der Dauer seines Dienstvertrages während seiner Arbeitszeit oder, sofern sie Bezug zu seinen dienstvertraglichen Aufgaben haben, auch außerhalb seiner Arbeitszeit erstellt, nicht bereits nach Absatz (1) und (2) übertragen sind, überträgt der Vorstand der Gesellschaft sämtliche Rechte an diesen Tätigkeitsergebnissen, insbesondere Marken- und sonstige Kennzeichenrechte sowie eingetragene Designs.
1.Insofar as works which the Board Member produces during the term of its Service Agreement, during its working hours or, insofar as they relate to its duties under the Service Agreement, also outside its working hours, have not already been transferred in accordance with paragraphs (1) and (2), the Board Member shall transfer to the Company all rights to these works, in particular trademark and other distinctive rights as well as registered designs.

Germany 10363769.1
Seite 13 von 19

1.Die Parteien sind sich einig, dass die Einräumung dieser Rechte und der Verzicht auf Rechte nach dieser Regelung vollumfänglich mit der Zahlung der Grundvergütung nach § 3 (1) lit. a) dieses Vertrages abgegolten sind, soweit dem nicht zwingende gesetzliche Regelungen entgegenstehen. Der Vorstand ist verpflichtet, jedwedes seiner schutzrechtsfähigen Tätigkeitsergebnisse unverzüglich der Gesellschaft, vertreten durch den Aufsichtsrat, zu melden und die Gesellschaft im erforderlichen Umfang, auch nach Beendigung dieses Dienstvertrages, bei der Erlangung von Schutzrechten zu unterstützen. Soweit der Vorstand seine Mitwirkungspflichten nach der Beendigung dieses Dienstvertrages erfüllt, erhält der Vorstand hierfür einen angemessenen Tagessatz sowie eine Erstattung aller Aufwendungen, die ihm durch seine Mitwirkung entstanden sind.
1.The parties agree that the granting of these rights and the waiver of rights under this provision are fully covered by the payment of the Basic Remuneration under § 3 (1) lit. a) this agreement, otherwise provided for by mandatory legal provisions. The Board Member is obliged to notify any of the works that are capable of being protected by intellectual property rights without delay to the Company, represented by the Supervisory Board, and to support the Company to the necessary extent, even after termination of this Service Agreement, in obtaining intellectual property rights. To the extent that the Board Member fulfils its duties to cooperate after the termination of this Service Agreement, the Board Member shall receive an appropriate daily rate as well as a reimbursement of all expenses incurred by him resulting from his cooperation.
§ 1
Geheimhaltung und Rückgabe von Unterlagen, Interessenkonflikte
§ 1
Confidentiality and return of documents, conflicts of interest

Germany 10363769.1
Seite 14 von 19

1.Der Vorstand verpflichtet sich, über alle ihm im Rahmen seiner Tätigkeit oder sonst zur Kenntnis gelangenden geschäftlichen und betrieblichen Angelegenheiten der Gesellschaft und aller Verbundenen Unternehmen strengstes Stillschweigen zu bewahren, einschließlich des Inhalts dieses Dienstvertrages sowie den Vertragsverhandlungen, die dem Abschluss dieses Dienstvertrages zugrunde liegen. Der Vorstand verpflichtet sich weiterhin, diese Informationen nicht für den eigenen oder den Nutzen anderer zu verwenden und alle solche geschäftlichen und betrieblichen Angelegenheiten betreffenden Geschäftsunterlagen der Gesellschaft und der Verbundenen Unternehmen unter Verschluss zu halten. Unter geschäftlichen und betrieblichen Angelegenheiten im Sinne dieser Regelung verstehen die Parteien insbesondere Geschäfts- und Betriebsgeheimnisse sowie alle Informationen und Daten mit Bezug zu vertraulichen Angelegenheiten und geschäftsbezogenem Know-how, sämtliche Informationen über alle mit dem existenten oder künftigen Geschäft der Gesellschaft und der Verbundenen Unternehmen in Zusammenhang stehenden Geschäftspläne und Geschäftsstrategien, Verfahren, Preis- oder Marktstrategien und Produkt-, Dienstleistungs- oder Entwicklungsplanungen, geplante Unternehmenserwerbe oder -veräußerungen, sämtliche Geschäftszahlen und Details der organisatorischen Strukturen sowie die wesentlichen Ideen und Prinzipien, welche diesen Strategien und Planungen zugrunde liegen, und alle Informationen, von denen vernünftigerweise erwartet werden kann, dass sie zu solchen Strategien oder Planungen führen werden und die von der Gesellschaft, von Verbundenen Unternehmen oder dem Vorstandsmitglied während der Dauer dieses Dienstvertrages erdacht, erfunden, überarbeitet, entdeckt, entwickelt, erworben, beurteilt, getestet oder angewendet worden sind.
1.The Board Member undertakes to maintain the strictest secrecy with regard to all business and operational matters of the Company and old affiliated companies that come to its attention in the course of its activities or otherwise, including the contents of this Service Agreement and the negotiations on which the conclusion of this Service Agreement is based. The Board Member further undertakes not to use this information for its own benefit or for the benefit of others and to keep all business documents of the Company and its Affiliates relating to such business and operational matters under lock and key. For the purposes of this provision, business and operational matters shall mean, in particular, business and trade secrets and all information and data relating to confidential matters and business-related know-how, all information, all business plans and strategies, procedures, price or market strategies and product, service or development plans relating to the existing or future business of the Company and its Affiliates, planned corporate acquisitions or disposals, all business figures and details of the organizational structures and the principal ideas and principles underlying such strategies and plans, and all information that can reasonably be expected to result in such strategies or plans and that has been invented, redacted, discovered, developed, assessed, tested or applied by the Company, its affiliates or the Board Member during the term of this Service Agreement.

Germany 10363769.1
Seite 15 von 19

1.Die Geheimhaltungsverpflichtung nach vorstehendem Absatz (1) dauert auch nach Beendigung des Dienstverhältnisses fort. Im Rahmen einer von dem Vorstand nach Beendigung dieses Dienstvertrages ausgeübten beruflichen oder unternehmerischen Tätigkeit kann er sein als Vorstandsmitglied erworbenes Wissen einsetzen, sofern dabei die gesetzlichen Beschränkungen insbesondere nach §§ 3, 17 UWG, § 823 (1) und (2) BGB i.V. m. UWG, § 826 BGB und den datenschutzrechtlichen Regelungen sowie die Beschränkungen aus dem nachvertraglichen Wettbewerbsverbot nach § 16 dieses Vertrages strikt beachtet werden.
1.The obligation to maintain secrecy pursuant to the previous paragraph (1) shall continue even after the termination of the employment relationship. The Board Member may use his knowledge acquired as a Board Member within the scope of a professional or entrepreneurial activity carried out by the Board Member after termination of this Service Agreement, provided that the statutory restrictions - in particular pursuant to Sections 3, 17 UWG (German Act Against Unfair Competition), Section 823 (1) and (2) BGB associated with Sections 3, 17 UWG, Section 823 (1) and (2) BGB associated with the UWG, Section 826 BGB and the data protection regulations.
1.Der Vorstand ist verpflichtet, in Zweifelsfällen über den Umfang der Geheimhaltungsverpflichtung nach vorstehenden Absätzen (1) und (2) mit dem Aufsichtsrat der Gesellschaft eine Klärung herbeizuführen.
1.In cases of doubt, the Board Member is obliged to reach a clarification with the Supervisory Board of the Company regarding the scope of the confidentiality obligation pursuant to the previous paragraphs (1) and (2).
1.Der Vorstand verpflichtet sich, auf Verlangen der Gesellschaft jederzeit und spätestens bei Ende seiner Bestellung zum Organ auch ohne gesonderte Aufforderung alle in seinem Besitz befindlichen Unterlagen der Gesellschaft oder Verbundener Unternehmen, insbesondere alle Notizen, Memoranden, Aufzeichnungen, Protokolle und Berichte, Akten sowie alle anderen ähnlichen Dokumente (einschließlich Abschriften, Ablichtungen, Kopien oder sonstiger Reproduktionen), die im Zusammenhang mit seiner Tätigkeit stehen, unverzüglich und vollständig an die Gesellschaft zurückzugeben. Ein Zurückbehaltungsrecht ist ausgeschlossen. Diese Regelung gilt sinngemäß für elektronisch gespeicherte Daten sowie die jeweiligen Daten- oder Programmträger.
1.The Board Member undertakes, at the request of the Company at any time and at the latest at the end of its appointment to the Board and without separate request, to return to the Company all documents of the Company or affiliated companies in its possession, in particular all notes, memoranda, records, minutes and reports, files as well as all other similar documents (including copies, photocopies or other reproductions) in connection with its activities without delay and in full. A right of retention is excluded. This provision applies to electronically stored data as well as the respective data or program carriers.
1.Die Herausgabeverpflichtung bezieht sich auch auf sonstiges, im Besitz des Vorstands befindliches Eigentum der Gesellschaft oder Verbundener Unternehmen bzw. von der Gesellschaft oder von einem Verbundenen Unternehmen geleaste Gegenstände. Diese Herausgabeverpflichtung erstreckt sich insbesondere auch auf ein dem Vorstand etwa überlassenes Mobiltelefon, Laptop oder sonstige Geräte der Datenverarbeitung, bei Ende seiner Bestellung zum Organ auch, wenn insoweit eine private Nutzung gestattet war.
1.The release obligation also applies to other property of the Company or affiliates or items leased by the Company or an affiliate that is in possession of the Board Member. This release obligation also extends in particular to a mobile phone, laptop or other data processing device left in the possession of the Board Member, at the end of its appointment to the Board even if private use was permitted in this respect.

Germany 10363769.1
Seite 16 von 19

1.Der Vorstand hat mögliche und tatsächliche Interessenkonflikte unverzüglich dem Aufsichtsrat gegenüber offenzulegen und die anderen Vorstandsmitglieder hierüber zu informieren.
1.The Board Member must immediately disclose possible and actual conflicts of interest to the Supervisory Board and inform the other members of the Management Board hereof.
§ 1
Vertragsdauer
§ 1
Term of the Agreement
1.Der Vertrag steht insgesamt unter der (A) aufschiebenden Bedingung, dass (i) der Vorstand zum Vorstand der Gesellschaft bestellt wird und (ii) dass die Tranche I gem. Sec. 4 Abs. 2 des Investment Agreements vom 10 August an die Gesellschaft vollständig gezahlt und (B) auflösenden Bedingung, dass die Option aus dem Asset Purchase Agreement zwischen der Gesellschaft und der 4SC AG nicht bis zum 30. September 2016 ausgeübt wird.
1.The agreement is subject to (A) the condition precedent that (i) the Board Member is appointed to the Management Board of the Company and (ii) that Tranche I pursuant to Sec. 4 (2) of the Investment Agreement of 10 August is paid in full to the Company and (B) the condition precedent that the option under the Asset Purchase Agreement between the Company and 4SC AG is not exercised by 30 September 2016.
1.Dieser Vertrag wird mit Wirkung zum frühestmöglichen Termin, jedoch spätestens dem 1. April 2017, abgeschlossen. Er endet mit Ablauf von drei Jahren.
1.This contract will be concluded with effect at the earliest possible date, but no later than 1 April 2017. It ends with the expiration of three years.
1.Das Recht zur außerordentlichen Kündigung bleibt unberührt.
1.The right to extraordinary termination remains unaffected.
1.Im Fall eines Widerrufs der Bestellung, der Amtsniederlegung durch das Vorstandsmitglied oder bei einer sonstigen Beendigung der Organstellung endet dieser Dienstvertrag mit Ablauf eines Jahres nach dem Ende des Amtes, spätestens jedoch zum Ende der Laufzeit nach Absatz (1). Eine etwaige frühere Beendigung aufgrund Absatz (2) dieses Vertrages bleibt unberührt.
1.In the event of revocation of the appointment, demission by the Board Member or other termination of the position, this Service Agreement shall end at the end of one year after the end of the term of office, at the latest, however, at the end of the term pursuant to paragraph (1). A possible termination due to paragraph (2) of this agreement remains unaffected.

Germany 10363769.1
Seite 17 von 19

1.Der Vorsitzende des Aufsichtsrats wird dem Vorstand spätestens neun Monate vor Ablauf dieses Vertrages schriftlich mitteilen, ob und unter welchen Bedingungen der Aufsichtsrat den Vorstand erneut zum Vorstandsmitglied bestellen wird und ob er bereit ist, den Dienstvertrag entsprechend der Dauer der neuen Bestellung zu verlängern oder einen neuen Dienstvertrag zu mindestens gleichen Bedingungen mit ihm abzuschließen. Der Vorstand wird innerhalb von zwei Monaten ab Zugang des Angebots des Aufsichtsratsvorsitzenden erklären, ob er die erneute Bestellung annimmt und bereit ist, den für die Fortsetzung oder Erneuerung des Dienstvertrages angebotenen Bedingungen zuzustimmen.
1.The Chairman of the Supervisory Board will inform the Board Member in writing no later than nine months before the expiry of this agreement, whether and under which conditions the Supervisory Board will reappoint the Board Member and whether he is willing to extend the Service Agreement for the duration of the new appointment or to conclude a new Service Agreement on at least the same terms. Within two months of receipt of the Supervisory Board Chairman's offer, the Board Member will declare whether it accepts the reappointment and is prepared to agree to the terms and conditions offered for the continuation or renewal of the Service Agreement.

Germany 10363769.1
Seite 18 von 19

1.Die Gesellschaft ist berechtigt, den Vorstand nach dem Widerruf seiner Bestellung gemäß § 84 (3) AktG oder im Zusammenhang mit einer Beendigung des Dienstvertrages, insbesondere nach einer Kündigung oder im Anschluss an den Abschluss eines Aufhebungsvertrages, ganz oder teilweise von seiner Pflicht zur Dienstleistung unter Fortzahlung der Grundvergütung gemäß § 3 (1) lit. a) widerruflich oder unwiderruflich freizustellen. lm Fall der unwiderruflichen Freistellung werden offene Urlaubs- und sonstige Freizeitausgleichsanspruche angerechnet, die damit erledigt sind. Der Dienstvertrag im Übrigen wird von der Freistellung nicht berührt; insoweit bestehen insbesondere die Verschwiegenheitspflicht und das vertragliche Wettbewerbsverbot bis zum Ende des Dienstvertrages fort. Anderweitiger Verdienst während der Freistellungszeit wird gemäß § 615 Satz 2 BGB angerechnet. Eine Anrechnung erfolgt nicht, wenn und soweit der anderweitige Verdienst aus einer genehmigten Nebentätigkeit (§ 2 (1) dieses Dienstvertrages) stammt.
1.The Company is entitled, after the revocation of its appointment pursuant to Section 84 (3) AktG or in connection with a termination of the Service Agreement, in particular following a termination or following the conclusion of a termination agreement, to release the Board Member in whole or in part from its obligation to provide services with continued payment of the Basic Remuneration pursuant to § 3 (1) a) revocably or irrevocably. In the event of irrevocable release, receivable holiday and other time off compensation claims shall be credited and settled. The rest of the Service Agreement remains unaffected by the indemnification; in this respect, the obligation to maintain secrecy and the contractual non-competition clause continue to apply until the end of the Service Agreement. Other earnings during the exemption period shall be deducted in accordance with Section 615 sentence 2 BGB. If and as far as the other earnings originate from an approved ancillary activity (§ 2 (1) of this Service Agreement) they are not subject to deduction.
1.Bei vorzeitiger Beendigung der Vorstandstätigkeit ohne wichtigen Grund entsprechen die Zahlungen an den Vorstand einschließlich Nebenleistungen maximal dem Wert von zwei Jahresvergütungen (Abfindungs-Cap) und überschreiten nicht die Gesamtvergütung (Grundvergütung, variable Vergütung sowie Nebenleistungen) für die Restlaufzeit des Dienstvertrages. Bei einem Kontrollerwerb nach § 7 gilt ein Abfindungs-Cap von maximal drei Jahresvergütungen.
1.In the event of premature termination of the board activity without good cause, payments to the Board Member including fringe benefits shall not exceed the value of two years' remuneration (severance payment cap) and shall not exceed the total remuneration (Basic Remuneration, variable remuneration and fringe benefits) for the remaining term of the Service Agreement. In the case of an acquisition of control pursuant to § 7, a severance payment cap of a maximum of three years' remuneration applies.
§ 1
Ausschlussfristen
§ 1
Preclusive Period

Germany 10363769.1
Seite 19 von 19

1.Ansprüche der Gesellschaft und des Vorstands aus dem Dienstverhältnis oder im Zusammenhang mit diesem Dienstverhältnis verfallen, ungeachtet ihres Rechtsgrundes, wenn die bzw. der Anspruchsberechtigte den Anspruch nicht innerhalb einer Frist von sechs Monaten, berechnet ab dem Zeitpunkt der Fälligkeit und der Kenntnis oder grob fahrlässigen Unkenntnis des Anspruchsberechtigten von den anspruchsbegründenden Umständen, durch schriftliche Erklärung gegenüber der jeweils anderen Vertragspartei geltend macht. Für die Beurteilung der Rechtzeitigkeit der Geltendmachung ist der Zugang der schriftlichen Erklärung maßgeblich. Dies gilt nicht für die Geltendmachung von Ansprüchen wegen Verletzung des Lebens, des Körpers oder der Gesundheit sowie bei vorsätzlichen Pflichtverletzungen. Die Versäumung der Ausschlussfrist führt zum Verlust des Anspruchs.
1.Claims of the Company and the Board Member arising from or in connection with the employment relationship shall excluded, irrespective of their legal basis, if the entitled person does not assert the claim within a period of six months, calculated from the due date and the knowledge or grossly negligent ignorance of the entitled person of the circumstances giving rise to the claim, by means of a written declaration to the respective other party. For the assessment of the timeliness of the assertion, the receipt of the written declaration is decisive. This does not apply to the assertion of claims due to injury to life, body or health as well as in the case of intentional breaches of duty. Failure to comply with the preclusive period will result in the loss of the claim.
1.Etwaige Ansprüche der Gesellschaft nach § 93 (2) und (3) AktG gegen das Vorstandsmitglied bleiben gemäß § 93 (4) Satz 3 AktG von vorstehendem Absatz (1) unberührt.
1.Any claims of the Company pursuant to Section 93 (2) and (3) AktG against the Board Member shall remain unaffected by the above paragraph (1) pursuant to Section 93 (4) sentence 3 AktG.
§ 1
Schlussbestimmungen

Final Provisions
1.Dieser Vertrag enthält die gesamte Vereinbarung zwischen den Parteien. Bereits getroffene Vereinbarungen zwischen den Parteien werden hiermit ausdrücklich aufgehoben.
1.This agreement contains the entire agreement between the parties. Prior agreements between the parties are hereby expressly cancelled.

Germany 10363769.1
Seite 20 von 19

1.Änderungen oder Ergänzungen dieses Vertrages einschließlich dieser Schriftformklausel bedürfen zu ihrer Wirksamkeit der Schriftform.
1.Changes or additions to this agreement, including this written form clause, must be made in writing to be effective.
1.Dieser Vertrag unterliegt dem Recht der Bundesrepublik Deutschland.
1.This agreement is subject to the law of the Federal Republic of Germany.
1.Erfüllungsort ist der Sitz der Gesellschaft. Gerichtsstand für Streitigkeiten aus diesem Vertrag ist der Sitz der Gesellschaft.
1.Place of performance is the seat of the Company, place of jurisdiction for disputes from this agreement is the seat of the Company.
1.Sollte eine Bestimmung dieses Vertrages ganz oder teilweise rechtsunwirksam oder undurchführbar sein oder werden, so wird die Gültigkeit der übrigen Bestimmungen dieses Vertrages nicht berührt. Vielmehr ist die ganz oder teilweise rechtsunwirksame oder undurchführbare Bestimmung durch eine Bestimmung zu ersetzen, die den mit der unwirksamen Bestimmung angestrebten wirtschaftlichen Erfolg soweit wie möglich erreicht. Das gleiche gilt im Fall von Lücken dieses Vertrages.
1.Should any provision of this agreement be or become invalid or unenforceable in whole or in part, the validity of the remaining provisions of this agreement shall not be affected. Rather, the invalid or unenforceable provision, in whole or in part, shall be replaced by a provision that achieves as far as possible the economic purpose intended by the invalid provision. The same shall apply in the event of any gaps in this agreement.
Martinsried, denMartinsried, this
/s/ Dr. Daniel Vitt/s/ Dr. Jörg Neermann
Dr. Daniel VittDr. Jörg Neermann
Aufsichtsratsvorsitzender


Germany 10363769.1
Seite 21 von 19

AnlagenverzeichnisSchedule of Annexes
Anlage 1:     AR-BeschlussAnnex 1:     Supervisory Board Resolution
Anlage 2:     Geschäftsverteilungsplan aktuellAnnex 2:     Schedule of Responsibilities
Anlage 3:     Genehmigte Nebentätigkeiten des VorstandsAnnex 3:     Approved Ancillary Activities of the Board Member



Germany 10363769.1
 EX-21.1 5 imux-123122xexhibit211.htm EX-21.1 Document

Exhibit 21.1
Subsidiaries of the Registrant
Set forth below is a list of subsidiaries of the Registrant. All of the subsidiaries listed below are wholly-owned subsidiaries of Immunic, Inc. and are owned directly by Immunic, Inc.
 
Subsidiary  Jurisdiction of
Formation
Immunic AG  Germany


 EX-23.1 6 exhibit23111.htm EX-23.1 Document
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S‑3 (File No. 333‑225230, 333-250083, 333-255303, and 333-268737), Form S‑4 (File No. 333‑229510), and Form S-8 (File No. 333‑233864 and 333-258235) of Immunic, Inc. of our report dated February 23, 2023, relating to the consolidated financial statements of Immunic, Inc., which appears in this annual report on Form 10-K for the year ended December 31, 2022.


/s/ Baker Tilly US, LLP

Minneapolis, Minnesota
February 23, 2023

 EX-31.1 7 imux-123122xexhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS
I, Daniel Vitt, certify that:
1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2022 of Immunic, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: February 23, 2023By:/s/ Daniel Vitt
Daniel Vitt
Chief Executive Officer and President
(Principal Executive Officer)


 EX-31.2 8 imux-123122xexhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS
I, Glenn Whaley, certify that:
1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2022 of Immunic, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: February 23, 2023By:/s/ Glenn Whaley
Glenn Whaley
Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 9 imux-123122xexhibit321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Immunic, Inc. (the “Company”) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Daniel Vitt, as Chief Executive Officer and President of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: February 23, 2023By:/s/ Daniel Vitt
Daniel Vitt
Chief Executive Officer and President
(Principal Executive Officer)


 EX-32.2 10 imux-123122xexhibit322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Immunic, Inc. (the “Company”) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Glenn Whaley as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge::
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: February 23, 2023By:/s/ Glenn Whaley
Glenn Whaley
Chief Financial Officer
(Principal Financial Officer)


 EX-101.SCH 11 imux-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Description of Business and Basis of Financial Statements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stock-based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Stock-based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Description of Business and Basis of Financial Statements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Summary of Significant Accounting Policies - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Fair Value - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Common Stock - Shelf Registration Statement (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Common Stock - Equity Offering (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Common Stock - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Common Stock - Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Stock-based Compensation Plans - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Stock-based Compensation Plans - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 imux-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 imux-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 imux-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Other Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Audit Information [Abstract] Audit Information Total lease payments Lessee, Operating Lease, Liability, to be Paid Foreign Currency Translation and Presentation Foreign Currency Transactions and Translations Policy [Policy Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Clinical and related costs Clinical Costs Payable, Current Clinical Costs Payable, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Goodwill impairment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Common stock options available for future grant: Employee Stock Options for Future Grant [Member] Employee Stock Options for Future Grant [Member] Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Fair Value Measurement Fair Value of Financial Instruments, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Increase or decrease not in excess of percentage Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent Range [Domain] Statistical Measurement [Domain] Investment interest rate Investment Interest Rate Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Net deferred tax assets, valuation allowance total Deferred Tax Assets, Net Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Federal Domestic Tax Authority [Member] Net loss Net loss Net Income (Loss) Attributable to Parent Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Australian research and development tax incentive Research And Development Tax Incentive, Current Research And Development Tax Incentive, Current Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Event Type [Axis] Subsequent Event Type [Axis] Earning interest at a rate maturity (in months) Investment, Earning Interest Rate, Remaining Maturity Period Investment, Earning Interest Rate, Remaining Maturity Period Tax Period [Domain] Tax Period [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] Assets Assets, Fair Value Disclosure Prefunded stock warrants Pre-Funded Warrants [Member] Pre-Funded Warrants Related Party [Domain] Related Party [Domain] Plan Name [Axis] Plan Name [Axis] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Plan Name [Domain] Plan Name [Domain] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, State and Local Total long-term liabilities Liabilities, Noncurrent Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Other Current Liabilities Other Current Liabilities [Table Text Block] Number of financial institutions used for cash deposits Number of Financial Institutions Used For Cash Deposits Number of Financial Institutions Used For Cash Deposits Outstanding, weighted-average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Other Accounts Payable, Other, Current Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Lease liabilities Operating Lease, Liability, Current Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Collaborative Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Maximum annual contributions per employee (as a percent) Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Document Annual Report Document Annual Report Investments - other Other Short-Term Investments Legal Entity [Axis] Legal Entity [Axis] Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Total liabilities Liabilities Time Deposits Time Deposits Bank Time Deposits [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Issuance of common stock Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Estimated useful life (in years) Property, Plant and Equipment, Useful Life Forfeited and expired (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Assets Assets, Fair Value Disclosure [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Deferred income tax expense Deferred Income Tax Expense (Benefit) Other liabilities Increase (Decrease) in Accrued Liabilities 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Rent holiday period Lessee, Operating Lease, Rent Holiday Period Lessee, Operating Lease, Rent Holiday Period July 2021 Public Equity Offering July 2021 Public Equity Offering [Member] July 2021 Public Equity Offering Affiliated Entity Affiliated Entity [Member] Subsequent Event Subsequent Event [Member] 2014 Equity Incentive Plan Two Thousand Fourteen Equity Incentive Plan [Member] Two Thousand Fourteen Equity Incentive Plan [Member] Document Period End Date Document Period End Date Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Total assets Assets Incremental borrowing rate on operating leases Operating Lease, Incremental Borrowing Rate Operating Lease, Incremental Borrowing Rate Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Schedule of Accounts Payable and Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accrued expenses Total Accrued Liabilities, Current Exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Other current assets and prepaid expenses Total Prepaid Expense and Other Assets, Current Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Executive Chairman Agreement Executive Chairman Agreement [Member] Executive Chairman Agreement Shares Issued, Weighted Average Share Price Per Share Shares Issued, Weighted Average Share Price Per Share Shares Issued, Weighted Average Share Price Per Share Schedule of Valuation Assumptions Used Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Australia and Germany Australia and Germany [Member] Australia and Germany Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Equity Award [Domain] Award Type [Domain] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Period over which compensation cost will be recognized (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Options exercisable, weighted-average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Income Tax Contingency [Table] Income Tax Contingency [Table] Purchases of Investments-other Payments to Acquire Other Investments 2019 Omnibus Equity Incentive Plan Two Thousand Nineteen Omnibus Equity Incentive Plan [Member] Two Thousand Nineteen Omnibus Equity Incentive Plan Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Registrant Name Entity Registrant Name Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Maximum Aggregate Offering Price Of Securities Under Shelf Registration Maximum Aggregate Offering Price Of Securities Under Shelf Registration Maximum Aggregate Offering Price Of Securities Under Shelf Registration Accrued legal and audit costs Accrued Legal And Audit Costs, Current Accrued Legal And Audit Costs, Current Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Government assistance, amount Government Assistance, Amount Entity Address, City or Town Entity Address, City or Town Operating expenses: Operating Expenses [Abstract] Net deferred tax assets Deferred Tax Assets and Liabilities, Gross Deferred Tax Assets and Liabilities, Gross Germany GERMANY Minimum Minimum [Member] Government assistance Government Assistance [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Foreign net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Foreign Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Auditor Name Auditor Name Fair Value Fair Value Disclosures [Text Block] Share price (in USD per share) Share Price Net operating loss carryforwards Operating Loss Carryforwards Trading Symbol Trading Symbol Entity File Number Entity File Number Research and development Research and Development Expense Options vested and expected to vest , weighted-average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Title of Individual [Axis] Title of Individual [Axis] Shares issued under the ESPP (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Effective tax rate Effective Income Tax Rate Reconciliation, Percent Grafelfing, Germany Grafelfing, Germany [Member] Grafelfing, Germany Options vested and expected to vest (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Options to purchase common stock Equity Option [Member] Accounts payable Increase (Decrease) in Accounts Payable Australia AUSTRALIA Additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Income Taxes Income Tax Disclosure [Text Block] VAT receivable Value Added Tax Receivable, Current Schedule of Goodwill Schedule of Goodwill [Table Text Block] Net loss per share, basic (in USD per share) Earnings Per Share, Basic Government assistance rate Government Assistance Rate Government Assistance Rate 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Prepaid clinical and related costs Prepaid Clinical And Related Costs, Current Prepaid Clinical And Related Costs, Current Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent 2017 Inducement Equity Incentive Plan 2017 Inducement Equity Incentive Plan [Member] 2017 Inducement Equity Incentive Plan [Member] Other, net Deferred Tax Assets, Other Entity Interactive Data Current Entity Interactive Data Current Shares issues in private placement transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Money market funds Money Market Funds [Member] Cash And Cash Equivalents And Other Investments Cash And Cash Equivalents And Other Investments [Policy Text Block] Cash And Cash Equivalents And Other Investments Accumulated Deficit Retained Earnings [Member] May not exercise of percentage Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Common Stock Common Stock [Member] Schedule of Stock-based Compensation Expense for Stock Awards Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Income Taxes Income Tax, Policy [Policy Text Block] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Statement [Table] Statement [Table] Current assets: Assets, Current [Abstract] Operating lease liabilities Operating Lease, Liability, Noncurrent Schedule of Investment Investment [Table Text Block] Non-Statutory Employee Stock Option Non-Statutory Employee Stock Option [Member] Non-Statutory Employee Stock Option [Member] Range [Axis] Statistical Measurement [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Accrued compensation Accrued Compensation, Current Accrued Compensation, Current Equity Components [Axis] Equity Components [Axis] Scenario, Unspecified [Domain] Scenario [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Proceeds from issuance of private placement Proceeds from Issuance of Private Placement Options exercisable, Weighted-Average Exercise Price (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related Party Transactions Related Party Transactions Disclosure [Text Block] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Statement [Line Items] Statement [Line Items] Immunic AG Immunic AG [Member] Immunic AG [Member] Total other expense, net Nonoperating Income (Expense) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Loss Contingencies [Table] Loss Contingencies [Table] Right of use asset, net Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Impairment of Long-lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Auditor Firm ID Auditor Firm ID Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Options vested and expected to vest, Weighted-Average Exercise Price (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Foreign Foreign Tax Authority [Member] Local Phone Number Local Phone Number Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Germany Federal Ministry of Finance, Germany [Member] Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Goodwill (note 2) Carrying amount of goodwill at December 31, 2021 Carrying amount of goodwill at December 31, 2022 Goodwill Geographical [Domain] Geographical [Domain] Less valuation allowance Deferred Tax Assets, Valuation Allowance Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Public Float Entity Public Float Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Employee Employee [Member] Employee [Member] Weighted-average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Expected term of options (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Loss Contingencies [Line Items] Loss Contingencies [Line Items] Prior to 2018 Tax Years Prior to 2018 [Member] Tax Years Prior to 2018 Unrealized gain or loss Deferred Tax Assets, Unrealized Currency Losses Number of existing operating leases Lessee, Operating Leases, Number Of Existing Leases Lessee, Operating Leases, Number Of Existing Leases Common stock cash dividends paid (in USD per share) Common Stock, Dividends, Per Share, Cash Paid ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Common stock, $0.0001 par value; 130,000,000 shares authorized and 39,307,286 and 26,335,418 shares issued and outstanding at December 31, 2022 and 2021, respectively Common stock issued Common Stock, Value, Issued Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Common stock, shares issued (in shares) Common Stock, Shares, Issued Board of Directors Chairman Board of Directors Chairman [Member] Foreign currency loss Foreign Currency Transaction Gain (Loss), before Tax Income Statement Location [Domain] Income Statement Location [Domain] 2019 Omnibus Equity Incentive Plan, Evergreen Provision Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member] Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Duane Nash, MD, JD, MBA Duane Nash, MD, JD, MBA [Member] Duane Nash, MD, JD, MBA United States Internal Revenue Service (IRS) [Member] Investment Type [Axis] Investment Type [Axis] Foreign exchange translation adjustment Other Comprehensive Income (Loss), Net of Tax Shares issued in connection with the Company's employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Increase or decrease not In excess of prior notice period Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Total Other Liabilities, Current Other long-term assets Other Assets, Noncurrent Other Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Options exercisable, (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Impairment losses Tangible Asset Impairment Charges Depreciation and amortization Depreciation, Depletion and Amortization Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Lease term (in months) Lease term (in years) Lessee, Operating Lease, Term of Contract Shares issued in connection with the Company's employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Outstanding, Beginning balance (in shares) Outstanding, Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Stock options Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Underwriter commissions Payments for Commissions Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code New York City New York City [Member] New York City Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property, Plant and Equipment, Net Outstanding stock options Share-Based Payment Arrangement, Option [Member] Relationship to Entity [Domain] Title of Individual [Domain] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other expense, net Other Nonoperating Income (Expense) Sale of stock, price per share (in USD per share) Sale of Stock, Price Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total operating expenses Operating Expenses Maximum Maximum [Member] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Royalty settlement agreement, cash payment, percent Royalty Settlement Agreement, Cash Payment, Percent Royalty Settlement Agreement, Cash Payment, Percent Entity Small Business Entity Small Business Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Common Stock Stockholders' Equity Note Disclosure [Text Block] 4SC Royalty Settlement 4SC Royalty Settlement [Member] 4SC Royalty Settlement Common stock, cash dividends declared (in USD per share) Common Stock, Dividends, Per Share, Declared December 2020 ATM December 2020 ATM [Member] December 2020 ATM Warrants Stockholders' Equity, Policy [Policy Text Block] Common stock issued in connection with the 4SC royalty settlement (see Note 4) Issuance of Stock and Warrants for Services or Claims Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Increase in operating lease, right-of-use asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Total unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Operating and variable lease cost Operating And Variable Leases, Cost Operating And Variable Leases, Cost Title of 12(b) Security Title of 12(b) Security Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Present value of lease obligation Operating Lease, Liability Stock-based Compensation Share-Based Payment Arrangement [Policy Text Block] Foreign Foreign, Excluding Germany [Member] Foreign, Excluding Germany 2021 Employee stock purchase plan 2021 Employee Stock Purchase Plan [Member] 2021 Employee Stock Purchase Plan Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Foreign currency translation income, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Forfeited or expired (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Deferred tax assets: Deferred Tax Assets, Net of Valuation Allowance [Abstract] 4SC Royalty Settlement (See Note 4) 4SC royalty settlement Royalty Settlement Agreement, Sales Net Royalty Settlement Agreement, Sales Net Consideration received on transaction Sale of Stock, Consideration Received on Transaction Accounts payable Total Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Shelf registration, termination, prior written notice Shelf Registration, Termination, Prior Written Notice Shelf Registration, Termination, Prior Written Notice Monthly base salary Salary Costs, Monthly Base Salary Salary Costs, Monthly Base Salary Options vested and expected to vest , aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Number of employees Entity Number of Employees Royalty settlement agreement, shares payment, percent Royalty Settlement Agreement, Shares Payment, Percent Royalty Settlement Agreement, Shares Payment, Percent Auditor Location Auditor Location Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Prefunded stock warrants Warrant [Member] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Weighted-average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES Share-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (note 4) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding, Beginning balance (in USD per share) Outstanding, Ending balance (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock issued in connection with the 4SC royalty settlement (see Note 4) Stock Issued Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December 31, 2022 and 2021 Preferred Stock, Value, Issued Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative General and Administrative Expense [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Legal and audit costs Legal And Audit Costs Payable, Current Legal And Audit Costs Payable, Current Total common shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Long-term liabilities: Liabilities, Noncurrent [Abstract] Cover page. Cover [Abstract] Leases Lessee, Leases [Policy Text Block] At The Market Sales Agreement At The Market Sales Agreement [Member] At The Market Sales Agreement Level 3 Fair Value, Inputs, Level 3 [Member] Entity Voluntary Filers Entity Voluntary Filers Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Goodwill impairment (see Note 2) Goodwill impairment Impairment of goodwill during the year ended December 31, 2022 Goodwill, Impairment Loss Stock-based Compensation Plans Share-Based Payment Arrangement [Text Block] Schedule of Prepaid Expenses and Other Current Assets Schedule of Other Current Assets [Table Text Block] Investments [Domain] Investments [Domain] Forecast Forecast [Member] Post 2017 Tax Years Post 2017 [Member] Tax Years Post 2017 Contractual obligation Contractual Obligation Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Additional shares authorized, percent Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Asset purchase agreement, royalties as percent of aggregated net sales Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales Proceeds from shares issued in connection with the Company's employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Accrued clinical and related costs Accrued Clinical Costs, Current Accrued Clinical Costs, Current Related Party [Axis] Related Party [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Intangible Assets Deferred Tax Assets, Goodwill and Intangible Assets Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total deferred tax assets Deferred Tax Assets, Gross Net Loss before Income Tax Based on Jurisdictions Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less: interest portion Lessee, Operating Lease, Liability, Undiscounted Excess Amount Net loss per share, diluted (in USD per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Issuance costs Payments of Stock Issuance Costs Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Other Other Assets, Current Shelf Registration Statement, Amount Remaining Shelf Registration Statement, Amount Remaining Shelf Registration Statement, Amount Remaining Other Other Sundry Liabilities, Current Uncertain tax positions Unrecognized Tax Benefits October 2022 PIPE Transaction October 2022 PIPE Transaction [Member] October 2022 PIPE Transaction Uncertain tax positions that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration] Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration] Other income (expense): Nonoperating Income (Expense) [Abstract] Maturities of Operating Lease Obligations Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Income Tax Authority [Domain] Income Tax Authority [Domain] 2019 Omnibus Equity Incentive Plan 2019 Omnibus Equity Incentive Plan [Member] 2019 Omnibus Equity Incentive Plan [Member] May 2022 ATM May 2022 ATM [Member] May 2022 ATM Valuation allowance increase Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Tax effect of rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Equity [Abstract] Equity [Abstract] Entity Tax Identification Number Entity Tax Identification Number Net loss before income tax Income (Loss) Attributable to Parent, before Tax Purchase price of the stock, at discount from market price at purchase date (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Commission, percent of gross proceeds from sale of common stock Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Total deferred tax liability Deferred Tax Liabilities, Gross Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Incentive Employee Stock Option Incentive Employee Stock Option [Member] Incentive Employee Stock Option [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Number of development programs pursued Number Of Development Programs Number Of Development Programs Interest income Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Tax Period [Axis] Tax Period [Axis] Accrued other Other Accrued Liabilities, Current Entity [Domain] Entity [Domain] City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Shares Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Public Offering Public Offering [Member] Public Offering Remaining capacity Sale Of Stock, Remaining Capacity Sale Of Stock, Remaining Capacity Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Supplemental disclosure of noncash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted-average grant date fair value (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accrued expenses and other current liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense [Member] Operating lease right-of use asset obtained in exchange for lease obligation Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Description of Business and Basis of Financial Statements Business Description and Basis of Presentation [Text Block] EX-101.PRE 15 imux-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 image_0.jpg begin 644 image_0.jpg MB5!.1PT*&@H -24A$4@ 0 "S" ( A7"KD )4E$051X7F-@ M (/_8 !ACW)&.:.<4 GRAPHIC 17 imux-20221231_g1.jpg begin 644 imux-20221231_g1.jpg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end XML 18 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Feb. 17, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-36201    
Entity Registrant Name Immunic, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 56-2358443    
Entity Address, Address Line One 1200 Avenue of the Americas,    
Entity Address, Address Line Two Suite 200    
Entity Address, City or Town New York,    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10036    
City Area Code 332    
Local Phone Number 255-9818    
Title of 12(b) Security Common Stock, $0.0001 par value    
Trading Symbol IMUX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 106.1
Entity Common Stock, Shares Outstanding   44,403,838  
Documents Incorporated by Reference Certain portions of the registrant’s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.    
Entity Central Index Key 0001280776    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Amendment Flag false    

XML 19 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
 12 Months Ended
Dec. 31, 2022
Audit Information [Abstract]  
Auditor Name Baker Tilly US, LLP
Auditor Location Minneapolis, MN
Auditor Firm ID 23
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 106,745 $ 86,863
Investments - other 9,629 0
Other current assets and prepaid expenses 9,490 18,125
Total current assets 125,864 104,988
Property and equipment, net 294 152
Goodwill (note 2) 0 32,970
Right of use asset, net 1,552 948
Other long-term assets 43 42
Total assets 127,753 139,100
Current liabilities:    
Accounts payable 4,281 3,745
Accrued expenses 7,986 7,071
Other current liabilities 810 585
Total current liabilities 13,077 11,401
Long-term liabilities:    
Operating lease liabilities 992 584
Total long-term liabilities 992 584
Total liabilities 14,069 11,985
Commitments and contingencies (note 4)
Stockholders’ equity:    
Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December 31, 2022 and 2021 0 0
Common stock, $0.0001 par value; 130,000,000 shares authorized and 39,307,286 and 26,335,418 shares issued and outstanding at December 31, 2022 and 2021, respectively 4 3
Additional paid-in capital 427,925 324,237
Accumulated other comprehensive income (loss) 3,035 (252)
Accumulated deficit (317,280) (196,873)
Total stockholders’ equity 113,684 127,115
Total liabilities and stockholders’ equity $ 127,753 $ 139,100
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in USD per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in USD per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 130,000,000 130,000,000
Common stock, shares issued (in shares) 39,307,286 26,335,418
Common stock, shares outstanding (in shares) 39,307,286 26,335,418
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development $ 71,255 $ 61,115
General and administrative 15,263 13,300
Goodwill impairment (see Note 2) 32,970 0
4SC Royalty Settlement (See Note 4) 0 17,250
Total operating expenses 119,488 91,665
Loss from operations (119,488) (91,665)
Other income (expense):    
Interest income 1,041 66
Other expense, net (1,960) (1,346)
Total other expense, net (919) (1,280)
Net loss $ (120,407) $ (92,945)
Net loss per share, basic (in USD per share) $ (3.78) $ (3.93)
Net loss per share, diluted (in USD per share) $ (3.78) $ (3.93)
Weighted-average common shares outstanding, basic (in shares) 31,819,006 23,652,779
Weighted-average common shares outstanding, diluted (in shares) 31,819,006 23,652,779
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]    
Net loss $ (120,407) $ (92,945)
Other comprehensive income:    
Foreign currency translation income, net of tax 3,287 3,860
Total comprehensive loss $ (117,120) $ (89,085)
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
July 2021 Public Equity Offering
At The Market Sales Agreement
4SC Royalty Settlement
October 2022 PIPE Transaction
Common Stock
Common Stock
July 2021 Public Equity Offering
Common Stock
At The Market Sales Agreement
Common Stock
4SC Royalty Settlement
Common Stock
October 2022 PIPE Transaction
Additional Paid-in Capital
Additional Paid-in Capital
July 2021 Public Equity Offering
Additional Paid-in Capital
At The Market Sales Agreement
Additional Paid-in Capital
4SC Royalty Settlement
Additional Paid-in Capital
October 2022 PIPE Transaction
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020           21,168,240                      
Beginning balance at Dec. 31, 2020 $ 158,785         $ 2         $ 266,823         $ (4,112) $ (103,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net loss (92,945)                               (92,945)
Foreign exchange translation adjustment 3,860                             3,860  
Stock-based compensation 5,949                   5,949            
Issuance of common stock (in shares)             4,500,000 73,221 581,199                
Issuance of common stock   $ 42,020 $ 729 $ 8,625     $ 1         $ 42,019 $ 729 $ 8,625      
Shares issued in connection with the Company's employee stock purchase plan (in shares)           12,758                      
Shares issued in connection with the Company's employee stock purchase plan $ 92                   92            
Ending balance (in shares) at Dec. 31, 2021 26,335,418         26,335,418                      
Ending balance at Dec. 31, 2021 $ 127,115         $ 3         324,237         (252) (196,873)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net loss (120,407)                               (120,407)
Foreign exchange translation adjustment 3,287                             3,287  
Stock-based compensation 7,929                   7,929            
Issuance of common stock (in shares)           852   4,204,113   8,696,552              
Issuance of common stock 5   $ 39,584   $ 55,989         $ 1 5   $ 39,584   $ 55,988    
Shares issued in connection with the Company's employee stock purchase plan (in shares)           70,351                      
Shares issued in connection with the Company's employee stock purchase plan $ 182                   182            
Ending balance (in shares) at Dec. 31, 2022 39,307,286         39,307,286                      
Ending balance at Dec. 31, 2022 $ 113,684         $ 4         $ 427,925         $ 3,035 $ (317,280)
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
July 2021 Public Equity Offering    
Issuance costs   $ 2,980
At The Market Sales Agreement    
Issuance costs $ 1,226 $ 23
October 2022 PIPE Transaction    
Issuance costs $ 4,012  
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (120,407) $ (92,945)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 77 85
Goodwill impairment (see Note 2) 32,970 0
Stock-based compensation 7,929 5,949
Foreign currency loss 4,757 4,332
Common stock issued in connection with the 4SC royalty settlement (see Note 4) 0 8,625
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 7,493 (12,800)
Accounts payable 799 176
Other liabilities (124) 170
Accrued expenses and other current liabilities 1,362 3,175
Net cash used in operating activities (65,144) (83,233)
Cash flows from investing activities:    
Purchases of Investments-other (9,629) 0
Purchases of property and equipment (112) (67)
Net cash used in investing activities (9,741) (67)
Cash flows from financing activities:    
Proceeds from the exercise of stock options 5 0
Proceeds from shares issued in connection with the Company's employee stock purchase plan 182 92
Net cash provided by financing activities 95,760 42,841
Effect of exchange rate changes on cash and cash equivalents (993) (130)
Net change in cash and cash equivalents 19,882 (40,589)
Cash and cash equivalents, beginning of year 86,863 127,452
Cash and cash equivalents, end of year 106,745 86,863
Supplemental disclosure of noncash investing and financing activities:    
Common stock issued in connection with the 4SC royalty settlement (see Note 4) 0 8,625
Operating lease right-of use asset obtained in exchange for lease obligation 974 435
Public Offering    
Cash flows from financing activities:    
Proceeds from issuance of common stock 39,584 729
October 2022 PIPE Transaction    
Cash flows from financing activities:    
Proceeds from issuance of common stock 55,989 0
July 2021 Public Equity Offering    
Cash flows from financing activities:    
Proceeds from issuance of common stock $ 0 $ 42,020
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Public Offering    
Issuance costs $ 1,226 $ 23
October 2022 PIPE Transaction    
Issuance costs $ 4,012 0
July 2021 Public Equity Offering    
Issuance costs   $ 2,980
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Description of Business and Basis of Financial Statements
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Description of Business and Basis of Financial Statements Description of Business and Basis of Financial Statements
Description of Business
Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gräfelfing near Munich, Germany. The Company currently has approximately 66 employees.
The Company is currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (“MS”); the izumerogant (proposed International Nonproprietary Name (“INN”) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (“RORγt”) that inhibits the interleukin-17 (“IL-17”) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.
The Company’s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.
Liquidity and Financial Condition
Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $317.3 million as of December 31, 2022 and approximately $196.9 million as of December 31, 2021. Substantially all of Immunic’s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.
Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.
From inception through December 31, 2022, Immunic has raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, the Company had cash and cash equivalents of approximately $106.7 million and investments - other of $9.6 million. With these funds the Company expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying financial statements.
Basis of Presentation and Consolidation
The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018). All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.
Foreign Currency Translation and Presentation
The Company’s reporting currency is United States (“U.S.”) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.’s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:
• assets and liabilities at reporting period-end rates;
• income statement accounts at average exchange rates for the reporting period; and
• components of equity at historical rates.
Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders’ equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.
Cash and Cash Equivalents and Investments- other
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Time Deposits with an original maturity greater than three months are classified as Investments-other
Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7 million, Germany of approximately $19.1 million and Australia of approximately $1.9 million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of —% to 0.87%
Investments - other consists of the following as of (in thousands):
December 31, 2022December 31, 2021
Time Deposits$9,629$0
$9,629$0
The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.
Fair Value Measurement
Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.
Level 2— Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.
Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.
The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.
Property and Equipment
Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years. Depreciation and amortization expense was $77,000 and $85,000 for the years ended December 31, 2022 and 2021, respectively.
Impairment of Long-Lived Assets
The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the years ended December 31, 2022 and 2021 other than goodwill which is described below.
Goodwill
Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.
On October 20, 2022, the Company announced the outcome of a significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization. The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired. The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0 million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance. The Company did not have any goodwill impairment during the year ended December 31, 2021. The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):
Carrying amount of goodwill at December 31, 2021$32,970 
Impairment of goodwill during the year ended December 31, 2022(32,970)
Carrying amount of goodwill at December 31, 2022$— 
Research and Development Expenses
These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.
Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.
The Company enters into agreements with contract research organizations (“CROs”) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (“MSA”). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.
Collaboration Arrangements
Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers” and ASU No. 2018-18, “Collaborative Arrangements” ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.
In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.
On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent & Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.
Government assistance
Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We recognized $2.3 million and $1.7 million of other income related to research activities performed during the years ended December 31, 2022 and 2021, respectively.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.
Stock-Based Compensation 
The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award’s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.
The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company’s common stock, the expected volatility of the price of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the
application of management’s judgment. If factors change and different assumptions are used, the Company’s stock-based compensation expense could be materially different in the future.
Leases
The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.
The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company’s balance sheet. A right-of-use lease asset represents the Company’s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.
Comprehensive Income (Loss)
Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders’ equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).
Income Taxes
The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.
The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December 31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.
It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.
Warrants
The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) or ASC 815-40, Accounting
for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (“ASC 815-40”). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.
Net Loss Per Share
Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position
Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:
As of December 31,
20222021
Options to purchase common stock3,791,688 2,157,460 
Prefunded stock warrants5,096,552 — 
8,888,240 2,157,460 
Recently Adopted Accounting Standards
There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Details
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Details Balance Sheet Details
Prepaid Expenses and Other Current Assets
Prepaid Expense and Other Current Assets consist of (in thousands):
December 31,
20222021
Prepaid clinical and related costs$5,608 $14,853 
VAT receivable296 279 
Australian research and development tax incentive2,361 1,871 
Other1,225 1,122 
Total$9,490 $18,125 
Accounts Payable
Accounts Payable consist of (in thousands):
December 31,
20222021
Clinical and related costs$3,749 $3,427 
Legal and audit costs288 72 
Other244 246 
Total$4,281 $3,745 
Accrued Expenses
Accrued Expenses consist of (in thousands):
 December 31,
 20222021
Accrued clinical and related costs$6,807 $6,214 
Accrued legal and audit costs169 96 
Accrued compensation890 674 
Accrued other120 87 
Total$7,986 $7,071 
Other Current Liabilities
Other Current Liabilities consist of (in thousands):
December 31,
20222021
Lease liabilities$571 $408 
Other239 177 
Total$810 $585 
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Operating Lease
The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office and June 30, 2025 for the Gräfelfing, Germany office. The Company formerly leased office space in
Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gräfelfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gräfelfing, Germany office. Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions to right of use assets of $435,000 and $642,000 as a result of signing for additional lease space at the Gräfelfing, Germany office in March 2021 and August 2022, respectively. There were net additions to right of use assets of $332,000 as a result of extending the New York City lease in December 2022.
 The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.
 Immunic’s operating lease costs and variable lease costs were $727,000 and $503,000 for the years ended December 31, 2022 and 2021, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.
 Maturities of the operating lease obligation are as follows as of December 31, 2022 (in thousands):
2023$647 
2024$680 
2025$355 
2026$— 
2027$— 
Thereafter$— 
Total lease payments$1,682 
Less: interest portion$147 
Present value of lease obligation$1,535 
Contractual Obligations
As of December 31, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs in vidofludimus calcium, izumerogant and IMU-856 totaling approximately $4.5 million, all of which is expected to be paid in 2023.
Other Commitments and Obligations
In May 2016, the Company entered into a purchase agreement (the “Agreement”) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company’s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019.
On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25 million
(Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic’s common stock (the “Shares”). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.
Legal Proceedings
The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Fair Value
The following fair value hierarchy table present information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):
Fair Value Measurement at December 31, 2022
Fair ValueLevel 1Level 2Level 3
Assets
Money market funds85,521 85,521 — — 
Total assets at fair value$85,521 $85,521 $— $— 
Fair Value Measurement at December 31, 2021
Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$31,630 $31,630 $— $— 
Total assets at fair value$31,630 $31,630 $— $— 

There were no transfers between Level 1, Level 2 or Level 3 assets during the periods presented.
For the Company’s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations.
Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 4.3% in a U.S. Government money market fund.
The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of December 31, 2022. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.
The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same. For the assessment of the fair value of goodwill and the related impairment of goodwill we used a level one assessment in our testing of goodwill. See Note 2, Summary of significant accounting policies "Goodwill".
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Common Stock
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Common Stock Common StockShelf Registration Statements
In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of February 17, 2023, there is $75.0 million remaining on this shelf registration statement

In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days’ prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company. As of February 17, 2023, $8.4 million in capacity remains under the December 2020 ATM.

In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days’ prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company. As of February 17, 2023, $80.0 million in capacity remains under the May 2022 ATM.
  The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.
For the year ended December 31, 2022, the Company raised gross proceeds of $40.9 million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6 million after deducting underwriter commissions of $1.2 million.
For the year ended December 31, 2021, the Company raised gross proceeds of $0.8 million pursuant to the December 2020 ATM through the sale of 73,221 shares of common stock at a weighted average price of $10.27 per share. The net proceeds from the December 2020 ATM were $0.7 million after deducting underwriter commissions of $22,555.
Equity Offerings
$60 Million Private Placement Equity Financing
On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with select accredited investors and certain existing investors (each, a “Purchaser” and collectively, the “Purchasers”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return. All of the pre-funded warrants were exercised in January of 2023.

The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0 million, before deducting offering expenses payable by the Company of approximately $4.0 million. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.

The registration statement for these securities was deemed effective by Securities and Exchange Commission on December 20, 2022.
July 2021 Public Equity Offering

On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler & Co., in connection with the Company’s public offering of 4,500,000 shares of the Company’s common stock, $0.0001 par value per share, at a public offering price of $10.00 per share.

On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was approximately $42.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
Common Stock
As of December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001. The voting, dividend and liquidation rights of the holders of the Company’s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December 31, 2022, no cash dividends had been declared or paid.
Preferred Stock
The Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue 20,000,000 shares of $0.0001 par value preferred stock, rights and preferences to be set by the board of directors. No preferred shares were outstanding as of December 31, 2022.
Stock Reserved for Future Issuance
Shares reserved for future issuance as of December 31, 2022 are as follows:
 Number of
Shares
Common stock reserved for issuance for:
2021 Employee stock purchase plan116,891 
Prefunded stock warrants5,096,552 
Outstanding stock options3,791,688 
Common stock options available for future grant:
2014 Equity Incentive Plan43,311 
2017 Inducement Equity Incentive Plan46,250 
2019 Omnibus Equity Incentive Plan188,655 
Total common shares reserved for future issuance9,283,347 
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Plans
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Plans Stock-based Compensation Plans
2021 Employee Stock Purchase Plan

On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company’s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.

The Company has issued 70,351 and 12,758 shares under the ESPP for the twelve months ended December 31, 2022 and 2021, respectively. The Company recognized $96,000 and $46,000 of expense related to the plan in the twelve months ended December 31, 2022 and 2021, respectively.
Stock Option Programs
In July 2019, the Company’s stockholders approved the 2019 Omnibus Equity Incentive Plan (the “2019 Plan”) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company’s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company’s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over three or four years.
Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards.
Movements during the year
The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:
OptionsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding as of January 1, 20222,157,460 $13.54 
Granted1,886,263 $8.73 
Exercised(852)$5.67 
Forfeited or expired(251,183)$10.79 
Outstanding as of December 31, 20223,791,688 $11.33 8.35$375 
Options vested and expected to vest as of December 31, 20223,791,688 $11.33 8.35$375 
Options exercisable as of December 31, 20221,398,490 $13.33 7.50$— 
OptionsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding as of January 1, 20211,117,160 $12.96 
Granted1,193,809 $14.08 
Exercised— $— 
Forfeited or expired(153,509)$13.50 
Outstanding as of December 31, 20212,157,460 $13.54 8.74$302,155 
Options vested and expected to vest as of December 31, 20212,157,460 $13.54 8.74$302,155 
Options exercisable as of December 31, 2021752,954 $13.48 8.15$79,431 
Measurement
The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:
Risk-Free Interest Rate
The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.
Expected Dividend Yield
The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.
Expected Volatility
Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards.
Expected Term
The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.
The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December 31, 2022 and 2021 was $6.81 and $10.52, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:
20222021
Risk-free interest rate2.09%0.93%
Expected dividend yield0%0%
Expected volatility97.8%93.0%
Expected term of options (years)6.06.0
Stock-Based Compensation Expense
Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands):
 Year
 Ended December 31,
 20222021
Research and development$3,219 $1,760 
General and administrative4,710 4,189 
Total$7,929 $5,949 
As of December 31, 2022 there was $15.6 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.74 years.
Summary of Equity Incentive Plans Assumed from Vital
Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital’s 2012 Stock Option Plan (the “2012 Plan”), Vital’s 2014 Equity Incentive Plan (the “2014 Plan”) and Vital’s 2017 Inducement Equity Incentive Plan (the “Inducement Plan”), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.
There remain 43,311 shares available for grant under the 2014 Plan as of December 31, 2022.
In September 2017, Vital’s Board of Directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital’s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.
No expense was recorded for the plans assumed from Vital during the twelve months ended December 31, 2022 and 2021, respectively.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):
 Years Ended December 31,
 20222021
United States$(47,049)$(11,222)
Germany(67,448)(78,869)
Foreign(5,911)(2,854)
$(120,408)$(92,945)
The rate reconciliation consists of the following:
 Years Ended December 31,
 20222021
Federal statutory rate21.0 %21.0 %
Foreign rate differential2.2 %3.2 %
Stock options(1.1)%(0.9)%
Tax effect of rate change0.0 %0.0 %
Goodwill impairment(5.7)%0.0 %
Other(0.7)%(0.4)%
Change in valuation allowance(15.7)%(22.9)%
Effective tax rate0.0 %0.0 %

Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is no current or deferred income tax expense in the years ended December 31, 2022 and 2021, respectively.

Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.
 December 31,
 20222021
 (in thousands)
Deferred tax assets:
Net operating loss carryforwards$19,830 $18,437 
Stock-based compensation742 576 
Intangible Assets2,923 3,848 
Foreign net operating loss carryforwards47,179 34,819 
Unrealized gain or loss1,686 1,130 
Other, net693 9 
     Total deferred tax assets73,053 58,819 
Deferred tax liabilities:
Property, plant and equipment— (2)
     Total deferred tax liability — (2)
Net deferred tax assets73,053 58,817 
Less valuation allowance(73,053)(58,817)
$— $— 

The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $14.2 million and $22.3 million and for the years ended December 31, 2021 and 20, respectively.

As of December 31, 2022, Immunic had available NOLs of approximately $190.2 million in Germany and Australia. These NOLs do not expire.

The U.S. federal NOL carryforwards of $15.6 million were generated prior to 2018 and expire over 20 years beginning in 2023. The $78.9 million of post 2017 federal NOL carryforwards do not expire. Sections 382 of the Internal Revenue Code of 1986 subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined. The Company may have undergone ownership changes and therefore may be limited in the amount of net operating losses available for utilization in the future.

The Company did not have any uncertain tax positions for the years ended December 31, 2022 and 2021, respectively.

Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are no uncertain tax positions that would impact the effective tax rate if recognized.

The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2018 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.
Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
Executive Chairman Agreement with Duane Nash

On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the “Executive Chairman Agreement”) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an “at will” employment relationship with a base salary of $25,417 per month pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, the Company and Dr. Nash entered into an addendum (the “First Addendum”) to extend the term of the Executive Chairman Agreement to April 15, 2021. In connection with the First Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 120,000 shares of Company common stock, which vests monthly over six months commencing on November 15, 2020. On April 15, 2021, the Company and Dr. Nash entered into Addendum No. Two (the “Second Addendum”) to extend the term of the Executive Chairman Agreement to April 15, 2022. In connection with the Second Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly over 12 months commencing on May 15, 2021, and to increase Dr. Nash’s monthly base salary to $27,960 from $25,417. On March 15, 2022, the Company and Dr. Nash entered into Addendum No. Three (the “Third Addendum”), which extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month. In connection with the Third Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company’s common stock, which vests monthly over 12 months commencing on April 10, 2022. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company’s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.
Foreign Currency Translation and Presentation
Foreign Currency Translation and Presentation
The Company’s reporting currency is United States (“U.S.”) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.’s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:
• assets and liabilities at reporting period-end rates;
• income statement accounts at average exchange rates for the reporting period; and
• components of equity at historical rates.
Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders’ equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.
Cash And Cash Equivalents And Other Investments
Cash and Cash Equivalents and Investments- other
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Time Deposits with an original maturity greater than three months are classified as Investments-other
Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7 million, Germany of approximately $19.1 million and Australia of approximately $1.9 million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of —% to 0.87%
Investments - other consists of the following as of (in thousands):
December 31, 2022December 31, 2021
Time Deposits$9,629$0
$9,629$0
The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.
Fair Value Measurement
Fair Value Measurement
Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.
Level 2— Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.
Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.
The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.
Property and Equipment Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years.
Impairment of Long-lived Assets Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Impaired assets are then recorded at their estimated fair value.
Goodwill
Goodwill
Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.
On October 20, 2022, the Company announced the outcome of a significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization. The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.
Research and Development Expenses
Research and Development Expenses
These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.
Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.
The Company enters into agreements with contract research organizations (“CROs”) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (“MSA”). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.
Collaborative Arrangements
Collaboration Arrangements
Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers” and ASU No. 2018-18, “Collaborative Arrangements” ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.
In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.
On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent & Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.
Government assistance
Government assistance
Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We recognized $2.3 million and $1.7 million of other income related to research activities performed during the years ended December 31, 2022 and 2021, respectively.
General and Administrative Expenses
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.
Stock-based Compensation
Stock-Based Compensation 
The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award’s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.
The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company’s common stock, the expected volatility of the price of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the
application of management’s judgment. If factors change and different assumptions are used, the Company’s stock-based compensation expense could be materially different in the future.
Leases
Leases
The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.
The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company’s balance sheet. A right-of-use lease asset represents the Company’s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.
Comprehensive Income (Loss)
Comprehensive Income (Loss)
Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders’ equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).
Income Taxes
Income Taxes
The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.
The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December 31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.
It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.
Warrants
Warrants
The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) or ASC 815-40, Accounting
for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (“ASC 815-40”). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.
Net Loss Per Share
Net Loss Per Share
Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position
Recently Adopted Accounting Standards
Recently Adopted Accounting Standards
There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of Investment
Investments - other consists of the following as of (in thousands):
December 31, 2022December 31, 2021
Time Deposits$9,629$0
$9,629$0
Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share
As of December 31,
20222021
Options to purchase common stock3,791,688 2,157,460 
Prefunded stock warrants5,096,552 — 
8,888,240 2,157,460 
Schedule of Goodwill The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):
Carrying amount of goodwill at December 31, 2021$32,970 
Impairment of goodwill during the year ended December 31, 2022(32,970)
Carrying amount of goodwill at December 31, 2022$— 
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets Prepaid Expense and Other Current Assets consist of (in thousands):
December 31,
20222021
Prepaid clinical and related costs$5,608 $14,853 
VAT receivable296 279 
Australian research and development tax incentive2,361 1,871 
Other1,225 1,122 
Total$9,490 $18,125 
Schedule of Accounts Payable and Accrued Expenses
Accounts Payable consist of (in thousands):
December 31,
20222021
Clinical and related costs$3,749 $3,427 
Legal and audit costs288 72 
Other244 246 
Total$4,281 $3,745 
Accrued Expenses
Accrued Expenses consist of (in thousands):
 December 31,
 20222021
Accrued clinical and related costs$6,807 $6,214 
Accrued legal and audit costs169 96 
Accrued compensation890 674 
Accrued other120 87 
Total$7,986 $7,071 
Schedule of Other Current Liabilities Other Current Liabilities consist of (in thousands):
December 31,
20222021
Lease liabilities$571 $408 
Other239 177 
Total$810 $585 
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Maturities of Operating Lease Obligations Maturities of the operating lease obligation are as follows as of December 31, 2022 (in thousands):
2023$647 
2024$680 
2025$355 
2026$— 
2027$— 
Thereafter$— 
Total lease payments$1,682 
Less: interest portion$147 
Present value of lease obligation$1,535 
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value (Tables)
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
The following fair value hierarchy table present information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):
Fair Value Measurement at December 31, 2022
Fair ValueLevel 1Level 2Level 3
Assets
Money market funds85,521 85,521 — — 
Total assets at fair value$85,521 $85,521 $— $— 
Fair Value Measurement at December 31, 2021
Fair ValueLevel 1Level 2Level 3
Assets
Money market funds$31,630 $31,630 $— $— 
Total assets at fair value$31,630 $31,630 $— $— 
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Common Stock (Tables)
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Shares Reserved for Future Issuance Shares reserved for future issuance as of December 31, 2022 are as follows:
 Number of
Shares
Common stock reserved for issuance for:
2021 Employee stock purchase plan116,891 
Prefunded stock warrants5,096,552 
Outstanding stock options3,791,688 
Common stock options available for future grant:
2014 Equity Incentive Plan43,311 
2017 Inducement Equity Incentive Plan46,250 
2019 Omnibus Equity Incentive Plan188,655 
Total common shares reserved for future issuance9,283,347 
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Plans (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activity The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:
OptionsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding as of January 1, 20222,157,460 $13.54 
Granted1,886,263 $8.73 
Exercised(852)$5.67 
Forfeited or expired(251,183)$10.79 
Outstanding as of December 31, 20223,791,688 $11.33 8.35$375 
Options vested and expected to vest as of December 31, 20223,791,688 $11.33 8.35$375 
Options exercisable as of December 31, 20221,398,490 $13.33 7.50$— 
OptionsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
Outstanding as of January 1, 20211,117,160 $12.96 
Granted1,193,809 $14.08 
Exercised— $— 
Forfeited or expired(153,509)$13.50 
Outstanding as of December 31, 20212,157,460 $13.54 8.74$302,155 
Options vested and expected to vest as of December 31, 20212,157,460 $13.54 8.74$302,155 
Options exercisable as of December 31, 2021752,954 $13.48 8.15$79,431 
Schedule of Valuation Assumptions Used The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:
20222021
Risk-free interest rate2.09%0.93%
Expected dividend yield0%0%
Expected volatility97.8%93.0%
Expected term of options (years)6.06.0
Schedule of Stock-based Compensation Expense for Stock Awards Recognized
Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands):
 Year
 Ended December 31,
 20222021
Research and development$3,219 $1,760 
General and administrative4,710 4,189 
Total$7,929 $5,949 
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Net Loss before Income Tax Based on Jurisdictions Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):
 Years Ended December 31,
 20222021
United States$(47,049)$(11,222)
Germany(67,448)(78,869)
Foreign(5,911)(2,854)
$(120,408)$(92,945)
Income Tax Rate Reconciliation The rate reconciliation consists of the following:
 Years Ended December 31,
 20222021
Federal statutory rate21.0 %21.0 %
Foreign rate differential2.2 %3.2 %
Stock options(1.1)%(0.9)%
Tax effect of rate change0.0 %0.0 %
Goodwill impairment(5.7)%0.0 %
Other(0.7)%(0.4)%
Change in valuation allowance(15.7)%(22.9)%
Effective tax rate0.0 %0.0 %
Deferred Tax Assets and Liabilities
 December 31,
 20222021
 (in thousands)
Deferred tax assets:
Net operating loss carryforwards$19,830 $18,437 
Stock-based compensation742 576 
Intangible Assets2,923 3,848 
Foreign net operating loss carryforwards47,179 34,819 
Unrealized gain or loss1,686 1,130 
Other, net693 9 
     Total deferred tax assets73,053 58,819 
Deferred tax liabilities:
Property, plant and equipment— (2)
     Total deferred tax liability — (2)
Net deferred tax assets73,053 58,817 
Less valuation allowance(73,053)(58,817)
$— $— 
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Description of Business and Basis of Financial Statements - Additional Information (Details)
$ in Thousands
 12 Months Ended
Oct. 12, 2022
USD ($)
Dec. 31, 2022
USD ($)
employee
lease
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Accounting Policies [Abstract]        
Number of employees | employee   66    
Number of development programs pursued | lease   3    
Accumulated deficit   $ 317,280 $ 196,873  
Proceeds from issuance of private placement $ 60,000 355,500    
Cash and cash equivalents   106,745 86,863 $ 127,452
Investments - other   $ 9,629 $ 0  
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Additional Information (Details)
 3 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
lease
financialInstitution
Dec. 31, 2022
USD ($)
lease
financialInstitution
Dec. 31, 2021
USD ($)
Property, Plant and Equipment [Line Items]      
Cash and cash equivalents $ 106,745,000 $ 106,745,000 $ 86,863,000
Number of financial institutions used for cash deposits | financialInstitution 2 2  
Depreciation and amortization expense   $ 77,000 85,000
Impairment losses   0 0
Goodwill impairment $ 33,000,000 $ 32,970,000 0
Government assistance rate   43.50%  
Government assistance, amount   $ 2,300,000 $ 1,700,000
Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]   Nonoperating Income (Expense) Nonoperating Income (Expense)
Number of existing operating leases | lease 2 2  
Minimum      
Property, Plant and Equipment [Line Items]      
Estimated useful life (in years)   3 years  
Lease term (in months) 12 months 12 months  
Maximum      
Property, Plant and Equipment [Line Items]      
Estimated useful life (in years)   13 years  
Lease term (in months) 60 months 60 months  
United States      
Property, Plant and Equipment [Line Items]      
Cash and cash equivalents $ 85,700,000 $ 85,700,000  
United States | Money market funds      
Property, Plant and Equipment [Line Items]      
Investment interest rate 4.30% 4.30%  
Australia and Germany | Minimum      
Property, Plant and Equipment [Line Items]      
Investment interest rate 0.00% 0.00%  
Australia and Germany | Maximum      
Property, Plant and Equipment [Line Items]      
Investment interest rate 0.87% 0.87%  
Germany      
Property, Plant and Equipment [Line Items]      
Cash and cash equivalents $ 19,100,000 $ 19,100,000  
Germany | Minimum | Time Deposits      
Property, Plant and Equipment [Line Items]      
Investment interest rate 0.61% 0.61%  
Earning interest at a rate maturity (in months)   3 months  
Germany | Maximum | Time Deposits      
Property, Plant and Equipment [Line Items]      
Investment interest rate 0.87% 0.87%  
Earning interest at a rate maturity (in months)   4 months  
Australia      
Property, Plant and Equipment [Line Items]      
Cash and cash equivalents $ 1,900,000 $ 1,900,000  
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Cash and Cash Equivalents [Line Items]    
Investments - other $ 9,629 $ 0
Time Deposits    
Cash and Cash Equivalents [Line Items]    
Investments - other $ 9,629 $ 0
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Goodwill [Roll Forward]      
Carrying amount of goodwill at December 31, 2021   $ 32,970  
Impairment of goodwill during the year ended December 31, 2022 $ (33,000) (32,970) $ 0
Carrying amount of goodwill at December 31, 2022 $ 0 $ 0 $ 32,970
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares) 8,888,240 2,157,460
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares) 3,791,688 2,157,460
Prefunded stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares) 5,096,552 0
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Prepaid clinical and related costs $ 5,608 $ 14,853
VAT receivable 296 279
Australian research and development tax incentive 2,361 1,871
Other 1,225 1,122
Total $ 9,490 $ 18,125
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Details - Schedule of Accounts Payable (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Clinical and related costs $ 3,749 $ 3,427
Legal and audit costs 288 72
Other 244 246
Total $ 4,281 $ 3,745
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued clinical and related costs $ 6,807 $ 6,214
Accrued legal and audit costs 169 96
Accrued compensation 890 674
Accrued other 120 87
Total $ 7,986 $ 7,071
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Details - Schedule of Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Lease liabilities $ 571 $ 408
Other 239 177
Total $ 810 $ 585
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total Total
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2022
Aug. 31, 2022
Mar. 31, 2021
May 31, 2016
Dec. 31, 2022
Dec. 31, 2021
Apr. 07, 2020
Apr. 12, 2019
Loss Contingencies [Line Items]                  
Incremental borrowing rate on operating leases   6.00%       6.00%      
Operating and variable lease cost           $ 727 $ 503    
Contractual obligation   $ 4,500       $ 4,500      
Asset purchase agreement, royalties as percent of aggregated net sales         4.40%        
Common stock, shares issued (in shares)   39,307,286       39,307,286 26,335,418   120,070
Common stock issued   $ 4       $ 4 $ 3   $ 1,500
4SC royalty settlement           $ 0 $ 17,250    
Immunic AG                  
Loss Contingencies [Line Items]                  
Asset purchase agreement, royalties as percent of aggregated net sales 4.40%                
4SC royalty settlement $ 17,250                
Royalty settlement agreement, cash payment, percent 50.00%     50.00%          
Royalty settlement agreement, shares payment, percent 50.00%     50.00%          
Grafelfing, Germany                  
Loss Contingencies [Line Items]                  
Lease term (in years)               5 years  
Increase in operating lease, right-of-use asset     $ 642 $ 435          
New York City                  
Loss Contingencies [Line Items]                  
Rent holiday period           6 months      
Increase in operating lease, right-of-use asset   $ 332              
Incremental borrowing rate on operating leases   8.00%       8.00%      
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2023 $ 647
2024 680
2025 355
2026 0
2027 0
Thereafter 0
Total lease payments 1,682
Less: interest portion 147
Present value of lease obligation $ 1,535
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Assets    
Assets $ 85,521 $ 31,630
Money market funds    
Assets    
Assets 85,521 31,630
Level 1    
Assets    
Assets 85,521 31,630
Level 1 | Money market funds    
Assets    
Assets 85,521 31,630
Level 2    
Assets    
Assets 0 0
Level 2 | Money market funds    
Assets    
Assets 0 0
Level 3    
Assets    
Assets 0 0
Level 3 | Money market funds    
Assets    
Assets $ 0 $ 0
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value - Additional Information (Detail)
Dec. 31, 2022
United States | Money market funds  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Investment interest rate 4.30%
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Common Stock - Shelf Registration Statement (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
d
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Feb. 17, 2023
USD ($)
May 10, 2022
USD ($)
Dec. 31, 2020
USD ($)
Nov. 30, 2020
USD ($)
Class of Stock [Line Items]            
Maximum Aggregate Offering Price Of Securities Under Shelf Registration           $ 250,000,000
Commission, percent of gross proceeds from sale of common stock 3.00%          
Issuance of common stock $ 5,000          
December 2020 ATM            
Class of Stock [Line Items]            
Maximum Aggregate Offering Price Of Securities Under Shelf Registration         $ 50,000,000  
Shelf registration, termination, prior written notice | d 10          
Issuance of common stock $ 40,900,000 $ 800,000        
Issuance of common stock (in shares) | shares 4,204,113 73,221        
Shares Issued, Weighted Average Share Price Per Share | $ / shares $ 9.72 $ 10.27        
Proceeds from issuance of common stock $ 39,600,000 $ 700,000        
Underwriter commissions $ 1,200,000 $ 22,555        
May 2022 ATM            
Class of Stock [Line Items]            
Maximum Aggregate Offering Price Of Securities Under Shelf Registration       $ 80,000,000    
Shelf registration, termination, prior written notice | d 10          
Subsequent Event            
Class of Stock [Line Items]            
Shelf Registration Statement, Amount Remaining     $ 75,000,000      
Subsequent Event | December 2020 ATM            
Class of Stock [Line Items]            
Remaining capacity     8,400,000      
Subsequent Event | May 2022 ATM            
Class of Stock [Line Items]            
Remaining capacity     $ 80,000,000      
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Common Stock - Equity Offering (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Oct. 12, 2022
Oct. 10, 2022
Jul. 19, 2021
Jul. 15, 2021
Dec. 31, 2022
Dec. 31, 2021
Class of Stock [Line Items]            
Proceeds from issuance of private placement $ 60.0       $ 355.5  
Common stock, par value (in USD per share)         $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares)         130,000,000 130,000,000
Common stock, cash dividends declared (in USD per share)         $ 0  
Common stock cash dividends paid (in USD per share)         $ 0  
Preferred stock, shares authorized (in shares)         20,000,000 20,000,000
Preferred stock, par value (in USD per share)         $ 0.0001 $ 0.0001
Preferred Stock, Shares Outstanding         0 0
Common Stock            
Class of Stock [Line Items]            
Shares issues in private placement transaction (in shares)   8,696,552        
Sale of stock, price per share (in USD per share)   $ 0.0001        
Share price (in USD per share)   $ 4.35        
May not exercise of percentage   9.99%        
Prefunded stock warrants            
Class of Stock [Line Items]            
Shares issues in private placement transaction (in shares)   5,096,552        
Sale of stock, price per share (in USD per share)   $ 0.01        
Share price (in USD per share)   $ 4.34        
Increase or decrease not in excess of percentage   19.99%        
Increase or decrease not In excess of prior notice period   61 days        
July 2021 Public Equity Offering            
Class of Stock [Line Items]            
Shares issues in private placement transaction (in shares)       4,500,000    
Sale of stock, price per share (in USD per share)       $ 10.00    
Common stock, par value (in USD per share)       $ 0.0001    
Consideration received on transaction     $ 42.0      
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Common Stock - Common Stock (Details) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Common stock, shares authorized (in shares) 130,000,000 130,000,000
Common stock, par value (in USD per share) $ 0.0001 $ 0.0001
Common stock, cash dividends declared (in USD per share) 0  
Common stock cash dividends paid (in USD per share) $ 0  
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Common Stock - Preferred Stock (Details) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, par value (in USD per share) $ 0.0001 $ 0.0001
Preferred stock, shares outstanding (in shares) 0 0
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Common Stock - Shares Reserved for Future Issuance (Details)
Dec. 31, 2022
shares
Class of Stock [Line Items]  
Total common shares reserved for future issuance (in shares) 9,283,347
Outstanding stock options  
Class of Stock [Line Items]  
Total common shares reserved for future issuance (in shares) 3,791,688
Outstanding stock options | 2021 Employee stock purchase plan  
Class of Stock [Line Items]  
Total common shares reserved for future issuance (in shares) 116,891
Prefunded stock warrants  
Class of Stock [Line Items]  
Total common shares reserved for future issuance (in shares) 5,096,552
Common stock options available for future grant: | 2014 Equity Incentive Plan  
Class of Stock [Line Items]  
Total common shares reserved for future issuance (in shares) 43,311
Common stock options available for future grant: | 2017 Inducement Equity Incentive Plan  
Class of Stock [Line Items]  
Total common shares reserved for future issuance (in shares) 46,250
Common stock options available for future grant: | 2019 Omnibus Equity Incentive Plan  
Class of Stock [Line Items]  
Total common shares reserved for future issuance (in shares) 188,655
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Plans - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended 21 Months Ended
Apr. 25, 2021
Jul. 31, 2019
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Expected dividend yield     0.00%      
Total unrecognized compensation expense     $ 15,600,000      
Period over which compensation cost will be recognized (in years)     2 years 8 months 26 days      
2021 Employee stock purchase plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Maximum annual contributions per employee (as a percent) 15.00%          
Purchase price of the stock, at discount from market price at purchase date (as a percent) 85.00%          
Shares available for grant (in shares) 200,000          
Shares issued under the ESPP (in shares)     70,351 12,758    
Share-based compensation expense     $ 96,000 $ 46,000    
2019 Omnibus Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares available for grant (in shares)   1,500,000        
Expected term of options (years)     6 years 6 years    
Expected dividend yield     0.00% 0.00%    
Weighted-average grant date fair value (in USD per share)     $ 6.81 $ 10.52    
2019 Omnibus Equity Incentive Plan | Incentive Employee Stock Option            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period (in years)     4 years      
2019 Omnibus Equity Incentive Plan | Minimum | Non-Statutory Employee Stock Option            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period (in years)     3 years      
2019 Omnibus Equity Incentive Plan | Maximum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Expected term of options (years)     10 years      
2019 Omnibus Equity Incentive Plan | Maximum | Non-Statutory Employee Stock Option            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period (in years)     4 years      
2019 Omnibus Equity Incentive Plan, Evergreen Provision            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Additional shares authorized, percent   4.00%        
Additional shares authorized (in shares)   4,900,000     4,408,871  
2014 Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares available for grant (in shares)     43,311      
2017 Inducement Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares available for grant (in shares)           46,250
Share-based compensation expense     $ 0 $ 0    
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Plans - Summary of Stock Option Activity (Details) - Outstanding stock options - 2019 Omnibus Equity Incentive Plan - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Options    
Outstanding, Beginning balance (in shares) 2,157,460 1,117,160
Granted (in shares) 1,886,263 1,193,809
Exercised (in shares) (852) 0
Forfeited and expired (shares) (251,183) (153,509)
Outstanding, Ending balance (in shares) 3,791,688 2,157,460
Options vested and expected to vest (shares) 3,791,688 2,157,460
Options exercisable, (shares) 1,398,490 752,954
Weighted- Average Exercise Price    
Outstanding, Beginning balance (in USD per share) $ 13.54 $ 12.96
Granted (in USD per share) 8.73 14.08
Exercised (in USD per share) 5.67 0
Forfeited or expired (in USD per share) 10.79 13.50
Outstanding, Ending balance (in USD per share) 11.33 13.54
Options vested and expected to vest, Weighted-Average Exercise Price (usd per share) 11.33 13.54
Options exercisable, Weighted-Average Exercise Price (usd per share) $ 13.33 $ 13.48
Other Disclosures    
Outstanding, weighted-average remaining contractual term (in years) 8 years 4 months 6 days 8 years 8 months 26 days
Options vested and expected to vest , weighted-average remaining contractual term (in years) 8 years 4 months 6 days 8 years 8 months 26 days
Options exercisable, weighted-average remaining contractual term (in years) 7 years 6 months 8 years 1 month 24 days
Outstanding, aggregate intrinsic value $ 375 $ 302,155
Options vested and expected to vest , aggregate intrinsic value 375 302,155
Options exercisable, aggregate intrinsic value $ 0 $ 79,431
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected dividend yield 0.00%  
2019 Omnibus Equity Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Risk-free interest rate 2.09% 0.93%
Expected dividend yield 0.00% 0.00%
Expected volatility 97.80% 93.00%
Expected term of options (years) 6 years 6 years
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation $ 7,929 $ 5,949
Employee    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation 7,929 5,949
Employee | Research and development    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation 3,219 1,760
Employee | General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation $ 4,710 $ 4,189
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Contingency [Line Items]    
Net loss before income tax $ (120,408) $ (92,945)
Federal | United States    
Income Tax Contingency [Line Items]    
Net loss before income tax (47,049) (11,222)
Foreign | Germany    
Income Tax Contingency [Line Items]    
Net loss before income tax (67,448) (78,869)
Foreign | Foreign    
Income Tax Contingency [Line Items]    
Net loss before income tax $ (5,911) $ (2,854)
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Federal statutory rate 21.00% 21.00%
Foreign rate differential 2.20% 3.20%
Stock options (1.10%) (0.90%)
Tax effect of rate change 0.00% 0.00%
Goodwill impairment (5.70%) 0.00%
Other (0.70%) (0.40%)
Change in valuation allowance (15.70%) (22.90%)
Effective tax rate (0.00%) 0.00%
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating Loss Carryforwards [Line Items]    
Deferred income tax expense $ 0 $ 0
Valuation allowance increase 14,200,000 22,300,000
Uncertain tax positions 0 $ 0
Uncertain tax positions that would impact effective tax rate 0  
Foreign    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards 190,200,000  
Federal | Prior to 2018    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards 15,600,000  
Federal | Post 2017    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards $ 78,900,000  
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Deferred tax assets:    
Net operating loss carryforwards $ 19,830 $ 18,437
Stock-based compensation 742 576
Intangible Assets 2,923 3,848
Foreign net operating loss carryforwards 47,179 34,819
Unrealized gain or loss 1,686 1,130
Other, net 693 9
Total deferred tax assets 73,053 58,819
Deferred tax liabilities:    
Property, plant and equipment 0 (2)
Total deferred tax liability 0 (2)
Net deferred tax assets 73,053 58,817
Less valuation allowance (73,053) (58,817)
Net deferred tax assets, valuation allowance total $ 0 $ 0
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions - Additional Information (Details) - Duane Nash, MD, JD, MBA - Board of Directors Chairman - Executive Chairman Agreement - Affiliated Entity - USD ($)
 4 Months Ended 8 Months Ended 10 Months Ended 12 Months Ended
Mar. 15, 2022
Apr. 15, 2021
Nov. 15, 2020
May 14, 2021
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2023
Related Party Transaction [Line Items]              
Monthly base salary       $ 25,417 $ 27,960 $ 29,358  
Granted (in shares) 75,000 90,000 120,000        
Forecast              
Related Party Transaction [Line Items]              
Monthly base salary             $ 30,250
XML 72 imux-20221231_htm.xml IDEA: XBRL DOCUMENT 0001280776 2022-01-01 2022-12-31 0001280776 2022-06-30 0001280776 2023-02-17 0001280776 2022-12-31 0001280776 2021-12-31 0001280776 2021-01-01 2021-12-31 0001280776 us-gaap:CommonStockMember 2020-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001280776 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001280776 us-gaap:RetainedEarningsMember 2020-12-31 0001280776 2020-12-31 0001280776 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001280776 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001280776 imux:July2021PublicEquityOfferingMember 2021-01-01 2021-12-31 0001280776 us-gaap:CommonStockMember imux:July2021PublicEquityOfferingMember 2021-01-01 2021-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember imux:July2021PublicEquityOfferingMember 2021-01-01 2021-12-31 0001280776 imux:AtTheMarketSalesAgreementMember 2021-01-01 2021-12-31 0001280776 us-gaap:CommonStockMember imux:AtTheMarketSalesAgreementMember 2021-01-01 2021-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember imux:AtTheMarketSalesAgreementMember 2021-01-01 2021-12-31 0001280776 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001280776 us-gaap:CommonStockMember imux:A4SCRoyaltySettlementMember 2021-01-01 2021-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember imux:A4SCRoyaltySettlementMember 2021-01-01 2021-12-31 0001280776 imux:A4SCRoyaltySettlementMember 2021-01-01 2021-12-31 0001280776 us-gaap:CommonStockMember 2021-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001280776 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001280776 us-gaap:RetainedEarningsMember 2021-12-31 0001280776 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001280776 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001280776 imux:October2022PIPETransactionMember 2022-01-01 2022-12-31 0001280776 us-gaap:CommonStockMember imux:October2022PIPETransactionMember 2022-01-01 2022-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember imux:October2022PIPETransactionMember 2022-01-01 2022-12-31 0001280776 imux:AtTheMarketSalesAgreementMember 2022-01-01 2022-12-31 0001280776 us-gaap:CommonStockMember imux:AtTheMarketSalesAgreementMember 2022-01-01 2022-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember imux:AtTheMarketSalesAgreementMember 2022-01-01 2022-12-31 0001280776 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001280776 us-gaap:CommonStockMember 2022-12-31 0001280776 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001280776 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001280776 us-gaap:RetainedEarningsMember 2022-12-31 0001280776 imux:PublicOfferingMember 2022-01-01 2022-12-31 0001280776 imux:PublicOfferingMember 2021-01-01 2021-12-31 0001280776 imux:October2022PIPETransactionMember 2021-01-01 2021-12-31 0001280776 imux:July2021PublicEquityOfferingMember 2022-01-01 2022-12-31 0001280776 country:US 2022-12-31 0001280776 country:DE 2022-12-31 0001280776 country:AU 2022-12-31 0001280776 country:US us-gaap:MoneyMarketFundsMember 2022-12-31 0001280776 srt:MinimumMember imux:AustraliaAndGermanyMember 2022-12-31 0001280776 srt:MaximumMember imux:AustraliaAndGermanyMember 2022-12-31 0001280776 us-gaap:BankTimeDepositsMember 2022-12-31 0001280776 us-gaap:BankTimeDepositsMember 2021-12-31 0001280776 srt:MinimumMember country:DE us-gaap:BankTimeDepositsMember 2022-12-31 0001280776 srt:MaximumMember country:DE us-gaap:BankTimeDepositsMember 2022-12-31 0001280776 srt:MinimumMember country:DE us-gaap:BankTimeDepositsMember 2022-01-01 2022-12-31 0001280776 srt:MaximumMember country:DE us-gaap:BankTimeDepositsMember 2022-01-01 2022-12-31 0001280776 srt:MinimumMember 2022-01-01 2022-12-31 0001280776 srt:MaximumMember 2022-01-01 2022-12-31 0001280776 2022-10-01 2022-12-31 0001280776 srt:MinimumMember 2022-12-31 0001280776 srt:MaximumMember 2022-12-31 0001280776 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001280776 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001280776 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001280776 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001280776 imux:GrafelfingGermanyMember 2020-04-07 0001280776 imux:NewYorkCityMember 2022-01-01 2022-12-31 0001280776 imux:GrafelfingGermanyMember 2021-03-01 2021-03-31 0001280776 imux:GrafelfingGermanyMember 2022-08-01 2022-08-31 0001280776 imux:NewYorkCityMember 2022-12-01 2022-12-31 0001280776 imux:NewYorkCityMember 2022-12-31 0001280776 2016-05-01 2016-05-31 0001280776 2019-04-12 0001280776 imux:ImmunicAGMember 2021-03-31 2021-03-31 0001280776 imux:ImmunicAGMember 2021-03-31 0001280776 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001280776 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001280776 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001280776 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001280776 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001280776 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001280776 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001280776 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001280776 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001280776 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001280776 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001280776 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001280776 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001280776 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001280776 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001280776 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001280776 2020-11-30 0001280776 us-gaap:SubsequentEventMember 2023-02-17 0001280776 imux:December2020ATMMember 2020-12-31 0001280776 imux:December2020ATMMember 2022-12-31 0001280776 us-gaap:SubsequentEventMember imux:December2020ATMMember 2023-02-17 0001280776 imux:May2022ATMMember 2022-05-10 0001280776 imux:May2022ATMMember 2022-12-31 0001280776 us-gaap:SubsequentEventMember imux:May2022ATMMember 2023-02-17 0001280776 imux:December2020ATMMember 2022-01-01 2022-12-31 0001280776 imux:December2020ATMMember 2021-01-01 2021-12-31 0001280776 us-gaap:CommonStockMember 2022-10-10 2022-10-10 0001280776 us-gaap:CommonStockMember 2022-10-10 0001280776 imux:PreFundedWarrantsMember 2022-10-10 2022-10-10 0001280776 imux:PreFundedWarrantsMember 2022-10-10 0001280776 2022-10-12 2022-10-12 0001280776 imux:July2021PublicEquityOfferingMember 2021-07-15 2021-07-15 0001280776 imux:July2021PublicEquityOfferingMember 2021-07-15 0001280776 imux:July2021PublicEquityOfferingMember 2021-07-19 2021-07-19 0001280776 us-gaap:EmployeeStockOptionMember imux:A2021EmployeeStockPurchasePlanMember 2022-12-31 0001280776 imux:PreFundedWarrantsMember 2022-12-31 0001280776 us-gaap:EmployeeStockOptionMember 2022-12-31 0001280776 imux:EmployeeStockOptionsforFutureGrantMember imux:TwoThousandFourteenEquityIncentivePlanMember 2022-12-31 0001280776 imux:EmployeeStockOptionsforFutureGrantMember imux:A2017InducementEquityIncentivePlanMember 2022-12-31 0001280776 imux:EmployeeStockOptionsforFutureGrantMember imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember 2022-12-31 0001280776 imux:A2021EmployeeStockPurchasePlanMember 2021-04-25 2021-04-25 0001280776 imux:A2021EmployeeStockPurchasePlanMember 2021-04-25 0001280776 imux:A2021EmployeeStockPurchasePlanMember 2022-01-01 2022-12-31 0001280776 imux:A2021EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001280776 imux:A2019OmnibusEquityIncentivePlanMember 2019-07-31 0001280776 imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember 2019-07-01 2019-07-31 0001280776 imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember 2020-01-01 2021-09-30 0001280776 srt:MaximumMember imux:A2019OmnibusEquityIncentivePlanMember 2022-01-01 2022-12-31 0001280776 imux:IncentiveEmployeeStockOptionMember imux:A2019OmnibusEquityIncentivePlanMember 2022-01-01 2022-12-31 0001280776 srt:MinimumMember imux:NonStatutoryEmployeeStockOptionMember imux:A2019OmnibusEquityIncentivePlanMember 2022-01-01 2022-12-31 0001280776 srt:MaximumMember imux:NonStatutoryEmployeeStockOptionMember imux:A2019OmnibusEquityIncentivePlanMember 2022-01-01 2022-12-31 0001280776 us-gaap:EmployeeStockOptionMember imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember 2021-12-31 0001280776 us-gaap:EmployeeStockOptionMember imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember 2022-01-01 2022-12-31 0001280776 us-gaap:EmployeeStockOptionMember imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember 2022-12-31 0001280776 us-gaap:EmployeeStockOptionMember imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember 2020-12-31 0001280776 us-gaap:EmployeeStockOptionMember imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember 2021-01-01 2021-12-31 0001280776 imux:A2019OmnibusEquityIncentivePlanMember 2022-01-01 2022-12-31 0001280776 imux:A2019OmnibusEquityIncentivePlanMember 2021-01-01 2021-12-31 0001280776 imux:EmployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001280776 imux:EmployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001280776 imux:EmployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001280776 imux:EmployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001280776 imux:EmployeeMember 2022-01-01 2022-12-31 0001280776 imux:EmployeeMember 2021-01-01 2021-12-31 0001280776 imux:TwoThousandFourteenEquityIncentivePlanMember 2022-12-31 0001280776 imux:A2017InducementEquityIncentivePlanMember 2017-09-30 0001280776 imux:A2017InducementEquityIncentivePlanMember 2021-01-01 2021-12-31 0001280776 imux:A2017InducementEquityIncentivePlanMember 2022-01-01 2022-12-31 0001280776 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2022-01-01 2022-12-31 0001280776 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2021-01-01 2021-12-31 0001280776 us-gaap:ForeignCountryMember us-gaap:FederalMinistryOfFinanceGermanyMember 2022-01-01 2022-12-31 0001280776 us-gaap:ForeignCountryMember us-gaap:FederalMinistryOfFinanceGermanyMember 2021-01-01 2021-12-31 0001280776 us-gaap:ForeignCountryMember imux:ForeignExcludingGermanyMember 2022-01-01 2022-12-31 0001280776 us-gaap:ForeignCountryMember imux:ForeignExcludingGermanyMember 2021-01-01 2021-12-31 0001280776 us-gaap:ForeignCountryMember 2022-12-31 0001280776 us-gaap:DomesticCountryMember imux:TaxYearsPriorTo2018Member 2022-12-31 0001280776 us-gaap:DomesticCountryMember imux:TaxYearsPost2017Member 2022-12-31 0001280776 imux:DuaneNashMDJDMBAMember srt:BoardOfDirectorsChairmanMember imux:ExecutiveChairmanAgreementMember srt:AffiliatedEntityMember 2021-01-01 2021-05-14 0001280776 imux:DuaneNashMDJDMBAMember srt:BoardOfDirectorsChairmanMember imux:ExecutiveChairmanAgreementMember srt:AffiliatedEntityMember 2020-11-15 2020-11-15 0001280776 imux:DuaneNashMDJDMBAMember srt:BoardOfDirectorsChairmanMember imux:ExecutiveChairmanAgreementMember srt:AffiliatedEntityMember 2021-04-15 2021-04-15 0001280776 imux:DuaneNashMDJDMBAMember srt:BoardOfDirectorsChairmanMember imux:ExecutiveChairmanAgreementMember srt:AffiliatedEntityMember 2021-05-15 2021-12-31 0001280776 imux:DuaneNashMDJDMBAMember srt:BoardOfDirectorsChairmanMember imux:ExecutiveChairmanAgreementMember srt:AffiliatedEntityMember 2022-03-15 2022-12-31 0001280776 imux:DuaneNashMDJDMBAMember srt:BoardOfDirectorsChairmanMember imux:ExecutiveChairmanAgreementMember srt:AffiliatedEntityMember 2022-03-15 2022-03-15 0001280776 imux:DuaneNashMDJDMBAMember srt:ScenarioForecastMember srt:BoardOfDirectorsChairmanMember imux:ExecutiveChairmanAgreementMember srt:AffiliatedEntityMember 2022-12-28 2023-12-31 iso4217:USD shares iso4217:USD shares imux:employee imux:lease imux:financialInstitution pure utr:D 0001280776 2022 FY false http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent P3Y 10-K 10-K true 2022-12-31 --12-31 false 001-36201 Immunic, Inc. DE 56-2358443 1200 Avenue of the Americas, Suite 200 New York, NY 10036 332 255-9818 Common Stock, $0.0001 par value IMUX NASDAQ No No Yes Yes Non-accelerated Filer true false false false 106100000 44403838 Certain portions of the registrant’s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K. 23 Baker Tilly US, LLP Minneapolis, MN 106745000 86863000 9629000 0 9490000 18125000 125864000 104988000 294000 152000 0 32970000 1552000 948000 43000 42000 127753000 139100000 4281000 3745000 7986000 7071000 810000 585000 13077000 11401000 992000 584000 992000 584000 14069000 11985000 0.0001 0.0001 20000000 20000000 0 0 0 0 0 0 0.0001 0.0001 130000000 130000000 39307286 39307286 26335418 26335418 4000 3000 427925000 324237000 3035000 -252000 -317280000 -196873000 113684000 127115000 127753000 139100000 71255000 61115000 15263000 13300000 32970000 0 0 17250000 119488000 91665000 -119488000 -91665000 1041000 66000 -1960000 -1346000 -919000 -1280000 -120407000 -92945000 -3.78 -3.78 -3.93 -3.93 31819006 31819006 23652779 23652779 -120407000 -92945000 3287000 3860000 -117120000 -89085000 21168240 2000 266823000 -4112000 -103928000 158785000 -92945000 -92945000 3860000 3860000 5949000 5949000 2980000 4500000 1000 42019000 42020000 23000 73221 729000 729000 12758 92000 92000 581199 8625000 8625000 26335418 3000 324237000 -252000 -196873000 127115000 -120407000 -120407000 3287000 3287000 7929000 7929000 4012000 8696552 1000 55988000 55989000 1226000 4204113 39584000 39584000 70351 182000 182000 852 5000 5000 39307286 4000 427925000 3035000 -317280000 113684000 -120407000 -92945000 77000 85000 32970000 0 7929000 5949000 -4757000 -4332000 0 8625000 -7493000 12800000 799000 176000 -124000 170000 1362000 3175000 -65144000 -83233000 9629000 0 112000 67000 -9741000 -67000 1226000 23000 39584000 729000 182000 92000 4012000 0 55989000 0 5000 0 2980000 0 42020000 95760000 42841000 -993000 -130000 19882000 -40589000 86863000 127452000 106745000 86863000 0 8625000 974000 435000 Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gräfelfing near Munich, Germany. The Company currently has approximately 66 employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently pursuing clinical development of three orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (“MS”); the izumerogant (proposed International Nonproprietary Name (“INN”) for IMU-935) program, which is an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (“RORγt”) that inhibits the interleukin-17 (“IL-17”) pathway in diseases such as psoriasis; and the IMU-856 program, which is targeted to restore intestinal barrier function and regenerate bowel epithelium.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $317.3 million as of December 31, 2022 and approximately $196.9 million as of December 31, 2021. Substantially all of Immunic’s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December 31, 2022, Immunic has raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of December 31, 2022, the Company had cash and cash equivalents of approximately $106.7 million and investments - other of $9.6 million. With these funds the Company expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div>The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018). All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. 66 3 -317300000 -196900000 355500000 106700000 9600000 Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reporting currency is United States (“U.S.”) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.’s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">• assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">• income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">• components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders’ equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Time Deposits with an original maturity greater than three months are classified as Investments-other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7 million, Germany of approximately $19.1 million and Australia of approximately $1.9 million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of —% to 0.87%</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2— Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years. Depreciation and amortization expense was $77,000 and $85,000 for the years ended December 31, 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the years ended December 31, 2022 and 2021 other than goodwill which is described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, the Company announced the outcome of a significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization. The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired. The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0 million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance. The Company did not have any goodwill impairment during the year ended December 31, 2021. The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:75.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill during the year ended December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (“CROs”) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (“MSA”). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (“ASU”) 2014-09 “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” and ASU No. 2018-18, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We recognized $2.3 million and $1.7 million of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92">other income</span></span> related to research activities performed during the years ended December 31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award’s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company’s common stock, the expected volatility of the price of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application of management’s judgment. If factors change and different assumptions are used, the Company’s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company’s balance sheet. A right-of-use lease asset represents the Company’s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders’ equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December 31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) or ASC 815-40, Accounting </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (“ASC 815-40”). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,888,240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reporting currency is United States (“U.S.”) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.’s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">• assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">• income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">• components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders’ equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Time Deposits with an original maturity greater than three months are classified as Investments-other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S of approximately $85.7 million, Germany of approximately $19.1 million and Australia of approximately $1.9 million. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. Our Cash and Cash equivalents in the U.S. is primarily held in a U.S. Government money market fund account and was earning interest at a rate of 4.3%. Our cash and cash equivalents in Germany and Australia were earning interest at a rate of —% to 0.87%</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.61% to 0.87% and have a remaining maturity 3-4 months.</span></div> 85700000 19100000 1900000 2 0.043 0 0.0087 <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td></tr></table></div> 9629000 0 9629000 0 0.0061 0.0087 P3M P4M <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2— Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div> Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years. P3Y P13Y 77000 85000 Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Impaired assets are then recorded at their estimated fair value. 0 0 <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div>On October 20, 2022, the Company announced the outcome of a significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization. The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired. 33000000 The changes in the carrying amount of goodwill for the years presented are as follows (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:75.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill during the year ended December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount of goodwill at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 32970000 32970000 0 <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div>The Company enters into agreements with contract research organizations (“CROs”) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (“MSA”). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period. <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div>The Company enters into agreements with contract research organizations (“CROs”) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (“MSA”). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period. <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (“ASU”) 2014-09 “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” and ASU No. 2018-18, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo’s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. Government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We recognized $2.3 million and $1.7 million of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3221b224-b06b-4599-934b-4790913ca766"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzYvZnJhZzo2ZDdjMzg2Nzg4MzE0OWNkOTA5NWY0YzdhMTIxMjVlYi90ZXh0cmVnaW9uOjZkN2MzODY3ODgzMTQ5Y2Q5MDk1ZjRjN2ExMjEyNWViXzIxOTkwMjMzMTM2MjY_3cdcee94-7c82-4bf3-999e-30ecd1c05a92">other income</span></span> related to research activities performed during the years ended December 31, 2022 and 2021, respectively.</span></div> 0.435 2300000 1700000 <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award’s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company’s common stock, the expected volatility of the price of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the </span></div>application of management’s judgment. If factors change and different assumptions are used, the Company’s stock-based compensation expense could be materially different in the future. <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company’s balance sheet. A right-of-use lease asset represents the Company’s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div> P12M P60M 2 2 <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders’ equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December 31, 2022 and 2021, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) or ASC 815-40, Accounting </span></div>for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (“ASC 815-40”). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,888,240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3791688 2157460 5096552 0 8888240 2157460 <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div> Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid Expense and Other Current Assets consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,125 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid Expense and Other Current Assets consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,125 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5608000 14853000 296000 279000 2361000 1871000 1225000 1122000 9490000 18125000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3749000 3427000 288000 72000 244000 246000 4281000 3745000 6807000 6214000 169000 96000 890000 674000 120000 87000 7986000 7071000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_4a1a30a6-155d-4e96-9d47-e78ee944ec76"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xMzkvZnJhZzo0Y2QyMTZhNjhkYjg0ZWIzODkwNDYxOGFjMmEzY2JjOS90YWJsZTplYzk5N2UwNGE4MjE0MTc4OWI1MmE3Yjg2NWM0NTMzNi90YWJsZXJhbmdlOmVjOTk3ZTA0YTgyMTQxNzg5YjUyYTdiODY1YzQ1MzM2XzItMC0xLTEtMzQ4NjI_58a0a228-b7d2-495a-8002-5c76ada4c7a6">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 571000 408000 239000 177000 810000 585000 Commitments and Contingencies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office and June 30, 2025 for the Gräfelfing, Germany office. The Company formerly leased office space in </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gräfelfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gräfelfing, Germany office. Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions to right of use assets of $435,000 and $642,000 as a result of signing for additional lease space at the Gräfelfing, Germany office in March 2021 and August 2022, respectively. There were net additions to right of use assets of $332,000 as a result of extending the New York City lease in December 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Immunic’s operating lease costs and variable lease costs were $727,000 and $503,000 for the years ended December 31, 2022 and 2021, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Maturities of the operating lease obligation are as follows as of December 31, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs in vidofludimus calcium, izumerogant and IMU-856 totaling approximately $4.5 million, all of which is expected to be paid in 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement (the “Agreement”) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company’s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25 million </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic’s common stock (the “Shares”). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div> P5Y P6M 435000 642000 332000 0.06 0.08 727000 503000 Maturities of the operating lease obligation are as follows as of December 31, 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 647000 680000 355000 0 0 0 1682000 147000 1535000 4500000 0.044 120070 1500000 0.044 17250000 0.50 0.50 Fair Value <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table present information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 or Level 3 assets during the periods presented. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company’s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 4.3% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of December 31, 2022. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same. For the assessment of the fair value of goodwill and the related impairment of goodwill we used a level one assessment in our testing of goodwill. See Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of significant accounting policies "Goodwill".</span></div> <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table present information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 85521000 85521000 0 0 85521000 85521000 0 0 31630000 31630000 0 0 31630000 31630000 0 0 0.043 Common StockShelf Registration Statements<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of February 17, 2023, there is $75.0 million remaining on this shelf registration statement </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days’ prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 17, 2023, $8.4 million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days’ prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company. As of February 17, 2023, $80.0 million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company raised gross proceeds of $40.9 million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6 million after deducting underwriter commissions of $1.2 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, the Company raised gross proceeds of $0.8 million pursuant to the December 2020 ATM through the sale of 73,221 shares of common stock at a weighted average price of $10.27 per share. The net proceeds from the December 2020 ATM were $0.7 million after deducting underwriter commissions of $22,555.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with select accredited investors and certain existing investors (each, a “Purchaser” and collectively, the “Purchasers”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return. All of the pre-funded warrants were exercised in January of 2023.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0 million, before deducting offering expenses payable by the Company of approximately $4.0 million. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), izumerogant (IMU-935) and IMU-856, and for other general corporate purposes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration statement for these securities was deemed effective by Securities and Exchange Commission on December 20, 2022. </span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">July 2021 Public Equity Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp; Co., in connection with the Company’s public offering of 4,500,000 shares of the Company’s common stock, $0.0001 par value per share, at a public offering price of $10.00 per share. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was approximately $42.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:113%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001. The voting, dividend and liquidation rights of the holders of the Company’s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December 31, 2022, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue 20,000,000 shares of $0.0001 par value preferred stock, rights and preferences to be set by the board of directors. No preferred shares were outstanding as of December 31, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance as of December 31, 2022 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,283,347 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 250000000 75000000 50000000 10 8400000 80000000 10 80000000 0.030 40900000 4204113 9.72 39600000 1200000 800000 73221 10.27 700000 22555 8696552 0.0001 4.35 5096552 4.34 0.01 0.0999 0.1999 P61D 60000000 4500000 0.0001 10.00 42000000 130000000 0.0001 0 0 20000000 0.0001 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance as of December 31, 2022 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,283,347 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 116891 5096552 3791688 43311 46250 188655 9283347 Stock-based Compensation Plans<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company’s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has issued 70,351 and 12,758 shares under the ESPP for the twelve months ended December 31, 2022 and 2021, respectively. The Company recognized $96,000 and $46,000 of expense related to the plan in the twelve months ended December 31, 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company’s stockholders approved the 2019 Omnibus Equity Incentive Plan (the “2019 Plan”) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company’s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company’s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZjc4NTU5NTY3YzQxNzNiNjY1ZTg3NWQ0MTljZjQxL3NlYzpkZmY3ODU1OTU2N2M0MTczYjY2NWU4NzVkNDE5Y2Y0MV8xNTEvZnJhZzoyNDg0MDNlMjQ0ZWU0YjA4ODFjY2NjOTBlYzE5MmY1Yy90ZXh0cmVnaW9uOjI0ODQwM2UyNDRlZTRiMDg4MWNjY2M5MGVjMTkyZjVjXzEwOTk1MTE2MzkwMzI_3b155f68-f249-4b5a-829c-f22ff2797b9c">three</span> or four years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398,490 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,954 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December 31, 2022 and 2021 was $6.81 and $10.52, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.526%"><tr><td style="width:1.0%"/><td style="width:57.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/> Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 there was $15.6 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.74 years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital’s 2012 Stock Option Plan (the “2012 Plan”), Vital’s 2014 Equity Incentive Plan (the “2014 Plan”) and Vital’s 2017 Inducement Equity Incentive Plan (the “Inducement Plan”), were assumed by the Company. All awards granted under these plans have either been forfeited or expired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital’s Board of Directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital’s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the twelve months ended December 31, 2022 and 2021, respectively.</span></div> 0.15 0.85 200000 70351 12758 96000 46000 1500000 0.04 4900000 4408871 P10Y P4Y P4Y <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the twelve months ended December 31, 2022 and 2021 under the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398,490 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,954 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table> 2157460 13.54 1886263 8.73 852 5.67 251183 10.79 3791688 11.33 P8Y4M6D 375 3791688 11.33 P8Y4M6D 375 1398490 13.33 P7Y6M 0 1117160 12.96 1193809 14.08 0 0 153509 13.50 2157460 13.54 P8Y8M26D 302155 2157460 13.54 P8Y8M26D 302155 752954 13.48 P8Y1M24D 79431 0 6.81 10.52 The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.526%"><tr><td style="width:1.0%"/><td style="width:57.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr></table> 0.0209 0.0093 0 0 0.978 0.930 P6Y P6Y <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/> Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3219000 1760000 4710000 4189000 7929000 5949000 15600000 P2Y8M26D 43311 46250 0 0 Income Taxes <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,049)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,945)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate reconciliation consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is no current or deferred income tax expense in the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.</span></div><div style="text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,923 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,053 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,819 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total deferred tax liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $14.2 million and $22.3 million and for the years ended December 31, 2021 and 20, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Immunic had available NOLs of approximately $190.2 million in Germany and Australia. These NOLs do not expire.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal NOL carryforwards of $15.6 million were generated prior to 2018 and expire over 20 years beginning in 2023. The $78.9 million of post 2017 federal NOL carryforwards do not expire. Sections 382 of the Internal Revenue Code of 1986 subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined. The Company may have undergone ownership changes and therefore may be limited in the amount of net operating losses available for utilization in the future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any uncertain tax positions for the years ended December 31, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are no uncertain tax positions that would impact the effective tax rate if recognized.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2018 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div>Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,049)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,945)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table> -47049000 -11222000 -67448000 -78869000 -5911000 -2854000 -120408000 -92945000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate reconciliation consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.210 0.210 0.022 0.032 -0.011 -0.009 0.000 0.000 -0.057 0.000 -0.007 -0.004 -0.157 -0.229 -0.000 0.000 0 0 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,923 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain or loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,053 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,819 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total deferred tax liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 19830000 18437000 742000 576000 2923000 3848000 47179000 34819000 1686000 1130000 693000 9000 73053000 58819000 0 2000 0 2000 73053000 58817000 73053000 58817000 0 0 14200000 22300000 190200000 15600000 78900000 0 0 0 Related Party Transactions<div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the “Executive Chairman Agreement”) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an “at will” employment relationship with a base salary of $25,417 per month pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, the Company and Dr. Nash entered into an addendum (the “First Addendum”) to extend the term of the Executive Chairman Agreement to April 15, 2021. In connection with the First Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 120,000 shares of Company common stock, which vests monthly over six months commencing on November 15, 2020. On April 15, 2021, the Company and Dr. Nash entered into Addendum No. Two (the “Second Addendum”) to extend the term of the Executive Chairman Agreement to April 15, 2022. In connection with the Second Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly over 12 months commencing on May 15, 2021, and to increase Dr. Nash’s monthly base salary to $27,960 from $25,417. On March 15, 2022, the Company and Dr. Nash entered into Addendum No. Three (the “Third Addendum”), which extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month. In connection with the Third Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company’s common stock, which vests monthly over 12 months commencing on April 10, 2022. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company’s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div> 25417 120000 90000 27960 25417 29358 75000 30250 EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 161 281 1 false 58 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://imux.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://imux.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets Sheet http://imux.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://imux.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations Sheet http://imux.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://imux.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statements of Cash Flows Sheet http://imux.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical) Sheet http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical Consolidated Statements of Cash Flows (Parenthetical) Statements 10 false false R11.htm 0000011 - Disclosure - Description of Business and Basis of Financial Statements Sheet http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements Description of Business and Basis of Financial Statements Notes 11 false false R12.htm 0000012 - Disclosure - Summary of Significant Accounting Policies Sheet http://imux.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 12 false false R13.htm 0000013 - Disclosure - Balance Sheet Details Sheet http://imux.com/role/BalanceSheetDetails Balance Sheet Details Notes 13 false false R14.htm 0000014 - Disclosure - Commitments and Contingencies Sheet http://imux.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 14 false false R15.htm 0000015 - Disclosure - Fair Value Sheet http://imux.com/role/FairValue Fair Value Notes 15 false false R16.htm 0000016 - Disclosure - Common Stock Sheet http://imux.com/role/CommonStock Common Stock Notes 16 false false R17.htm 0000017 - Disclosure - Stock-based Compensation Plans Sheet http://imux.com/role/StockbasedCompensationPlans Stock-based Compensation Plans Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://imux.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Related Party Transactions Sheet http://imux.com/role/RelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 0000020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://imux.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 0000021 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://imux.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://imux.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 0000022 - Disclosure - Balance Sheet Details (Tables) Sheet http://imux.com/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://imux.com/role/BalanceSheetDetails 22 false false R23.htm 0000023 - Disclosure - Commitments and Contingencies (Tables) Sheet http://imux.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://imux.com/role/CommitmentsandContingencies 23 false false R24.htm 0000024 - Disclosure - Fair Value (Tables) Sheet http://imux.com/role/FairValueTables Fair Value (Tables) Tables http://imux.com/role/FairValue 24 false false R25.htm 0000025 - Disclosure - Common Stock (Tables) Sheet http://imux.com/role/CommonStockTables Common Stock (Tables) Tables http://imux.com/role/CommonStock 25 false false R26.htm 0000026 - Disclosure - Stock-based Compensation Plans (Tables) Sheet http://imux.com/role/StockbasedCompensationPlansTables Stock-based Compensation Plans (Tables) Tables http://imux.com/role/StockbasedCompensationPlans 26 false false R27.htm 0000027 - Disclosure - Income Taxes (Tables) Sheet http://imux.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://imux.com/role/IncomeTaxes 27 false false R28.htm 0000028 - Disclosure - Description of Business and Basis of Financial Statements - Additional Information (Details) Sheet http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails Description of Business and Basis of Financial Statements - Additional Information (Details) Details 28 false false R29.htm 0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 29 false false R30.htm 0000030 - Disclosure - Summary of Significant Accounting Policies - Investments (Details) Sheet http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails Summary of Significant Accounting Policies - Investments (Details) Details 30 false false R31.htm 0000031 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details) Sheet http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails Summary of Significant Accounting Policies - Goodwill (Details) Details 31 false false R32.htm 0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) Sheet http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) Details 32 false false R33.htm 0000033 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 33 false false R34.htm 0000034 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Details) Sheet http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails Balance Sheet Details - Schedule of Accounts Payable (Details) Details 34 false false R35.htm 0000035 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details) Sheet http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails Balance Sheet Details - Schedule of Accrued Expenses (Details) Details 35 false false R36.htm 0000036 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Details) Sheet http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails Balance Sheet Details - Schedule of Other Current Liabilities (Details) Details 36 false false R37.htm 0000037 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 37 false false R38.htm 0000038 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details) Sheet http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details) Details 38 false false R39.htm 0000039 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 39 false false R40.htm 0000040 - Disclosure - Fair Value - Additional Information (Detail) Sheet http://imux.com/role/FairValueAdditionalInformationDetail Fair Value - Additional Information (Detail) Details 40 false false R41.htm 0000041 - Disclosure - Common Stock - Shelf Registration Statement (Details) Sheet http://imux.com/role/CommonStockShelfRegistrationStatementDetails Common Stock - Shelf Registration Statement (Details) Details 41 false false R42.htm 0000042 - Disclosure - Common Stock - Equity Offering (Details) Sheet http://imux.com/role/CommonStockEquityOfferingDetails Common Stock - Equity Offering (Details) Details 42 false false R43.htm 0000043 - Disclosure - Common Stock - Common Stock (Details) Sheet http://imux.com/role/CommonStockCommonStockDetails Common Stock - Common Stock (Details) Details 43 false false R44.htm 0000044 - Disclosure - Common Stock - Preferred Stock (Details) Sheet http://imux.com/role/CommonStockPreferredStockDetails Common Stock - Preferred Stock (Details) Details 44 false false R45.htm 0000045 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details) Sheet http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails Common Stock - Shares Reserved for Future Issuance (Details) Details 45 false false R46.htm 0000046 - Disclosure - Stock-based Compensation Plans - Additional Information (Details) Sheet http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails Stock-based Compensation Plans - Additional Information (Details) Details 46 false false R47.htm 0000047 - Disclosure - Stock-based Compensation Plans - Summary of Stock Option Activity (Details) Sheet http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails Stock-based Compensation Plans - Summary of Stock Option Activity (Details) Details 47 false false R48.htm 0000048 - Disclosure - Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details) Sheet http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details) Details 48 false false R49.htm 0000049 - Disclosure - Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) Sheet http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) Details 49 false false R50.htm 0000050 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details) Sheet http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details) Details 50 false false R51.htm 0000051 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details) Sheet http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails Income Taxes - Income Tax Rate Reconciliation (Details) Details 51 false false R52.htm 0000052 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://imux.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 52 false false R53.htm 0000053 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 53 false false R54.htm 0000054 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 54 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - imux-20221231.htm 4 imux-20221231.htm exhibit23111.htm exhibit422022.htm imux-123122xexhibit211.htm imux-123122xexhibit311.htm imux-123122xexhibit312.htm imux-123122xexhibit321.htm imux-123122xexhibit322.htm imux-20221231.xsd imux-20221231_cal.xml imux-20221231_def.xml imux-20221231_lab.xml imux-20221231_pre.xml imux-ex105dienstvertragand.htm imux-ex106dienstvertragdan.htm imux-20221231_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "imux-20221231.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 514, "http://xbrl.sec.gov/dei/2022": 40 }, "contextCount": 161, "dts": { "calculationLink": { "local": [ "imux-20221231_cal.xml" ] }, "definitionLink": { "local": [ "imux-20221231_def.xml" ] }, "inline": { "local": [ "imux-20221231.htm" ] }, "labelLink": { "local": [ "imux-20221231_lab.xml" ] }, "presentationLink": { "local": [ "imux-20221231_pre.xml" ] }, "schema": { "local": [ "imux-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 442, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://xbrl.sec.gov/dei/2022": 4, "total": 9 }, "keyCustom": 34, "keyStandard": 247, "memberCustom": 27, "memberStandard": 28, "nsprefix": "imux", "nsuri": "http://imux.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "dei:DocumentType", "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://imux.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "dei:DocumentType", "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "menuCat": "Statements", "order": "10", "role": "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ic79be0a87a2d43ae992ef8e7625d53e2_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Description of Business and Basis of Financial Statements", "menuCat": "Notes", "order": "11", "role": "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements", "shortName": "Description of Business and Basis of Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "12", "role": "http://imux.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Balance Sheet Details", "menuCat": "Notes", "order": "13", "role": "http://imux.com/role/BalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "14", "role": "http://imux.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Fair Value", "menuCat": "Notes", "order": "15", "role": "http://imux.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Common Stock", "menuCat": "Notes", "order": "16", "role": "http://imux.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Stock-based Compensation Plans", "menuCat": "Notes", "order": "17", "role": "http://imux.com/role/StockbasedCompensationPlans", "shortName": "Stock-based Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://imux.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "19", "role": "http://imux.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://imux.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "20", "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "21", "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Balance Sheet Details (Tables)", "menuCat": "Tables", "order": "22", "role": "http://imux.com/role/BalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "23", "role": "http://imux.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Fair Value (Tables)", "menuCat": "Tables", "order": "24", "role": "http://imux.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Common Stock (Tables)", "menuCat": "Tables", "order": "25", "role": "http://imux.com/role/CommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Stock-based Compensation Plans (Tables)", "menuCat": "Tables", "order": "26", "role": "http://imux.com/role/StockbasedCompensationPlansTables", "shortName": "Stock-based Compensation Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "27", "role": "http://imux.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "dei:EntityNumberOfEmployees", "reportCount": 1, "unique": true, "unitRef": "employee", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Description of Business and Basis of Financial Statements - Additional Information (Details)", "menuCat": "Details", "order": "28", "role": "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails", "shortName": "Description of Business and Basis of Financial Statements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "dei:EntityNumberOfEmployees", "reportCount": 1, "unique": true, "unitRef": "employee", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "29", "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "3", "role": "http://imux.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentTableTextBlock", "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherShortTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)", "menuCat": "Details", "order": "30", "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails", "shortName": "Summary of Significant Accounting Policies - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentTableTextBlock", "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i29c8be7c0e67485390b3fa4ca6373ec9_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i1b28bf41d41a44729bb53cadae860beb_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)", "menuCat": "Details", "order": "31", "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails", "shortName": "Summary of Significant Accounting Policies - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)", "menuCat": "Details", "order": "32", "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "imux:PrepaidClinicalAndRelatedCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "33", "role": "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "imux:PrepaidClinicalAndRelatedCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "imux:ClinicalCostsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Details)", "menuCat": "Details", "order": "34", "role": "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails", "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "imux:ClinicalCostsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "imux:AccruedClinicalCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)", "menuCat": "Details", "order": "35", "role": "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails", "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "imux:AccruedClinicalCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Details)", "menuCat": "Details", "order": "36", "role": "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails", "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "imux:OperatingLeaseIncrementalBorrowingRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "menuCat": "Details", "order": "37", "role": "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "imux:OperatingAndVariableLeasesCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)", "menuCat": "Details", "order": "38", "role": "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails", "shortName": "Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i4387fb9fcb644cbfa9f299c3c426b334_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "menuCat": "Details", "order": "39", "role": "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i4387fb9fcb644cbfa9f299c3c426b334_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "us-gaap:PreferredStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "imux:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "id15e6eed9a474921925790496d9be215_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentInterestRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Fair Value - Additional Information (Detail)", "menuCat": "Details", "order": "40", "role": "http://imux.com/role/FairValueAdditionalInformationDetail", "shortName": "Fair Value - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i89236a268ded4c38beb10ce49d29d398_I20201130", "decimals": "-5", "first": true, "lang": "en-US", "name": "imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Common Stock - Shelf Registration Statement (Details)", "menuCat": "Details", "order": "41", "role": "http://imux.com/role/CommonStockShelfRegistrationStatementDetails", "shortName": "Common Stock - Shelf Registration Statement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i89236a268ded4c38beb10ce49d29d398_I20201130", "decimals": "-5", "first": true, "lang": "en-US", "name": "imux:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i444f4698aac042ccbe20eda2d1da8d8b_D20221012-20221012", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Common Stock - Equity Offering (Details)", "menuCat": "Details", "order": "42", "role": "http://imux.com/role/CommonStockEquityOfferingDetails", "shortName": "Common Stock - Equity Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i88aea673e8c04440a92d7eb913623ddd_D20221010-20221010", "decimals": "INF", "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Common Stock - Common Stock (Details)", "menuCat": "Details", "order": "43", "role": "http://imux.com/role/CommonStockCommonStockDetails", "shortName": "Common Stock - Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Common Stock - Preferred Stock (Details)", "menuCat": "Details", "order": "44", "role": "http://imux.com/role/CommonStockPreferredStockDetails", "shortName": "Common Stock - Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)", "menuCat": "Details", "order": "45", "role": "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "shortName": "Common Stock - Shares Reserved for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Stock-based Compensation Plans - Additional Information (Details)", "menuCat": "Details", "order": "46", "role": "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "shortName": "Stock-based Compensation Plans - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ia0414aabe31c45cfb03ec35d6944f613_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Stock-based Compensation Plans - Summary of Stock Option Activity (Details)", "menuCat": "Details", "order": "47", "role": "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails", "shortName": "Stock-based Compensation Plans - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i46791b70b39149f995d04e9d61847f37_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)", "menuCat": "Details", "order": "48", "role": "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails", "shortName": "Stock-based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5621a4c9af0345529c9a631b26c01878_D20220101-20221231", "decimals": "4", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)", "menuCat": "Details", "order": "49", "role": "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails", "shortName": "Stock-based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5f8826a093524faab9e1c7138d3c7734_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "5", "role": "http://imux.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details)", "menuCat": "Details", "order": "50", "role": "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails", "shortName": "Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)", "menuCat": "Details", "order": "51", "role": "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails", "shortName": "Income Taxes - Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Income Taxes - Additional Information (Details)", "menuCat": "Details", "order": "52", "role": "http://imux.com/role/IncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "53", "role": "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ice9c9f9b5bc349d8a29a72c15dc660b5_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "id31cbe772be540f6ae60d3269ef43568_D20210101-20210514", "decimals": "0", "first": true, "lang": "en-US", "name": "imux:SalaryCostsMonthlyBaseSalary", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Related Party Transactions - Additional Information (Details)", "menuCat": "Details", "order": "54", "role": "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "id31cbe772be540f6ae60d3269ef43568_D20210101-20210514", "decimals": "0", "first": true, "lang": "en-US", "name": "imux:SalaryCostsMonthlyBaseSalary", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "6", "role": "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ic389dfc27c9a4f599aa3e1e541429096_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "7", "role": "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "ic389dfc27c9a4f599aa3e1e541429096_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)", "menuCat": "Statements", "order": "8", "role": "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i42cae9630d124c15823d3c9c381fc07a_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "9", "role": "http://imux.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "imux-20221231.htm", "contextRef": "i5c2a76c58bc04dfdb26f0e141506227c_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 58, "tag": { "country_AU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AUSTRALIA", "terseLabel": "Australia" } } }, "localname": "AU", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityNumberOfEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of persons employed by the Entity", "label": "Entity Number of Employees", "terseLabel": "Number of employees" } } }, "localname": "EntityNumberOfEmployees", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imux.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "imux_A2017InducementEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 Inducement Equity Incentive Plan [Member]", "label": "2017 Inducement Equity Incentive Plan [Member]", "terseLabel": "2017 Inducement Equity Incentive Plan" } } }, "localname": "A2017InducementEquityIncentivePlanMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_A2019OmnibusEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Omnibus Equity Incentive Plan [Member]", "label": "2019 Omnibus Equity Incentive Plan [Member]", "terseLabel": "2019 Omnibus Equity Incentive Plan" } } }, "localname": "A2019OmnibusEquityIncentivePlanMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" ], "xbrltype": "domainItemType" }, "imux_A2021EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Employee Stock Purchase Plan", "label": "2021 Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee stock purchase plan" } } }, "localname": "A2021EmployeeStockPurchasePlanMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_A4SCRoyaltySettlementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4SC Royalty Settlement", "label": "4SC Royalty Settlement [Member]", "terseLabel": "4SC Royalty Settlement" } } }, "localname": "A4SCRoyaltySettlementMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "imux_AccruedClinicalCostsCurrent": { "auth_ref": [], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Clinical Costs, Current", "label": "Accrued Clinical Costs, Current", "terseLabel": "Accrued clinical and related costs" } } }, "localname": "AccruedClinicalCostsCurrent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "imux_AccruedCompensationCurrent": { "auth_ref": [], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Compensation, Current", "label": "Accrued Compensation, Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedCompensationCurrent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "imux_AccruedLegalAndAuditCostsCurrent": { "auth_ref": [], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Legal And Audit Costs, Current", "label": "Accrued Legal And Audit Costs, Current", "terseLabel": "Accrued legal and audit costs" } } }, "localname": "AccruedLegalAndAuditCostsCurrent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales", "label": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales", "terseLabel": "Asset purchase agreement, royalties as percent of aggregated net sales" } } }, "localname": "AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "imux_AtTheMarketSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At The Market Sales Agreement", "label": "At The Market Sales Agreement [Member]", "terseLabel": "At The Market Sales Agreement" } } }, "localname": "AtTheMarketSalesAgreementMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "imux_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://imux.com/20221231", "xbrltype": "stringItemType" }, "imux_AustraliaAndGermanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Australia and Germany", "label": "Australia and Germany [Member]", "terseLabel": "Australia and Germany" } } }, "localname": "AustraliaAndGermanyMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash And Cash Equivalents And Other Investments", "label": "Cash And Cash Equivalents And Other Investments [Policy Text Block]", "terseLabel": "Cash And Cash Equivalents And Other Investments" } } }, "localname": "CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "imux_ClinicalCostsPayableCurrent": { "auth_ref": [], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Clinical Costs Payable, Current", "label": "Clinical Costs Payable, Current", "terseLabel": "Clinical and related costs" } } }, "localname": "ClinicalCostsPayableCurrent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "imux_December2020ATMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2020 ATM", "label": "December 2020 ATM [Member]", "terseLabel": "December 2020 ATM" } } }, "localname": "December2020ATMMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "domainItemType" }, "imux_DeferredTaxAssetsAndLiabilitiesGross": { "auth_ref": [], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets and Liabilities, Gross", "label": "Deferred Tax Assets and Liabilities, Gross", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsAndLiabilitiesGross", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "imux_DuaneNashMDJDMBAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duane Nash, MD, JD, MBA", "label": "Duane Nash, MD, JD, MBA [Member]", "terseLabel": "Duane Nash, MD, JD, MBA" } } }, "localname": "DuaneNashMDJDMBAMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_EmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee [Member]", "label": "Employee [Member]", "terseLabel": "Employee" } } }, "localname": "EmployeeMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "domainItemType" }, "imux_EmployeeStockOptionsforFutureGrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Options for Future Grant [Member]", "label": "Employee Stock Options for Future Grant [Member]", "terseLabel": "Common stock options available for future grant:" } } }, "localname": "EmployeeStockOptionsforFutureGrantMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent", "label": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent", "terseLabel": "Increase or decrease not in excess of percentage" } } }, "localname": "EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "percentItemType" }, "imux_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage", "label": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage", "terseLabel": "May not exercise of percentage" } } }, "localname": "EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "percentItemType" }, "imux_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period", "label": "Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period", "terseLabel": "Increase or decrease not In excess of prior notice period" } } }, "localname": "EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "durationItemType" }, "imux_ExecutiveChairmanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive Chairman Agreement", "label": "Executive Chairman Agreement [Member]", "terseLabel": "Executive Chairman Agreement" } } }, "localname": "ExecutiveChairmanAgreementMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_ForeignExcludingGermanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign, Excluding Germany", "label": "Foreign, Excluding Germany [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignExcludingGermanyMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "domainItemType" }, "imux_GovernmentAssistanceRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government Assistance Rate", "label": "Government Assistance Rate", "terseLabel": "Government assistance rate" } } }, "localname": "GovernmentAssistanceRate", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "imux_GrafelfingGermanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grafelfing, Germany", "label": "Grafelfing, Germany [Member]", "terseLabel": "Grafelfing, Germany" } } }, "localname": "GrafelfingGermanyMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_ImmunicAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Immunic AG [Member]", "label": "Immunic AG [Member]", "terseLabel": "Immunic AG" } } }, "localname": "ImmunicAGMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_IncentiveEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Employee Stock Option [Member]", "label": "Incentive Employee Stock Option [Member]", "terseLabel": "Incentive Employee Stock Option" } } }, "localname": "IncentiveEmployeeStockOptionMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "terseLabel": "Increase in operating lease, right-of-use asset" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "imux_InvestmentEarningInterestRateRemainingMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment, Earning Interest Rate, Remaining Maturity Period", "label": "Investment, Earning Interest Rate, Remaining Maturity Period", "terseLabel": "Earning interest at a rate maturity (in months)" } } }, "localname": "InvestmentEarningInterestRateRemainingMaturityPeriod", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "imux_July2021PublicEquityOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July 2021 Public Equity Offering", "label": "July 2021 Public Equity Offering [Member]", "terseLabel": "July 2021 Public Equity Offering" } } }, "localname": "July2021PublicEquityOfferingMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "imux_LegalAndAuditCostsPayableCurrent": { "auth_ref": [], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Legal And Audit Costs Payable, Current", "label": "Legal And Audit Costs Payable, Current", "terseLabel": "Legal and audit costs" } } }, "localname": "LegalAndAuditCostsPayableCurrent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "imux_LesseeOperatingLeaseRentHolidayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Rent Holiday Period", "label": "Lessee, Operating Lease, Rent Holiday Period", "terseLabel": "Rent holiday period" } } }, "localname": "LesseeOperatingLeaseRentHolidayPeriod", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "imux_LesseeOperatingLeasesNumberOfExistingLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Leases, Number Of Existing Leases", "label": "Lessee, Operating Leases, Number Of Existing Leases", "terseLabel": "Number of existing operating leases" } } }, "localname": "LesseeOperatingLeasesNumberOfExistingLeases", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "imux_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration", "label": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration", "terseLabel": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration" } } }, "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "monetaryItemType" }, "imux_May2022ATMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2022 ATM", "label": "May 2022 ATM [Member]", "terseLabel": "May 2022 ATM" } } }, "localname": "May2022ATMMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "domainItemType" }, "imux_NewYorkCityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New York City", "label": "New York City [Member]", "terseLabel": "New York City" } } }, "localname": "NewYorkCityMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_NonStatutoryEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Statutory Employee Stock Option [Member]", "label": "Non-Statutory Employee Stock Option [Member]", "terseLabel": "Non-Statutory Employee Stock Option" } } }, "localname": "NonStatutoryEmployeeStockOptionMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_NumberOfDevelopmentPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Development Programs", "label": "Number Of Development Programs", "terseLabel": "Number of development programs pursued" } } }, "localname": "NumberOfDevelopmentPrograms", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "imux_NumberOfFinancialInstitutionsUsedForCashDeposits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Financial Institutions Used For Cash Deposits", "label": "Number of Financial Institutions Used For Cash Deposits", "terseLabel": "Number of financial institutions used for cash deposits" } } }, "localname": "NumberOfFinancialInstitutionsUsedForCashDeposits", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "imux_October2022PIPETransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 2022 PIPE Transaction", "label": "October 2022 PIPE Transaction [Member]", "terseLabel": "October 2022 PIPE Transaction" } } }, "localname": "October2022PIPETransactionMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "imux_OperatingAndVariableLeasesCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating And Variable Leases, Cost", "label": "Operating And Variable Leases, Cost", "terseLabel": "Operating and variable lease cost" } } }, "localname": "OperatingAndVariableLeasesCost", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "imux_OperatingLeaseIncrementalBorrowingRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Incremental Borrowing Rate", "label": "Operating Lease, Incremental Borrowing Rate", "terseLabel": "Incremental borrowing rate on operating leases" } } }, "localname": "OperatingLeaseIncrementalBorrowingRate", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "imux_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-Funded Warrants", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Prefunded stock warrants" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "imux_PrepaidClinicalAndRelatedCostsCurrent": { "auth_ref": [], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Clinical And Related Costs, Current", "label": "Prepaid Clinical And Related Costs, Current", "terseLabel": "Prepaid clinical and related costs" } } }, "localname": "PrepaidClinicalAndRelatedCostsCurrent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "imux_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "domainItemType" }, "imux_ResearchAndDevelopmentTaxIncentiveCurrent": { "auth_ref": [], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Tax Incentive, Current", "label": "Research And Development Tax Incentive, Current", "terseLabel": "Australian research and development tax incentive" } } }, "localname": "ResearchAndDevelopmentTaxIncentiveCurrent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "imux_RoyaltySettlementAgreementCashPaymentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Settlement Agreement, Cash Payment, Percent", "label": "Royalty Settlement Agreement, Cash Payment, Percent", "terseLabel": "Royalty settlement agreement, cash payment, percent" } } }, "localname": "RoyaltySettlementAgreementCashPaymentPercent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "imux_RoyaltySettlementAgreementSalesNet": { "auth_ref": [], "calculation": { "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty Settlement Agreement, Sales Net", "label": "Royalty Settlement Agreement, Sales Net", "terseLabel": "4SC Royalty Settlement (See Note 4)", "verboseLabel": "4SC royalty settlement" } } }, "localname": "RoyaltySettlementAgreementSalesNet", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "imux_RoyaltySettlementAgreementSharesPaymentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Settlement Agreement, Shares Payment, Percent", "label": "Royalty Settlement Agreement, Shares Payment, Percent", "terseLabel": "Royalty settlement agreement, shares payment, percent" } } }, "localname": "RoyaltySettlementAgreementSharesPaymentPercent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "imux_SalaryCostsMonthlyBaseSalary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Salary Costs, Monthly Base Salary", "label": "Salary Costs, Monthly Base Salary", "terseLabel": "Monthly base salary" } } }, "localname": "SalaryCostsMonthlyBaseSalary", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "imux_SaleOfStockRemainingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Remaining Capacity", "label": "Sale Of Stock, Remaining Capacity", "terseLabel": "Remaining capacity" } } }, "localname": "SaleOfStockRemainingCapacity", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "monetaryItemType" }, "imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]", "terseLabel": "Shares Reserved for Future Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockTables" ], "xbrltype": "textBlockItemType" }, "imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent", "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent", "terseLabel": "Additional shares authorized, percent" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "imux_SharesIssuedWeightedAverageSharePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued, Weighted Average Share Price Per Share", "label": "Shares Issued, Weighted Average Share Price Per Share", "terseLabel": "Shares Issued, Weighted Average Share Price Per Share" } } }, "localname": "SharesIssuedWeightedAverageSharePricePerShare", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "perShareItemType" }, "imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock", "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock", "terseLabel": "Commission, percent of gross proceeds from sale of common stock" } } }, "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "percentItemType" }, "imux_ShelfRegistrationStatementAmountRemaining": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shelf Registration Statement, Amount Remaining", "label": "Shelf Registration Statement, Amount Remaining", "terseLabel": "Shelf Registration Statement, Amount Remaining" } } }, "localname": "ShelfRegistrationStatementAmountRemaining", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "monetaryItemType" }, "imux_ShelfRegistrationTerminationPriorWrittenNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shelf Registration, Termination, Prior Written Notice", "label": "Shelf Registration, Termination, Prior Written Notice", "terseLabel": "Shelf registration, termination, prior written notice" } } }, "localname": "ShelfRegistrationTerminationPriorWrittenNotice", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "integerItemType" }, "imux_TaxYearsPost2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Years Post 2017", "label": "Tax Years Post 2017 [Member]", "terseLabel": "Post 2017" } } }, "localname": "TaxYearsPost2017Member", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_TaxYearsPriorTo2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Years Prior to 2018", "label": "Tax Years Prior to 2018 [Member]", "terseLabel": "Prior to 2018" } } }, "localname": "TaxYearsPriorTo2018Member", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_TwoThousandFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]", "label": "Two Thousand Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 Equity Incentive Plan" } } }, "localname": "TwoThousandFourteenEquityIncentivePlanMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision", "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]", "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision" } } }, "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan", "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]", "terseLabel": "2019 Omnibus Equity Incentive Plan" } } }, "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember", "nsuri": "http://imux.com/20221231", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r438", "r517", "r552", "r553", "r555" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors Chairman" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r163", "r164", "r229", "r233", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r216", "r217", "r218", "r219", "r256", "r380", "r403", "r439", "r440", "r451", "r456", "r461", "r514", "r558", "r559", "r560", "r561", "r562", "r563" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r216", "r217", "r218", "r219", "r256", "r380", "r403", "r439", "r440", "r451", "r456", "r461", "r514", "r558", "r559", "r560", "r561", "r562", "r563" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r216", "r217", "r218", "r219", "r248", "r256", "r287", "r288", "r289", "r379", "r380", "r403", "r439", "r440", "r451", "r456", "r461", "r508", "r514", "r559", "r560", "r561", "r562", "r563" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r216", "r217", "r218", "r219", "r248", "r256", "r287", "r288", "r289", "r379", "r380", "r403", "r439", "r440", "r451", "r456", "r461", "r508", "r514", "r559", "r560", "r561", "r562", "r563" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r163", "r164", "r229", "r233", "r443", "r444" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r257", "r488" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r178", "r257", "r473", "r488" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r202", "r203", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r452", "r460", "r515" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r202", "r203", "r425", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r452", "r460", "r515" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r178", "r257", "r473", "r474", "r488" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r489", "r554" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r459" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails", "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable, Other, Current", "terseLabel": "Other" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails", "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r25", "r26", "r143", "r399", "r408", "r409" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r23", "r26", "r108", "r368", "r404", "r405", "r479", "r480", "r481", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r11", "r459" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r296", "r297", "r298", "r485", "r486", "r487", "r548" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r90", "r91", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r72", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r115", "r123", "r139", "r161", "r196", "r198", "r200", "r204", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r329", "r331", "r344", "r459", "r512", "r513", "r556" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r134", "r145", "r161", "r204", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r329", "r331", "r344", "r459", "r512", "r513", "r556" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time Deposits", "verboseLabel": "Time Deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r51", "r57" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Description of Business and Basis of Financial Statements" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r46", "r136", "r441" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r40", "r46", "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r40", "r112" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r20", "r118", "r127" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (note 4)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r64", "r213", "r214", "r426", "r511" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Total common shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Common stock cash dividends paid (in USD per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockCommonStockDetails", "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common stock, cash dividends declared (in USD per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockCommonStockDetails", "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r485", "r486", "r548" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockCommonStockDetails", "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockCommonStockDetails", "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r72" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r459" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 130,000,000 shares authorized and 39,307,286 and 26,335,418 shares issued and outstanding at December\u00a031, 2022 and 2021, respectively", "verboseLabel": "Common stock issued" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r27", "r148", "r150", "r156", "r396", "r401" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Contractual obligation" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r44", "r104", "r316", "r321", "r322", "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r7", "r8", "r116", "r122", "r310" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "imux_DeferredTaxAssetsAndLiabilitiesGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible Assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r311" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "imux_DeferredTaxAssetsAndLiabilitiesGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r545" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets, valuation allowance total" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r102", "r546" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Foreign net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r102", "r546" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r102", "r546" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other, net" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r102", "r546" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": { "auth_ref": [ "r102", "r546" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.", "label": "Deferred Tax Assets, Unrealized Currency Losses", "terseLabel": "Unrealized gain or loss" } } }, "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r312" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r102", "r546" ], "calculation": { "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum annual contributions per employee (as a percent)" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r44", "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r44", "r195" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r261", "r292", "r293", "r295", "r300", "r457" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails", "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r157", "r170", "r171", "r172", "r173", "r174", "r179", "r181", "r183", "r184", "r185", "r187", "r335", "r336", "r397", "r402", "r445" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r157", "r170", "r171", "r172", "r173", "r174", "r181", "r183", "r184", "r185", "r187", "r335", "r336", "r397", "r402", "r445" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r349" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r304" ], "calculation": { "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r162", "r304", "r323" ], "calculation": { "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r544", "r547" ], "calculation": { "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r323", "r544" ], "calculation": { "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Tax effect of rate change" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r544", "r547" ], "calculation": { "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r544", "r547" ], "calculation": { "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r544", "r547" ], "calculation": { "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "terseLabel": "Stock options" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period over which compensation cost will be recognized (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Outstanding stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r72", "r132", "r152", "r153", "r154", "r165", "r166", "r167", "r169", "r175", "r177", "r188", "r205", "r247", "r296", "r297", "r298", "r318", "r319", "r334", "r350", "r351", "r352", "r353", "r354", "r356", "r368", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r337", "r338", "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r230", "r249", "r250", "r251", "r252", "r253", "r254", "r338", "r376", "r377", "r378", "r449", "r450", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r337", "r338", "r339", "r340", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r230", "r249", "r254", "r338", "r376", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r230", "r249", "r254", "r338", "r377", "r449", "r450", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r230", "r249", "r250", "r251", "r252", "r253", "r254", "r338", "r378", "r449", "r450", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r230", "r249", "r250", "r251", "r252", "r253", "r254", "r376", "r377", "r378", "r449", "r450", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r341", "r343" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalMinistryOfFinanceGermanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Germany.", "label": "Federal Ministry of Finance, Germany [Member]", "terseLabel": "Germany" } } }, "localname": "FederalMinistryOfFinanceGermanyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails", "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r345", "r346", "r347", "r348" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign currency loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Presentation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r32" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r137", "r206", "r394", "r448", "r459", "r497", "r504" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Carrying amount of goodwill at December 31, 2022", "periodStartLabel": "Carrying amount of goodwill at December 31, 2021", "verboseLabel": "Goodwill (note 2)" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets", "http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r209", "r210", "r448" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r44", "r207", "r208", "r209", "r448" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Impairment of goodwill during the year ended December 31, 2022", "terseLabel": "Goodwill impairment (see Note 2)", "verboseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofOperations", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GovernmentAssistanceAmount": { "auth_ref": [ "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of government assistance recognized.", "label": "Government Assistance, Amount", "terseLabel": "Government assistance, amount" } } }, "localname": "GovernmentAssistanceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GovernmentAssistancePolicyTextBlock": { "auth_ref": [ "r359", "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for government assistance.", "label": "Government Assistance [Policy Text Block]", "terseLabel": "Government assistance" } } }, "localname": "GovernmentAssistancePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes government assistance.", "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r59", "r63" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r31", "r154" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss) Attributable to Parent, before Tax", "terseLabel": "Net loss before income tax" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails", "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails", "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r96", "r97", "r98", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r162", "r305", "r308", "r315", "r320", "r324", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r151", "r302", "r303", "r308", "r309", "r314", "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r43" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r43" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r43" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r43" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "United States" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r33", "r194" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentInterestRate": { "auth_ref": [ "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Rate of interest on investment.", "label": "Investment Interest Rate", "terseLabel": "Investment interest rate" } } }, "localname": "InvestmentInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentTableTextBlock": { "auth_ref": [ "r492", "r493", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment.", "label": "Investment [Table Text Block]", "terseLabel": "Schedule of Investment" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r44" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Common stock issued in connection with the 4SC royalty settlement (see Note 4)" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of Operating Lease Obligations" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r367" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r367" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r367" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r367" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r367" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r367" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r367" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r367" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: interest portion" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term (in years)", "verboseLabel": "Lease term (in months)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r161", "r204", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r330", "r331", "r332", "r344", "r446", "r512", "r556", "r557" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r117", "r125", "r459", "r483", "r494", "r549" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r135", "r161", "r204", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r330", "r331", "r332", "r344", "r459", "r512", "r556", "r557" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r161", "r204", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r330", "r331", "r332", "r344", "r512", "r556", "r557" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r65", "r66", "r215", "r216", "r217", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueAdditionalInformationDetail", "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r158" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r158" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r40", "r42", "r45" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r29", "r45", "r120", "r129", "r133", "r146", "r149", "r154", "r161", "r168", "r170", "r171", "r172", "r173", "r176", "r177", "r182", "r196", "r197", "r199", "r201", "r204", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r336", "r344", "r447", "r512" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://imux.com/role/ConsolidatedStatementsofOperations", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r34" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r196", "r197", "r199", "r201", "r447" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r363" ], "calculation": { "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease obligation" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r363" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r363" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r362" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r144", "r459" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r138" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r105", "r106", "r107" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation income, net of tax" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r72", "r147", "r150", "r155", "r350", "r355", "r356", "r395", "r400", "r479", "r480" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Foreign exchange translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r18", "r459" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails", "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r35" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r119", "r128", "r476" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Other Short-Term Investments", "terseLabel": "Investments - other" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets", "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails", "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r18", "r67" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCommissions": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for commissions during the current period.", "label": "Payments for Commissions", "terseLabel": "Underwriter commissions" } } }, "localname": "PaymentsForCommissions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r37" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTerseLabel": "Purchases of Investments-other" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r36" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r9", "r231" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in USD per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockPreferredStockDetails", "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockPreferredStockDetails", "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r9", "r231" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockPreferredStockDetails", "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r9", "r459" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December\u00a031, 2022 and 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r477" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Other current assets and prepaid expenses", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails", "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r38" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails", "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from issuance of private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r38", "r88" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from shares issued in connection with the Company's employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r38", "r88" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r61", "r126", "r398", "r459" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r61", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r255", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r131", "r371", "r372", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r255", "r371", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r369", "r370", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r93", "r130", "r564" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r79", "r124", "r407", "r409", "r459" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets", "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r132", "r165", "r166", "r167", "r169", "r175", "r177", "r205", "r296", "r297", "r298", "r318", "r319", "r334", "r404", "r406" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r366", "r458" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of use asset obtained in exchange for lease obligation" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Consideration received on transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockShelfRegistrationStatementDetails", "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Shares issues in private placement transaction (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share (in USD per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r86", "r89" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r448", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Net Loss before Income Tax Based on Jurisdictions" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r113", "r114" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r258", "r260", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r81", "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Valuation Assumptions Used" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r68", "r69", "r71", "r73", "r74", "r75", "r76", "r77", "r78", "r79", "r140", "r141", "r142", "r189", "r231", "r232", "r233", "r235", "r239", "r244", "r246", "r451", "r472", "r482" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r43" ], "calculation": { "http://imux.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/StockbasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Purchase price of the stock, at discount from market price at purchase date (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares issued under the ESPP (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Other Disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable, (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable, Weighted-Average Exercise Price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited and expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited or expired (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, Ending balance (in shares)", "periodStartLabel": "Outstanding, Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, Ending balance (in USD per share)", "periodStartLabel": "Outstanding, Beginning balance (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options vested and expected to vest , aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options vested and expected to vest (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options vested and expected to vest, Weighted-Average Exercise Price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockSharesReservedforFutureIssuanceDetails", "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r265", "r284", "r285", "r286", "r287", "r290", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in USD per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of options (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansAdditionalInformationDetails", "http://imux.com/role/StockbasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, weighted-average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, weighted-average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested and expected to vest , weighted-average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r51", "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r22", "r72", "r132", "r152", "r153", "r154", "r165", "r166", "r167", "r169", "r175", "r177", "r188", "r205", "r247", "r296", "r297", "r298", "r318", "r319", "r334", "r350", "r351", "r352", "r353", "r354", "r356", "r368", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r165", "r166", "r167", "r188", "r381" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r47", "r48", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Common stock issued in connection with the 4SC royalty settlement (see Note 4)" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r9", "r10", "r72", "r79" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued in connection with the Company's employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r10", "r72", "r79" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r9", "r10", "r72", "r79", "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/StockbasedCompensationPlansSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r9", "r10", "r72", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Shares issued in connection with the Company's employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r9", "r10", "r72", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockShelfRegistrationStatementDetails", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Options to purchase common stock" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r13", "r14", "r58", "r459", "r483", "r494", "r549" ], "calculation": { "http://imux.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r80", "r160", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r247", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Warrants" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r357", "r375" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r357", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r357", "r375" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockShelfRegistrationStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/CommonStockEquityOfferingDetails", "http://imux.com/role/CommonStockShelfRegistrationStatementDetails", "http://imux.com/role/ConsolidatedStatementsofCashFlows", "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity", "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r0", "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "terseLabel": "Impairment losses" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r301", "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Uncertain tax positions that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r54", "r55", "r56", "r190", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Valuation allowance increase" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValueAddedTaxReceivableCurrent": { "auth_ref": [ "r475" ], "calculation": { "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Value Added Tax Receivable, Current", "terseLabel": "VAT receivable" } } }, "localname": "ValueAddedTaxReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Prefunded stock warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r180", "r185" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r179", "r185" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://imux.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342957-244231", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r467": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r468": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r469": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r471": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "https://asc.fasb.org/topic&trid=75115024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "https://asc.fasb.org/topic&trid=2197064", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 80 0001280776-23-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001280776-23-000004-xbrl.zip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�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�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